0000012208-24-00005210-Q BIO-RAD LABORATORIES, INC. 20240802202408021615191615191615191615191 0 0000012208-24-000052 10-Q 80 20240630 20240802 20240802 BIO-RAD LABORATORIES, INC. 0000012208 3826 941381833 DE 1231 10-Q 34 001-07928 241171177 1000 ALFRED NOBEL DRIVE HERCULES CA 94547 5107247000 1000 ALFRED NOBEL DRIVE HERCULES CA 94547 BIO RAD LABORATORIES INC 19920703 10-Q 1 bio-20240630.htm 10-Q bio-20240630000001220812/312024Q2false0.1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Rate00000122082024-01-012024-06-300000012208us-gaap:CommonClassAMember2024-01-012024-06-300000012208us-gaap:CommonClassBMember2024-01-012024-06-300000012208us-gaap:CommonClassAMember2024-07-290000012208us-gaap:CommonClassBMember2024-07-290000012208us-gaap:CommonClassAMember2024-06-300000012208us-gaap:CommonClassAMember2023-12-310000012208us-gaap:CommonClassBMember2024-06-300000012208us-gaap:CommonClassBMember2023-12-310000012208us-gaap:TreasuryStockCommonMember2024-06-300000012208us-gaap:TreasuryStockCommonMember2023-12-3100000122082024-04-012024-06-3000000122082023-04-012023-06-3000000122082023-01-012023-06-3000000122082022-12-3100000122082023-06-300000012208us-gaap:CommonStockMember2023-12-310000012208us-gaap:AdditionalPaidInCapitalMember2023-12-310000012208us-gaap:TreasuryStockCommonMember2023-12-310000012208us-gaap:RetainedEarningsMember2023-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000012208us-gaap:CommonStockMember2024-01-012024-03-310000012208us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000012208us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000012208us-gaap:RetainedEarningsMember2024-01-012024-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-3100000122082024-01-012024-03-310000012208us-gaap:CommonStockMember2024-03-310000012208us-gaap:AdditionalPaidInCapitalMember2024-03-310000012208us-gaap:TreasuryStockCommonMember2024-03-310000012208us-gaap:RetainedEarningsMember2024-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100000122082024-03-310000012208us-gaap:CommonStockMember2024-04-012024-06-300000012208us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000012208us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000012208us-gaap:RetainedEarningsMember2024-04-012024-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000012208us-gaap:CommonStockMember2024-06-300000012208us-gaap:AdditionalPaidInCapitalMember2024-06-300000012208us-gaap:TreasuryStockCommonMember2024-06-300000012208us-gaap:RetainedEarningsMember2024-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000012208us-gaap:CommonStockMember2022-12-310000012208us-gaap:AdditionalPaidInCapitalMember2022-12-310000012208us-gaap:TreasuryStockCommonMember2022-12-310000012208us-gaap:RetainedEarningsMember2022-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000012208us-gaap:CommonStockMember2023-01-012023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000012208us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000012208us-gaap:RetainedEarningsMember2023-01-012023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100000122082023-01-012023-03-310000012208us-gaap:CommonStockMember2023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-03-310000012208us-gaap:TreasuryStockCommonMember2023-03-310000012208us-gaap:RetainedEarningsMember2023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100000122082023-03-310000012208us-gaap:CommonStockMember2023-04-012023-06-300000012208us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000012208us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000012208us-gaap:RetainedEarningsMember2023-04-012023-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000012208us-gaap:CommonStockMember2023-06-300000012208us-gaap:AdditionalPaidInCapitalMember2023-06-300000012208us-gaap:TreasuryStockCommonMember2023-06-300000012208us-gaap:RetainedEarningsMember2023-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000012208country:US2024-04-012024-06-300000012208country:US2023-04-012023-06-300000012208country:US2024-01-012024-06-300000012208country:US2023-01-012023-06-300000012208srt:EuropeMember2024-04-012024-06-300000012208srt:EuropeMember2023-04-012023-06-300000012208srt:EuropeMember2024-01-012024-06-300000012208srt:EuropeMember2023-01-012023-06-300000012208srt:AsiaPacificMember2024-04-012024-06-300000012208srt:AsiaPacificMember2023-04-012023-06-300000012208srt:AsiaPacificMember2024-01-012024-06-300000012208srt:AsiaPacificMember2023-01-012023-06-300000012208srt:AmericasMember2024-04-012024-06-300000012208srt:AmericasMember2023-04-012023-06-300000012208srt:AmericasMember2024-01-012024-06-300000012208srt:AmericasMember2023-01-012023-06-300000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-06-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2024-06-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000012208us-

gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberbio:RestrictedInvestmentMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberbio:RestrictedInvestmentMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300000012208bio:OrdinaryVotingSharesMember2024-06-300000012208bio:PreferenceSharesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:MunicipalBondsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:ShortTermInvestmentsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2024-06-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:ShortTermInvestmentsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2024-06-300000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2023-12-310000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2024-06-300000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2023-12-310000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2024-06-300000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2023-12-310000012208bio:OtherLongTermDebtMemberbio:OtherLongTermDebtMember2024-06-300000012208bio:OtherLongTermDebtMemberbio:OtherLongTermDebtMember2023-12-310000012208bio:LifeScienceMember2023-12-310000012208bio:ClinicalDiagnosticsMember2023-12-310000012208bio:LifeScienceMember2024-01-012024-06-300000012208bio:ClinicalDiagnosticsMember2024-01-012024-06-300000012208bio:LifeScienceMember2024-06-300000012208bio:ClinicalDiagnosticsMember2024-06-300000012208us-gaap:CustomerRelationshipsMember2024-06-300000012208bio:KnowHowMember2024-06-300000012208us-gaap:DevelopedTechnologyRightsMember2024-06-300000012208us-gaap:LicensingAgreementsMember2024-06-300000012208us-gaap:TradeNamesMember2024-06-300000012208us-gaap:NoncompeteAgreementsMember2024-06-300000012208us-gaap:InProcessResearchAndDevelopmentMember2024-06-300000012208us-gaap:CustomerRelationshipsMember2023-12-310000012208bio:KnowHowMember2023-12-310000012208us-gaap:DevelopedTechnologyRightsMember2023-12-310000012208us-gaap:LicensingAgreementsMember2023-12-310000012208us-gaap:TradeNamesMember2023-12-310000012208us-gaap:NoncompeteAgreementsMember2023-12-310000012208us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000012208us-gaap:SeniorNotesMemberbio:A33SeniorNotesDue2027Member2024-06-300000012208us-gaap:SeniorNotesMemberbio:A33SeniorNotesDue2027Member2023-12-310000012208us-gaap:SeniorNotesMemberbio:A37SeniorNotesDue2032Member2024-06-300000012208us-gaap:SeniorNotesMemberbio:A37SeniorNotesDue2032Member2023-12-310000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2024-06-300000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2023-12-310000012208us-gaap:LineOfCreditMember2024-02-130000012208us-gaap:LineOfCreditMember2024-06-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-06-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-06-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-06-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-06-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-04-012024-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-012023-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-04-012024-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-06-300000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-06-300000012208bio:LifeScienceMember2024-04-012024-06-300000012208bio:ClinicalDiagnosticsMember2024-04-012024-06-300000012208us-gaap:AllOtherSegmentsMember2024-04-012024-06-300000012208bio:LifeScienceMember2023-04-012023-06-300000012208bio:ClinicalDiagnosticsMember2023-04-012023-06-300000012208us-gaap:AllOtherSegmentsMember2023-04-012023-06-300000012208us-gaap:AllOtherSegmentsMember2024-01-012024-06-300000012208bio:LifeScienceMember2023-01-012023-06-300000012208bio:ClinicalDiagnosticsMember2023-01-012023-06-300000012208us-gaap:AllOtherSegmentsMember2023-01-012023-06-300000012208us-gaap:OperatingSegmentsMember2024-04-012024-06-300000012208us-gaap:OperatingSegmentsMember2023-04-012023-06-300000012208us-gaap:OperatingSegmentsMember2024-01-012024-06-300000012208us-gaap:OperatingSegmentsMember2023-01-012023-06-300000012208us-gaap:MaterialReconcilingItemsMember2024-04-012024-06-300000012208us-gaap:MaterialReconcilingItemsMember2023-04-012023-06-300000012208us-gaap:MaterialReconcilingItemsMember2024-01-012024-06-300000012208us-gaap:MaterialReconcilingItemsMember2023-01-012023-06-300000012208bio:EuropeanReorganizationMember2021-02-012024-06-300000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2023-12-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2023-12-310000012208bio:EuropeanReorganizationMember2023-12-310000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2024-01-012024-06-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2024-01-012024-06-300000012208bio:EuropeanReorganizationMember2024-01-012024-06-300000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2024-06-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2024-06-300000012208bio:EuropeanReorganizationMember2024-06-300000012208us-gaap:OneTimeTerminationBenefitsMember2024-01-012024-06-300000012208us-gaap:FacilityClosingMember2024-01-012024-06-300000012208bio:EuropeanAndAmericanReorganizationMember2023-02-012024-06-300000012208bio:LifeScienceMemberbio:EuropeanAndAmericanReorganizationMember2023-12-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2023-12-310000012208bio:EuropeanAndAmericanReorganizationMember2023-12-310000012208bio:LifeScienceMemberbio:EuropeanAndAmericanReorganizationMember2024-04-012024-06-

300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2024-04-012024-06-300000012208bio:EuropeanAndAmericanReorganizationMember2024-04-012024-06-300000012208bio:EuropeanAndAmericanReorganizationMember2024-01-012024-06-300000012208bio:LifeScienceMemberbio:EuropeanAndAmericanReorganizationMember2024-01-012024-06-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2024-01-012024-06-300000012208bio:LifeScienceMemberbio:EuropeanAndAmericanReorganizationMember2024-06-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2024-06-300000012208bio:EuropeanAndAmericanReorganizationMember2024-06-300000012208us-gaap:CostOfSalesMember2024-04-012024-06-300000012208us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300000012208us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300000012208us-gaap:CostOfSalesMember2024-01-012024-06-300000012208us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300000012208us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300000012208srt:MinimumMember2024-01-012024-06-300000012208srt:MaximumMember2024-01-012024-06-300000012208us-gaap:SubsequentEventMember2024-07-29UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. Â 20549 FORM 10-Q (Mark One)â˜'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedJune 30, 2024or â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from_____to _____ Commission file number001-07928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware94-1381833(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)1000 Alfred Nobel Drive,Hercules,California94547(Address of principal executive offices)(Zip Code)(510)724-7000(Registrant's telephone number, including area code) No Change(Former name, former address and former fiscal year, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registeredClass A Common Stock, Par Value $0.0001 per shareBIONew York Stock ExchangeClass B Common Stock, Par Value $0.0001 per shareBIO.BNew York Stock ExchangeIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yesâ˜'Noâ˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files). Yesâ˜'Noâ˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. Â See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and "emerging growth company" in Rule 12b-2 of the Exchange Act. Â (Check one): Large accelerated filerâ˜'Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yesâ˜Noâ˜'.Indicate the number of shares outstanding of each of the issuerâ€™s classes of common stock, as of the latest practicable date. Common Shares Outstanding at JulyÂ 29, 2024:Class A - 22,794,641Class B - 5,076,017BIO-RAD LABORATORIES, INC.FORM 10-Q JUNEÂ 30, 2024 TABLE OF CONTENTSPart I â€“ Financial Information4Item 1. Financial Statements4Condensed Consolidated Balance Sheets4Condensed Consolidated Statements of Income (Loss)6Condensed Consolidated Statements of Comprehensive Income (Loss)7Condensed Consolidated Statements of Cash Flows8Condensed Consolidated Statements of Changes in Stockholders' Equity9Notes to Condensed Consolidated Financial Statements10Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 31Item 3. Quantitative and Qualitative Disclosures about Market Risk36Item 4. Controls and Procedures36Part II â€“ Other Information37Item 1. Legal Proceedings37Item 1A. Risk Factors37Item 2. Unregistered Sales of Equity Securities and Use of Proceeds49Item 3. Defaults Upon Senior Securities49Item 4. Mine Safety Disclosures49Item 5. Other Information49Item 6. Exhibits51Signatures522INFORMATION RELATING TO FORWARD-LOOKING STATEMENTSOther than statements of historical fact, statements made in this report include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our future financial performance, operating results, plans and objectives. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as â€œbelieve,â€ â€œexpect,â€ â€œanticipate,â€ â€œmay,â€ â€œwill,â€ â€œintend,â€ â€œestimate,â€ â€œcontinue,â€ or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, the risks relating to our international operations, supply chain issues, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, reductions in government funding or capital spending of our customers, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under â€œPart II, Item 1A, Risk Factorsâ€ of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.3PART I â€“ FINANCIAL INFORMATIONItem 1. Â Â Â Â Â Â Â Â Â Â Financial StatementsBIO-RAD LABORATORIES, INC.Condensed Consolidated Balance Sheets (In thousands, except share data)June 30, 2024December 31, 2023ASSETS:(Unaudited)Cash and cash equivalents$406,913Â $403,815Â Short-term investments1,209,193Â 1,203,327Â Restricted investments5,560Â 5,560Â Accounts receivable, less allowance for credit losses of $14,043 as of JuneÂ 30, 2024 and $14,926 as of DecemberÂ 31, 2023445,506Â 489,017Â Inventory803,693Â 780,517Â Prepaid expenses153,013Â 140,040Â Other current assets32,376Â 26,054Â Total current assets3,056,254Â 3,048,330Â Property, plant and equipment, net533,767Â 529,007Â Operating lease right-of-use assets181,473Â 194,730Â Goodwill, net412,116Â 413,569Â Purchased intangibles, net307,093Â 320,514Â Other investments5,099,554Â 7,698,070Â Other assets98,189Â 94,850Â Total assets$9,688,446Â $12,299,070Â The accompanying notes are an integral part of these condensed consolidated financial statements.4BIO-RAD LABORATORIES, INC.Condensed Consolidated Balance Sheets(continued)(In thousands, except share data)June 30, 2024December 31, 2023LIABILITIES AND STOCKHOLDERSâ€™ EQUITY:(Unaudited)Â Accounts payable$126,693Â $144,625Â Accrued payroll and employee benefits132,460Â 139,929Â Current maturities of long-term debt and notes payable483Â 486Â Income and other taxes payable35,896Â 35,759Â Current operating lease liabilities41,513Â 40,379Â Other current liabilities149,916Â 161,621Â Total current liabilities486,961Â 522,799Â Long-term debt, net of current maturities1,199,724Â 1,199,052Â Deferred income taxes878,462Â 1,475,495Â Operating lease liabilities150,975Â 165,478Â Other long-term liabilities193,537Â 195,113Â Total liabilities2,909,659Â 3,557,937Â Stockholdersâ€™ equity:Â Â Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - noneâ€”Â â€”Â Class A common stock, shares issued 25,189,806 and 25,169,944 as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively; shares outstanding 23,122,664 and 23,422,506 as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively2Â 2Â Class B common stock, shares issued and outstanding, 5,076,066 as of JuneÂ 30, 2024 and 5,095,930 as of DecemberÂ 31, 2023, respectively1Â 1Â Additional paid-in capital474,729Â 449,075Â Class A treasury stock at cost, 2,067,142 and 1,747,438 shares as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively(723,642)(632,536)Retained earnings7,479,059Â 9,260,629Â Accumulated other comprehensive loss(451,362)(336,038)Total stockholdersâ€™ equity6,778,787Â 8,741,133Â Total liabilities and stockholdersâ€™ equity$9,688,446Â $12,299,070Â The accompanying notes are an integral part of these condensed consolidated financial statements.Â 5BIO-RAD LABORATORIES, INC.Condensed Consolidated Statements of Income (Loss)(In thousands, except per share data)(Unaudited)Â Three Months EndedSix Months EndedÂ June 30,June 30,Â 20242023Net sales$638,476Â $681,110Â $1,249,296Â $1,357,954Â Cost of goods sold283,357Â 318,627Â 568,211Â 633,054Â Gross profit355,119Â 362,483Â 681,085Â 724,900Â Selling, general and administrative expense194,719Â 207,824Â 409,602Â 433,377Â Research and development expense58,904Â 65,042Â 125,279Â 139,993Â Income from operations101,496Â 89,617Â 146,204Â 151,530Â Interest expense12,264Â 12,343Â 24,541Â 24,680Â Foreign currency exchange gains, net(1,699)(1,253)(3,653)(3,600)Losses from change in fair market value of equity securities and loan receivable2,895,355Â 1,595,442Â 2,473,178Â 1,612,967Â Other income, net(18,143)(16,488)(52,659)(66,919)Loss before income taxes(2,786,281)(1,500,427)(2,295,203)(1,415,598)Benefit from income taxes620,795Â 338,176Â 513,633Â 322,309Â Net loss$(2,165,486)$(1,162,251)$(1,781,570)$(1,093,289)Basic and diluted loss per share:Â Â Net loss per share(76.26)(39.59)(62.61)(37.09)Weighted average common shares28,395Â 29,355Â 28,457Â 29,475Â The accompanying notes are an integral part of these condensed consolidated financial statements.Â 6BIO-RAD LABORATORIES, INC.Condensed Consolidated Statements of Comprehensive Income (Loss)(In thousands)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,Â 20242023Net loss$(2,165,486)$(1,162,251)$(1,781,570)$(1,093,289)Other comprehensive income (loss), net of tax:Foreign currency translation adjustments(24,694)36,605Â (116,362)91,823Â Foreign other post-employment benefits adjustments(470)237Â 884Â 271Â Net unrealized holding gains (losses) on available-for-sale investments(227)(1,352)154Â 1,866Â Other comprehensive income (loss)(25,391)35,490Â (115,324)93,960Â Comprehensive loss$(2,190,877)$(1,126,761)$(1,896,894)$(999,329)The accompanying notes are an integral part of these condensed consolidated financial statements.7BIO-RAD LABORATORIES, INC.Condensed Consolidated Statements of Cash Flows(In thousands, unaudited) Â Six Months EndedÂ June 30,Â 20242023Cash flows from operating activities:Â Â Cash received from customers$1,265,453Â $1,360,206Â Cash paid to suppliers and employees(1,084,925)(1,173,285)Interest paid, net(23,301)(23,535)Income tax payments, net(52,172)(31,556)Dividend proceeds and miscellaneous receipts, net51,097Â 65,422Â Proceeds from (payments for) forward foreign exchange contracts, net11,286Â (1,067)Net cash provided by operating activities167,438Â 196,185Â Cash flows from investing activities:Â Â Payments for purchases of property, plant and equipment(82,457)(70,364)Proceeds from dispositions of property, plant and equipment92Â 39Â Payments for purchases of marketable securities and investments(654,541)(341,522)Proceeds from sales of marketable securities and investments536,544Â 195,932Â Proceeds from maturities of marketable securities and investments126,342Â 173,426Â Net cash used in investing activities(74,020)(42,489)Cash flows from financing activities:Â Â Payments on long-term borrowings(236)(231)Payments for debt issuance costs(617)â€”Â Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options10,188Â 9,521Â Tax payments from net share settlement(152)(312)Payments for purchases of treasury stock(105,749)(207,407)Net cash used in financing activities(96,566)(198,429)Effect of foreign exchange rate changes on cash6,494Â 670Â Net increase (decrease) in cash, cash equivalents and restricted cash3,346Â (44,063)Cash, cash equivalents and restricted cash at beginning of period404,369Â 434,544Â Cash, cash equivalents and restricted cash at end of period$407,715Â $390,481Â Reconciliation of cash, cash equivalents and restricted cash (in thousands): June 30,20242023Cash and cash equivalents$406,913Â $390,001Â Restricted cash included in Other current assets384Â 82Â Restricted cash included in Other assets418Â 398Â Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$407,715Â $390,481Â These restricted cash items are primarily related to performance guarantees and other restricted deposits.The accompanying notes are an integral part of these condensed consolidated financial

statements.8BIO-RAD LABORATORIES, INC.Condensed Consolidated Statements of Changes in Stockholders' Equity(In thousands)(Unaudited)Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' EquityBalance at December 31, 2023$3Â $449,075Â $(632,536)$9,260,629Â $(336,038)$8,741,133Â Net incomeâ€”Â â€”Â â€”Â 383,916Â â€”Â 383,916Â Other comprehensive loss, net of taxâ€”Â â€”Â â€”Â â€”Â (89,933)(89,933)Stock compensation expenseâ€”Â 15,262Â â€”Â â€”Â â€”Â 15,262Â Purchase of treasury stockâ€”Â â€”Â (4,702)â€”Â â€”Â (4,702)Reissuance of treasury stockâ€”Â (1,710)7,215Â â€”Â â€”Â 5,505Â Excise tax on stock repurchaseâ€”Â â€”Â (47)â€”Â â€”Â (47)Balance at March 31, 2024$3Â $462,627Â $(630,070)$9,644,545Â $(425,971)$9,051,134Â Net lossâ€”Â â€”Â â€”Â (2,165,486)â€”Â (2,165,486)Other comprehensive loss, net of taxâ€”Â â€”Â â€”Â â€”Â (25,391)(25,391)Stock compensation expenseâ€”Â 14,999Â â€”Â â€”Â â€”Â 14,999Â Purchase of treasury stockâ€”Â â€”Â (100,000)â€”Â â€”Â (100,000)Reissuance of treasury stockâ€”Â (2,745)7,428Â â€”Â â€”Â 4,683Â Shares withheld related to net share settlement of equity awardsâ€”Â (152)â€”Â â€”Â â€”Â (152)Excise tax on stock repurchaseâ€”Â â€”Â (1,000)â€”Â â€”Â $(1,000)Balance at June 30, 2024$3Â $474,729Â $(723,642)$7,479,059Â $(451,362)$6,778,787Â Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' EquityBalance at December 31, 2022$3Â $447,454Â $(263,586)$9,898,203Â $(466,822)$9,615,252Â Net incomeâ€”Â â€”Â â€”Â 68,962Â â€”Â 68,962Â Other comprehensive income, net of taxâ€”Â â€”Â â€”Â â€”Â 58,470Â 58,470Â Stock compensation expenseâ€”Â 16,608Â â€”Â â€”Â â€”Â 16,608Â Reissuance of treasury stockâ€”Â (660)5,290Â (206)â€”Â 4,424Â Balance at March 31, 2023$3Â $463,402Â $(258,296)$9,966,959Â $(408,352)$9,763,716Â Net lossâ€”Â â€”Â â€”Â (1,162,251)â€”Â (1,162,251)Other comprehensive income, net of taxâ€”Â â€”Â â€”Â â€”Â 35,490Â 35,490Â Stock compensation expenseâ€”Â 12,559Â â€”Â â€”Â â€”Â 12,559Â Purchase of treasury stockâ€”Â â€”Â (207,407)â€”Â â€”Â (207,407)Reissuance of treasury stockâ€”Â (2,089)6,919Â (44)â€”Â 4,786Â Balance at June 30, 2023$3Â $473,872Â $(458,784)$8,804,664Â $(372,862)$8,446,893Â The accompanying notes are an integral part of these condensed consolidated financial statements.Â 9BIO-RAD LABORATORIES, INCNotes to Condensed Consolidated Financial Statements(Unaudited)1. BASIS OF PRESENTATION AND USE OF ESTIMATESBasis of PresentationIn this report, â€œBio-Rad,â€ â€œwe,â€ â€œus,â€ â€œthe Companyâ€ and â€œourâ€ refer to Bio-Rad Laboratories, Inc. and its subsidiaries. Â The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. Â All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. Â The condensed consolidated balance sheet at DecemberÂ 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. Â The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. Â To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.Use of EstimatesThe preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.Revenue RecognitionWe recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is 10allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.We concluded that the use of the instrument (referred to as â€œlease elementsâ€) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and six months ended JuneÂ 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).11Contract costs:We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). Disaggregation of Revenue:The following table presents our revenues disaggregated by geographic region (in millions):Three Months EndedSix Months EndedJune 30,June 30,20242023202420232023United States$254.2Â $287.7Â $507.1Â $584.7Â EMEA206.5Â 211.2Â 406.7Â 416.0Â APAC131.2Â 143.0Â 248.4Â 278.8Â Other (primarily Canada and Latin America)46.6Â 39.2Â 87.1Â 78.5Â Total net sales$638.5Â $681.1Â $1,249.3Â $1,358.0Â The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at JuneÂ 30, 2024 and DecemberÂ 31, 2023 was $67.4 million and $68.3 million, respectively. The short-term deferred revenue balance at JuneÂ 30, 2024 and DecemberÂ 31, 2023 was $52.0Â million and $51.1 million, respectively.We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the six months ended JuneÂ 30, 2024 and 2023 were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$8.4Â $10.6Â Provision for warranty3.4Â 4.2Â Actual warranty costs(4.0)(5.8)Balance at end of period$7.8Â $9.0Â Accounts Receivable and Allowance for Credit LossesWe record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.12Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.Changes in our allowance for credit losses were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$14.9Â $15.0Â Provision for expected credit losses2.0Â 1.2Â Write-offs charged against the allowance(2.9)(0.4)Balance at end of period$14.0Â $15.8Â Recent Accounting Pronouncements Issued and to be AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, â€œImprovements to Reportable Segment Disclosures.â€ The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker (CODM). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early

adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures.2. FAIR VALUE MEASUREMENTSWe determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. Â The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. Â A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:â€¢Level 1: Quoted prices in active markets for identical instrumentsâ€¢Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)â€¢Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)13Financial assets and liabilities carried at fair value and measured on a recurring basis as of JuneÂ 30, 2024 are classified in the hierarchy as follows (in millions):Level 1Level 2Level 3TotalFinancial assets carried at fair value:Cash equivalents:Time depositsâ€”Â 40.3Â â€”Â 40.3Â Money market funds76.3Â â€”Â â€”Â 76.3Â Total cash equivalents (a)76.3Â 40.3Â â€”Â 116.6Â Restricted investments (b)7.2Â â€”Â â€”Â 7.2Â Equity securities (c)4,825.6Â â€”Â â€”Â 4,825.6Â Loan under the fair value option (d)â€”Â â€”Â 305.6Â 305.6Â Available-for-sale investments:Corporate debt securitiesâ€”Â 545.0Â â€”Â 545.0Â U.S. government sponsored agenciesâ€”Â 246.1Â â€”Â 246.1Â Foreign government obligationsâ€”Â 2.6Â â€”Â 2.6Â Municipal obligationsâ€”Â 8.3Â â€”Â 8.3Â Asset-backed securitiesâ€”Â 333.6Â â€”Â 333.6Â Total available-for-sale investments (e)â€”Â 1,135.6Â â€”Â 1,135.6Â Forward foreign exchange contracts (f)â€”Â 1.5Â â€”Â 1.5Â Total financial assets carried at fair value$4,909.1Â $1,177.4Â $305.6Â $6,392.1Â Financial liabilities carried at fair value:Â Â Â Forward foreign exchange contracts (g)$â€”Â $1.2Â $â€”Â $1.2Â Contingent consideration (h)â€”Â â€”Â 17.9Â 17.9Â Total financial liabilities carried at fair value$â€”Â $1.2Â $17.9Â $19.1Â 14Financial assets and liabilities carried at fair value and measured on a recurring basis as of DecemberÂ 31, 2023 are classified in the hierarchy as follows (in millions):Level 1Level 2Level 3TotalFinancial assets carried at fair value:Cash equivalents:Commercial paper$â€”Â $12.5Â $â€”Â $12.5Â Time depositsâ€”Â 36.6Â â€”Â 36.6Â U.S. government sponsored agenciesâ€”Â 7.0Â â€”Â 7.0Â Money market funds28.0Â â€”Â â€”Â 28.0Â Total cash equivalents (a)28.0Â 56.1Â â€”Â 84.1Â Restricted investments (b)7.1Â â€”Â â€”Â 7.1Â Equity securities (c)7,399.3Â â€”Â â€”Â 7,399.3Â Loan under the fair value option (d)â€”Â â€”Â 325.7Â 325.7Â Available-for-sale investments:Corporate debt securitiesâ€”Â 531.6Â â€”Â 531.6Â U.S. government sponsored agenciesâ€”Â 255.9Â â€”Â 255.9Â Foreign government obligationsâ€”Â 12.7Â â€”Â 12.7Â Municipal obligationsâ€”Â 12.1Â â€”Â 12.1Â Asset-backed securitiesâ€”Â 323.7Â â€”Â 323.7Â Total available-for-sale investments (e)â€”Â 1,136.0Â â€”Â 1,136.0Â Forward foreign exchange contracts (f)â€”Â 4.1Â â€”Â 4.1Â Total financial assets carried at fair value$7,434.4Â $1,196.2Â $325.7Â $8,956.3Â Financial liabilities carried at fair value:Forward foreign exchange contracts (g)$â€”Â $11.7Â $â€”Â $11.7Â Contingent consideration (h)â€”Â â€”Â 17.5Â 17.5Â Total financial liabilities carried at fair value$â€”Â $11.7Â $17.5Â $29.2Â (a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Restricted investments$5.6Â $5.6Â Other investments1.6Â 1.5Â Â Â Â Â Total$7.2Â $7.1Â (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Short-term investments$73.6Â $67.2Â Other investments4,752.0Â 7,332.1Â Â Â Â Â Â Â Â Â Total$4,825.6Â $7,399.3Â (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. 15(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million and $0.4 million in the condensed consolidated statements of income (loss) for the three and six months ended JuneÂ 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of JuneÂ 30, 2024.Level 1 Fair Value MeasurementsAs of JuneÂ 30, 2024, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the outstanding ordinary shares (excluding treasury shares) and 27% of the preference shares of Sartorius as of JuneÂ 30, 2024. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.The change in fair market value of our investment in Sartorius for the three and six months ended JuneÂ 30, 2024 were a loss of $2,874.4 million and a loss of $2,472.1 million, respectively, and are recorded in our condensed consolidated statements of income (loss).Level 2 Fair Value MeasurementsTo estimate the fair value of Level 2 debt securities as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions):Â June 30, 2024AmortizedCostUnrealizedGainsUnrealizedLossesEstimatedFairValueShort-term investments:Â Â Â Â Corporate debt securities$547.3Â $0.7Â (3.0)545.0Â Municipal obligations8.3Â â€”Â â€”Â 8.3Â Asset-backed securities335.1Â 0.5Â (2.0)333.6Â U.S. government sponsored agencies248.1Â 0.1Â (2.1)246.1Â Foreign government obligations2.6Â â€”Â â€”Â 2.6Â Â $1,141.4Â $1.3Â (7.1)1,135.6Â 16The following is a summary of the amortized cost and estimated fair value of our debt securities at JuneÂ 30, 2024 by contractual maturity date (in millions):AmortizedCostEstimated FairValueMature in less than one year$216.1Â $214.8Â Mature in one to five years730.8Â 727.4Â Mature in more than five years194.5Â 193.4Â Total$1,141.4Â $1,135.6Â Available-for-sale investments consist of the following (in millions):Â December 31, 2023AmortizedCostUnrealizedGainsUnrealizedLossesEstimatedFairValueShort-term investments:Â Â Â Â Corporate debt securities$534.1Â $0.8Â (3.3)531.6Â Municipal obligations12.2Â â€”Â (0.1)12.1Â Asset-backed securities325.7Â 0.7Â (2.7)323.7Â U.S. government sponsored agencies257.4Â 0.1Â (1.6)255.9Â Foreign government obligations12.8Â â€”Â (0.1)12.7Â Total$1,142.2Â $1.6Â (7.8)1,136.0Â As of JuneÂ 30, 2024, there were no significant continuous unrealized losses greater than 12 months.Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.At JuneÂ 30, 2024, we have concluded that all payments related to our available-for-sale investments are expected to be made inÂ full and on timeÂ atÂ par value. The diminution of value in the intervening period is due to market conditions such as illiquidityÂ and interest rate movementsÂ and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of JuneÂ 30, 2024.Included in Other current assets are $9.8 million and $11.9 million of interest receivable as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the six months ended JuneÂ 30, 2024, we have not written-off any uncollected interest receivable.As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. Â As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of JuneÂ 30, 2024 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was 17derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange gains, net in the condensed consolidated statements of income (loss).The following is a summary of our forward foreign currency exchange contracts (in millions): Contracts to sell foreign currency:June 30, 2024December 31, 2023Notional value$698.1Â $873.5Â Unrealized gain/(loss)$0.5Â $(8.1)Contracts to purchase foreign currency:Â Notional value$59.1Â $133.6Â Unrealized (loss)/gain(0.1)0.5Â Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $6.5 million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023.Also included in Other investments in the condensed consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in Other income, net in our condensed consolidated statements of income (loss). The carrying value of these investments, net of impairments, was $33.9 million and $32.3 million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively.The carrying value and fair value of our long-term debt were as follows (in millions):June 30, 2024December 31, 2023Carrying ValueFair ValueCarrying ValueFair ValueSenior notes$1,190.3Â $1,093.3Â $1,189.5Â $1,102.5Â Other long-term debt9.4Â 9.4Â 9.6Â 9.6Â Total$1,199.7Â $1,102.7Â $1,199.1Â $1,112.1Â The fair value of our long-term debt was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.Level 3 Fair Value InvestmentsDuring the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of â‚¬400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (â€œLoanâ€). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (â€œTrustâ€) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and 18expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair

value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in Losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the three months ended JuneÂ 30, 2024 was a loss of $22.7 million, which includes a $6.2 million gain from change in fair market value of the Loan and a $28.9 million loss from change in fair market value of the value appreciation right. The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the six months ended JuneÂ 30, 2024 was a loss of $10.4 million, which includes a $15.0 million gain from change in fair market value of the Loan and a $25.4 million loss from change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decrease in the value of the Sartorius ordinary shares. As of JuneÂ 30, 2024, the â‚¬400 million principal amount of the loan is still due on January 31, 2029. The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):December 31, 2023$325.7Â Net decrease in estimated fair market value of the loan included in Losses in fair market value of equity securities and loan receivable$(10.4)Foreign currency exchange losses, net$(9.7)June 30, 2024$305.6Â 193. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETSChanges to goodwill by segment are as follows (in millions):LifeScienceClinicalDiagnosticsTotalBalances as of January 1, 2024:Goodwill$333.3Â $415.5Â $748.8Â Accumulated impairment losses(41.8)(293.4)(335.2)Goodwill, net291.5Â 122.1Â 413.6Â Foreign currency adjustmentsâ€”Â (1.5)(1.5)Period change, netâ€”Â (1.5)(1.5)Balances as of June 30, 2024:Goodwill333.3Â 414.0Â 747.3Â Accumulated impairment losses(41.8)(293.4)(335.2)Goodwill, net$291.5Â $120.6Â $412.1Â Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):June 30, 2024Weighted-Average Remaining Amortization Period (years)PurchasePriceAccumulatedAmortizationNetCarryingAmountCustomer relationships/lists5.0$105.0Â (96.6)8.4Â Know how1.3166.3Â (160.7)5.6Â Developed product technology11.7216.8Â (136.8)80.0Â Licenses4.458.9Â (44.0)14.9Â Tradenames5.15.9Â (4.6)1.3Â Covenants not to compete1.86.3Â (5.1)1.2Â Â Â Â Â Â Total finite-lived intangible assets559.2Â (447.8)111.4Â In-process research and development195.7Â â€”Â 195.7Â Â Â Â Â Â Total purchased intangible assetsÂ $754.9Â (447.8)307.1Â 20Â December 31, 2023Weighted-Average Remaining Amortization Period (years)PurchasePriceAccumulatedAmortizationNetCarryingAmountCustomer relationships/lists5.2$108.7Â (98.9)9.8Â Know how1.8168.9Â (161.1)7.8Â Developed product technology12.0217.8Â (132.9)84.9Â Licenses4.959.2Â (42.4)16.8Â Tradenames5.66.1Â (4.7)1.4Â Covenants not to compete2.36.4Â (4.8)1.6Â Â Â Â Â Â Total finite-lived intangible assets567.1Â (444.8)122.3Â In-process research and development198.2Â â€”Â 198.2Â Â Â Â Â Â Total purchased intangible assetsÂ $765.3Â (444.8)320.5Â Amortization expense related to purchased intangible assets is as follows (in millions):Three Months EndedSix Months EndedÂ June 30,June 30,Â 2024202320242023Amortization expense$5.3Â $5.9Â $10.8Â $11.9Â 4. INVENTORYFollowing are the components of Inventory at JuneÂ 30, 2024 and DecemberÂ 31, 2023 (in millions):June 30, 2024December 31, 2023Inventory:Â Â Raw materials$235.0Â $231.6Â Â Â Work in process255.0Â 246.0Â Â Â Finished goods 313.7Â 302.9Â Â Â Â Â Â Total Inventory$803.7Â $780.5Â 215. SUPPLEMENTAL CASH FLOW INFORMATIONThe reconciliation of net loss to net cash provided by operating activities is as follows (in millions):Six Months EndedJune 30,20242023Net loss$(1,781.6)$(1,093.3)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization73.5Â 71.4Â Reduction in the carrying amount of right-of-use assets20.9Â 19.9Â Share-based compensation30.3Â 29.2Â Losses from change in fair market value of equity securities and loan receivable2,473.2Â 1,613.0Â Payments for operating lease liabilities(21.4)(19.8)Decrease in accounts receivable33.0Â 5.2Â Increase in inventories(31.2)(55.3)(Increase) decrease in other current assets(31.0)16.5Â Decrease in accounts payable and other current liabilities(26.6)(34.7)Increase in income taxes payable5.6Â 31.5Â Decrease in deferred income taxes(575.1)(391.6)Increase (decrease) in other long-term liabilities(0.2)6.3Â Other(2.0)(2.1)Net cash provided by operating activities$167.4Â $196.2Â Non-cash investing activities:Purchased property, plant and equipment$7.8Â $12.0Â Purchased marketable securities and investments$2.2Â $1.2Â Sold marketable securities and investments$9.8Â $â€”Â 226. LONG-TERM DEBTThe principal components of long-term debt are as follows (in millions):June 30,2024December 31,20233.3Â 0.8Â (0.1)1.0Â Other comprehensive income (loss), net of income taxes(116.3)0.8Â 0.1Â (115.4)Balances as of June 30, 2024:(450.4)(2.0)$1.0Â $(451.4)23Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)Balances as of January 1, 2023:(466.5)10.0Â (10.3)(466.8)Other comprehensive income, before reclassifications92.1Â 0.5Â 1.4Â 94.0Â Amounts reclassified from Accumulated other comprehensive income (loss)â€”Â (0.2)1.0Â 0.8Â Income tax effects(0.3)â€”Â (0.6)(0.9)Other comprehensive income, net of income taxes91.8Â 0.3Â 1.8Â 93.9Â Balances as of June 30, 2023:(374.7)10.3Â (8.5)(372.9)All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.The impact to loss before income taxes for amounts reclassified out of accumulated other comprehensive income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,Components of comprehensive income (loss)20242023202420232023Amortization of foreign other post-employment benefit items$0.4Â $0.3Â $0.3Â $0.2Â Net holding losses on equity securities and available-for-sale investments(0.5)(1.2)(0.3)(1.0)8. LOSS PER SHAREBio-Radâ€™s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.We compute net loss per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Loss is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the six months ended JuneÂ 30, 2024 and 2023.24Accordingly, basic loss per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted loss per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted loss per share calculation if the effect of including such securities would be anti-dilutive.The weighted average number of common shares outstanding used to calculate basic and diluted loss per share, and the anti-dilutive shares that are excluded from the diluted loss per share calculation are as follows (in thousands):Three Months EndedSix Months EndedJune 30,June 30,Â 20242023202420232023Basic weighted average shares outstanding28,395Â 29,355Â 28,457Â 29,475Â Effect of potentially dilutive stock options, restricted stock and performance stock awardsâ€”Â â€”Â â€”Â â€”Â Diluted weighted average common shares outstanding28,395Â 29,355Â 28,457Â 29,475Â Anti-dilutive shares413Â 234Â 398Â 237Â 9. OTHER INCOME, NETOther income, net includes the following components (in millions):Three Months EndedSix Months EndedJune 30,June 30,Â 20242023202420232023Interest and investment income(16.6)(16.5)(50.6)(66.8)Net realized losses on investments0.1Â 0.8Â 0.3Â 1.5Â Other income(1.6)(0.8)(2.4)(1.6)Other income, net(18.1)(16.5)(52.7)(66.9)10. INCOME TAXESOur effective income tax rate was 22.3% and 22.5% for the three months ended JuneÂ 30, 2024 and 2023, respectively. Our effective income tax rate was 22.4% and 22.8% for the six months ended JuneÂ 30, 2024 and 2023, respectively. The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of JuneÂ 30, 2024, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $22.1Â million for the period ended JuneÂ 30, 2024 compared to the year ended DecemberÂ 31, 2023.Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and 25forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.Our gross unrecognized tax benefits were $87.1Â million and $84.7Â million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.As of JuneÂ 30, 2024, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $2.9Â million. Substantially all such amounts will impact our effective income tax rate if recognized. 11. SEGMENT INFORMATIONInformation regarding net sales and operating profit (loss) for the three months ended JuneÂ 30, 2024 and 2023 are as follows (inÂ millions):LifeScienceClinicalDiagnosticsOtherOperationsNet

sales2024$250.5Â $387.9Â $0.1Â Â 2023$300.2Â $380.1Â $0.8Â Operating profit (loss)2024$19.1Â $82.6Â $(0.2)Â 2023$28.0Â $61.8Â $(0.2)Information regarding net sales and operating profit (loss) for the six months ended JuneÂ 30, 2024 and 2023 are as follows (inÂ millions):LifeScienceClinicalDiagnosticsOtherOperationsNet sales2024$492.2Â $756.6Â $0.5Â Â 2023$623.8Â $732.2Â $2.0Â Operating profit (loss)2024$10.9Â $135.7Â $(0.4)Â 2023$63.7Â $88.1Â $(0.3)Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.26The following reconciles total operating profit to consolidated loss before income taxes (inÂ millions):Three Months EndedSix Months EndedJune 30,June 30,Â 2024202320242023Operating profit$101.5Â $89.6Â $146.2Â $151.5Â Interest expense(12.3)(12.4)(24.5)(24.7)Foreign currency exchange gains, net1.7Â 1.3Â 3.7Â 3.6Â Losses from change in fair market value of equity securities and loan receivable(2,895.3)(1,595.4)(2,473.3)(1,612.9)Other income, net18.1Â 16.5Â 52.7Â 66.9Â Consolidated loss before income taxes$(2,786.3)$(1,500.4)$(2,295.2)$(1,415.6)12. LEGAL PROCEEDINGSWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 13. RESTRUCTURING COSTSIn February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of JuneÂ 30, 2024. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to JuneÂ 30, 2024, total restructuring-related expenses were $72.3 million.The following table summarizes the activity of our February 2021 plan accrued restructuring reserve (in millions):Life ScienceClinical DiagnosticsTotalBalances as of January 1, 2024:$0.2Â $12.8Â $13.0Â Adjustment to expense0.1Â 1.5Â 1.6Â Cash payments(0.1)(7.7)(7.8)Foreign currency adjustmentsâ€”Â (0.4)(0.4)Balances as of June 30, 2024:$0.2Â $6.2Â $6.4Â During the fiscal year ended December 31, 2023, and continuing into the six months ended JuneÂ 30, 2024, management approved a restructuring action to further streamline and improve operating performance. The restructuring plan was approved and implemented in phases. The plan is expected to be substantially completed by the end of 2024.27During the six months ended JuneÂ 30, 2024, a new phase of the restructuring plan was approved, resulting in restructuring expenses of $4.5 million, representing estimated termination benefits to employees. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits on previously approved phases. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. Excluded from the accrued restructuring plan reserves are $1.5 million of restructuring expense related to the facility closure costs impacting the Life Science segment. From February 2023 to JuneÂ 30, 2024, total restructuring-related expenses were $29.9 million, primarily representing estimated termination benefits to employees.The following table summarizes the activity of our 2023 accrued restructuring plan reserve (in millions):Life ScienceClinical DiagnosticsTotalBalances as of January 1, 2024:$3.0Â $7.8Â $10.8Â Charged to expense - employee termination benefits2.1Â 2.4Â 4.5Â Adjustment to expense(0.4)(1.5)(1.9)Cash payments(3.6)(6.5)(10.1)Foreign currency adjustmentsâ€”Â (0.3)(0.3)Balances as of June 30, 2024:$1.1Â $1.9Â $3.0Â Combined, the accrued restructuring plan reserve of $9.4 million as of JuneÂ 30, 2024 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended JuneÂ 30, 2024 were $0.6 million, $(1.4) million and $(0.6) million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the six months ended JuneÂ 30, 2024 were $1.1 million, $3.1 million and $1.5 million, respectively, in the condensed consolidated statements of income (loss).14. LEASESWe have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 15 years, which includes our determination to exercise renewal options.We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (â€œROUâ€) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.28The components of lease expense were as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,2024202320242023Operating lease cost$16.8Â $15.7Â $34.9Â $31.5Â Finance lease cost:Â Â Amortization of right-of-use assets$0.1Â $0.1Â $0.2Â $0.2Â Â Â Interest on lease liabilities0.2Â 0.2Â 0.4Â 0.4Â Â Â Â Â Â Â Â Â Â Total finance lease cost$0.3Â $0.3Â $0.6Â $0.6Â Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and six months ended JuneÂ 30, 2024 and 2023. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and six months ended JuneÂ 30, 2024 and 2023. Supplemental cash flow information related to leases was as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,2024202320242023Cash paid for amounts included in the measurement of lease liabilities:Â Â Operating cash flows from operating leases$10.5Â $9.8Â $21.4Â $19.8Â Â Â Operating cash flows from finance leases$0.2Â $0.2Â $0.4Â $0.4Â Â Â Financing cash flows from finance leases$0.1Â $0.1Â $0.2Â $0.2Â Right-of-use assets obtained in exchange for new lease obligations:Â Â Operating leases$3.7Â $10.1Â $11.2Â $12.3Â Supplemental balance sheet information related to leases was as follows (in millions):June 30, 2024December 31, 2023Operating LeasesÂ Â Operating lease right-of-use assets$181.5Â $194.7Â Â Â Current operating lease liabilities$41.5Â $40.4Â Â Â Operating lease liabilities151.0Â 165.5Â Â Â Â Â Â Total operating lease liabilities$192.5Â $205.9Â Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):29June 30, 2024December 31, 2023Finance LeasesÂ Â Property, plant and equipment, gross$11.8Â $11.9Â Â Â Less: accumulated depreciation and amortization(6.0)(5.9)Â Â Â Â Â Â Property, plant and equipment, net$5.8Â $6.0Â Â Â Current maturities of long-term debt and notes payable$0.5Â $0.5Â Â Â Long-term debt, net of current maturities9.4Â 9.6Â Â Â Â Â Â Â Total finance lease liabilities$9.9Â $10.1Â June 30, 2024December 31, 2023Weighted Average Remaining Lease TermÂ Â Operating leases - in years77Â Â Finance leases - in years1414Weighted Average Discount RateÂ Â Operating leases4.0Â %3.9Â %Â Â Finance leases6.5Â %6.4Â %Maturities of lease liabilities were as follows (in millions):Year Ending December 31,Operating LeasesFinance Leases2024 (excluding the six months ended JuneÂ 30, 2024)$22.7Â $0.6Â 202547.7Â 1.1Â 202636.2Â 1.1Â 202728.1Â 1.1Â 202821.7Â 1.1Â Thereafter62.4Â 10.8Â Â Â Â Total lease payments218.8Â 15.8Â Less imputed interest(26.3)(5.9)Â Â Â Â Total$192.5Â $9.9Â The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.As of JuneÂ 30, 2024, operating leases that have not commenced are not material. 15. SUBSEQUENT EVENTSOn July 29, 2024, Bio-Rad's board of directors authorized increasing the amount available under the company's 2023 Share Repurchase Program to allow the company to repurchase up to an additional $500Â million of the companyâ€™s outstanding common stock. Repurchases may be made at management's discretion from time to time on the open market, through trading plans in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through privately negotiated transactions. The 2023 Share Repurchase Program has no time limit and may be suspended for periods or discontinued at any time.30Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThis discussion should be read in conjunction with the information contained in both our consolidated financial statements for the year ended DecemberÂ 31, 2023 and the condensed consolidated financial statements for the three and six months ended JuneÂ 30, 2024.Overview. Â We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and health care specialists with products needed for clinical diagnostics.We sell more than 12,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components. As our customers require standardization for their experiments and test results, much of our revenues are recurring in nature. We rely on the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control social spending by many governments limits opportunities for growth. Approximately 41% of our year-to-date 2024 consolidated net sales are derived from the United States and approximately 59% are derived from international locations, with Europe being our largest international region. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.We are impacted by ongoing global economic conditions and our business continued to be negatively impacted by the ongoing challenges impacting the biopharma market and small biotech companies. We expect that these conditions will continue to impact our business in 2024. Results of OperationsThe following table shows cost of goods sold, gross profit, components of operating expense, losses from change in fair market value of equity securities and loan receivable, and net loss as a percentage of net sales:Three Months EndedSix Months EndedJune 30,June 30,Â 2024202320242023Net sales100.0Â %100.0Â %100.0Â %100.0Â %Cost of goods sold44.4Â 46.8Â 45.5Â 46.6Â Gross profit55.6Â 53.2Â 54.5Â 53.4Â Selling, general and administrative expense30.5Â 30.5Â 32.8Â 31.9Â Research and development expense9.2Â 9.5Â 10.0Â 10.3Â Losses from change in fair market value of equity securities and loan receivable453.5Â 234.2Â 198.0Â 118.8Â Net loss(339.2)(170.6)(142.6)(80.5)31Critical Accounting Policies and EstimatesAn accounting policy is deemed to be critical if it affects our financial statements

materially and requires subjective or complex judgements by management. An accounting estimate is deemed to be critical if it requires assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the three and six months ended JuneÂ 30, 2024 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on FormÂ 10-K for the fiscal year ended DecemberÂ 31, 2023. Â There have been no substantial changes in our significant accounting policies during the three and six months ended JuneÂ 30, 2024, compared with the significant accounting policies described in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Three Months Ended JuneÂ 30, 2024 Compared toThree Months Ended JuneÂ 30, 2023 Results of Operations -- Sales, Margins and ExpensesPercentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.Net sales (sales) for the second quarter of 2024 were $638.5 million compared to $681.1 million in the second quarter of 2023, a decrease of 6.3%. Â On a currency neutral basis, second quarter 2024 sales decreased by approximately 5.4% compared to the same period in 2023. The decrease in net sales was driven by lower sales in our Life Science segment.The Life Science segment sales for the second quarter of 2024 were $250.5 million, a decrease of 16.5% compared to the same period last year. Â On a currency neutral basis, sales decreased 15.9% compared to the second quarter in 2023, driven broadly by ongoing weakness in the biotech and biopharma end-markets. Currency neutral sales decreased across all regions.The Clinical Diagnostics segment sales for the second quarter of 2024 were $387.9 million, an increase of 2.1% compared to the same period last year. Â On a currency neutral basis, sales increased 3.2% compared to the second quarter in 2023. The currency neutral sales increase was primarily driven by an increased demand for quality controls and blood typing. Currency neutral sales increased across all regions.Consolidated gross margin was 55.6% for the second quarter of 2024 compared to 53.2% for the second quarter of 2023. Gross margin for the Life Science segment for the second quarter of 2024 increased by approximately 2.8 percentage points from the same period last year. The increase in gross margin was primarily driven by cost control measures and product mix, partially offset by lower sales volume and higher material costs. Gross margin for the Clinical Diagnostics segment for the second quarter of 2024 increased by approximately 2.3 percentage points from the same period last year. The increase in gross margin was primarily driven by cost control measures, higher sales volume, and product mix, partially offset by higher material costs.Selling, general and administrative (SG&A) expense for the second quarter of 2024 was $194.7Â million or 30.5% of sales, compared to $207.8Â million, or 30.5% of sales for the second quarter of 2023. The decrease in SG&A expense was primarily due to lower employee-related expenses, lower restructuring costs, and a reduction in discretionary spending.Research and development (R&D) expense for the second quarter of 2024 was $58.9 million or 9.2% of sales, compared to $65.0 million or 9.5% of sales in the second quarter of 2023. The decrease in R&D expense was primarily due to cost control and lower restructuring costs.32Results of Operations â€“ Non-operatingInterest expense was $12.3 million for both the second quarter of 2024 and 2023, which primarily consisted of interest expense related to the $1.2 billion Senior Notes.Foreign currency exchange gains, net consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Foreign currency exchange gains, net was $1.7Â million for the second quarter of 2024 compared to foreign currency exchange gains, net of $1.3Â million for the second quarter of 2023. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.Losses from change in fair market value of equity securities and loan receivable was $2.90Â billion and $1.60Â billion for the second quarter of 2024 and 2023, respectively. The change in the fair market value primarily resulted from the recognition of higher holding losses of $2.87 billion in the second quarter of 2024 compared to holding losses of $1.58 billion in the second quarter of 2023 on our position in Sartorius AG. In addition, higher losses from the change in fair value of our loan receivable of $22.7 million in the second quarter of 2024 compared to a loss of $18 million in the second quarter of 2023 contributed to the change.Other income, net for the second quarter of 2024 was $18.1Â million compared to $16.5Â million for the second quarter of 2023. The difference in Other income, net was primarily attributable to lower net realized loss on investments.Our effective income tax rate was 22.3% and 22.5% for the second quarter of 2024 and 2023, respectively. The effective tax rate reported in these periods was primarily affected by the accounting treatment of our equity securities. The difference in the rate is primarily driven by geographical mix of earnings. Six Months Ended JuneÂ 30, 2024 Compared toSix Months Ended JuneÂ 30, 2023 Results of Operations -- Sales, Margins and ExpensesNet sales (sales) for the first six months of 2024 were $1.25 billion compared to $1.36 billion in the first six months of 2023, a decrease of 8.0%. On a currency neutral basis, the first six months of 2024 sales decreased by approximately 7.5% compared to the same period in 2023. The decrease in net sales was driven by lower sales in our Life Science segment. The Life Science segment sales for the first six months of 2024 were $492.2 million, a decrease of 21.1% compared to the same period last year.Â On a currency neutral basis, sales decreased 20.8% compared to the first six months of 2023, driven broadly by ongoing weakness in the biotech and biopharma end-markets. Currency neutral sales decreased across all regions.The Clinical Diagnostics segment sales for the first six months of 2024 were $756.6 million, an increase of 3.3% compared to the same period last year. On a currency neutral basis, sales increased 4.0% compared to the first six months of 2023. The currency neutral sales increase was primarily driven by an increased demand for quality controls and blood typing. Currency neutral sales increased across all regions.Consolidated gross margins were 54.5% for the first six months of 2024 compared to 53.4% for the first six months of 2023. Gross margins for the Life Science segment for the first six months of 2024 decreased by approximately 0.4 percentage points from the same period last year. The decrease in gross margin was primarily driven by lower sales volume, higher material costs, partially offset by product mix and cost control measures. Gross margin for the Clinical Diagnostics segment for the first six months of 2024 increased by approximately 2.6 percentage points 33from the same period last year. The increase in gross margins was primarily driven by higher sales volume, favorable product mix, and cost control measures, partially offset by higher material costs.Selling, general and administrative (SG&A) expense for the first six months of 2024 was $409.6 million or 32.8% of sales, compared to $433.4 million or 31.9% of sales for the first six months of 2023. The decrease in SG&A expense was primarily due to lower employee-related expenses, lower restructuring costs, and a reduction in discretionary spending.Research and development (R&D) expense for the first six months of 2024 was $125.3 million or 10.0% of sales, compared to $140.0 million or 10.3% of sales in the first six months of 2023. The decrease in R&D expense was primarily due to cost control, lower restructuring costs, and lower employee-related expenses.Results of Operations â€“ Non-operatingInterest expense for the first six months of 2024 and 2023 was $24.5Â million and $24.7Â million, respectively, which primarily consisted of interest expense related to the $1.2 billion Senior Notes.Foreign currency exchange gains, net consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Â Foreign currency exchange gains, net was $3.7Â million for the first six months of 2024 compared to $3.6Â million for the first six months of 2023. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.Losses from change in fair market value of equity securities and loan receivable was $2.47Â billion and $1.61Â billion for the first six months of 2024 and 2023, respectively. The change in the fair market value primarily resulted from the recognition of higher holding losses of $2.47 billion in the first six months of 2024 compared to holding losses of $1.60 billion in the first six months of 2023 on our position in Sartorius AG. In addition, lower losses from the change in fair value of our loan receivable of $10.4 million in the first six months of 2024 compared to a loss of $24.0 million in the first six months of 2023 contributed to the change.Other income, net for the first six months of 2024 was $52.7Â million compared to $66.9Â million for the first six months of 2023. The difference in Other income, net was primarily attributable to lower dividend income from Sartorius AG.Our effective income tax rate was 22.4% and 22.8% for the first six months of 2024 and 2023, respectively. The effective tax rate reported in the first half of both 2024 and 2023 was primarily affected by the accounting treatment of our equity securities. The difference in the rate is primarily driven by geographical mix of earnings.Liquidity and Capital ResourcesBio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade. Â Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world. Â Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price. Â Gross margins are generally sufficient to exceed normal operating costs, andÂ funding for research and development of new products, as well as routine outflows for capital expenditures, interest and taxes. Â In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured Revolving Credit Agreement that we entered into in February 2024, and to a lesser extent international lines of credit. Â Borrowings under the Revolving Credit Agreement are available on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Revolving Credit Agreement as of JuneÂ 30, 2024, however, an immaterial amount was utilized for domestic standby letters of credit that reduced our borrowing availability. As of JuneÂ 30, 2024, our short-term investments include the net cash proceeds from the sale of Senior Notes of $1.186 billion. Interest is payable semiannually in arrears on May 15 and September 15 of each year. Management believes that this availability, 34together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and acquisitions of reasonable proportion to our existing total available capital.At JuneÂ 30, 2024, we had available $1.62 billion in cash, cash equivalents and short-term investments, of which approximately 18% was held in our foreign subsidiaries. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as acquisitions and borrowings. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).It is generallyÂ ourÂ intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws, and there are no substantial incremental costs.Â Cash Flows from OperationsNet cash provided by operations was $167.4Â million and $196.2Â million for the six months ended JuneÂ 30, 2024 and 2023, respectively. The decrease in operating cash flows was primarily due to lower cash received from customers, higher income tax paid and lower dividend proceeds, partially offset by lower cash paid to suppliers and employees and higher proceeds from foreign exchange contracts.Cash Flows from Investing ActivitiesNet cash used in investing activities was $74.0 million and $42.5 million for the six months ended JuneÂ 30, 2024 and 2023, respectively. The increase in cash used in investing activities was primarily due to the timing of our purchases, maturities and sales of marketable securities and investments, and higher capital expenditures.Cash Flows from Financing ActivitiesNet cash used in financing activities was $96.6 million and $198.4Â million for the six months ended JuneÂ 30, 2024, and 2023, respectively. The decrease in net cash used in financing activities was primarily attributable to lower payments for purchases of treasury stock.Treasury SharesDuring the second quarter of 2024, 21,017 shares of Class A treasury stock with an aggregate total cost of $7.4 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $2.7 million from share reissuance activity during the quarter.During the second quarter of 2024, we repurchased 346,226 shares of Class A common stock for $100 million under our 2023 Share Repurchase Program. We designated these repurchased shares as treasury stock. As of JuneÂ 30, 2024, $174.0 million remained available for repurchases under the 2023 Share Repurchase Program.On July 29, 2024, Bio-Rad's board of directors authorized increasing the amount available under the company's 2023 Share Repurchase Program to allow the company to repurchase up to an additional $500Â million of the companyâ€™s outstanding common stock.During the first quarter of 2024, 19,755 shares of Class A treasury stock with an aggregate total cost of $7.2 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $1.7 million from share reissuance activity during the quarter.35During the first quarter of 2024, we repurchased

14,250 shares of Class A common stock for $4.7 million under our 2023 Share Repurchase Program. We designated these repurchased shares as treasury stock.During the second quarter of 2023, 17,428 shares of Class A treasury stock with an aggregate total cost of $6.9 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $2.1 million from share reissuance activity during the quarter..During the second quarter of 2023, we repurchased 549,863 shares of Class A common stock for $207.4 million under our Share Repurchase Program. We designated these repurchased shares as treasury stock.During the first quarter of 2023, 12,853 shares of Class A treasury stock with an aggregate total cost of $5.3 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $0.7 million from share reissuance activity during the quarter.Recent Accounting Pronouncements AdoptedWe did not adopt any new accounting pronouncements during the three and six months ended JuneÂ 30, 2024.Item 3. Quantitative and Qualitative Disclosures about Market RiskDuring the six months ended JuneÂ 30, 2024, there have been no material changes from the disclosures about market risk provided in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Item 4. Controls and Procedures Disclosure Controls and ProceduresWe maintain â€œdisclosure controls and procedures,â€ as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.36Changes to Internal Control Over Financial ReportingWe identified no changes in internal control over financial reporting that occurred during our quarter ended JuneÂ 30, 2024 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting. PART II â€“ OTHER INFORMATIONItem 1. Legal ProceedingsWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.Item 1A. Risk FactorsIn evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this report. We believe that any of the following risks (some of which have occurred and any of which may occur in the future) could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock. We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry, the value of our equity holdings, or the trading price of our common stock. Please carefully consider the following discussion of significant factors, events and uncertainties that make an investment in our securities risky and provide important information for the understanding of the â€œforward-lookingâ€ statements discussed in this report. Additional or unforeseen effects from the global economic climate may give rise to or amplify many of these risks discussed below.Business, Economic, Legal and Industry Risks Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition. We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the six months ended JuneÂ 30, 2024 our foreign entities generated 59% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements, labor relations laws, tax laws, unfair competition regulations, import and trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the Foreign Corrupt Practices Act ("FCPA") and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions. Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. In addition, we operate in some countries in which the business environment is subject to a higher risk of corruption. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to 37ensure that our international selling operations comply with laws and regulations, and our global policies and procedures. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factors regarding the COVID-19 pandemic, government regulations, and global economic conditions below. The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively. The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts, or to source high-demand materials and components. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition. We may not be able to grow our business because of our failure to develop new or improved products. Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new products that integrate technological advances. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new products successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. Supply chain disruptions, including those caused by the COVID-19 pandemic, have caused some delays to our ability to develop and introduce new products. We have experienced product launch delays in the past and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition. Global economic and geopolitical conditions could adversely affect our operations. In recent years, we have been faced with challenging global economic conditions. U.S. and international markets have experienced inflationary pressures, and inflation rates in the U.S. and in other countries in which we operate have been at elevated levels. Our raw material costs have increased, and we are not always able to recover these increased costs from our customers. Russiaâ€™s invasion of Ukraine and sanctions against Russia also are causing disruptions to global economic conditions and are negatively impacting our business in Russia. The escalation, in October 2023, of the conflict between Israel and Hamas also has caused some disruptions to the global business environment (including impacting international logistics), the stability of the Middle East region and our business in that region. It is unknown how long any of these disruptions will continue and whether such disruptions will become more severe. In addition, we expect moderating economic growth and changing government policies in China will continue to affect our commercial opportunities in the country. The bank failures in March 2023 and the resulting volatility in the banking sector did cause and could continue to cause disruptions to global economic conditions and may impact access to cash and other financial resources by our customers and suppliers. A deterioration in the global economic environment may result in a decrease in demand for our products, increased competition, downward pressure on prices for our products and longer sales cycles. A weakening of macroeconomic conditions is also adversely affecting our suppliers, which could continue to result in interruptions in the supply of components and raw materials necessary for our products and raw material cost increases. Additionally, the United States and other countries, such as China and India, have imposed tariffs on certain goods. Further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. See also our risk 38factors regarding our international operations above and regarding the COVID-19 pandemic and government regulations below. Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition. Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and companies have a significant effect on the demand for our products. Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods. If funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected. A reduction or interruption in the supply of components and raw materials has adversely affected and could continue to adversely affect our manufacturing operations and related product sales. The manufacture of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply, but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. The COVID-19 pandemic created delays and shortages in the supply of components and raw materials. These shortages, along with challenges in ramping up new production facilities, caused a backlog of sales orders, some of which we consider to be significant, and delays in certain new product development activities. Some of the backlog of sales orders continued into 2023 but has now moderated to a more typical level. We have experienced raw material cost increases, some of which will likely continue. In addition, due to the regulatory environment in which we operate, we may need to cease use of certain essential components and materials and be unable to

establish acceptable replacement sources for such components or materials. When our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner is adversely affected, which affects our ability to sell our products. See also our risk factor regarding the COVID-19 pandemic below. Pandemics or disease outbreaks, such as the COVID-19 pandemic, have affected and could materially adversely affect our business, operations, financial condition and results of operations. The COVID-19 pandemic has had, and similar outbreaks could again have, an adverse effect on the United States and global economies, as well as on aspects of our business, operations and financial condition and those of third parties on whom we rely. If a new pandemic were to occur, we expect that parts of our business could again suffer negative impacts, and that our customers, suppliers, logistics providers, and the global economy could also be negatively impacted. Breaches of our information systems could have a material adverse effect on our business and results of operations. We have experienced and expect to continue to experience attempts by individuals and organizations to attack and penetrate our layered security controls, like the December 2019 Cyberattack that was previously discussed in Item 7 of our Annual Report for the period ended December 31, 2019. Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our web site. We also acquire and retain information about suppliers and employees in the normal course of business. Such information on our systems includes personally identifiable information and, in limited instances, protected health information. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. The Company is also subject to phishing and other fraud schemes including fraudulent vendor communications with requests for payments and fraudulent attempts to redirect payments to improper bank accounts, some of which have been successful. While the Company has adopted training and process 39changes to limit the success of such fraudulent activity, the Company will be unable to stop all such fraudulent activity which may lead to unrecoverable payments to criminal accounts. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not recognized until launched against a target, we may not be able to anticipate all of these techniques or to implement adequate preventive measures. Computer hackers have attempted to penetrate and will likely continue to attempt to penetrate our and our vendorsâ€™ information systems and, if successful, could misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers and suppliers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted, as they were in the December 2019 Cyberattack. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our information technology systems below. If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed. Our information technology (IT) systems are an integral part of our business, and a significant disruption of our IT systems (which increasingly include cloud-based systems provided by third party vendors) could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory, pay our vendors and collect accounts receivable. Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency. Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes. We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems or migrate to cloud-based systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our data security above and events beyond our control below. We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition. A significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. In addition, we hold investments and a loan receivable that are subject to foreign exchange fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition. Changes in the market value of our position in Sartorius AG materially impact our financial results.Changes in the market value of our position in Sartorius AG will continue to materially impact our consolidated statements of income (loss) and other financial statements. A decline in the market value of our position in Sartorius AG will result in decreases in net income due to write-downs in the value of the equity securities. An increase in the market value of our position in Sartorius AG will result in a favorable impact to net income independent of the actual operating performance of our business. Depending on the extent of the decline or of the 40increase in the market value of our position in Sartorius AG, these negative or positive impacts on us could continue to be material. Our share price may change significantly based upon changes in the market value of our position in Sartorius AG, independent of the actual performance of our business. Additionally, non-operating income for a period may be significantly impacted by any distribution of dividends by Sartorius AG, particularly when the dividends amount varies in comparison to prior year periods. The value of our position in Sartorius AG might cause us to be deemed an investment company under the Investment Company Act of 1940.As a result of the market value of our position in Sartorius AG, we might be deemed to be an â€œinvestment companyâ€ under Section 3(a)(1)(C) of the Investment Company Act of 1940, as amended (the â€œInvestment Company Actâ€) The Company does not believe it is an investment company primarily in reliance on Section 3(b)(1) of the Investment Company Act because we are â€œprimarily engagedâ€ in a business other than that of investing, reinvesting, owning, holding or trading in securities. Rather, we are primarily engaged in the development, manufacturing and marketing of products for the life science research and clinical diagnostic markets, and we believe that our historical development, our public representations of policy, the activity of our officers and directors, the nature of our present assets, the sources of our present income, and the public perception of the nature of our business all support the conclusion that we are an operating company and not an investment company. Although we have discussed this issue with the staff of the SEC and we are comfortable with our position, if it is determined later that the Company may not rely on Section 3(b)(1) or any other exemption under the Investment Company Act and the Company were deemed to be an unregistered investment company, such determination would have a material adverse effect on our business as we would need to register as an investment company and be subject to the regulations of the Investment Company Act which are designed to restrict and regulate mutual funds rather than operating companies. It could also call into question the validity of all contracts to which the Company is a party. If it appeared likely that we would be deemed to be an investment company, we may modify our position in Sartorius AG in order to avoid such determination.We may incur losses in future periods due to write-downs in the value of financial instruments.We have positions in a variety of financial instruments including asset backed securities and other similar investments. Financial markets are volatile and the markets for these securities can be illiquid. The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions, low trading volume of the securities, or other market considerations.As discussed further in the Notes to Condensed Consolidated Financial Statements, in Note 2. Fair Value Measurements, under the heading â€œLevel 3 Fair Value Investmentsâ€, we made a loan of 400 million Euros to Sartorius-Herbst Beteiligungen II GmbH in November 2021 that is secured by the pledge of certain trust interests which upon termination of the trust represent the right to receive Sartorius ordinary shares (the "Loan"). Prior to a termination of the trust, the trust interests, which are provided as collateral for the Loan, are not tradable on the capital markets and may, in case of an enforcement, have to be sold with a significant discount to the value of the underlying shares.We also have positions in equity securities, including our position in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments in equity securities has resulted and could continue to result in significant losses due to write-downs in the value of the equity securities. Also, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses. In addition, significant declines in the value of the Sartorius ordinary shares have reduced the value of the collateral for the Loan discussed in the previous paragraph. The value of the collateral may be insufficient to cover the repayment of the Loan if the decline in value continues, and Sartorius-Herbst Beteiligungen II GmbH will likely have no other assets from which to repay the Loan. Furthermore, the change in the market value of Sartorius ordinary shares will have an impact on the value appreciation rights acquired in connection with the Loan discussed in the previous paragraph. Recent and planned changes to our organizational structure could negatively impact our business.41 We made significant changes to our organizational structure over the past few years, including the reorganization of aspects of our European operations that was announced in February 2021 and additional restructurings approved in 2023 and 2024. These changes may have unintended consequences, such as distraction of our management and employees, labor unrest, business disruption, disruption of supply, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.Risks relating to intellectual property rights may negatively impact our business.We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. Unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages or royalties to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include: â€¢The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers and consolidation

among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage. In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets. â€¢Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates. To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations 42and financial condition could be adversely affected. If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDAâ€™s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Any delay in, or failure to receive or maintain, clearance or approval for our products or changes in regulation could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.The FDA has issued a final rule applicable to certain clinical diagnostic products referred to as laboratory developed tests. This change in the FDA approach could negatively impact our customers who use our Life Science products for laboratory developed tests.Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. The EU in-vitro Diagnostics Regulation (the â€œEU IVDRâ€) includes broad changes regarding in vitro diagnostic devices and medical devices. The EU IVDR required us to modify or re-register some products, and we expect will continue to result in additional costs for ongoing compliance. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. The United Kingdom's withdrawal from the EU is resulting in additional regulatory requirements associated with goods manufactured and sold in the United Kingdom and additional complexities and delays with respect to goods, raw materials and personnel moving between the United Kingdom and the EU. In addition, new government administrations may interpret existing regulations or practices differently. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. We may not be able to participate in certain public tenders in China, India and Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above.We are also subject to government regulation of the use and handling of a number of materials and controlled substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, 43suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or that we will be able to realize the anticipated benefits from the acquisitions.As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. The benefits of any acquisition or investment may prove to be less than anticipated and may not outweigh the costs reported in our financial statements. Completing any potential future acquisitions could cause significant diversion of our managementâ€™s time and resources. If we acquire or invest in new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur, as they have occurred in the past. Increased antitrust enforcement and greater government scrutiny of mergers in the healthcare sector may impact our ability to consummate acquisitions. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions or investments, and any such acquisitions or investments could adversely affect our business, results of operations and financial condition.Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. In responding to shortages, we may source components from alternative suppliers and distributors. Quality issues associated with components from these alternative sources may lead to product failures and associated costs notwithstanding our efforts to detect and remediate such quality issues. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.Lack of key personnel could hurt our business.Our products are very technical in nature, and we operate in a complex and competitive business environment. In general, only highly qualified and well-trained scientists, technicians and other specialized individuals have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills. In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business. Further, our ability to successfully execute organizational changes, including management transitions within our senior leadership team, are critical to our business success. If we are not able to fully integrate new executives, these changes could impact our ability to successfully execute our business strategy, which could adversely affect our business, results of operations and financial condition.We may have higher than anticipated tax liabilities.44We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Determination of our tax liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. In recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the â€œTax Actâ€) which made a number of substantial changes to how the United States imposes income tax on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies continue to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements.On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes an Alternative Minimum Tax based on the Adjusted Financial Statement Income of Applicable Corporations. We do not believe the Inflation Reduction Act will have a material impact on our income tax provision and cash taxes, but we continue to monitor U.S. Department of the Treasury guidance and regulations. The tax effect of our position in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow. In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Developmentâ€™s project on â€œBase Erosion and Profit Shiftingâ€ (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.On October 8, 2021, the OECD announced that 136 countries have agreed on a two-pillar framework that would dramatically alter the taxation of multinational enterprises and require that all profit be subject to a global minimum tax rate of 15%.

On December 15, 2022, the European Union formally adopted the Pillar Two Directive and EU member states were expected to enact the Pillar Two Directive by December 31, 2023. Other countries are taking similar actions. We do not believe Pillar 2 legislation will have a material impact on our income tax provision and cash taxes.Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, materials that we use in our products, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate. The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.45We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.In addition, there is an increasing focus by U.S. and international regulators, investors, customers, and other stakeholders on environmental, social and governance (ESG) matters. Complying with new laws or regulations concerning sustainability matters, climate related matters or other ESG matters will result in increased compliance costs and create additional non-compliance risks. Failure to adequately meet our stakeholderâ€™s expectations or comply with any such laws or regulations may result in loss of business, reputational damage, an inability to attract customers, an inability to attract and retain top talent, and a negative impact on our business, results of operations and financial condition.We also have announced certain sustainability goals, which require ongoing investment and operational changes. Our efforts may not achieve their intended outcomes, and we may not achieve such goals, which could negatively impact our reputation and business.Our current and future debt and related covenants may restrict our future operations.We have substantial debt and have the ability to incur additional debt. As of JuneÂ 30, 2024, we had approximately $1.2 billion of outstanding long-term indebtedness, primarily consisting of the 3.300% Senior Notes due in March 2027 and the 3.700% Senior Notes due in March 2032 as further discussed in Note 6 of the condensed consolidated financial statements. In addition, we have a revolving credit facility that provides for up to $200.0Â million in borrowing capacity, $0.2Â million of which was utilized for domestic standby letters of credit as of JuneÂ 30, 2024. Our incurrence of substantial amounts of debt may have important consequences. For instance, it could:â€¢make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;â€¢require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;â€¢increase our vulnerability to general adverse economic and industry conditions;â€¢limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;â€¢place us at a competitive disadvantage compared with some of our competitors that have less debt; andâ€¢limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes. Our existing credit facility, our Senior Notes and agreements we may enter in the future, contain or may contain covenants imposing restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. Existing covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; enter into transactions with affiliates; sell assets; and in the case of some of our subsidiaries, guarantee debt. Our existing credit facility also requires that we comply with a maximum consolidated leverage ratio test. Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest.46We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example: â€¢the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs; â€¢U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;â€¢the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals; â€¢the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and â€¢state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our managementâ€™s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.Risks Related to Being a Public CompanyOur failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements. Material weaknesses in our internal control over financial reporting have adversely affected us in the past and could affect us in the future and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause the trading price of our common stock to decline.47General Business Risks Natural disasters, climate related events, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.We have significant manufacturing and distribution facilities, including in the United States, France, Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years. These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, lack of fuel resources due to geo-political instability (such as Russiaâ€™s reduction in energy resources supplied to Western Europe), electricity outages, the inability to operate our production and distribution facilities due to power grid failures or lack of fuel, and strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business. Acts of terrorism, bioterrorism, violence or war (such as Russia's invasion of Ukraine and the conflict between Israel and Hamas), weather-related events, or public health issues such as the outbreak of a contagious disease like COVID-19 could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.Risks Related to Our Common Stock A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors. As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company. The Schwartz family may exercise its control over us according to interests that are different from other investorsâ€™ or debtorsâ€™ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.The forum selection provision in our bylaws could increase costs to bring a claim, discourage claims or limit the ability of the Companyâ€™s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Companyâ€™s directors, officers or other employees. Our bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Companyâ€™s stockholders, (iii) any action arising pursuant to any provision of the General Corporation Law of the State of Delaware, the Certificate of Incorporation or the Bylaws (in each case, as may be amended from time to time) or (iv) any action asserting a claim against the Company or any of its directors, officers or other employees governed by the internal affairs doctrine of the State of Delaware. This choice of forum provision may increase costs to bring a claim, discourage claims or limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Companyâ€™s directors, officers or other employees, which may discourage such lawsuits against the Company or the Companyâ€™s directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in the Companyâ€™s bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions.48Application of the choice of forum provision may be limited in some instances by applicable law. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the choice of forum provision will not apply to actions arising under the Exchange Act or the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and

regulations thereunder, subject to a limited exception for certain â€œcovered class actions.â€ There is uncertainty, particularly in light of current litigation, as to whether a court would enforce the choice of forum provision with respect to claims under the Securities Act. Our stockholders will not be deemed, by operation of the Companyâ€™s choice of forum provision, to have waived claims arising under the federal securities laws and the rules and regulations thereunder.Item 2. Unregistered Sales of Equity Securities and Use of ProceedsAs of JuneÂ 30, 2024, $174.0 million of stock remained available for repurchases under the Company's 2023 Share Repurchase Program, which was authorized by the Board of Directors in July 2023. Repurchases under the 2023 Share Repurchase Program may be made at management's discretion from time to time on the open market, through trading plans in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through privately negotiated transactions. The authorization has no expiration.The following table contains information on the shares of our common stock that we purchased or otherwise acquired during the three months ended JuneÂ 30, 2024.PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number (or Approximate Dollar Value) of Shares that May yet be Purchased Under the Plans or Programs (in millions)April 1 to April 30, 2024â€”$â€”Â â€”$274.0Â May 1 to May 31, 2024221,893$289.69Â 221,893$209.7Â June 1 to June 30, 2024124,333$287.29Â 124,333$174.0Â On July 29, 2024, Bio-Rad's board of directors authorized increasing the amount available under the company's 2023 Share Repurchase Program to allow the company to repurchase up to an additional $500Â million of the companyâ€™s outstanding common stock.Item 3. Defaults Upon Senior SecuritiesNone.Item 4. Mine Safety DisclosuresNot applicable.Item 5. Other Information49During the three months ended JuneÂ 30, 2024, no director or officer of the Company adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K.50Item 6. Exhibits(a) Â ExhibitsThe following documents are filed as part of this report:ExhibitNo.Â 31.1Chief Executive Officer Section 302 CertificationÂ Â 31.2Chief Financial Officer Section 302 CertificationÂ Â 32.1Chief Executive Officer Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Â Â 32.2Chief Financial Officer Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Â Â 101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.101.SCHInline XBRL Taxonomy Extension Schema Document101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document101.LABInline XBRL Taxonomy Extension Labels Linkbase Document101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document104.1The cover page Interactive Data File is formatted in Inline XBRL and is contained in Exhibits 101 51SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.BIO-RAD LABORATORIES, INC.(Registrant)Â Â Â Â Date:August 2, 2024Â /s/ Norman SchwartzÂ Â Â Norman Schwartz, Chairman of the Board, Â Â Â President and Chief Executive OfficerÂ Â Â Â Date:August 2, 2024Â /s/ Roop K. LakkarajuÂ Â Â Roop K. Lakkaraju, Executive Vice President,Â Â Â Chief Financial Officer52 EX-31.1 2 ex31163024.htm EX-31.1 DocumentExhibit 31.1Certification of Chief Executive Officer Required ByExchange Act Rules 13a-14(a) and 15d-14(a)I, Norman Schwartz, certify that:1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date:August 2, 2024Â /s/ Norman SchwartzÂ Â Â Norman Schwartz, Chairman of the Board,Â Â Â President and Chief Executive Officer EX-31.2 3 ex31263024.htm EX-31.2 DocumentExhibit 31.2Certification of Chief Financial Officer Required ByExchange Act Rules 13a-14(a) and 15d-14(a)I, Roop K. Lakkaraju, certify that:1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date:August 2, 2024Â /s/ Roop K. LakkarajuÂ Â Â Roop K. LakkarajuÂ Â Â Executive Vice President,Â Â Â Chief Financial Officer EX-32.1 4 ex32163024.htm EX-32.1 DocumentExhibit 32.1Certification of Periodic ReportI, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the â€œCompanyâ€), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended JuneÂ 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date:August 2, 2024Â /s/ Norman SchwartzÂ Â Â Norman Schwartz, Chairman of the Board, President andÂ Â Â Chief Executive OfficerThe foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document. EX-32.2 5 ex32263024.htm EX-32.2 DocumentExhibit 32.2Certification of Periodic ReportI, Roop K. Lakkaraju, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the â€œCompanyâ€), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended JuneÂ 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date:August 2, 2024Â /s/ Roop K. LakkarajuÂ Â Â Roop K. LakkarajuÂ Â Â Executive Vice President,Â Â Â Chief Financial OfficerThe foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document. EX-101.SCH 6 bio-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets Parenthetical link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Use of Estimates link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Goodwill and Other Purchased Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Other Income, Net link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Restructuring Costs link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 -

Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Other Income, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - 1. Basis of Presentation and Use of Estimates Capitalized Cloud Computing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - 1. Basis of Presentation and Use of Estimates (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Fair Value Measurements - Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Other Income, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bio-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bio-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bio-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from Sale of Debt Securities, Available-for-Sale Statistical Measurement [Domain] Statistical Measurement [Domain] European and American Reorganization European and American Reorganization [Member] European and American Reorganization Line of credit maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and Development Expense Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Debt Securities, Trading, and Equity Securities, FV-NI Debt Securities, Trading, and Equity Securities, FV-NI Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Increase in other long term liabilities Increase (Decrease) in Other Noncurrent Liabilities Corporate Debt Securities [Member] Corporate Debt Securities [Member] Payments for purchases of marketable securities and investments Payments to Acquire Investments Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restructuring Reserve, Foreign Currency Translation (Gain) Loss Restructuring Reserve, Foreign Currency Translation Gain (Loss) Deferred Revenue, Current Deferred Revenue, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Unrealized Gain (Loss) on Derivatives Foreign Currency Derivative, Unrealized Gain (Loss) Foreign Currency Derivative, Unrealized Gain (Loss) Accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Preferred Stock, Value, Issued Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Net income per share diluted attributable to Bio-Rad Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Treasury stock Treasury Stock, Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Treasury Stock, Shares Treasury Stock, Common, Shares Line of Credit Line of Credit [Member] Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Mature in more than five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Interest and investment income Investment Income, Interest and Dividend Noncompete Agreements [Member] Noncompete Agreements [Member] Total long-term debt, excluding leases and current maturities Long-Term Debt, Fair Value Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Net income attributable to Bio-Rad Net Income (Loss) Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Finance Lease, Liability, Payments, Due Year Two Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Mature in one to five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Revenue from external customers [Table] Accounting Standards Update and Change in Accounting Principle [Table] Leases Lessee, Operating Leases [Text Block] Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stockholders' equity: Equity, Attributable to Parent [Abstract] Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract] Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract] Cost of goods sold Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Common Class B [Member] Common Class B [Member] Common Class B [Member] Finance Leases and Other Debt Finance Leases and Other Debt [Member] Finance Leases and Other Debt [Member] Organization, Consolidation and Presentation of Financial Statements [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares Schedule of Weighted Average Number of Shares [Table Text Block] Life Science Life Science [Member] Life Sciences [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Name Forgone Recovery, Individual Name Goodwill, net Goodwill Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Sold marketable securities and investments Noncash or Part Noncash Acquisition, Accounts Receivable Acquired Investment Type [Axis] Investment Type [Axis] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Derivative, Notional Amount Derivative, Notional Amount Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Net unrealized holding gains (losses) on available-for-sale investments net of tax expense OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Foreign Government Debt [Member] Foreign Government Debt [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities Operating Lease, Liability, Noncurrent Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Foreign exchange (gains) losses, net Realized Gain (Loss), Foreign Currency Transaction, before Tax Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Payments for debt issuance costs Payments of Debt Issuance Costs Reclassification Out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount Share-Based Payment Arrangement, Shares Withheld for

Settlement of Equity Awards, Amount Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Europe [Member] Europe [Member] (Gains) losses from change in fair market value of equity securities and loan receivable Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss Investment ownership percentage Investment ownership percentage Investment ownership percentage Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Decrease (increase) in inventories Increase (Decrease) in Inventories Lease, Cost Lease, Cost [Table Text Block] Fair Value, Option, Changes in Fair Value, Gain (Loss) Fair Value, Option, Changes in Fair Value, Gain (Loss) Research and Development Expense Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Restructuring Reserve Restructuring Reserve Award Type Award Type [Axis] Anti-dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Goodwill [Line Items] Goodwill [Line Items] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash or Part Noncash Acquisition, Fixed Assets Acquired Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Current operating lease liabilities Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Accumulated Net Unrealized Investment Gain (Loss) AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Finance Lease, Interest Expense Finance Lease, Interest Expense Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, to be Paid, Year Three Other investments Long-Term Investments Net Carrying Amount Finite-Lived Intangible Assets, Net Recent Accounting Pronouncements Issued and to be Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Increase in income taxes payable Increase (Decrease) in Income Taxes Payable Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Beginning Cash, Cash Equivalents, and Restricted Cash Ending Cash, Cash Equivalents, and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, to be Paid, Year Two Subsequent Events, Policy Subsequent Events, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Other Long-Term Debt Other Long-Term Debt [Member] Other Long-Term Debt Restructuring Costs [Abstract] Restructuring Costs [Abstract] Operating Lease, Cost Operating Lease, Cost Common Stock, Shares, Issued Common Stock, Shares, Issued Gross profit Gross Profit Security Exchange Name Security Exchange Name Long-term debt Long-Term Debt Assets, Fair Value Disclosure Assets, Fair Value Disclosure Selling, general and administrative expense Selling, General and Administrative Expense Accumulated other comprehensive loss Beginning balance, Accumulated other comprehensive income Ending balance, Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Share-Based Payment Arrangement, Option [Member] Accumulated Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Interest Receivable, Current Interest Receivable, Current Stock Repurchased During Period, Excise Tax, Amount Stock Repurchased During Period, Excise Tax, Amount Stock Repurchased During Period, Excise Tax, Amount Finite-lived Intangible Assets Amortization Expense [Table Text Block] Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Common Class A [Member] Common Class A [Member] Common Class A [Member] Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Maximum Maximum [Member] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Document Type Document Type Goodwill, Acquired During Period Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Finance Lease, Liability, Payments, Due Year Three Finance Lease, Liability, to be Paid, Year Three Subsequent Event [Table] Subsequent Event [Table] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year One Income and other taxes payable Taxes Payable, Current Equity Securities, FV-NI, Unrealized Loss Equity Securities, FV-NI, Unrealized Loss Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accounts receivable allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Subsequent Event Subsequent Event [Member] Derivative [Table] Derivative [Table] Restricted Cash, Noncurrent Restricted Cash, Noncurrent Investment Owned, Balance, Shares Investment Owned, Balance, Shares Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Goodwill Goodwill, Gross Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Other current assets Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Amortization [Abstract] Amortization [Abstract] Entity Tax Identification Number Entity Tax Identification Number Goodwill, Foreign Currency Translation Gain (Loss) Goodwill, Foreign Currency Translation Gain (Loss) Equity Method Investments Equity Method Investments Inventory Inventory, Net Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Statistical Measurement [Axis] Statistical Measurement [Axis] Increase in other current assets Increase (Decrease) in Other Current Assets Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Other Investments [Member] Other Investments [Member] Financial Instrument [Axis] Financial Instrument [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Long-term Debt Long-Term Debt [Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Total Shareholder Return Amount Total Shareholder Return Amount Payments for purchases of treasury stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Segments [Domain] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Leases [Abstract] Other Long-term Debt Other Long-Term Debt Entity Address, Country Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Finance Lease, Liability, Payment, Due Finance Lease, Liability, to be Paid Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Operating Lease, Payments Operating Lease, Payments Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Basic earnings per share: Earnings Per Share, Basic [Abstract] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] PEO PEO [Member] Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Cash Equivalents [Member] Cash Equivalents [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Equity Securities Equity Securities, FV-NI, Current Reclassification Out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Other Long-Term Debt, Current Other Long-Term Debt, Current Debt Instrument [Axis] Debt Instrument [Axis] Goodwill, Period Increase (Decrease) Goodwill, Period Increase (Decrease) Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Operating Lease, Liability Operating Lease, Liability Finance Lease, Liability, Payments, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Debt Securities Debt Securities Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Accumulated Defined Benefit Plans Adjustment Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Clinical Diagnostics Clinical Diagnostics [Member] Clinical Diagnostics [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Restricted investment [Member] Restricted investment [Member] Restricted investment Common stock Common Stock, Value, Issued Derivative, Forward Interest Rate Derivative, Forward Interest Rate Mature in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade Names [Member] Trade Names [Member] Reduction in the carrying amount of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Legal Proceedings Legal Matters and Contingencies [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Finance Lease, Principal Payments Finance Lease, Principal Payments Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability All Individuals All Individuals

[Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Other Nonoperating Income (Expense) Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Goodwill and Other Purchased Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Unrecognized Tax Benefits Unrecognized Tax Benefits PEO Name PEO Name Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Asia Pacific [Member] Asia Pacific [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized US Government Sponsored Agencies [Member] US Treasury and Government [Member] Restricted Cash, Current Restricted Cash, Current Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Finance Lease, Liability, Payments, Due Year Four Finance Lease, Liability, to be Paid, Year Four Asset-backed Securities [Member] Asset-Backed Securities [Member] Accounts Receivable and Allowance for Credit Losses Accounts Receivable [Policy Text Block] Net cash provided by operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Line of Credit, Current Line of Credit, Current Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Warranty accrual, beginning of period Warranty accrual, end of period Standard and Extended Product Warranty Accrual Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders' equity Total Stockholders' Equity Total Stockholders' Equity Total stockholders' equity Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Commercial Paper [Member] Commercial Paper [Member] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Finance Lease, Right-Of-Use Asset, Accumulated Amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Ordinary voting shares [Member] Ordinary voting shares [Member] Ordinary voting shares Subsequent Events [Abstract] Subsequent Events [Abstract] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Other Income, Net Other Income and Other Expense Disclosure [Text Block] Equity Securities without Readily Determinable Fair Value, Amount Equity Securities without Readily Determinable Fair Value, Amount Restructuring Costs Restructuring and Related Activities Disclosure [Text Block] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Schedule of Product Warranty Liability [Table Text Block] Schedule of Product Warranty Liability [Table Text Block] Standard Product Warranty, Policy Standard Product Warranty, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Share-based Compensation Share-Based Payment Arrangement, Noncash Expense Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Common Stock [Member] Common Stock [Member] Individual: Individual [Axis] Finance Lease, Right-Of-Use Asset, before Accumulated Amortization Finance Lease, Right-of-Use Asset, before Accumulated Amortization Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Earnings Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Fair Value, Option, Loans Held as Assets [Abstract] Fair Value, Option, Loans Held as Assets [Abstract] Minimum Minimum [Member] Schedule of identifiable purchased intangible assets with definite lives Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Exercise Price Award Exercise Price Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total other comprehensive income (loss) net of tax Total other comprehensive income (loss) net of tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS: Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Common Stock, Voting Rights Common Stock, Voting Rights Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure Foreign exchange (gains) losses, net Foreign Currency Transaction Gain (Loss), before Tax Gain (Loss), Foreign Currency Transaction, before Tax Tax payments from net share settlement Payment, Tax Withholding, Share-Based Payment Arrangement US Treasury Securities US Treasury Securities [Member] Income tax payments, net Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Cash paid to suppliers and employees Payments to Suppliers and Employees Developed Technology Rights [Member] Developed Technology Rights [Member] Retained Earnings [Member] Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total liabilities and stockholders' equity Liabilities and Equity Amortized Cost Total Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Net income per share basic attributable to Bio-Rad Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment One-time Termination Benefits One-time Termination Benefits [Member] Finance Lease Obligations Finance Lease Obligations [Member] Finance Lease Obligations [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration In Process Research and Development [Member] In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Decrease in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Current maturities of long-term debt and notes payable Notes and Loans Payable, Current Restructuring Charges Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Preference shares [Member] Preference shares [Member] Preference shares Proceeds from forward foreign exchange contracts, net Payments for (proceeds from) derivative instruments, operating activities Payments for (proceeds from) derivative instruments, operating activities Termination Date Trading Arrangement Termination Date Depreciation and amortization Other Depreciation and Amortization Americas [Member] Americas [Member] Debt Securities, Available-for-sale Estimated Fair Value Debt Securities, Available-for-Sale Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Short-term Investments [Member] Short-Term Investments [Member] Finance Lease Cost Finance Lease Cost Finance Lease Cost Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Restricted investments Restricted Investments, Current All Trading Arrangements All Trading Arrangements [Member] Election Percentage for Board of Directors Election Percentage for Board of Directors Election Percentage for Board of Directors Mature in less than one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Lessee Supplemental Balance Sheet Information Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Additional paid-in capital Additional paid-in-capital Additional Paid in Capital Mature in more than five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Subsequent Event Type [Axis] Subsequent Event Type [Axis] Restructuring Plan [Axis] Restructuring Plan [Axis] 3.3%, Senior Notes due 2027 3.3%, Senior Notes due 2027 [Member] 3.3%, Senior Notes due 2027 Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Finance Lease, Liability Finance Lease, Liability Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Municipal Obligations (Member) Municipal obligations [Member] Municipal Bonds [Member] Insider Trading Arrangements [Line Items] Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Deferred Revenue Deferred Revenue Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other assets Other Assets Know How [Member] Know How [Member] Know how [Member] Other Segments Other Segments [Member] Entity Registrant Name Entity Registrant Name Other Nonoperating (Income) Other Nonoperating Income Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Cost of Sales Cost of Sales [Member] Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payments for Restructuring Payments for Restructuring Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Payments on long-term borrowings Repayments of Long-Term Debt Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Accounts Receivable, Allowance for Credit Loss [Table Text Block] Accounts Receivable, Allowance for Credit Loss [Table Text Block] Treasury Stock, Common Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Reclassification Out Of Accumulated Other Comprehensive Income Reclassification out of

Accumulated Other Comprehensive Income [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Purchase Price Finite-Lived Intangible Assets, Gross (Provision) benefit for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Accrued payroll and employee benefits Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3.7%, Senior Notes due 2032 3.7%, Senior Notes due 2032 [Member] 3.7%, Senior Notes due 2032 Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Net sales Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Money Market Funds [Member] Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Increase in deferred income taxes Increase (Decrease) in Deferred Income Taxes Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Licensing Agreements [Member] Licensing Agreements [Member] Interest paid, net Interest Paid, Excluding Capitalized Interest, Operating Activities Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Mature in less than one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Time Deposits [Member] Bank Time Deposits [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net of current maturities Long-Term Debt, Excluding Current Maturities Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Senior Notes, Noncurrent Senior Notes, Noncurrent Weighted average common shares - diluted Diluted weighted average common shares Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Cash received from customers Proceeds from Customers Noncash or Part Noncash Acquisition, Investments Acquired Noncash or Part Noncash Acquisition, Investments Acquired Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount European Reorganization European Reorganization [Member] European Reorganization Restricted Investments, at Fair Value Restricted Investments, at Fair Value Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Finance Lease, Liability, Payments, Due after Year Five Finance Lease, Liability, to be Paid, after Year Five Stock Issued During Period, Value, Treasury Stock Reissued Stock Issued During Period, Value, Treasury Stock Reissued Payments of operating lease liabilities Increase (Decrease) in Deferred Liabilities Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net Sartorius Loan value appreciation rights - Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net Subsequent Events Subsequent Events [Text Block] APIC, Share-based Payment Arrangement, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Increase for Cost Recognition UNITED STATES UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Segment Reconciling Items Segment Reconciling Items [Member] Finance Lease, Interest Payment on Liability Finance Lease, Interest Payment on Liability Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, to be Paid Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Short-term investments Short-Term Investments Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization Segment Information Segment Reporting Disclosure [Text Block] Foreign Government Obligations [Member] Debt Security, Government, Non-US [Member] Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Finance Lease, Liability, Current Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average common shares - basic Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Statement, Scenario [Axis] Statement, Scenario [Axis] Scenario [Axis] Entity Current Reporting Status Entity Current Reporting Status Marketable Securities, Unrealized (Gain) Loss Marketable Securities, Unrealized Gain (Loss) Marketable Security, Unrealized Gain (Loss) Segment profit (loss) Operating Income (Loss) Net realized (gain) loss on investments Realized Investment Gains (Losses) Facility Closing [Member] Facility Closing [Member] Allowance for Loan and Lease Losses, Write-offs Allowance for Loan and Lease Losses, Writeoff Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Lessee Supplemental Cash Flow Information Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Scenario [Domain] Scenario [Domain] Discussion of current derivative risk management Schedule of Derivative Instruments [Table Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer Relationships [Member] Customer Relationships [Member] Debt Securities, Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] Type of Restructuring [Domain] Type of Restructuring [Domain] Reclassification Out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] EX-101.PRE 10 bio-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Jul. 29, 2024 Document Transition Report false Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Shell Company false Â City Area Code (510) Â Document Quarterly Report true Â Entity Incorporation, State or Country Code DE Â Entity File Number 001-07928 Â Entity Registrant Name BIO-RAD LABORATORIES, INC. Â Entity Central Index Key 0000012208 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Large Accelerated Filer Â Document Type 10-Q Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â Entity Small Business false Â Entity Tax Identification Number 94-1381833 Â Entity Address, Address Line One 1000 Alfred Nobel Drive, Â Entity Address, City or Town Hercules, Â Entity Address, Country CA Â Entity Address, Postal Zip Code 94547 Â Local Phone Number 724-7000 Â Entity Emerging Growth Company false Â Common Class A [Member] Â Â Title of 12(b) Security Class A Common Stock, Par Value $0.0001 per share Â Trading Symbol BIO Â Security Exchange Name NYSE Â Entity Common Stock, Shares Outstanding Â 22,794,641 Common Class B [Member] Â Â Title of 12(b) Security Class B Common Stock, Par Value $0.0001 per share Â Trading Symbol BIO.B Â Security Exchange Name NYSE Â Entity Common Stock, Shares Outstanding Â 5,076,017 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing

requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 ASSETS: Â Â Cash and cash equivalents $ 406,913 $ 403,815 Short-term investments 1,209,193 1,203,327 Restricted investments 5,560 5,560 Accounts receivable, net 445,506 489,017 Inventory 803,693 780,517 Prepaid expenses 153,013 140,040 Other current assets 32,376 26,054 Total current assets 3,056,254 3,048,330 Property, plant and equipment, net 533,767 529,007 Operating lease right-of-use assets 181,473 194,730 Goodwill, net 412,116 413,569 Purchased intangibles, net 307,093 320,514 Other investments 5,099,554 7,698,070 Other assets 98,189 94,850 Assets 9,688,446 12,299,070 LIABILITIES AND STOCKHOLDERS' EQUITY: Â Â Accounts payable 126,693 144,625 Accrued payroll and employee benefits 132,460 139,929 Current maturities of long-term debt and notes payable 483 486 Income and other taxes payable 35,896 35,759 Current operating lease liabilities 41,513 40,379 Other current liabilities 149,916 161,621 Total current liabilities 486,961 522,799 Long-term debt, net of current maturities 1,199,724 1,199,052 Deferred income taxes 878,462 1,475,495 Operating lease liabilities 150,975 165,478 Other long-term liabilities 193,537 195,113 Total liabilities 2,909,659 3,557,937 Preferred Stock, Value, Issued 0 0 Stockholders' equity: Â Â Additional paid-in capital 474,729 449,075 Retained earnings 7,479,059 9,260,629 Accumulated other comprehensive loss (451,362) (336,038) Total stockholders' equity 6,778,787 8,741,133 Total liabilities and stockholders' equity 9,688,446 12,299,070 Common Class A [Member] Â Â Stockholders' equity: Â Â Common stock 2 2 Common Class B [Member] Â Â Stockholders' equity: Â Â Common stock 1 1 Treasury Stock, Common Â Â Stockholders' equity: Â Â Treasury stock $ (723,642) $ (632,536) X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX

210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesAndLoansPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2 + Details Name: us-gaap_RestrictedInvestmentsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph

(SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29,30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Accounts receivable allowance for doubtful accounts $ 14,043 $ 14,926 Preferred Stock, Par or Stated Value Per Share $ 0.0001 Â Preferred Stock, Shares Authorized 7,500,000 Â Preferred Stock, Shares Issued 0 Â Common Class A [Member] Â Â Common Stock, Shares, Issued 25,189,806 25,169,944 Common Stock, Shares, Outstanding 23,122,664 23,422,506 Common Class B [Member] Â Â Common Stock, Shares, Issued 5,076,066 5,095,930 Common Stock, Shares, Outstanding 5,076,066 5,095,930 Treasury Stock, Common Â Â Treasury Stock, Shares 2,067,142 1,747,438 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Â Â Â Â Net sales $ 638,476 $ 681,110 $ 1,249,296 $ 1,357,954 Cost of goods sold 283,357 318,627 568,211 633,054 Gross profit 355,119 362,483 681,085 724,900 Selling, general and administrative expense 194,719 207,824 409,602 433,377 Research and Development Expense 58,904 65,042 125,279 139,993 Segment profit (loss) 101,496 89,617 146,204 151,530 Interest expense 12,264 12,343 24,541 24,680 Foreign exchange (gains) losses, net (1,699) (1,253) (3,653) (3,600) Marketable Securities, Unrealized (Gain) Loss 2,895,355 1,595,442 2,473,178 1,612,967 Other Nonoperating Income (Expense) 18,143 16,488 52,659 66,919 Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (2,786,281) (1,500,427) (2,295,203) (1,415,598) (Provision) benefit for income taxes 620,795 338,176 513,633 322,309 Net income attributable to Bio-Rad $ (2,165,486) $ (1,162,251) $ (1,781,570) $ (1,093,289) Basic earnings per share: Â Â Â Â Net income per share basic attributable to Bio-Rad $ (76.26) $ (39.59) $ (62.61) $ (37.09) Weighted average common shares - basic 28,395 29,355 28,457 29,475 Diluted earnings per share: Â Â Â Â Net income per share diluted attributable to Bio-Rad $ (76.26) $ (39.59) $ (62.61) $ (37.09) Weighted average common shares - diluted 28,395 29,355 28,457 29,475 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph

1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 1 -SubTopic 20 -Topic 940 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting

Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated

Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Net Income (Loss) Attributable to Parent $ (2,165,486) $ (1,162,251) $ (1,781,570) $ (1,093,289) Foreign currency translation adjustments (24,694) 36,605 (116,362) 91,823 Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent (470) 237 884 271 Net unrealized holding gains (losses) on available-for-sale investments net of tax expense (227) (1,352) 154 1,866 Total other comprehensive income (loss) net of tax (25,391) 35,490 (115,324) 93,960 Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ (2,190,877) $ (1,126,761) $ (1,896,894) $ (999,329) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i-k) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive

income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Â Â Cash received from customers $ 1,265,453 $ 1,360,206 Cash paid to suppliers and employees (1,084,925) (1,173,285) Interest paid, net (23,301) (23,535) Income tax payments, net (52,172) (31,556) Investment proceeds and miscellaneous receipts, net 51,097 65,422 Proceeds from forward foreign exchange contracts, net 11,286 (1,067) Net cash provided by operating activities 167,438 196,185 Cash flows from investing activities: Â Â Capital expenditures (82,457) (70,364) Proceeds from dispositions of property, plant and equipment 92 39 Payments for purchases of marketable securities and investments (654,541) (341,522) Proceeds from maturities of marketable securities and investments 126,342 173,426 Proceeds from Sale of Debt Securities, Available-for-sale 536,544 195,932 Net cash used in investing activities (74,020) (42,489) Cash flows from financing activities: Â Â Payments on long-term borrowings (236) (231) Payments for debt issuance costs (617) 0 Proceeds from Issuance of Common Stock 10,188 9,521 Tax payments from net share settlement (152) (312) Payments for purchases of treasury stock (105,749) (207,407) Net cash used in financing activities (96,566) (198,429) Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6,494 670 Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3,346 (44,063) Beginning Cash, Cash Equivalents, and Restricted Cash 404,369 434,544 Cash and cash equivalents 406,913 390,001 Restricted Cash, Current 384 82 Restricted Cash, Noncurrent 418 398 Ending Cash, Cash Equivalents, and Restricted Cash $ 407,715 $ 390,481 X - DefinitionPayments for (proceeds from) derivative instruments, operating activities + ReferencesNo definition available. + Details Name: bio_Paymentsforproceedsfromderivativeinstrumentsoperatingactivities Namespace Prefix: bio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-

gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash payments to suppliers for goods and services provided and to employees for services provided. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsToSuppliersAndEmployees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash receipts from customers during the current period which are usually for sales of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCustomers Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from operating activities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromOtherOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands Total Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock, Common Retained Earnings [Member] AOCI Attributable to Parent Total Stockholders' Equity at Dec. 31, 2022 $ 9,615,252 $ 3 $ 447,454 $ (263,586) $ 9,898,203 $ (466,822) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Net Income (Loss) Attributable to Parent 68,962 0 0 0 68,962 0 Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 58,470 0 0 0 0 58,470 APIC, Share-based Payment Arrangement, Increase for Cost Recognition 16,608 0 16,608 0 0 0 Stock Issued During Period, Value, Treasury Stock Reissued 4,424 0 (660) 5,290 (206) 0 Total Stockholders' Equity at Mar. 31, 2023 9,763,716 3 463,402 (258,296) 9,966,959 (408,352) Total Stockholders' Equity at Dec. 31, 2022 9,615,252 3 447,454 (263,586) 9,898,203 (466,822) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Net Income (Loss) Attributable to Parent (1,093,289) Â Â Â Â Â Proceeds from Issuance of Common Stock (9,521) Â Â Â Â Â Total Stockholders' Equity at Jun. 30, 2023 8,446,893 3 473,872 (458,784) 8,804,664 (372,862) Total Stockholders' Equity at Mar. 31, 2023 9,763,716 3 463,402 (258,296) 9,966,959 (408,352) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Net Income (Loss) Attributable to Parent (1,162,251) 0 0 0 (1,162,251) 0 Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 35,490 0 0 0 0 35,490 APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12,559 0 12,559 0 0 0 Treasury Stock, Value, Acquired, Cost Method (207,407) 0 0 (207,407) 0 0 Stock Issued During Period, Value, Treasury Stock Reissued 4,786 0 (2,089) 6,919 (44) 0 Total Stockholders' Equity at Jun. 30, 2023 8,446,893 3 473,872 (458,784) 8,804,664 (372,862) Total Stockholders' Equity at Dec. 31, 2023 8,741,133 3 449,075 (632,536) 9,260,629 (336,038) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Net Income (Loss) Attributable to Parent 383,916 0 0 0 383,916 0 Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (89,933) 0 0 0 0 (89,933) APIC, Share-based

Payment Arrangement, Increase for Cost Recognition 15,262 0 15,262 0 0 0 Treasury Stock, Value, Acquired, Cost Method (4,702) 0 0 (4,702) 0 0 Stock Issued During Period, Value, Treasury Stock Reissued 5,505 0 (1,710) 7,215 0 0 Stock Repurchased During Period, Excise Tax, Amount (47) 0 0 (47) 0 0 Total Stockholders' Equity at Mar. 31, 2024 9,051,134 3 462,627 (630,070) 9,644,545 (425,971) Total Stockholders' Equity at Dec. 31, 2023 8,741,133 3 449,075 (632,536) 9,260,629 (336,038) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Net Income (Loss) Attributable to Parent (1,781,570) Â Â Â Â Â Proceeds from Issuance of Common Stock (10,188) Â Â Â Â Â Total Stockholders' Equity at Jun. 30, 2024 6,778,787 3 474,729 (723,642) 7,479,059 (451,362) Total Stockholders' Equity at Mar. 31, 2024 9,051,134 3 462,627 (630,070) 9,644,545 (425,971) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Net Income (Loss) Attributable to Parent (2,165,486) 0 0 0 (2,165,486) 0 Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (25,391) 0 0 0 0 (25,391) APIC, Share-based Payment Arrangement, Increase for Cost Recognition 14,999 0 14,999 0 0 0 Treasury Stock, Value, Acquired, Cost Method (100,000) 0 0 (100,000) 0 0 Stock Issued During Period, Value, Treasury Stock Reissued 4,683 0 (2,745) 7,428 0 0 Stock Repurchased During Period, Excise Tax, Amount (1,000) 0 0 (1,000) 0 0 Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount (152) 0 (152) 0 0 0 Total Stockholders' Equity at Jun. 30, 2024 $ 6,778,787 $ 3 $ 474,729 $ (723,642) $ 7,479,059 $ (451,362) X - DefinitionShare-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount + ReferencesNo definition available. + Details Name: bio_ShareBasedPaymentArrangementSharesWithheldForSettlementOfEquityAwardsAmount Namespace Prefix: bio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock Repurchased During Period, Excise Tax, Amount + ReferencesNo definition available. + Details Name: bio_StockRepurchasedDuringPeriodExciseTaxAmount Namespace Prefix: bio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Use of Estimates 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Basis of Presentation and Use of Estimates 1. BASIS OF PRESENTATION AND USE OF ESTIMATESBasis of PresentationIn this report, â€œBio-Rad,â€ â€œwe,â€ â€œus,â€ â€œthe Companyâ€ and â€œourâ€ refer to Bio-Rad Laboratories, Inc. and its subsidiaries. Â The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. Â All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. Â The condensed consolidated balance sheet at DecemberÂ 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. Â The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. Â To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.Use of EstimatesThe preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.Revenue RecognitionWe recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.We concluded that the use of the instrument (referred to as â€œlease elementsâ€) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and six months ended JuneÂ 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).Contract costs:We elected a practical expedient and expense costs to obtain

contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). Disaggregation of Revenue:The following table presents our revenues disaggregated by geographic region (in millions):Three Months EndedSix Months EndedJune 30,June 30,2024202320242023United States$254.2Â $287.7Â $507.1Â $584.7Â EMEA206.5Â 211.2Â 406.7Â 416.0Â APAC131.2Â 143.0Â 248.4Â 278.8Â Other (primarily Canada and Latin America)46.6Â 39.2Â 87.1Â 78.5Â Total net sales$638.5Â $681.1Â $1,249.3Â $1,358.0Â The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at JuneÂ 30, 2024 and DecemberÂ 31, 2023 was $67.4 million and $68.3 million, respectively. The short-term deferred revenue balance at JuneÂ 30, 2024 and DecemberÂ 31, 2023 was $52.0Â million and $51.1 million, respectively.We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the six months ended JuneÂ 30, 2024 and 2023 were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$8.4Â $10.6Â Provision for warranty3.4Â 4.2Â Actual warranty costs(4.0) (5.8)Balance at end of period$7.8Â $9.0Â Accounts Receivable and Allowance for Credit LossesWe record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.Changes in our allowance for credit losses were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$14.9Â $15.0Â Provision for expected credit losses2.0Â 1.2Â Write-offs charged against the allowance(2.9) (0.4)Balance at end of period$14.0Â $15.8Â Recent Accounting Pronouncements Issued and to be AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, â€œImprovements to Reportable Segment Disclosures.â€ The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker (CODM). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 3 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 2. FAIR VALUE MEASUREMENTSWe determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. Â The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. Â A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:â€¢Level 1: Quoted prices in active markets for identical instrumentsâ€¢Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)â€¢Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)Financial assets and liabilities carried at fair value and measured on a recurring basis as of JuneÂ 30, 2024 are classified in the hierarchy as follows (in millions):Level 1Level 2Level 3TotalFinancial assets carried at fair value:Cash equivalents:Time depositsâ€”Â 40.3Â â€”Â 40.3Â Money market funds76.3Â â€”Â â€”Â 76.3Â Total cash equivalents (a)76.3Â 40.3Â â€”Â 116.6Â Restricted investments (b)7.2Â â€”Â â€”Â 7.2Â Equity securities (c)4,825.6Â â€”Â â€”Â 4,825.6Â Loan under the fair value option (d)â€”Â â€”Â 305.6Â 305.6Â Available-for-sale investments:Corporate debt securitiesâ€”Â 545.0Â â€”Â 545.0Â U.S. government sponsored agenciesâ€”Â 246.1Â â€”Â 246.1Â Foreign government obligationsâ€”Â 2.6Â â€”Â 2.6Â Municipal obligationsâ€”Â 8.3Â â€”Â 8.3Â Asset-backed securitiesâ€”Â 333.6Â â€”Â 333.6Â Total available-for-sale investments (e)â€”Â 1,135.6Â â€”Â 1,135.6Â Forward foreign exchange contracts (f)â€”Â 1.5Â â€”Â 1.5Â Total financial assets carried at fair value$4,909.1Â $1,177.4Â $305.6Â $6,392.1Â Financial liabilities carried at fair value:Â Â Â Forward foreign exchange contracts (g)$â€”Â $1.2Â $â€”Â $1.2Â Contingent consideration (h)â€”Â â€”Â 17.9Â 17.9Â Total financial liabilities carried at fair value$â€”Â $1.2Â $17.9Â $19.1Â Financial assets and liabilities carried at fair value and measured on a recurring basis as of DecemberÂ 31, 2023 are classified in the hierarchy as follows (in millions):Level 1Level 2Level 3TotalFinancial assets carried at fair value:Cash equivalents:Commercial paper$â€”Â $12.5Â $â€”Â $12.5Â Time depositsâ€”Â 36.6Â â€”Â 36.6Â U.S. government sponsored agenciesâ€”Â 7.0Â â€”Â 7.0Â Money market funds28.0Â â€”Â â€”Â 28.0Â Total cash equivalents (a)28.0Â 56.1Â â€”Â 84.1Â Restricted investments (b)7.1Â â€”Â â€”Â 7.1Â Equity securities (c)7,399.3Â â€”Â â€”Â 7,399.3Â Loan under the fair value option (d)â€”Â â€”Â 325.7Â 325.7Â Available-for-sale investments:Corporate debt securitiesâ€”Â 531.6Â â€”Â 531.6Â U.S. government sponsored agenciesâ€”Â 255.9Â â€”Â 255.9Â Foreign government obligationsâ€”Â 12.7Â â€”Â 12.7Â Municipal obligationsâ€”Â 12.1Â â€”Â 12.1Â Asset-backed securitiesâ€”Â 323.7Â â€”Â 323.7Â Total available-for-sale investments (e)â€”Â 1,136.0Â â€”Â 1,136.0Â Forward foreign exchange contracts (f)â€”Â 4.1Â â€”Â 4.1Â Total financial assets carried at fair value$7,434.4Â $1,196.2Â $325.7Â $8,956.3Â Financial liabilities carried at fair value:Forward foreign exchange contracts (g)$â€”Â $11.7Â $â€”Â $11.7Â Contingent consideration (h)â€”Â â€”Â 17.5Â 17.5Â Total financial liabilities carried at fair value$â€”Â $11.7Â $17.5Â $29.2Â (a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Restricted investments$5.6Â $5.6Â Other investments1.6Â 1.5Â Â Â Â Â Total$7.2Â $7.1Â (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Short-term investments$73.6Â $67.2Â Other investments4,752.0Â 7,332.1Â Â Â Â Â Â Â Â Â Â Total$4,825.6Â $7,399.3Â (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million and $0.4 million in the condensed consolidated statements of income (loss) for the three and six months ended JuneÂ 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of JuneÂ 30, 2024.Level 1 Fair Value MeasurementsAs of JuneÂ 30, 2024, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the outstanding ordinary shares (excluding treasury shares) and 27% of the preference shares of Sartorius as of JuneÂ 30, 2024. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.The change in fair market value of our investment in Sartorius for the three and six months ended JuneÂ 30, 2024 were a loss of $2,874.4 million and a loss of $2,472.1 million, respectively, and are recorded in our condensed consolidated statements of income (loss).Level 2 Fair Value MeasurementsTo estimate the fair value of Level 2 debt securities as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions):Â June 30, 2024AmortizedCostUnrealizedGainsUnrealizedLossesEstimatedFairValueShort-term investments:Â Â Â Â Corporate debt securities$547.3Â $0.7Â (3.0)545.0Â Municipal obligations8.3Â â€”Â â€”Â 8.3Â Asset-backed securities335.1Â 0.5Â (2.0)333.6Â U.S. government sponsored agencies248.1Â 0.1Â (2.1)246.1Â Foreign government obligations2.6Â â€”Â â€”Â 2.6Â Â $1,141.4Â $1.3Â (7.1)1,135.6Â The following is a summary of the amortized cost and estimated fair value of our debt securities at JuneÂ 30, 2024 by contractual maturity date (in millions):AmortizedCostEstimated FairValueMature in less than one year$216.1Â $214.8Â Mature in one to five years730.8Â 727.4Â Mature in more than five years194.5Â 193.4Â Total$1,141.4Â $1,135.6Â Available-for-sale investments consist of the following (in millions):Â December 31,

2023AmortizedCostUnrealizedGainsUnrealizedLossesEstimatedFairValueShort-term investments:Â Â Â Â Corporate debt securities$534.1Â $0.8Â (3.3)531.6Â Municipal obligations12.2Â â€”Â (0.1)12.1Â Asset-backed securities325.7Â 0.7Â (2.7)323.7Â U.S. government sponsored agencies257.4Â 0.1Â (1.6)255.9Â Foreign government obligations12.8Â â€”Â (0.1)12.7Â Total$1,142.2Â $1.6Â (7.8)1,136.0Â As of JuneÂ 30, 2024, there were no significant continuous unrealized losses greater than 12 months.Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.At JuneÂ 30, 2024, we have concluded that all payments related to our available-for-sale investments are expected to be made inÂ full and on timeÂ atÂ par value. The diminution of value in the intervening period is due to market conditions such as illiquidityÂ and interest rate movementsÂ and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of JuneÂ 30, 2024.Included in Other current assets are $9.8 million and $11.9 million of interest receivable as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the six months ended JuneÂ 30, 2024, we have not written-off any uncollected interest receivable.As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. Â As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of JuneÂ 30, 2024 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange gains, net in the condensed consolidated statements of income (loss).The following is a summary of our forward foreign currency exchange contracts (in millions): Contracts to sell foreign currency:June 30, 2024December 31, 2023Notional value$698.1Â $873.5Â Unrealized gain/(loss)$0.5Â $(8.1)Contracts to purchase foreign currency:Â Notional value$59.1Â $133.6Â Unrealized (loss)/gain(0.1)0.5Â Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $6.5 million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023.Also included in Other investments in the condensed consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in Other income, net in our condensed consolidated statements of income (loss). The carrying value of these investments, net of impairments, was $33.9 million and $32.3 million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively.The carrying value and fair value of our long-term debt were as follows (in millions):June 30, 2024December 31, 2023Carrying ValueFair ValueCarrying ValueFair ValueSenior notes$1,190.3Â $1,093.3Â $1,189.5Â $1,102.5Â Other long-term debt9.4Â 9.4Â 9.6Â 9.6Â Total$1,199.7Â $1,102.7Â $1,199.1Â $1,112.1Â The fair value of our long-term debt was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.Level 3 Fair Value InvestmentsDuring the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of â‚¬400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (â€œLoanâ€). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (â€œTrustâ€) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in Losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the three months ended JuneÂ 30, 2024 was a loss of $22.7 million, which includes a $6.2 million gain from change in fair market value of the Loan and a $28.9 million loss from change in fair market value of the value appreciation right. The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the six months ended JuneÂ 30, 2024 was a loss of $10.4 million, which includes a $15.0 million gain from change in fair market value of the Loan and a $25.4 million loss from change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decrease in the value of the Sartorius ordinary shares. As of JuneÂ 30, 2024, the â‚¬400 million principal amount of the loan is still due on January 31, 2029. The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):December 31, 2023$325.7Â Net decrease in estimated fair market value of the loan included in Losses in fair market value of equity securities and loan receivable$(10.4)Foreign currency exchange losses, net$(9.7)June 30, 2024$305.6Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Goodwill and Other Purchased Intangible Assets 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and Other Purchased Intangible Assets 3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETSChanges to goodwill by segment are as follows (in millions):LifeScienceClinicalDiagnosticsTotalBalances as of January 1, 2024:Goodwill$333.3Â $415.5Â $748.8Â Accumulated impairment losses(41.8)(293.4)(335.2)Goodwill, net291.5Â 122.1Â 413.6Â Foreign currency adjustmentsâ€”Â (1.5)(1.5)Period change, netâ€”Â (1.5)(1.5)Balances as of June 30, 2024:Goodwill333.3Â 414.0Â 747.3Â Accumulated impairment losses(41.8)(293.4)(335.2)Goodwill, net$291.5Â $120.6Â $412.1Â Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):June 30, 2024Weighted-Average Remaining Amortization Period (years)PurchasePriceAccumulatedAmortizationNetCarryingAmountCustomer relationships/lists5.0$105.0Â (96.6)8.4Â Know how1.3166.3Â (160.7)5.6Â Developed product technology11.7216.8Â (136.8)80.0Â Licenses4.458.9Â (44.0)14.9Â Tradenames5.15.9Â (4.6)1.3Â Covenants not to compete1.86.3Â (5.1)1.2Â Â Â Â Â Â Â Total finite-lived intangible assets559.2Â (447.8)111.4Â In-process research and development195.7Â â€”Â 195.7Â Â Â Â Â Â Â Total purchased intangible assetsÂ $754.9Â (447.8)307.1Â Â December 31, 2023Weighted-Average Remaining Amortization Period (years)PurchasePriceAccumulatedAmortizationNetCarryingAmountCustomer relationships/lists5.2$108.7Â (98.9)9.8Â Know how1.8168.9Â (161.1)7.8Â Developed product technology12.0217.8Â (132.9)84.9Â Licenses4.959.2Â (42.4)16.8Â Tradenames5.66.1Â (4.7)1.4Â Covenants not to compete2.36.4Â (4.8)1.6Â Â Â Â Â Â Â Total finite-lived intangible assets567.1Â (444.8)122.3Â In-process research and development198.2Â â€”Â 198.2Â Â Â Â Â Â Â Total purchased intangible assetsÂ $765.3Â (444.8)320.5Â Amortization expense related to purchased intangible assets is as follows (in millions):Three Months EndedSix Months EndedÂ June 30,June 30,Â 2024202320242023Amortization expense$5.3Â $5.9Â $10.8Â $11.9Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory 6 Months Ended Jun. 30, 2024 Inventory Disclosure [Abstract] Â Inventory 4. INVENTORYFollowing are the components of Inventory at JuneÂ 30, 2024 and DecemberÂ 31, 2023 (in millions):June 30, 2024December 31, 2023Inventory:Â Â Raw materials$235.0Â $231.6Â Â Â Work in process255.0Â 246.0Â Â Â Finished goods 313.7Â 302.9Â Â Â Â Â Â Â Total Inventory$803.7Â $780.5Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Cash Flow Information 6 Months Ended Jun. 30, 2024 Supplemental Cash Flow Elements [Abstract] Â Supplemental Cash Flow Information 5. SUPPLEMENTAL CASH FLOW INFORMATIONThe reconciliation of net loss to net cash provided by operating activities is as follows (in millions):Six Months EndedJune 30,20242023Net loss$(1,781.6)$(1,093.3)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization73.5Â 71.4Â Reduction in the

carrying amount of right-of-use assets20.9Â 19.9Â Share-based compensation30.3Â 29.2Â Losses from change in fair market value of equity securities and loan receivable2,473.2Â 1,613.0Â Payments for operating lease liabilities(21.4)(19.8)Decrease in accounts receivable33.0Â 5.2Â Increase in inventories(31.2)(55.3)(Increase) decrease in other current assets(31.0)16.5Â Decrease in accounts payable and other current liabilities(26.6)(34.7)Increase in income taxes payable5.6Â 31.5Â Decrease in deferred income taxes(575.1)(391.6)Increase (decrease) in other long-term liabilities(0.2)6.3Â Other(2.0)(2.1)Net cash provided by operating activities$167.4Â $196.2Â Non-cash investing activities:Purchased property, plant and equipment$7.8Â $12.0Â Purchased marketable securities and investments$2.2Â $1.2Â Sold marketable securities and investments$9.8Â $â€”Â X - DefinitionThe entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//230/tableOfContent + Details Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Long-Term Debt 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Long-term Debt 6. LONG-TERM DEBTThe principal components of long-term debt are as follows (in millions):June 30,2024December 31,20233.3%, Senior Notes due 2027$400.0Â $400.0Â 3.7%, Senior Notes due 2032800.0Â 800.0Â Less unamortized discounts and debt issuance costs(9.7)(10.5)Long-term debt less unamortized discounts and debt issuance costs1,190.3Â 1,189.5Â Finance leases and other debt9.9Â 10.1Â Less current maturities(0.5)(0.5)Long-term debt$1,199.7Â $1,199.1Â On February 13, 2024, we entered into a new $200.0Â million unsecured revolving credit agreement ("Revolving Credit Agreement") with a group of financial institutions. The Revolving Credit Agreement replaced the Company's previous credit agreement, dated as of April 15, 2019. Borrowings under the Revolving Credit Agreement are on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. The Revolving Credit Agreement requires Bio-Rad to comply with certain financial ratios and other customary covenants and provisions. The Revolving Credit Agreement matures on February 13, 2029. As of JuneÂ 30, 2024, no borrowings were outstanding under the Revolving Credit Agreement, although available capacity was reduced by immaterial outstanding letters of credit. We were in compliance with the covenants for the Revolving Credit Agreement during the six months ended JuneÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accumulated Other Comprehensive Income (Loss) 6 Months Ended Jun. 30, 2024 Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Â Accumulated Other Comprehensive Income (Loss) 7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)Balances as of January 1, 2024:(334.1)(2.8)$0.9Â $(336.0)Other comprehensive income (loss), before reclassifications(116.6)0.3Â (0.1)(116.4)Amounts reclassified from Accumulated other comprehensive income (loss)â€”Â (0.3)0.3Â â€”Â Income tax effects0.3Â 0.8Â (0.1)1.0Â Other comprehensive income (loss), net of income taxes(116.3)0.8Â 0.1Â (115.4)Balances as of June 30, 2024:(450.4)(2.0)$1.0Â $(451.4)Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)Balances as of January 1, 2023:(466.5)10.0Â (10.3)(466.8)Other comprehensive income, before reclassifications92.1Â 0.5Â 1.4Â 94.0Â Amounts reclassified from Accumulated other comprehensive income (loss)â€”Â (0.2)1.0Â 0.8Â Income tax effects(0.3)â€”Â (0.6)(0.9)Other comprehensive income, net of income taxes91.8Â 0.3Â 1.8Â 93.9Â Balances as of June 30, 2023:(374.7)10.3Â (8.5)(372.9)All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.The impact to loss before income taxes for amounts reclassified out of accumulated other comprehensive income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,Components of comprehensive income (loss)20242023202420232Amortization of foreign other post-employment benefit items$0.4Â $0.3Â $0.3Â $0.2Â Net holding losses on equity securities and available-for-sale investments(0.5)(1.2)(0.3)(1.0) X - ReferencesNo definition available. + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//220/tableOfContent + Details Name: us-gaap_ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings Per Share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Earnings Per Share 8. LOSS PER SHAREBio-Radâ€™s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.We compute net loss per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Loss is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the six months ended JuneÂ 30, 2024 and 2023.Accordingly, basic loss per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted loss per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted loss per share calculation if the effect of including such securities would be anti-dilutive.The weighted average number of common shares outstanding used to calculate basic and diluted loss per share, and the anti-dilutive shares that are excluded from the diluted loss per share calculation are as follows (in thousands):Three Months EndedSix Months EndedJune 30,June 30,Â 20242023202420232Basic weighted average shares outstanding28,395Â 29,355Â 28,457Â 29,475Â Effect of potentially dilutive stock options, restricted stock and performance stock awardsâ€”Â â€”Â â€”Â â€”Â Diluted weighted average common shares outstanding28,395Â 29,355Â 28,457Â 29,475Â Anti-dilutive shares413Â 234Â 398Â 237Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Other Income, Net 6 Months Ended Jun. 30, 2024 Other Income and Expenses [Abstract] Â Other Income, Net 9. OTHER INCOME, NETOther income, net includes the following components (in millions):Three Months EndedSix Months EndedJune 30,June 30,Â 20242023202420232Interest and investment income(16.6)(16.5)(50.6)(66.8)Net realized losses on investments0.1Â 0.8Â 0.3Â 1.5Â Other income(1.6)(0.8)(2.4)(1.6)Other income, net(18.1)(16.5)(52.7)(66.9) X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 610 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//610/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 720 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//720/tableOfContent + Details Name: us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes 10. INCOME TAXESOur effective income tax rate was 22.3% and 22.5% for the three months ended JuneÂ 30, 2024 and 2023, respectively. Our effective income tax rate was 22.4% and 22.8% for the six months ended JuneÂ 30, 2024 and 2023, respectively. The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of JuneÂ 30, 2024, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $22.1Â million for the period ended JuneÂ 30, 2024 compared to the year ended DecemberÂ 31, 2023.Our

income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.Our gross unrecognized tax benefits were $87.1Â million and $84.7Â million as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.As of JuneÂ 30, 2024, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $2.9Â million. Substantially all such amounts will impact our effective income tax rate if recognized. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information 6 Months Ended Jun. 30, 2024 Segment Reporting [Abstract] Â Segment Information 11. SEGMENT INFORMATIONInformation regarding net sales and operating profit (loss) for the three months ended JuneÂ 30, 2024 and 2023 are as follows (inÂ millions):LifeScienceClinicalDiagnosticsOtherOperationsNet sales2024$250.5Â $387.9Â $0.1Â Â 2023$300.2Â $380.1Â $0.8Â Operating profit (loss)2024$19.1Â $82.6Â $(0.2)Â 2023$28.0Â $61.8Â $(0.2)Information regarding net sales and operating profit (loss) for the six months ended JuneÂ 30, 2024 and 2023 are as follows (inÂ millions):LifeScienceClinicalDiagnosticsOtherOperationsNet sales2024$492.2Â $756.6Â $0.5Â Â 2023$623.8Â $732.2Â $2.0Â Operating profit (loss)2024$10.9Â $135.7Â $(0.4)Â 2023$63.7Â $88.1Â $(0.3)Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.The following reconciles total operating profit to consolidated loss before income taxes (inÂ millions):Three Months EndedSix Months EndedJune 30,June 30,Â 20242023202420232023Operating profit$101.5Â $89.6Â $146.2Â $151.5Â Interest expense(12.3)(12.4)(24.5)(24.7)Foreign currency exchange gains, net1.7Â 1.3Â 3.7Â 3.6Â Losses from change in fair market value of equity securities and loan receivable(2,895.3)(1,595.4)(2,473.3)(1,612.9)Other income, net18.1Â 16.5Â 52.7Â 66.9Â Consolidated loss before income taxes$(2,786.3)$(1,500.4)$(2,295.2)$(1,415.6) X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContentReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Legal Proceedings 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Legal Proceedings 12. LEGAL PROCEEDINGSWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent + Details Name: us-gaap_LegalMattersAndContingenciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring Costs 6 Months Ended Jun. 30, 2024 Restructuring Costs [Abstract] Â Restructuring Costs 13. RESTRUCTURING COSTSIn February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of JuneÂ 30, 2024. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to JuneÂ 30, 2024, total restructuring-related expenses were $72.3 million.The following table summarizes the activity of our February 2021 plan accrued restructuring reserve (in millions):Life ScienceClinical DiagnosticsTotalBalances as of January 1, 2024:$0.2Â $12.8Â $13.0Â Adjustment to expense0.1Â 1.5Â 1.6Â Cash payments(0.1)(7.7)(7.8)Foreign currency adjustmentsâ€”Â (0.4)(0.4)Balances as of June 30, 2024:$0.2Â $6.2Â $6.4Â During the fiscal year ended December 31, 2023, and continuing into the six months ended JuneÂ 30, 2024, management approved a restructuring action to further streamline and improve operating performance. The restructuring plan was approved and implemented in phases. The plan is expected to be substantially completed by the end of 2024.During the six months ended JuneÂ 30, 2024, a new phase of the restructuring plan was approved, resulting in restructuring expenses of $4.5 million, representing estimated termination benefits to employees. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits on previously approved phases. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. Excluded from the accrued restructuring plan reserves are $1.5 million of restructuring expense related to the facility closure costs impacting the Life Science segment. From February 2023 to JuneÂ 30, 2024, total restructuring-related expenses were $29.9 million, primarily representing estimated termination benefits to employees.The following table summarizes the activity of our 2023 accrued restructuring plan reserve (in millions):Life ScienceClinical DiagnosticsTotalBalances as of January 1, 2024:$3.0Â $7.8Â $10.8Â Charged to expense - employee termination

benefits2.1Â 2.4Â 4.5Â Adjustment to expense(0.4)(1.5)(1.9)Cash payments(3.6)(6.5)(10.1)Foreign currency adjustmentsâ€”Â (0.3)(0.3)Balances as of June 30, 2024:$1.1Â $1.9Â $3.0Â Combined, the accrued restructuring plan reserve of $9.4 million as of JuneÂ 30, 2024 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended JuneÂ 30, 2024 were $0.6 million, $(1.4) million and $(0.6) million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the six months ended JuneÂ 30, 2024 were $1.1 million, $3.1 million and $1.5 million, respectively, in the condensed consolidated statements of income (loss). X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//420/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringCostsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Leases 14. LEASESWe have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 15 years, which includes our determination to exercise renewal options.We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (â€œROUâ€) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.The components of lease expense were as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,20242023Operating lease cost$16.8Â $15.7Â $34.9Â $31.5Â Finance lease cost:Â Â Amortization of right-of-use assets$0.1Â $0.1Â $0.2Â $0.2Â Â Â Interest on lease liabilities0.2Â 0.2Â 0.4Â 0.4Â Â Â Â Â Â Â Â Â Total finance lease cost$0.3Â $0.3Â $0.6Â $0.6Â Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and six months ended JuneÂ 30, 2024 and 2023. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and six months ended JuneÂ 30, 2024 and 2023. Supplemental cash flow information related to leases was as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,20242023Cash paid for amounts included in the measurement of lease liabilities:Â Â Operating cash flows from operating leases$10.5Â $9.8Â $21.4Â $19.8Â Â Â Operating cash flows from finance leases$0.2Â $0.2Â $0.4Â $0.4Â Â Â Financing cash flows from finance leases$0.1Â $0.1Â $0.2Â $0.2Â Right-of-use assets obtained in exchange for new lease obligations:Â Â Operating leases$3.7Â $10.1Â $11.2Â $12.3Â Supplemental balance sheet information related to leases was as follows (in millions):June 30, 2024December 31, 2023Operating LeasesÂ Â Operating lease right-of-use assets$181.5Â $194.7Â Â Â Current operating lease liabilities$41.5Â $40.4Â Â Â Operating lease liabilities151.0Â 165.5Â Â Â Â Â Â Â Total operating lease liabilities$192.5Â $205.9Â Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):June 30, 2024December 31, 2023Finance LeasesÂ Â Property, plant and equipment, gross$11.8Â $11.9Â Â Â Less: accumulated depreciation and amortization(6.0)(5.9)Â Â Â Â Â Â Property, plant and equipment, net$5.8Â $6.0Â Â Â Current maturities of long-term debt and notes payable$0.5Â $0.5Â Â Â Long-term debt, net of current maturities9.4Â 9.6Â Â Â Â Â Â Â Total finance lease liabilities$9.9Â $10.1Â June 30, 2024December 31, 2023Weighted Average Remaining Lease TermÂ Â Operating leases - in years77Â Â Finance leases - in years1414Weighted Average Discount RateÂ Â Operating leases4.0Â %3.9Â %Â Â Finance leases6.5Â %6.4Â %Maturities of lease liabilities were as follows (in millions):Year Ending December 31,Operating LeasesFinance Leases2024 (excluding the six months ended JuneÂ 30, 2024)$22.7Â $0.6Â 202547.7Â 1.1Â 202636.2Â 1.1Â 202728.1Â 1.1Â 202821.7Â 1.1Â Thereafter62.4Â 10.8Â Â Â Â Total lease payments218.8Â 15.8Â Less imputed interest(26.3)(5.9)Â Â Â Â Total$192.5Â $9.9Â The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.As of JuneÂ 30, 2024, operating leases that have not commenced are not material. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events 3 Months Ended Jun. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events 15. SUBSEQUENT EVENTSOn July 29, 2024, Bio-Rad's board of directors authorized increasing the amount available under the company's 2023 Share Repurchase Program to allow the company to repurchase up to an additional $500Â million of the companyâ€™s outstanding common stock. Repurchases may be made at management's discretion from time to time on the open market, through trading plans in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through privately negotiated transactions. The 2023 Share Repurchase Program has no time limit and may be suspended for periods or discontinued at any time. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Net Income (Loss) Attributable to Parent $ (2,165,486) $ 383,916 $ (1,162,251) $ 68,962 $ (1,781,570) $ (1,093,289) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX

210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and Use of Estimates (Policies) 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Basis of Presentation Basis of PresentationIn this report, â€œBio-Rad,â€ â€œwe,â€ â€œus,â€ â€œthe Companyâ€ and â€œourâ€ refer to Bio-Rad Laboratories, Inc. and its subsidiaries. Â The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. Â All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. Â The condensed consolidated balance sheet at DecemberÂ 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Subsequent Events, Policy We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. Â The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. Â To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates Use of EstimatesThe preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates. Revenue Recognition Revenue RecognitionWe recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have

historically been immaterial and we do not enter into direct finance leases.We concluded that the use of the instrument (referred to as â€œlease elementsâ€) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and six months ended JuneÂ 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).Contract costs:We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). Disaggregation of Revenue:The following table presents our revenues disaggregated by geographic region (in millions):Three Months EndedSix Months EndedJune 30,June 30,2024202320242023United States$254.2Â $287.7Â $507.1Â $584.7Â EMEA206.5Â 211.2Â 406.7Â 416.0Â APAC131.2Â 143.0Â 248.4Â 278.8Â Other (primarily Canada and Latin America)46.6Â 39.2Â 87.1Â 78.5Â Total net sales$638.5Â $681.1Â $1,249.3Â $1,358.0Â The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at JuneÂ 30, 2024 and DecemberÂ 31, 2023 was $67.4 million and $68.3 million, respectively. The short-term deferred revenue balance at JuneÂ 30, 2024 and DecemberÂ 31, 2023 was $52.0Â million and $51.1 million, respectively. Standard Product Warranty, Policy We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the six months ended JuneÂ 30, 2024 and 2023 were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$8.4Â $10.6Â Provision for warranty3.4Â 4.2Â Actual warranty costs(4.0)(5.8)Balance at end of period$7.8Â $9.0Â Accounts Receivable and Allowance for Credit Losses Accounts Receivable and Allowance for Credit LossesWe record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.Changes in our allowance for credit losses were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$14.9Â $15.0Â Provision for expected credit losses2.0Â 1.2Â Write-offs charged against the allowance(2.9)(0.4)Balance at end of period$14.0Â $15.8Â Recent Accounting Pronouncements Issued and to be Adopted Recent Accounting Pronouncements Issued and to be AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, â€œImprovements to Reportable Segment Disclosures.â€ The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker (CODM). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures. X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for standard warranties including the methodology for measuring the liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reporting subsequent events. + ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11BReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15 + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Revenue from External Customers by Geographic Areas [Table Text Block] The following table presents our revenues disaggregated by geographic region (in millions):Three Months EndedSix Months EndedJune 30,June

30,20242023202420232023United States$254.2Â $287.7Â $507.1Â $584.7Â EMEA206.5Â 211.2Â 406.7Â 416.0Â APAC131.2Â 143.0Â 248.4Â 278.8Â Other (primarily Canada and Latin America)46.6Â 39.2Â 87.1Â 78.5Â Total net sales$638.5Â $681.1Â $1,249.3Â $1,358.0Â Schedule of Product Warranty Liability [Table Text Block] Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the six months ended JuneÂ 30, 2024 and 2023 were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$8.4Â $10.6Â Provision for warranty3.4Â 4.2Â Actual warranty costs(4.0)(5.8)Balance at end of period$7.8Â $9.0Â Accounts Receivable, Allowance for Credit Loss [Table Text Block] Changes in our allowance for credit losses were as follows (in millions):Six Months EndedJune 30,20242023Balance at beginning of period$14.9Â $15.0Â Provision for expected credit losses2.0Â 1.2Â Write-offs charged against the allowance(2.9)(0.4)Balance at end of period$14.0Â $15.8Â X - DefinitionTabular disclosure of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph a -SubTopic 10 -Topic 280 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements, Recurring and Nonrecurring Financial assets and liabilities carried at fair value and measured on a recurring basis as of JuneÂ 30, 2024 are classified in the hierarchy as follows (in millions):Level 1Level 2Level 3TotalFinancial assets carried at fair value:Cash equivalents:Time depositsâ€”Â 40.3Â â€”Â 40.3Â Money market funds76.3Â â€”Â â€”Â 76.3Â Total cash equivalents (a)76.3Â 40.3Â â€”Â 116.6Â Restricted investments (b)7.2Â â€”Â â€”Â 7.2Â Equity securities (c)4,825.6Â â€”Â â€”Â 4,825.6Â Loan under the fair value option (d)â€”Â â€”Â 305.6Â 305.6Â Available-for-sale investments:Corporate debt securitiesâ€”Â 545.0Â â€”Â 545.0Â U.S. government sponsored agenciesâ€”Â 246.1Â â€”Â 246.1Â Foreign government obligationsâ€”Â 2.6Â â€”Â 2.6Â Municipal obligationsâ€”Â 8.3Â â€”Â 8.3Â Asset-backed securitiesâ€”Â 333.6Â â€”Â 333.6Â Total available-for-sale investments (e)â€”Â 1,135.6Â â€”Â 1,135.6Â Forward foreign exchange contracts (f)â€”Â 1.5Â â€”Â 1.5Â Total financial assets carried at fair value$4,909.1Â $1,177.4Â $305.6Â $6,392.1Â Financial liabilities carried at fair value:Â Â Â Forward foreign exchange contracts (g)$â€”Â $1.2Â $â€”Â $1.2Â Contingent consideration (h)â€”Â â€”Â 17.9Â 17.9Â Total financial liabilities carried at fair value$â€”Â $1.2Â $17.9Â $19.1Â Financial assets and liabilities carried at fair value and measured on a recurring basis as of DecemberÂ 31, 2023 are classified in the hierarchy as follows (in millions):Level 1Level 2Level 3TotalFinancial assets carried at fair value:Cash equivalents:Commercial paper$â€”Â $12.5Â $â€”Â $12.5Â Time depositsâ€”Â 36.6Â â€”Â 36.6Â U.S. government sponsored agenciesâ€”Â 7.0Â â€”Â 7.0Â Money market funds28.0Â â€”Â â€”Â 28.0Â Total cash equivalents (a)28.0Â 56.1Â â€”Â 84.1Â Restricted investments (b)7.1Â â€”Â â€”Â 7.1Â Equity securities (c)7,399.3Â â€”Â â€”Â 7,399.3Â Loan under the fair value option (d)â€”Â â€”Â 325.7Â 325.7Â Available-for-sale investments:Corporate debt securitiesâ€”Â 531.6Â â€”Â 531.6Â U.S. government sponsored agenciesâ€”Â 255.9Â â€”Â 255.9Â Foreign government obligationsâ€”Â 12.7Â â€”Â 12.7Â Municipal obligationsâ€”Â 12.1Â â€”Â 12.1Â Asset-backed securitiesâ€”Â 323.7Â â€”Â 323.7Â Total available-for-sale investments (e)â€”Â 1,136.0Â â€”Â 1,136.0Â Forward foreign exchange contracts (f)â€”Â 4.1Â â€”Â 4.1Â Total financial assets carried at fair value$7,434.4Â $1,196.2Â $325.7Â $8,956.3Â Financial liabilities carried at fair value:Forward foreign exchange contracts (g)$â€”Â $11.7Â $â€”Â $11.7Â Contingent consideration (h)â€”Â â€”Â 17.5Â 17.5Â Total financial liabilities carried at fair value$â€”Â $11.7Â $17.5Â $29.2Â (a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Restricted investments$5.6Â $5.6Â Other investments1.6Â 1.5Â Â Â Â Â Total$7.2Â $7.1Â (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Short-term investments$73.6Â $67.2Â Other investments4,752.0Â 7,332.1Â Â Â Â Â Â Â Â Â Â Total$4,825.6Â $7,399.3Â (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million and $0.4 million in the condensed consolidated statements of income (loss) for the three and six months ended JuneÂ 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of JuneÂ 30, 2024. Debt Securities, Available-for-sale Available-for-sale investments consist of the following (in millions):Â June 30, 2024AmortizedCostUnrealizedGainsUnrealizedLossesEstimatedFairValueShort-term investments:Â Â Â Â Corporate debt securities$547.3Â $0.7Â (3.0)545.0Â Municipal obligations8.3Â â€”Â â€”Â 8.3Â Asset-backed securities335.1Â 0.5Â (2.0)333.6Â U.S. government sponsored agencies248.1Â 0.1Â (2.1)246.1Â Foreign government obligations2.6Â â€”Â â€”Â 2.6Â Â $1,141.4Â $1.3Â (7.1)1,135.6Â Available-for-sale investments consist of the following (in millions):Â December 31, 2023AmortizedCostUnrealizedGainsUnrealizedLossesEstimatedFairValueShort-term investments:Â Â Â Â Corporate debt securities$534.1Â $0.8Â (3.3)531.6Â Municipal obligations12.2Â â€”Â (0.1)12.1Â Asset-backed securities325.7Â 0.7Â (2.7)323.7Â U.S. government sponsored agencies257.4Â 0.1Â (1.6)255.9Â Foreign government obligations12.8Â â€”Â (0.1)12.7Â Total$1,142.2Â $1.6Â (7.8)1,136.0Â Summary of amortized cost and estimated fair value of debt securities by contractual maturity date The following is a summary of the amortized cost and estimated fair value of our debt securities at JuneÂ 30, 2024 by contractual maturity date (in millions):AmortizedCostEstimated FairValueMature in less than one year$216.1Â $214.8Â Mature in one to five years730.8Â 727.4Â Mature in more than five years194.5Â 193.4Â Total$1,141.4Â $1,135.6Â Discussion of current derivative risk management The following is a summary of our forward foreign currency exchange contracts (in millions): Contracts to sell foreign currency:June 30, 2024December 31, 2023Notional value$698.1Â $873.5Â Unrealized gain/(loss)$0.5Â $(8.1)Contracts to purchase foreign currency:Â Notional value$59.1Â $133.6Â Unrealized (loss)/gain(0.1)0.5Â Schedule of Carrying Values and Estimated Fair Values of Debt Instruments The carrying value and fair value of our long-term debt were as follows (in millions):June 30, 2024December 31, 2023Carrying ValueFair ValueCarrying ValueFair ValueSenior notes$1,190.3Â $1,093.3Â $1,189.5Â $1,102.5Â Other long-term debt9.4Â 9.4Â 9.6Â 9.6Â Total$1,199.7Â $1,102.7Â $1,199.1Â $1,112.1Â Fair Value Measurement Inputs and Valuation Techniques The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):December 31, 2023$325.7Â Net decrease in estimated fair market value of the loan included in Losses in fair market value of equity securities and loan receivable$(10.4)Foreign currency exchange losses, net$(9.7)June 30, 2024$305.6Â X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2C -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2CReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 3:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments. + ReferencesNo definition available. + Details Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Goodwill and Other Purchased Intangible Assets (Tables) 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Changes to goodwill by segment Changes to goodwill by segment are as follows (in millions):LifeScienceClinicalDiagnosticsTotalBalances as of January 1, 2024:Goodwill$333.3Â $415.5Â $748.8Â Accumulated impairment losses(41.8)(293.4)(335.2)Goodwill, net291.5Â 122.1Â 413.6Â Foreign currency adjustmentsâ€”Â (1.5)(1.5)Period change, netâ€”Â (1.5)(1.5)Balances as of June 30, 2024:Goodwill333.3Â 414.0Â 747.3Â Accumulated impairment losses(41.8)(293.4)(335.2)Goodwill, net$291.5Â $120.6Â $412.1Â Schedule of identifiable purchased intangible assets with definite lives Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):June 30, 2024Weighted-Average Remaining Amortization Period (years)PurchasePriceAccumulatedAmortizationNetCarryingAmountCustomer relationships/lists5.0$105.0Â (96.6)8.4Â Know how1.3166.3Â (160.7)5.6Â Developed product technology11.7216.8Â (136.8)80.0Â Licenses4.458.9Â (44.0)14.9Â Tradenames5.15.9Â (4.6)1.3Â Covenants not to compete1.86.3Â (5.1)1.2Â Â Â Â Â Â Total finite-lived intangible assets559.2Â (447.8)111.4Â In-process research and development195.7Â â€”Â 195.7Â Â Â Â Â Â Total purchased intangible assetsÂ $754.9Â (447.8)307.1Â Â December 31, 2023Weighted-Average Remaining Amortization Period (years)PurchasePriceAccumulatedAmortizationNetCarryingAmountCustomer relationships/lists5.2$108.7Â (98.9)9.8Â Know how1.8168.9Â (161.1)7.8Â Developed product technology12.0217.8Â (132.9)84.9Â Licenses4.959.2Â (42.4)16.8Â Tradenames5.66.1Â (4.7)1.4Â Covenants not to compete2.36.4Â (4.8)1.6Â Â Â Â Â Â Total finite-lived intangible assets567.1Â (444.8)122.3Â In-process research and development198.2Â â€”Â 198.2Â Â Â Â Â Â Total purchased intangible assetsÂ $765.3Â (444.8)320.5Â Finite-lived Intangible Assets Amortization Expense [Table Text Block] Amortization expense related to purchased intangible assets is as follows (in millions):Three Months EndedSix Months EndedÂ June 30,June 30,Â 2024202320242023Amortization expense$5.3Â $5.9Â $10.8Â $11.9Â X - DefinitionTabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 + Details Name: us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Tables) 6 Months Ended Jun. 30, 2024 Inventory Disclosure [Abstract] Â Schedule of Inventory, Current Following are the components of Inventory at JuneÂ 30, 2024 and DecemberÂ 31, 2023 (in millions):June 30, 2024December 31, 2023Inventory:Â Â Raw materials$235.0Â $231.6Â Â Â Work in process255.0Â 246.0Â Â Â Finished goods 313.7Â 302.9Â Â Â Â Â Â Â Total Inventory$803.7Â $780.5Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Cash Flow Information (Tables) 6 Months Ended Jun. 30, 2024 Supplemental Cash Flow Elements [Abstract] Â Schedule of Cash Flow, Supplemental Disclosures The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):Six Months EndedJune 30,20242023Net loss$(1,781.6)$(1,093.3)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization73.5Â 71.4Â Reduction in the carrying amount of right-of-use assets20.9Â 19.9Â Share-based compensation30.3Â 29.2Â Losses from change in fair market value of equity securities and loan receivable2,473.2Â 1,613.0Â Payments for operating lease liabilities(21.4)(19.8)Decrease in accounts receivable33.0Â 5.2Â Increase in inventories(31.2)(55.3)(Increase) decrease in other current assets(31.0)16.5Â Decrease in accounts payable and other current liabilities(26.6)(34.7)Increase in income taxes payable5.6Â 31.5Â Decrease in deferred income

taxes(575.1)(391.6)Increase (decrease) in other long-term liabilities(0.2)6.3Â Other(2.0)(2.1)Net cash provided by operating activities$167.4Â $196.2Â Non-cash investing activities:Purchased property, plant and equipment$7.8Â $12.0Â Purchased marketable securities and investments$2.2Â $1.2Â Sold marketable securities and investments$9.8Â $â€”Â X - DefinitionTabular disclosure of supplemental cash flow information for the periods presented. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Long-Term Debt (Tables) 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Long-term Debt Instruments The principal components of long-term debt are as follows (in millions):June 30,2024December 31,20233.3%, Senior Notes due 2027$400.0Â $400.0Â 3.7%, Senior Notes due 2032800.0Â 800.0Â Less unamortized discounts and debt issuance costs(9.7)(10.5)Long-term debt less unamortized discounts and debt issuance costs1,190.3Â 1,189.5Â Finance leases and other debt9.9Â 10.1Â Less current maturities(0.5)(0.5)Long-term debt$1,199.7Â $1,199.1Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1AReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accumulated Other Comprehensive Income (Loss) (Tables) 6 Months Ended Jun. 30, 2024 Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Â Schedule of Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)Balances as of January 1, 2024:(334.1)(2.8)$0.9Â $(336.0)Other comprehensive income (loss), before reclassifications(116.6)0.3Â (0.1)(116.4)Amounts reclassified from Accumulated other comprehensive income (loss)â€”Â (0.3)0.3Â â€”Â Income tax effects0.3Â 0.8Â (0.1)1.0Â Other comprehensive income (loss), net of income taxes(116.3)0.8Â 0.1Â (115.4)Balances as of June 30, 2024:(450.4)(2.0)$1.0Â $(451.4)Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)Balances as of January 1, 2023:(466.5)10.0Â (10.3)(466.8)Other comprehensive income, before reclassifications92.1Â 0.5Â 1.4Â 94.0Â Amounts reclassified from Accumulated other comprehensive income (loss)â€”Â (0.2)1.0Â 0.8Â Income tax effects(0.3)â€”Â (0.6)(0.9)Other comprehensive income, net of income taxes91.8Â 0.3Â 1.8Â 93.9Â Balances as of June 30, 2023:(374.7)10.3Â (8.5)(372.9) Reclassification Out of Accumulated Other Comprehensive Income The impact to loss before income taxes for amounts reclassified out of accumulated other comprehensive income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,Components of comprehensive income (loss)2024202320242023Amortization of foreign other post-employment benefit items$0.4Â $0.3Â $0.3Â $0.2Â Net holding losses on equity securities and available-for-sale investments(0.5)(1.2)(0.3)(1.0) X - ReferencesNo definition available. + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss). + ReferencesNo definition available. + Details Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings Per Share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares The weighted average number of common shares outstanding used to calculate basic and diluted loss per share, and the anti-dilutive shares that are excluded from the diluted loss per share calculation are as follows (in thousands):Three Months EndedSix Months EndedJune 30,June 30,Â 2024202320242023Basic weighted average shares outstanding28,395Â 29,355Â 28,457Â 29,475Â Effect of potentially dilutive stock options, restricted stock and performance stock awardsâ€”Â â€”Â â€”Â â€”Â Diluted weighted average common shares outstanding28,395Â 29,355Â 28,457Â 29,475Â Anti-dilutive shares413Â 234Â 398Â 237Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Other Income, Net (Tables) 6 Months Ended Jun. 30, 2024 Other Income and Expenses [Abstract] Â Schedule of other income (expense), net Other income, net includes the following components (in millions):Three Months EndedSix Months EndedJune 30,June 30,Â 2024202320242023Interest and investment income(16.6)(16.5)(50.6)(66.8)Net realized losses on investments0.1Â 0.8Â 0.3Â 1.5Â Other income(1.6)(0.8)(2.4)(1.6)Other income, net(18.1)(16.5)(52.7)(66.9) X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Tables) 6 Months Ended Jun. 30, 2024 Segment Reporting [Abstract] Â Schedule of Segment Reporting Information, by Segment Information regarding net sales and operating profit (loss) for the three months ended JuneÂ 30, 2024 and 2023 are as follows (inÂ millions):LifeScienceClinicalDiagnosticsOtherOperationsNet sales2024$250.5Â $387.9Â $0.1Â Â 2023$300.2Â $380.1Â $0.8Â Operating profit (loss)2024$19.1Â $82.6Â $(0.2)Â 2023$28.0Â $61.8Â $(0.2)Information regarding net sales and operating profit (loss) for the six months ended JuneÂ 30, 2024 and 2023 are as follows (inÂ millions):LifeScienceClinicalDiagnosticsOtherOperationsNet sales2024$492.2Â $756.6Â $0.5Â Â 2023$623.8Â $732.2Â $2.0Â Operating profit (loss)2024$10.9Â $135.7Â $(0.4)Â 2023$63.7Â $88.1Â $(0.3) Reconciliation of Operating Profit (Loss) from Segments to Consolidated The following reconciles total operating profit to consolidated loss before income taxes (inÂ millions):Three Months EndedSix Months EndedJune 30,June 30,Â 2024202320242023Operating profit$101.5Â $89.6Â $146.2Â $151.5Â Interest expense(12.3)(12.4)(24.5)(24.7)Foreign currency exchange gains, net1.7Â 1.3Â 3.7Â 3.6Â Losses from change in fair market value of equity securities and loan receivable(2,895.3)(1,595.4)(2,473.3)(1,612.9)Other income, net18.1Â 16.5Â 52.7Â 66.9Â Consolidated loss before income taxes$(2,786.3)$(1,500.4)$(2,295.2)$(1,415.6) X - DefinitionTabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25Reference 3:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring Costs (Tables) 6 Months Ended Jun. 30, 2024 Restructuring Costs [Abstract] Â Restructuring and Related Costs The following table summarizes the activity of our February 2021 plan accrued restructuring reserve (in millions):Life ScienceClinical DiagnosticsTotalBalances as of January 1, 2024:$0.2Â $12.8Â $13.0Â Adjustment to expense0.1Â 1.5Â 1.6Â Cash payments(0.1)(7.7)(7.8)Foreign currency adjustmentsâ€”Â (0.4)(0.4)Balances as of June 30, 2024:$0.2Â $6.2Â $6.4Â The following table summarizes the activity of our 2023 accrued restructuring plan reserve (in millions):Life ScienceClinical DiagnosticsTotalBalances as of January 1, 2024:$3.0Â $7.8Â $10.8Â Charged to expense - employee termination benefits2.1Â 2.4Â 4.5Â Adjustment to expense(0.4)(1.5)(1.9)Cash payments(3.6)(6.5)(10.1)Foreign currency adjustmentsâ€”Â (0.3)(0.3)Balances as of June 30, 2024:$1.1Â $1.9Â $3.0Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringCostsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Lease, Cost The components of lease expense were as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,20242023Operating lease cost$16.8Â $15.7Â $34.9Â $31.5Â Finance lease cost:Â Â Amortization of right-of-use assets$0.1Â $0.1Â $0.2Â $0.2Â Â Â Interest on lease liabilities0.2Â 0.2Â 0.4Â 0.4Â Â Â Â Â Â Â Â Â Â Total finance lease cost$0.3Â $0.3Â $0.6Â $0.6Â Lessee Supplemental Cash Flow Information Supplemental cash flow information related to leases was as follows (in millions):Three Months EndedSix Months EndedJune 30,June 30,20242023Cash paid for amounts included in the measurement of lease liabilities:Â Â Operating cash flows from operating leases$10.5Â $9.8Â $21.4Â $19.8Â Â Â Operating cash flows from finance leases$0.2Â $0.2Â $0.4Â $0.4Â Â Â Financing cash flows from finance leases$0.1Â $0.1Â $0.2Â $0.2Â Right-of-use assets obtained in exchange for new lease obligations:Â Â Operating leases$3.7Â $10.1Â $11.2Â $12.3Â Lessee Supplemental Balance Sheet Information Supplemental balance sheet information related to leases was as follows (in millions):June 30, 2024December 31, 2023Operating LeasesÂ Â Operating lease right-of-use assets$181.5Â $194.7Â Â Â Current operating lease liabilities$41.5Â $40.4Â Â Â Operating lease liabilities151.0Â 165.5Â Â Â Â Â Â Total operating lease liabilities$192.5Â $205.9Â Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):June 30, 2024December 31, 2023Finance LeasesÂ Â Property, plant and equipment, gross$11.8Â $11.9Â Â Â Less: accumulated depreciation and amortization(6.0)(5.9)Â Â Â Â Â Â Property, plant and equipment, net$5.8Â $6.0Â Â Â Current maturities of long-term debt and notes payable$0.5Â $0.5Â Â Â Long-term debt, net of current maturities9.4Â 9.6Â Â Â Â Â Â Â Total finance lease liabilities$9.9Â $10.1Â June 30, 2024December 31, 2023Weighted Average Remaining Lease TermÂ Â Operating leases - in years77Â Â Finance leases - in years1414Weighted Average Discount RateÂ Â Operating leases4.0Â %3.9Â %Â Â Finance leases6.5Â %6.4Â % Maturities Of Lease Liabilities For Operating and Finance Leases Maturities of lease liabilities were as follows (in millions):Year Ending December 31,Operating LeasesFinance Leases2024 (excluding the six months ended JuneÂ 30, 2024)$22.7Â $0.6Â 202547.7Â 1.1Â 202636.2Â 1.1Â 202728.1Â 1.1Â 202821.7Â 1.1Â Thereafter62.4Â 10.8Â Â Â Â Total lease payments218.8Â 15.8Â Less imputed interest(26.3)(5.9)Â Â Â Â Total$192.5Â $9.9Â X - DefinitionLessee Supplemental Balance Sheet Information [Table Text Block] + ReferencesNo definition available. + Details Name: bio_LesseeSupplementalBalanceSheetInformationTableTextBlock Namespace Prefix: bio_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLessee Supplemental Cash Flow Information [Table Text Block] + ReferencesNo definition available. + Details Name: bio_LesseeSupplementalCashFlowInformationTableTextBlock Namespace Prefix: bio_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionMaturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] + ReferencesNo definition available. + Details Name: bio_MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock Namespace Prefix: bio_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 Dec. 31, 2023 Mar. 31, 2023 Dec. 31, 2022 Organization, Consolidation and Presentation of Financial Statements [Line Items] Â Â Â Â Â Â Â Net sales $ 638,476 $ 681,110 $ 1,249,296 $ 1,357,954 Â Â Â Â Cost of goods sold 283,357 318,627 568,211 633,054 Â Â Â Â Deferred Revenue 67,400 Â 67,400 Â Â $ 68,300 Â Â Retained earnings 7,479,059 Â 7,479,059 Â Â 9,260,629 Â Â Accumulated other comprehensive loss (451,362) Â (451,362) Â Â (336,038) Â Â Total stockholders' equity $ 6,778,787 8,446,893 $ 6,778,787 8,446,893 $ 9,051,134 8,741,133 $ 9,763,716 $ 9,615,252 Revenue Allocation Percent To Lease Elements 3.00% Â 3.00% Â Â Â Â Â Additional paid-in-capital $ 474,729 Â $ 474,729 Â Â 449,075 Â Â Selling, general and administrative expense 194,719 207,824 409,602 433,377 Â Â Â Â Research and Development Expense 58,904 65,042 125,279 139,993 Â Â Â Â Interest expense 12,264 12,343 24,541 24,680 Â Â Â Â Other Nonoperating Income (Expense) 18,143 16,488 52,659 66,919 Â Â Â Â Deferred Revenue, Current 52,000 Â 52,000 Â Â $ 51,100 Â Â Europe [Member] Â Â Â Â Â Â Â Organization, Consolidation and Presentation of Financial Statements [Line Items] Â Â Â Â Â Â Â Net sales 206,500 211,200 406,700 416,000 Â Â Â Â Asia Pacific [Member] Â Â Â Â Â Â Â Organization, Consolidation and Presentation of Financial Statements [Line Items] Â Â Â Â Â Â Â Net sales 131,200 143,000 248,400 278,800 Â Â Â Â UNITED STATES Â Â Â Â Â Â Â Organization, Consolidation and Presentation of Financial Statements [Line Items] Â Â Â Â Â Â Â Net sales 254,200 287,700 507,100 584,700 Â Â Â Â Americas [Member] Â Â Â Â Â Â Â Organization, Consolidation and Presentation of Financial Statements [Line Items] Â Â Â Â Â Â Â Net sales $ 46,600 $ 39,200 $ 87,100 $ 78,500 Â Â Â Â X - DefinitionRevenue Allocation Percent To Lease Elements + ReferencesNo definition available. + Details Name: bio_RevenueAllocationPercentToLeaseElements Namespace Prefix: bio_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph

(SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 43: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 44: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 45: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 46: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 47: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 48: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting

Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 66: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 67: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 68: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 69: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 70: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 71: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 72: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 73: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 74: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6Reference 75: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 76: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 77: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 78: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 79: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 80: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 81: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 82: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 83: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 84: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 85: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 86: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 87: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 88: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 89: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 90: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 91: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 92: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3 + Details Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_AsiaPacificMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_AmericasMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($) $ in Millions 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Warranty accrual, beginning of period $ 8.4 $ 10.6 Provision for warranty 3.4 4.2 Actual warranty costs (4.0) (5.8) Warranty accrual, end of period $ 7.8 $ 9.0 X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ProductWarrantyAccrual Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in the standard and extended product warranty accrual from warranties issued. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualWarrantiesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($) $ in Millions 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Â Â Accounts Receivable, Allowance for Credit Loss $ 14.0 $ 15.8 $ 14.9 $ 15.0 Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 2.0 1.2 Â Â Allowance for Loan and Lease Losses, Write-offs $ (2.9) $ (0.4) Â Â X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of loans and leases that have been written off from both loan receivables and allowance reserve for credit loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(3) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B + Details Name: us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 1. Basis of Presentation and Use of Estimates (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Revenue Allocation Percent To Lease Elements 3.00% 3.00% X - DefinitionRevenue Allocation Percent To Lease Elements + ReferencesNo definition available. + Details Name: bio_RevenueAllocationPercentToLeaseElements Namespace Prefix: bio_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-

gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Dec. 31, 2022 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Trading, and Equity Securities, FV-NI $ 305.6 $ 305.6 $ 325.7 Â Debt Securities, Available-for-sale [1] 1,135.6 1,135.6 Â Â Fair Value, Option, Changes in Fair Value, Gain (Loss) (22.7) (10.4) Â Â Foreign exchange (gains) losses, net Â (9.7) Â Â Fair Value, Option, Loans Held as Assets [Abstract] Â Â Â Â Debt Securities [2] Â Â Â $ 400.0 Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions (6.2) (15.0) Â Â Derivative, Forward Interest Rate Â Â Â 1.50% Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract] Â Â Â Â Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net $ 28.9 $ 25.4 Â Â Ordinary voting shares [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Investment ownership percentage 38.00% 38.00% Â Â Preference shares [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Investment ownership percentage 27.00% 27.00% Â Â Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Restricted Investments, at Fair Value [3] $ 7.2 $ 7.2 7.1 Â Equity Securities [4] 4,825.6 4,825.6 7,399.3 Â Debt Securities, Trading, and Equity Securities, FV-NI [2] 305.6 305.6 325.7 Â Debt Securities, Available-for-sale [1] 1,135.6 1,135.6 1,136.0 Â Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 1.5 1.5 4.1 Â Assets, Fair Value Disclosure 6,392.1 6,392.1 8,956.3 Â Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 1.2 1.2 11.7 Â Business Combination, Contingent Consideration, Liability [7] 17.9 17.9 17.5 Â Liabilities, Fair Value Disclosure 19.1 19.1 29.2 Â Fair Value, Recurring | Research and Development Expense Â Â Â Â Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract] Â Â Â Â Changes in fair value of contingent consideration 0.2 0.4 Â Â Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Restricted Investments, at Fair Value [3] 7.2 7.2 7.1 Â Equity Securities [4] 4,825.6 4,825.6 7,399.3 Â Debt Securities, Trading, and Equity Securities, FV-NI [2] 0.0 0.0 0.0 Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.0 0.0 0.0 Â Assets, Fair Value Disclosure 4,909.1 4,909.1 7,434.4 Â Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.0 0.0 0.0 Â Business Combination, Contingent Consideration, Liability [7] 0.0 0.0 0.0 Â Liabilities, Fair Value Disclosure 0.0 0.0 0.0 Â Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Restricted Investments, at Fair Value [3] 0.0 0.0 0.0 Â Equity Securities [4] 0.0 0.0 0.0 Â Debt Securities, Trading, and Equity Securities, FV-NI [2] 0.0 0.0 0.0 Â Debt Securities, Available-for-sale 1,135.6 1,135.6 1,136.0 [1] Â Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 1.5 1.5 4.1 Â Assets, Fair Value Disclosure 1,177.4 1,177.4 1,196.2 Â Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 1.2 1.2 11.7 Â Business Combination, Contingent Consideration, Liability [7] 0.0 0.0 0.0 Â Liabilities, Fair Value Disclosure 1.2 1.2 11.7 Â Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Restricted Investments, at Fair Value [3] 0.0 0.0 0.0 Â Equity Securities [4] 0.0 0.0 0.0 Â Debt Securities, Trading, and Equity Securities, FV-NI [2] 305.6 305.6 325.7 Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.0 0.0 0.0 Â Assets, Fair Value Disclosure 305.6 305.6 325.7 Â Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.0 0.0 0.0 Â Business Combination, Contingent Consideration, Liability [7] 17.9 17.9 17.5 Â Liabilities, Fair Value Disclosure 17.9 17.9 17.5 Â Commercial Paper [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 12.5 Â Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 0.0 Â Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 12.5 Â Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 0.0 Â Time Deposits [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 40.3 40.3 36.6 Â Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0 0.0 Â Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 40.3 40.3 36.6 Â Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0 0.0 Â Money Market Funds [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 76.3 76.3 28.0 Â Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 76.3 76.3 28.0 Â Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0 0.0 Â Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0 0.0 Â Cash Equivalents [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 116.6 116.6 84.1 Â Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 76.3 76.3 28.0 Â Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 40.3 40.3 56.1 Â Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0 0.0 Â US Treasury Securities | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 7.0 Â US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 7.0 Â US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 0.0 Â Foreign Government Debt [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Cash and Cash Equivalents, Fair Value Disclosure [8] Â Â 0.0 Â Municipal Obligations (Member) | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 8.3 8.3 12.1 Â Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 8.3 8.3 12.1 Â Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Foreign Government Obligations [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 2.6 2.6 12.7 Â Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 2.6 2.6 12.7 Â Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Corporate Debt Securities [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 545.0 545.0 531.6 Â Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 545.0 545.0 531.6 Â Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â US Government Sponsored Agencies [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 246.1 246.1 255.9 Â US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 246.1 246.1 255.9 Â US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Asset-backed Securities [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 333.6 333.6 323.7 Â Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 333.6 333.6 323.7 Â Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 0.0 0.0 0.0 Â Short-term Investments [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Equity Securities [4] 73.6 73.6 67.2 Â Debt Securities, Available-for-sale [1] 1,135.6 1,135.6 1,136.0 Â Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 8.3 8.3 12.1 Â Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on

Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 2.6 2.6 12.7 Â Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 545.0 545.0 531.6 Â Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 246.1 246.1 255.9 Â Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Debt Securities, Available-for-sale [1] 333.6 333.6 323.7 Â Other Investments [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Restricted Investments, at Fair Value [3] 1.6 1.6 1.5 Â Equity Securities [4] 4,752.0 4,752.0 7,332.1 Â Restricted investment [Member] | Fair Value, Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Restricted Investments, at Fair Value [3] $ 5.6 $ 5.6 $ 5.6 Â [1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. [2] The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. [3] Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Restricted investments$5.6Â $5.6Â Other investments1.6Â 1.5Â Â Â Â Â Â Total$7.2Â $7.1Â [4] Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):June 30, 2024December 31, 2023Short-term investments$73.6Â $67.2Â Other investments4,752.0Â 7,332.1Â Â Â Â Â Â Â Â Â Â Total$4,825.6Â $7,399.3Â [5] Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. [6] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. [7] Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million and $0.4 million in the condensed consolidated statements of income (loss) for the three and six months ended JuneÂ 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of JuneÂ 30, 2024. [8] Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. X - DefinitionInvestment ownership percentage + ReferencesNo definition available. + Details Name: bio_Investmentownershippercentage Namespace Prefix: bio_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionSartorius Loan value appreciation rights - Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net + ReferencesNo definition available. + Details Name: bio_ValueAppreciationRightsUnrecognizedUnrealizedAppreciationDepreciationNet Namespace Prefix: bio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer. + ReferencesNo definition available. + Details Name: us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1 + Details Name: us-gaap_DebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionStated rate on an interest rate forward or futures contract. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeForwardInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30 + Details Name: us-gaap_FairValueOptionChangesInFairValueGainLoss1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueOptionLoansHeldAsAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesNo definition available. + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into. + ReferencesNo definition available. + Details Name: us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossRealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentOwnedUnrealizedAppreciationDepreciationNetAbstract Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe aggregate value of all restricted investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2 + Details Name: us-gaap_RestrictedInvestmentsAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_TradingSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_InvestmentTypeAxis=bio_OrdinaryVotingSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=bio_PreferenceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_ForeignGovernmentDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=bio_RestrictedInvestmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Forward foreign exchange contract to sell foreign currency [Member] Â Â Derivatives, Fair Value [Line Items] Â Â Derivative, Notional Amount $ 698.1 $ 873.5 Unrealized Gain (Loss) on Derivatives 0.5 (8.1) Forward foreign exchange contract to purchase foreign currency [Member] Â Â Derivatives, Fair Value [Line Items] Â Â Derivative, Notional Amount 59.1 133.6 Unrealized Gain (Loss) on Derivatives $ (0.1) $ 0.5 X - DefinitionForeign Currency Derivative, Unrealized Gain (Loss) + ReferencesNo definition available. + Details Name: bio_ForeignCurrencyDerivativeUnrealizedGainLoss Namespace Prefix: bio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=bio_ForwardforeignexchangecontracttosellforeigncurrencyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] Â Â Â Amortized Cost [1] $ 1,141.4 $ 1,141.4 Â Debt Securities, Available-for-sale [1] 1,135.6 1,135.6 Â Equity Securities, FV-NI, Unrealized Loss (2,874.4) (2,472.1) Â Equity Securities without Readily Determinable Fair Value, Amount 6.5 6.5 $ 6.5 Equity Method Investments 33.9 33.9 32.3 Fair Value, Recurring Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Debt Securities, Available-for-sale [1] 1,135.6 1,135.6 1,136.0 Fair Value, Recurring | Corporate Debt Securities [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Debt Securities, Available-for-sale [1] 545.0 545.0 531.6 Fair Value, Recurring | Municipal obligations [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Debt Securities, Available-for-sale [1] 8.3 8.3 12.1 Fair Value, Recurring | US Government Sponsored Agencies [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Debt Securities, Available-for-sale [1] 246.1 246.1 255.9 Fair Value, Recurring | Foreign Government Obligations [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Debt Securities, Available-for-sale [1] 2.6 2.6 12.7 Fair Value, Recurring | Asset-backed Securities [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Debt Securities, Available-for-sale [1] 333.6 333.6 323.7 Fair Value, Recurring | Short-term Investments [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Amortized Cost [1] 1,141.4 1,141.4 1,142.2 Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 1.3 1.3 1.6 Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (7.1) (7.1) (7.8) Debt Securities, Available-for-sale [1] 1,135.6 1,135.6 1,136.0 Fair Value, Recurring | Short-term Investments [Member] | Corporate Debt Securities [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Amortized Cost [1] 547.3 547.3 534.1 Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.7 0.7 0.8 Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (3.0) (3.0) (3.3) Debt Securities, Available-for-sale [1] 545.0 545.0 531.6 Fair Value, Recurring | Short-term Investments [Member] | Municipal obligations [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Amortized Cost [1] 8.3 8.3 12.2 Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.0 0.0 0.0 Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] 0.0 0.0 (0.1) Debt Securities, Available-for-sale [1] 8.3 8.3 12.1 Fair Value, Recurring | Short-term Investments [Member] | US Government Sponsored Agencies [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Amortized Cost [1] 248.1 248.1 257.4 Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.1 0.1 0.1 Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (2.1) (2.1) (1.6) Debt Securities, Available-for-sale [1] 246.1 246.1 255.9 Fair Value, Recurring | Short-term Investments [Member] | Foreign Government Obligations [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Amortized Cost [1] 2.6 2.6 12.8 Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.0 0.0 0.0 Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] 0.0 0.0 (0.1) Debt Securities, Available-for-sale [1] 2.6 2.6 12.7 Fair Value, Recurring | Short-term Investments [Member] | Asset-backed Securities [Member] Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Amortized Cost [1] 335.1 335.1 325.7 Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.5 0.5 0.7 Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (2.0) (2.0) (2.7) Debt Securities, Available-for-sale [1] $ 333.6 $ 333.6 $ 323.7 [1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-

1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions Jun. 30, 2024 USD ($) [1] Fair Value Disclosures [Abstract] Â Mature in less than one year $ 216.1 Mature in one to five years 730.8 Mature in more than five years 194.5 Total Amortized Cost 1,141.4 Mature in less than one year 214.8 Mature in one to five years 727.4 Mature in more than five years 193.4 Estimated Fair Value $ 1,135.6 [1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Long-term debt, net of current maturities $ 1,199,724 $ 1,199,052 Total long-term debt, excluding leases and current maturities 1,102,700 1,112,100 Senior Notes | Senior Notes Â Â Debt Instrument [Line Items] Â Â Long-term debt 1,190,300 1,189,500 Total long-term debt, excluding leases and current maturities 1,093,300 1,102,500 Other Long-Term Debt | Other Long-Term Debt Â Â Debt Instrument [Line Items] Â Â Long-term debt 9,400 9,600 Total long-term debt, excluding leases and current maturities $ 9,400 $ 9,600 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. + ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bio_OtherLongTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=bio_OtherLongTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Interest Receivable, Current $ 9.8 $ 11.9 Ordinary voting shares [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Investment ownership percentage 38.00% Â Investment Owned, Balance, Shares 12,987,900 Â Preference shares [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Investment ownership percentage 27.00% Â Investment Owned, Balance, Shares 9,588,908 Â X - DefinitionInvestment ownership percentage + ReferencesNo definition available. + Details Name: bio_Investmentownershippercentage Namespace Prefix: bio_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of shares of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalanceShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_InvestmentTypeAxis=bio_OrdinaryVotingSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=bio_PreferenceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Goodwill and Other Purchased Intangible Assets (Details) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Goodwill [Line Items] Â Â Goodwill $ 747,300 $ 748,800 Accumulated impairment loss (335,200) (335,200) Goodwill, net 412,116 413,569 Goodwill, Foreign Currency Translation Gain (Loss) (1,500) Â Goodwill, Period Increase (Decrease) (1,500) Â Clinical Diagnostics Â Â Goodwill [Line Items] Â Â Goodwill 414,000 415,500 Accumulated impairment loss (293,400) (293,400) Goodwill, net 120,600 122,100 Goodwill, Foreign Currency Translation Gain (Loss) (1,500) Â Goodwill, Period Increase (Decrease) (1,500) Â Life Science Â Â Goodwill [Line Items] Â Â Goodwill 333,300 333,300 Accumulated impairment loss (41,800) (41,800) Goodwill, net 291,500 $ 291,500 Goodwill, Foreign Currency Translation Gain (Loss) 0 Â Goodwill, Period Increase (Decrease) $ 0 Â X - DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2 + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_ClinicalDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_LifeScienceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Goodwill and Other Purchased Intangible Assets (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Purchase Price $ 559,200 Â $ 559,200 Â $ 567,100 Accumulated Amortization (447,800) Â (447,800) Â (444,800) Net Carrying Amount 111,400 Â 111,400 Â 122,300 Amortization [Abstract] Â Â Â Â Â Amortization expense 5,300 $ 5,900 10,800 $ 11,900 Â Purchased intangibles, net 307,093 Â 307,093 Â 320,514 Intangible Assets, Gross (Excluding Goodwill) $ 754,900 Â $ 754,900 Â $ 765,300 Customer Relationships [Member] Â Â Â Â Â Acquired Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Finite-Lived Intangible Assets, Remaining Amortization Period 5 years Â 5 years Â 5 years 2 months 12 days Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Purchase Price $ 105,000 Â $ 105,000 Â $ 108,700 Accumulated Amortization (96,600) Â (96,600) Â (98,900) Net Carrying Amount $ 8,400 Â $ 8,400 Â $ 9,800 Know How [Member] Â Â Â Â Â Acquired Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Finite-Lived Intangible Assets, Remaining Amortization Period 1 year 3 months 18 days Â 1 year 3 months 18 days Â 1 year 9 months 18 days Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Purchase Price $ 166,300 Â $ 166,300 Â $ 168,900 Accumulated Amortization (160,700) Â (160,700) Â (161,100) Net Carrying Amount $ 5,600 Â $ 5,600 Â $ 7,800 Developed Technology Rights [Member] Â Â Â Â Â Acquired Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Finite-Lived Intangible Assets, Remaining Amortization Period 11 years 8 months 12 days Â 11 years 8 months 12 days Â 12 years Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Purchase Price $ 216,800 Â $ 216,800 Â $ 217,800 Accumulated Amortization (136,800) Â (136,800) Â (132,900) Net Carrying Amount $ 80,000 Â $ 80,000 Â $ 84,900 Licensing Agreements [Member] Â Â Â Â Â Acquired Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Finite-Lived Intangible Assets, Remaining Amortization Period 4 years 4 months 24 days Â 4 years 4 months 24 days Â 4 years 10 months 24 days Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Purchase Price $ 58,900 Â $ 58,900 Â $ 59,200 Accumulated Amortization (44,000) Â (44,000) Â (42,400) Net Carrying Amount $ 14,900 Â $ 14,900 Â $ 16,800 Trade Names [Member] Â Â Â Â Â Acquired Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Finite-Lived Intangible Assets, Remaining Amortization Period 5 years 1 month 6 days Â 5 years 1 month 6 days Â 5 years 7 months 6 days Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Purchase Price $ 5,900 Â $ 5,900 Â $ 6,100 Accumulated Amortization (4,600) Â (4,600) Â (4,700) Net Carrying Amount $ 1,300 Â $ 1,300 Â $ 1,400 Noncompete Agreements [Member] Â Â Â Â Â Acquired Finite-Lived Intangible Assets

[Line Items] Â Â Â Â Â Finite-Lived Intangible Assets, Remaining Amortization Period 1 year 9 months 18 days Â 1 year 9 months 18 days Â 2 years 3 months 18 days Finite-Lived Intangible Assets, Net [Abstract] Â Â Â Â Â Purchase Price $ 6,300 Â $ 6,300 Â $ 6,400 Accumulated Amortization (5,100) Â (5,100) Â (4,800) Net Carrying Amount 1,200 Â 1,200 Â 1,600 In Process Research and Development [Member] Â Â Â Â Â Amortization [Abstract] Â Â Â Â Â Indefinite-lived Intangible Assets (Excluding Goodwill) $ 195,700 Â $ 195,700 Â $ 198,200 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentForAmortizationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bio_KnowHowMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 235,000 $ 231,600 Work in process 255,000 246,000 Finished goods 313,700 302,900 Inventory $ 803,693 $ 780,517 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Supplemental Cash Flow Elements [Abstract] Â Â Â Â Â Net loss $ (2,165,486) $ 383,916 $ (1,162,251) $ 68,962 $ (1,781,570) $ (1,093,289) Depreciation and amortization Â Â Â Â 73,500 71,400 Reduction in the carrying amount of right-of-use assets Â Â Â Â 20,900 19,900 Share-based Compensation Â Â Â Â 30,300 29,200 (Gains) losses from change in fair market value of equity securities and loan receivable Â Â Â Â 2,473,200 1,613,000 Payments of operating lease liabilities Â Â Â Â (21,400) (19,800) Decrease in accounts receivable Â Â Â Â 33,000 5,200 Decrease (increase) in inventories Â Â Â Â (31,200) (55,300) Increase in other current assets Â Â Â Â (31,000) 16,500 Decrease in accounts payable and other current liabilities Â Â Â Â (26,600) (34,700) Increase in income taxes payable Â Â Â Â 5,600 31,500 Increase in deferred income taxes Â Â Â Â (575,100) (391,600) Increase in other long term liabilities Â Â Â Â (200) 6,300 Other Â Â Â Â (2,000) (2,100) Net cash provided by operating activities Â Â Â Â 167,438 196,185 Noncash or Part Noncash Acquisition, Fixed Assets Acquired Â Â Â Â 7,800 12,000 Noncash or Part Noncash Acquisition, Investments Acquired Â Â Â Â 2,200 1,200 Sold marketable securities and investments Â Â Â Â $ 9,800 $ 0 X - DefinitionAmount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from

customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionChange during the period in carrying value for all deferred liabilities due within one year or operating cycle. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI). + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Long-Term Debt (Details) - USD ($) Jun. 30, 2024 Feb. 13, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Â Other Long-Term Debt, Current $ (500,000) Â $ (500,000) Long-term debt, net of current maturities 1,199,724,000 Â 1,199,052,000 Line of Credit Â Â Â Debt Instrument [Line Items] Â Â Â Line of credit maximum borrowing capacity Â $ 200,000,000 Â Line of Credit, Current $ 0 Â Â Senior Notes | 3.3%, Senior Notes due 2027 Â Â Â Debt Instrument [Line Items] Â Â Â Debt Instrument, Interest Rate, Stated Percentage 3.30% Â Â Senior Notes, Noncurrent $ 400,000,000.0 Â 400,000,000.0 Senior Notes | 3.7%, Senior Notes due 2032 Â Â Â Debt Instrument [Line Items] Â Â Â Debt Instrument, Interest Rate, Stated Percentage 3.70% Â Â Senior Notes, Noncurrent $ 800,000,000.0 Â 800,000,000.0 Senior Notes | Senior Notes Â Â Â Debt Instrument [Line Items] Â Â Â Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net (9,700,000) Â (10,500,000) Long-term debt 1,190,300,000 Â 1,189,500,000 Finance Lease Obligations | Finance Leases and Other Debt Â Â Â Debt Instrument [Line Items] Â Â Â Other Long-term Debt $ 9,900,000 Â $ 10,100,000 X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B

-Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_OtherLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt classified as other, payable within one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SeniorLongTermNotes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bio_A33SeniorNotesDue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bio_A37SeniorNotesDue2032Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=bio_FinanceLeaseObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bio_FinanceLeasesandOtherDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Beginning balance, Accumulated other comprehensive income Â Â $ (336,038) Â Total other comprehensive income (loss) net of tax $ (25,391) $ 35,490 (115,324) $ 93,960 Ending balance, Accumulated other comprehensive income (451,362) Â (451,362) Â Other (income) expense, net (18,143) (16,488) (52,659) (66,919) Accumulated Translation Adjustment Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Beginning balance, Accumulated other comprehensive income Â Â (334,100) (466,500) Other Comprehensive Income (Loss), before Reclassifications, before Tax Â Â (116,600) 92,100 Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Â Â 0 0 Other Comprehensive Income (Loss), Tax Â Â 300 (300) Total other comprehensive income (loss) net of tax Â Â (116,300) 91,800 Ending balance, Accumulated other comprehensive income (450,400) (374,700) (450,400) (374,700) Accumulated Defined Benefit Plans Adjustment Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Beginning balance, Accumulated other comprehensive income Â Â (2,800) 10,000 Other Comprehensive Income (Loss), before Reclassifications, before Tax Â Â 300 500 Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Â Â 300 200 Other Comprehensive Income (Loss), Tax Â Â 800 0 Total other comprehensive income (loss) net of tax Â Â 800 300 Ending balance, Accumulated other comprehensive income (2,000) 10,300 (2,000) 10,300 Accumulated Defined Benefit Plans Adjustment | Reclassification Out Of Accumulated Other Comprehensive Income Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Other (income) expense, net 400 300 300 200 Accumulated Net Unrealized Investment Gain (Loss) Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Beginning balance, Accumulated other comprehensive income Â Â 900 (10,300) Other Comprehensive Income (Loss), before Reclassifications, before Tax Â Â (100) 1,400 Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Â Â (300) (1,000) Other Comprehensive Income (Loss), Tax Â Â (100) (600) Total other comprehensive income (loss) net of tax Â Â 100 1,800 Ending balance, Accumulated other comprehensive income 1,000 (8,500) 1,000 (8,500) Accumulated Net Unrealized Investment Gain (Loss) | Reclassification Out Of Accumulated Other Comprehensive Income Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Other (income) expense, net 500 1,200 300 1,000 AOCI Attributable to Parent Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Beginning balance, Accumulated other comprehensive income Â Â (336,000) (466,800) Other Comprehensive Income (Loss), before Reclassifications, before Tax Â Â (116,400) 94,000 Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Â Â 0 (800) Other Comprehensive Income (Loss), Tax Â Â 1,000 (900) Total other comprehensive income (loss) net of tax Â Â (115,400) 93,900 Ending balance, Accumulated other comprehensive income $ (451,400) $ (372,900) $ (451,400) $ (372,900) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting

Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4 + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4 + Details Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings Per Share (Details) 6 Months Ended Jun. 30, 2024 Common Class A [Member] Â Class of Stock [Line Items] Â Common Stock, Voting Rights 0.1 Election Percentage for Board of Directors 25.00% Common Class B [Member] Â Class of Stock [Line Items] Â Common Stock, Voting Rights one X - DefinitionElection Percentage for Board of Directors + ReferencesNo definition available. + Details Name: bio_ElectionPercentageForBoardOfDirectors Namespace Prefix: bio_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X -

DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings Per Share (Details) - shares shares in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Basic weighted average shares outstanding 28,395 29,355 28,457 29,475 Effect of potentially dilutive stock options and restricted stock awards 0 0 0 0 Diluted weighted average common shares 28,395 29,355 28,457 29,475 Anti-dilutive shares 413 234 398 237 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Other Income, Net (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Interest and investment income $ (16,600) $ (16,500) $ (50,600) $ (66,800) Net realized (gain) loss on investments 100 800 300 1,500 Other Nonoperating (Income) (1,600) (800) (2,400) (1,600) Other (income) expense, net $ (18,143) $ (16,488) $ (52,659) $ (66,919) X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(a),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeInterestAndDividend Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income related to nonoperating activities, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 + Details Name: us-gaap_RealizedInvestmentGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Â Effective tax rate 22.30% 22.50% 22.40% 22.80% Â Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $ 2.9 Â $ 2.9 Â Â Unrecognized Tax Benefits $ 87.1 Â 87.1 Â $ 84.7 Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Â Â $ 22.1 Â Â X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15 + Details Name: us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -

Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in the valuation allowance for a specified deferred tax asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2 + Details Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Segment Reporting Information [Line Items] Â Â Â Â Net sales $ 638,476 $ 681,110 $ 1,249,296 $ 1,357,954 Life Science Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 250,500 300,200 492,200 623,800 Income before income taxes 19,100 28,000 10,900 63,700 Clinical Diagnostics Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 387,900 380,100 756,600 732,200 Income before income taxes 82,600 61,800 135,700 88,100 Other Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net sales 100 800 500 2,000 Income before income taxes $ (200) $ (200) $ (400) $ (300) X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_LifeScienceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_ClinicalDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Interest expense $ 12,264 $ 12,343 $ 24,541 $ 24,680 Foreign Currency Transaction Gain (Loss), before Tax 1,699 1,253 3,653 3,600 Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (2,786,281) (1,500,427) (2,295,203) (1,415,598) Marketable Securities, Unrealized Gain (Loss) (2,895,355) (1,595,442) (2,473,178) (1,612,967) Other Nonoperating Income (Expense) 18,143 16,488 52,659 66,919 Net sales 638,476 681,110 1,249,296 1,357,954 Life Science Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Income before income taxes 19,100 28,000 10,900 63,700 Net sales 250,500 300,200 492,200 623,800 Other Segments Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Income before income taxes (200) (200) (400) (300) Net sales 100 800 500 2,000 Clinical Diagnostics Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Income before income taxes 82,600 61,800 135,700 88,100 Net sales 387,900 380,100 756,600 732,200 Operating Segments Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Income before income taxes 101,500 89,600 146,200 151,500 Segment Reconciling Items Â Â Â Â Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Â Â Â Â Interest expense (12,300) (12,400) (24,500) (24,700) Foreign Currency Transaction Gain (Loss), before Tax 1,700 1,300 3,700 3,600 Marketable Securities, Unrealized Gain (Loss) (2,895,300) (1,595,400) (2,473,300) (1,612,900) Other Nonoperating Income (Expense) $ 18,100 $ 16,500 $ 52,700 $ 66,900 X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 1 -SubTopic 20 -Topic 940 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_LifeScienceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_ClinicalDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Restructuring Costs (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended 17 Months Ended 41 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Reserve $ 9.4 $ 9.4 $ 9.4 $ 9.4 Â Facility Closing [Member] Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Charges Â 1.5 Â Â Â One-time Termination Benefits Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Charges Â 4.5 Â Â Â Selling, General and Administrative Expenses Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Reserve, Accrual Adjustment (1.4) 3.1 Â Â Â Cost of Sales Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Reserve, Accrual Adjustment 0.6 1.1 Â Â Â Research and Development Expense Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Reserve, Accrual Adjustment (0.6) 1.5 Â Â Â European Reorganization Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Charges Â Â Â 72.3 Â Restructuring Reserve 6.4 6.4 6.4 6.4 $ 13.0 Restructuring Reserve, Accrual Adjustment Â 1.6 Â Â Â Payments for Restructuring Â (7.8) Â Â Â Restructuring Reserve, Foreign Currency Translation (Gain) Loss Â (0.4) Â Â Â European Reorganization | Life Science Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Reserve 0.2 0.2 0.2 0.2 0.2 Restructuring Reserve, Accrual Adjustment Â 0.1 Â Â Â Payments for Restructuring Â (0.1) Â Â Â Restructuring Reserve, Foreign Currency Translation (Gain) Loss Â 0.0 Â Â Â European Reorganization | Clinical Diagnostics Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Reserve 6.2 6.2 6.2 6.2 12.8 Restructuring Reserve, Accrual Adjustment Â 1.5 Â Â Â Payments for Restructuring Â (7.7) Â Â Â Restructuring Reserve, Foreign Currency Translation (Gain) Loss Â (0.4) Â Â Â European and American Reorganization Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Charges 4.5 Â 29.9 Â Â Restructuring Reserve 3.0 3.0 3.0 3.0 10.8 Restructuring Reserve, Accrual Adjustment Â (1.9) Â Â Â Payments for Restructuring Â (10.1) Â Â Â Restructuring Reserve, Foreign Currency Translation (Gain) Loss Â (0.3) Â Â Â European and American Reorganization | Life Science Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Charges 2.1 Â Â Â Â Restructuring Reserve 1.1 1.1 1.1 1.1 3.0 Restructuring Reserve, Accrual Adjustment (0.4) Â Â Â Â Payments for Restructuring Â (3.6) Â Â Â Restructuring Reserve, Foreign Currency Translation (Gain) Loss Â 0.0 Â Â Â European and American Reorganization | Clinical Diagnostics Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Restructuring Charges 2.4 Â Â Â Â Â Restructuring Reserve 1.9 1.9 $ 1.9 $ 1.9 $ 7.8 Restructuring Reserve, Accrual Adjustment $ (1.5) Â Â Â Â Payments for Restructuring Â (6.5) Â Â Â Restructuring Reserve, Foreign Currency Translation (Gain) Loss Â $ (0.3) Â Â Â X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147479823/420-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details Name: us-gaap_RestructuringReserveAccrualAdjustment1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details Name: us-gaap_RestructuringReserveTranslationAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=bio_EuropeanReorganizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_LifeScienceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=bio_ClinicalDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=bio_EuropeanAndAmericanReorganizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Lessee, Lease, Description [Line Items] Â Â Â Â Â Operating Lease, Cost $ 16,800 $ 15,700 $ 34,900 $ 31,500 Â Finance Lease, Right-of-Use Asset, Amortization 100 100 200 200 Â Finance Lease, Interest Expense 200 200 400 400 Â Finance Lease Cost 300 300 600 600 Â Operating Lease, Payments 10,500 9,800 21,400 19,800 Â Finance Lease, Interest Payment on Liability 200 200 400 400 Â Finance Lease, Principal Payments 100 100 200 200 Â Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3,700 $ 10,100 11,200 $ 12,300 Â Operating lease right-of-use assets 181,473 Â 181,473 Â $ 194,730 Current operating lease liabilities 41,513 Â 41,513 Â 40,379 Operating lease liabilities 150,975 Â 150,975 Â 165,478 Operating Lease, Liability 192,500 Â 192,500 Â 205,900 Finance Lease, Right-Of-Use Asset, before Accumulated Amortization 11,800 Â 11,800 Â 11,900 Finance Lease, Right-Of-Use Asset, Accumulated Amortization 6,000 Â 6,000 Â 5,900 Finance Lease, Right-Of-Use Asset, after Accumulated Amortization 5,800 Â 5,800 Â 6,000 Finance Lease, Liability, Current 500 Â 500 Â 500 Finance Lease, Liability, Noncurrent 9,400 Â 9,400 Â 9,600 Finance Lease, Liability $ 9,900 Â $ 9,900 Â $ 10,100 Operating Lease, Weighted Average Remaining Lease Term 7 years Â 7 years Â 7 years Finance Lease, Weighted Average Remaining Lease Term 14 years Â 14 years Â 14 years Operating Lease, Weighted Average Discount Rate, Percent 4.00% Â 4.00% Â 3.90% Finance Lease, Weighted Average Discount Rate, Percent 6.50% Â 6.50% Â 6.40% Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year $ 22,700 Â $ 22,700 Â Â Finance Lease, Liability, Payments, Remainder of Fiscal Year 600 Â 600 Â Â Lessee, Operating Lease, Liability, to be Paid, Year One 47,700 Â 47,700 Â Â Finance Lease, Liability, to be Paid, Year One 1,100 Â 1,100 Â Â Lessee, Operating Lease, Liability, Payments, Due Year Two 36,200 Â 36,200 Â Â Finance Lease, Liability, Payments, Due Year Two 1,100 Â 1,100 Â Â Lessee, Operating Lease, Liability, Payments, Due Year Three 28,100 Â 28,100 Â Â Finance Lease, Liability, Payments, Due Year Three 1,100 Â 1,100 Â Â Lessee, Operating Lease, Liability, Payments, Due Year Four 21,700 Â 21,700 Â Â Finance Lease, Liability, Payments, Due Year Four 1,100 Â 1,100 Â Â Lessee, Operating Lease, Liability, Payments, Due after Year Five 62,400 Â 62,400 Â Â Finance Lease, Liability, Payments, Due after Year Five 10,800 Â 10,800 Â Â Lessee, Operating Lease, Liability, Payments, Due 218,800 Â 218,800 Â Â Finance Lease, Liability, Payment, Due 15,800 Â 15,800 Â Â Lessee, Operating Lease, Liability, Undiscounted Excess Amount (26,300) Â (26,300) Â Â Finance Lease, Liability, Undiscounted Excess Amount $ (5,900) Â $ (5,900) Â Â Minimum Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Lessee Operating And Finance Leases Remaining Lease Term Â Â 1 year Â Â Maximum Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Lessee Operating And Finance Leases Remaining Lease Term Â Â 15 years Â Â X - DefinitionFinance Lease Cost + ReferencesNo definition available. + Details Name: bio_FinanceLeaseCost Namespace Prefix: bio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFinance Lease, Right-Of-Use Asset, after Accumulated Amortization + ReferencesNo definition available. + Details Name: bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization Namespace Prefix: bio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLessee Operating And Finance Leases Remaining Lease Term + ReferencesNo definition available. + Details Name: bio_LesseeOperatingAndFinanceLeasesRemainingLeaseTerm Namespace Prefix: bio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim

periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated amortization of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-

gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events (Details) $ in Millions Jul. 29, 2024 USD ($) Subsequent Event A Subsequent Event [Line Items] A Stock Repurchase Program, Authorized Amount $ 500 X - DefinitionAmount of stock repurchase plan authorized. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}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

0+L9H$M9;ZAD4UQ0U3Q[:;, 7%!(3>$0)/4=V#W,6HIRLLAGCI58&*=' M?3*#RBX-8JTWRF>W)3R,=5/-$Y!I$+HO02D@I-IK9322J&"(#X.'$)D913B M'MV0FKYZ@N!\ZH(U-*5 ^!ASG4-+:6L@:;^#U(>#-NA8J3)]6#<51TERG M7J_C*IT1L%<%I 8X:R@U]3.,"U2%7L?ZVL/K4=DF1V6;'HMM?U:VAI?V.]Z= M1=K-B'X$"%/UFD7;=!+N+IN GS/8JKL_JZPA;=SHW*ST$PS'V3FW#!/&%YP? MS..M+:;]OOAK_=03/$'\"-4?'!.HEMBL: HLL*S%! MV3SS<#U%V;S QV5@6Z?,G-[\G:396JOPP@QFO;[[M1E\5+;)4=FFQV+;GY>M MH6?]AA[-X*2=K%?D<-O-JW(8:X/E,(;# MW\YB#(9D,&PO=V]R:W-H965T&ULI9==<^(V%(;_BH;9BV0F MB;^-G0%F$J#3=+I;9I.TUP(+K*XL44D&MK^^1[+C!:/03'L#EOV>(^GQJ\-A MM!?RFRH)T>A0,:[&@U+K[;WGJ55)*JSNQ)9P>+(6LL(:AG+CJ:TDN+!!%?-" MWT^]"E,^F(SLO865D(9&]JPK+[X^$B?UX$ S>;GREFU*;&]YDM,4; M\DSTZW8A8>1U60I:$:ZHX$B2]7CP$-S/,Z.W@M\IV:NC:V1VLA3BFQD\%>.! M;Q9$&%EIDP'#UXY,"6,F$2SCKS;GH)O2!!Y?OV7_R>X=]K+$BDP%^X,6NAP/ ML@$JR!K73'\5^Y])NY_$Y%L)INPGVK=:?X!6M=*B:H-A!17ES3<^M!R. B"/ M.R!L \)^0/Q.0-0&1!^=(6X#XH_.D+0!=NM>LW<+;H8UGHRDV"-IU)#-7%CZ M-AIX46Y\\JPE/*40IR=3P0MXZZ1 <*4$HP76,'C6\ 5VT J)-3RJP(2E<<>. MH">^$A5!5Z\:MV/8_- M>L)WUA.ASX+K4J$YK*MPQ,\NQZ<7XCU@TP$*WP]AA<3_E+S.Q3Y-RCTP]BQ MGNG'PR/7=O[? [// _//L)C*AS2V3S1>_D^P*%Z^WU_RJ4ND8/6DNZK#5>,H*T M0 LLP36N]]YD3FUF4[UVD]LP2),X2T?>[ABH0Q@$:W.1)0 (.6! ED)3FOKJ 8 + : 8 M >&PO=V]R:W-H965T&ULK5EM;Z,X$/XK5FYUVI7:#;:! M0*^-M'U9W9ZTJZK=O?OL@I-8!\%XXSYDH9LOS^MJM6I[+RF2BX+<*Z2K/F7JYY)E\NICAV?["G5AOC+TP7YZ7 M;,WON?E1WBHXF[=>4I'S0@M9(,57%[-/^.R*U@MJB[\%?]('Q\A2>9#RT9Y\ M22]FGD7$,YX8ZX+!UY9?\2RSG@#'OSNGL_8_[<+#X[WWSS5Y(// -+^2V3\B M-9N+631#*5^Q*C-W\NE/OB,46'^)S'3]B9YVMMX,)94V,M\M!@2Y*)IO]KP+ MQ,$"\.->0'8+2'^!/[* [A;0FFB#K*9US0Q;GBOYA)2U!F_VH(Y-O1K8B,)N MX[U1*N =69Y)8L4-H6G"(ZTS$3*#)S<&_B"W3(:R16Z8GJ#/L..:_3^1\&J M5(#-!W2*?MQ?H_?O/J!W2!3H^T96FA6I/I\;0&;]SY,=BLL&!1E!$:*OLC ; MC6X 37J\? @Z,6EID3^N23#K\JRH^(NJ=(.(1WX'GZN>7TPDXM(TRK?T%8U&V M 5S5 5PIF2.H0L6,*-9-&@LCN#YSA:UQ2]UN;8F?Z9(E_&(&-:RYVO+9\O?? M<.C]X>+\1LZ. (N"W$?"GO#<14#SA4+1I$X0FN[ERYDOC+:R]V5:T76(2!GX MN[$]Y.2PHZ%'O+"U.X(;M'"#U^&63*3(2&AQ99D) (H@NQ'/RTR^<.Z$W7CU M#^" <8B_R8Q+T<+L,\8*2*' ##UO@X23P+X7AL'NF!G^""FY<,,/AOQ-*/=P# MZ30+Z C$10MQ\0K$!+8=&?8,(%_J)C,*=#%$$!"\(#V@#C.*@V D":(6:/0* MT"U$T@)$I9()YVF3 ;G0">@.*S@TO":IRPD.T0!<@+UXT:,PM()T)\3-(&X9 MQ),,;O>PZX(#T7]B*K7?H&X%XL_)AA5KCA)HO@HZT3B'>(.8Q*%/0Y#*\C^ M<.'F@+U.HKQ)%M]@FDGJ@E1R*T @T,.+LX4ZA<<;0@\7/HUZV%UV<8C'ZA$? M""S^I=XOZJSZB=Z__M&S?^MO!U'@711(*\TU%(8ED'.P0 *\T.E1K:+#',H M(G[0+Q>7W<*CH3^R79U2XTD9[)5,*G0IM; 39ST)009"WIF7$U1"_9M&$/ZM M1&F[A),/">",^]W+84/C$1Z=WN)IP;W=M59;[:BL%)2ZYC4'&-: M)Y6J, [!F(MJ&Y]X;?QASJ\E^7S=P68#8B,[C3;#PMVL>L[ADP #[7_,&@^Y;)"?JT92*S_$YA3T\U MF#G9#%4[H+!-?I_-T ['04S']JB3=SRM[VV[KNQM!=P8N#J>$[E#QA<^#'-] MY X[G_C16,UT>H^C7VK5*U&P(OF95CTY2/QRJWXC;\=1Z&8&_,K0L.\<<)>= MR6)]"A-ECAZD D\0"_?6.:2? T/Y\X+;"[FTCW7Q IN>#HU:7VJH16E>PZ:)T.Y/PUQ7V4<5MX(VFX>()-*VROV+WND]C9;YCG$_-[(Y-&)&0\KUL-1 M?Y)QF,4P-(_@[A2<3"OX]X-YO<$.LR+2&Z9LOS4FXV,:2!Q:#6+0A^VPHGBD M&Y%.S\DK>CZJ@T9QIBOU@O1HP(?"# -ML/#C/G:'(?&@=$W,OJ23<3(MXX-F MZNI)3NP.#8[# (.S7I,L.QY%/1KHIZ;2:3&OUS6K%$V,C?;._T;ACAMNV8AOM M2?-8Z0:FIRU(67T> R6HR5=J?C M9%K'WXC6";KE2L@4P9VRS5&.WE_SYNC#B;V85:E-@..P-N%VAF2H])3Z@T1P MW.W[OA?2D:AT\P"9G@SX-!]7HL*/^X01TS*2; M#\CT X%V\^J*Y*\DXO"."J(9X_X3+(<=C3W/&VO8G8Z3:1WO110"7RDUUJ*' MRDRC0=$,C:*1_DP[\:;3XCU ^4T6R3A0.E1D'_<5T&%$XV@$:2?<=%JX;XKT M#9)X]R?A45HL%KC_@-!A!VGA1_VTF!\\^\^Y6M>O1#0,/E5AFN? E[=7VM;$R+)^P_@C9%Y M?;CA+.7*&L#O*RG-_L3^0?N2:OD?4$L#!!0 (.6! EF'(73P, H .U) M 8 >&PO=V]R:W-H965T&ULQ5QK;^,V%OTK@K?8[0#Q M6'SH-9L$R-B2FD6G#9)I^Z'8#XK-Q,+(EBO)R#RO/O=375Y7JZ;(E^RF\JIUXM%GW[MR(KR^6* !M]_<9L_SIOV%Z/+\U7VR.Y8\]OJIN+O1CN66;Y@RSHOET[%'BX& M5^A#2KUV0(?X/6?/]=YKISV5^[+\TKZYGET,W#8B5K!ITU)D_,<3&[.B:)EX M"']M20>[8[8#]U]_9T^ZD^9G]G4KQ-X 1 X,P-L!6!J \8$! M9#N 2 .(?V W0Z@\A$.A>1M!WCR@.# "\[P)<'A <&!-L!07>Q-NIVEV:2 M-=GE>54^.U6+YFSMB^[Z=J/Y%-17_:\['-9?C.3\X M^=+Y/"_7=;;>CAD?8'F? CZRPKG)\MF0G\LX6^4\)!UI;#@E/D'4Z^K;)KHS M9Q,KP)/H>6Y9PR<6?FGBK%KFR\=:%U-J.-%?Q]?.5=-4^?VZR>X+YC0E/^6* M7TR1;,2S:9=2>)=2N&.GNHL(YTS6.!,V?>\0=.9@%V.H0S:D?D?>3J1/EY&/ M/.QO\--^2J@X(B(F*H+2@'I4A,4J;(AJXH6^B$N P.(HQ*YTV!3@H[X?XOX$ M!%G)3E;2#?0.R'J]G+:IQ)P?N83=JW?MIPW4^<_;LB@XFE5/:'#YSW\@W_TW].FT23:Q21::)$MLDJ66R(14HKM4 MHMI/Z"_? IY7OUV:,JG8BYY=FWKJR)R;*>>:T"O.%\W/V]N#>'%RV&2+K;(E5ME26VQBT\5.6B,Q_9Y,< 3)'X**;8S)28(:D6(DK<-T.0H1LB[25N MNW574[["5&QVMM'S$VOF)=BK0U![P@VH&\ABJD!%3",D/O9PB9DKU4+$;+VW0"L M[P:<:.RQVA" C3T 5/:!50AH[$<:.RAX$!C#$'JC#W>VV.WM%4+Z>!)XL+U#(^P1[1-EH5X$1!ET?R\8>8B3$=TEX0-Z^+,5O MN=F.K>ZV6V6;6&6+K;(E5ME26VQB2O6E.'Z]37<,E-3&VAB *5*: MB]#C#I:8F5(M1)2R+T*QO@BU;.G5&L[S7$_6U5QY I A"I"BK0H+,/)D:QK3Z*O/8]OS%/P]DVU8HM5;TQ+H.!\2CTJ97(*,5+L10$Z(&]??9)3JD]C>42 @\LCP"@ M(B]0?4+E$8"#RR, ")=='$*.N/")]]4GP&Y9'Q.:&YM@JV\0J6VR5+;'*EMIB M$U-J[^YV_4;P*>41 ?9/41 B3[EG5A_$BY/#[KWJ=F]6MWNW^FO4SJ2OG8F^ M=O[_[QXAP-XOP'0FA I5U7H70@ ;RJAP#N&& B4_E$@H 578Q :1Q;'D3?\GCU3C.!=L@]$LFWZP X16]S^0,20 ##E.XM',<5FIL0,2;404>*^+4(-;9$3.\T4O$V_ M_4\64P4J8AHA\;&'2\Q<)2B++ MC@/9 MU\0 +* XE*4U'B_50D1I^W8 U;<#+'6;*=09 -)5A2FB&B'Q<0=+S$RI%B(J MNO>=;WT-O9E8/QZ>6#M [?R1-_Y*V;=_'K'FJ;8./.6#KW);*WK56M!:*SM4 M=2O?N@-0BNK'$,5FHL0,2;404?2^/J6O6I]NV?>?)0'7IP!0+] "%B? CBX M/@6 <'T*,8+UZ6CO.3;M@Y!X@?F8+VNG8]\I/L^X$35YME"FS=-N>H>;7-? M-DVYZ%[.6<9E;@'\[P]EV7Q_TSXM9_>$I\O_5!+ P04 " #E@0)9]QF M+X@4 "U.@ & 'AL+W=O]B5$>_VPL0]@%4BB7:SB%*I$<;]^3V8"*) J MR9[MB7F1R+H B6Q=')\?'%T5+;O/.%-7ZS=YH+URXL_-%0Q>.WKY>Z;F9F.;KZG.-;T=QE-PN3>EL5:K: MS-[LC4>OWIW1_S ?UFS=LEG12N95M5W^G*;O]D[)H%,8;*&1M#X=V^N35'0 M0!#C[W[,O3@EO9A^#J/_RFO'6J;:F>NJ^&;S9O%F[VI/Y6:FVZ*YJ]9_,WX] MYS1>5A6._ZJU?_9X3V6M:ZJE?OD2+&TI__6#U\//O'#B7SAAN64BEQ*];O3; MUW6U5C4]C='H R^5WX9PMB2C3)H:=RW>:]Z^T\XZ56+L"_6A*IN%4S=E;O+M]X\@9Q3V) C[M[N39 7]KRZ$Z/1ZHD^.3LV? &.XV+/^7QSI\8[U.]UZ7]7U[S0%U7I:L*FW69Y9W%Y9\^-_B=M^_S8HZ%Z-Y[<3M2G7]7GNYO)S<:;@W5%TRALTPFL>52AA"^SB!K7H0:Z"%,O]+U14V-*!0RL= (U7;,ESU#E>-(@(S8*_MV5# M,ZYJB_%6A7%J;DI3ZZ+8T"VS:N1=4L/7DF5BH/)TXZ6I;:;5_G^,QY\/>'70 M D5'A0&4SO] M!'AU@N;8<;:#,)HUFK+1M(L%0K_*URIU:"!9,/U1@"N);F3*3 _/2J5B6%WP+# M96U=DP)*W;2U&:H[/P%R4\\,/$!9-5%*"^ELF4,)E F"6/7.()C;XL6-T;58 M^PFS3G7!UI'M"R H&ASP]:+*I8T'?Q\5E4-'C7D8W]O+4%KNE$$ %XNH;@P M&+=OYF<7WRNJ6U1M@1E(IYJ!B'?^:$O)OXQB$E($ F ;&?\'H^*)!N1"D T7 M5N.R;/'('4<-A9$I/:O1\>%_1AN2\6!(9)W'5AFJ;$#RO2Y:TB@Y-U2#F7!- M% Z],0[N+5:>,90W &M%WQ7"!&Q 6K&T*J?,@W7LE6PH(W;RYMB!"!S+D*>Y M]'TVKJXK1&0]:TS=\V(T?;.HJW:^Z..A# VH 8*M^C4D+!+ZPK@&!^A0T&K>6@(*1RJ M3.]*69N#9'J1>:ESTN%N $',:+(+O!\5D[](;%?LR"L],X^?)38V?B2 M5B*+:? Y!M_:*"6_ PNR<\\]K9^P'1.]Y04->FR]?..:AQ7IQ:F\K8.EY"7. MO)*ZAC%W4T'@F"5TFH"6P6J(2F1DN0=ZB0,)C8^;]_"&JL5S&+N&&NOOICET M*Y/9FZ=++-UUBZA#8GA&SFK!7137Z]#;@N! &*NS2BKL/@MU":!(23T*4/!H MMR5Y2E5O>N[IS(<%$ ==SBUI3Y8SV'TP$[A@+F/O2N)?89'<0 MFN?W2I>)Z.!;6=,*- R&C/-V;FK]+I/^69(AH M&#$RX*\#=KOTY73!CHN\FK<9*9P48QFG!?Z5$LB(T17$44EAIJX*+Q_R !X* M@BHX2!"5?"\9E(SH XO W_-K%YD.&(2/PVO#D2'C4"JF(?J&B]D"4#2>RI#] M^V;N%KJ]E-*PT5&:$$(,F9;5%[AG)^T^6<#14P,/')T37^(+ILF&!X.N#DAH M4D$(AQ/ZI#NO[DU=,MAT"WEK]G[A6,3&R8)58@C62P8]!?8:HB%0/44 %Z0D MP&!C=]CH1-HJ?4CGM$:H")$^9TH&W0(N3(@I^E;3PLZUSY/C,'ZB5%)E,)+) MNT')FQ#-YVD44-E1$YEPLQRP$V"68ZH#(7091>($@<&GS>YIJ2:)AB"=3'% M4F;61T4F%SW2 3249ZIU25<9T"%/^!#:Q=P8;^^U+5C&0+?]M,(*&?:-Z/DV M/+%:J+;*I-(QS9JJF+#^]0]JR-M:+^5'3GKL\PBR^;$N*E T![?VM2P&V=^; M3#[O';#]C,;Z,PL^4L3PF6 3GA9L>XZPJH!!-H9%X%PO#'L?5]T.@KN9)1%1 M6/0OBRJF$!R8$B31@8?WR %&P[P@-+% :EDC'.1CQ% M"!Z;1G(&M1EIK)7>2!$NF:6Q#26EU6+CF'>L*F0'YS@I@GU_=SYJ(D_E;"D M"7%@85<#F20 4AH)K(2(?$]]FJF"1GI'*M4N5-)5[;:)=Q. M1-.'^D'95OG MY0S=$!.HH@-^NDOI0)[I^)Z0H3UYF.36%R:HZ\E-?89-4%5T7XH.!HT 1 MJW4>0]%662AQ5KM%9VX?J QW2#%JWC(3UOF]V&2VFYQYDKQB>7V/P,3BCE]H MRRZS/T56I &Z52!HHE9V;DM?MS-O+DPY)ZX%,4K?622D([<.U2<23-;A#75/ MQB3&0 %MLQ*K,#A\ $S5-8BMCEZ+X/$945%/UC!^I&(=/B*#"')8)QJ4K.TL M_&>&1%TV0IP_QX';-K0P6S;K1AR6 MEIK48I&YM$MAP_M^%G= 5*37; FUTCC@=>X'3F6&A&K<%6,'K3'C'P74"$- M[UC[J56A,^EC1BX3%+_5!]4LQ)CJC$>=_>^F7 1#KK51GRDFY3<^LXT9J=N"+Q_?MO7(C$?R0D>WO\(JZAA>& MXOAGEZ&1(!"-'IN4A;FMJ0*6L!(&9'-@]6QSKR!::.MZK$ZHZD@:!/=;?:(5 M4\AR_:[?0=A!V-5,ASGO-5+5RFZ)))9'K28U;VT>H#B>7*N+XPMN59%PO/WA MR-E0G+EN'!$KO@EQZ,VKLQ-JR5#0A,:+#9MZ9FO7Q,3R!$$*X: ;.RPY1I;R M*@]W;D66POF2 CO3GG[*/] $CAKS3T3:(;*>\Y&(D.7X\FLLZ(EAM*01ZQ M9#D_R6KNJZ)=&FG/2M@(28PRJG;>9U)).E+ND>9=B'$[LP^272"F7:;+'7F& MZD,27&(EI))%N]KRMIL<](G="QO1O;-88<;=*_B7K)/A"3+KM5;SPES \(MO=_U7%.H\633BY.)YP#$KD+O*L1Q$L,7/*)1IE-]3\GW#OT=5[R+ M;*ZI+9RF4^6,&GW"? Z M8D;R=1?KJL';E1",Z?_Q@&C:KC5Z=L$$'A:^9W(M9@''EY1K']12#JM(0?5;"U\(1TWX$=D[Y"9U,AA2/G&[$)D^F@ 4'VJ>V&C9 M/@G@H;$/(N,.AG00)>00U[A7W$OS33RD3;H3=Q9R&U*MW[B0=YB?31G\24'(M&&REK> 3^)(V-N0 3,0/-X.[:N0QZY%,+1.%W"RD%9&=N)-H -KQFQX9J@^2 MA3154LO?:RBC)MJ]"83#9YDZ,$BJ:X%#O#B1H!0+;WDP)U^FLS<\2%# GU#\ M>XNR9$[:=(&M>:"^8@8VJ^#X:Z:_OJICW#D/45^6Y=T@ OVYH=6M0*9H!Y & MWH>,2XLE0;(#&IM@F)Z54A/@<>M"Q.,V,/F80?=I^]#'"W5R?C8\H?]7E\-+ M_#\,OAR.Z/_5&;[??+@9X[V+X;DZ&8WPX!D^7ZJST<7P6(T_CZ_5Z)0NC\Y. M<>'D[&](:2ZOAE?JDT0'*5ZHT7BM2YUK-LOOQ!O":9,#=78QO%"G+S',%%R>"U.? \OD11#%P?&>DJQ>WKWXHH'ON_9!'?2#$()[XAVZ3 MP74APV]I=@< M2J+NP#L^.4-?OROH8T>FN.V/Y/\XPCX^0+-&G'IQ<0G<>7?AYUY<7 $:_@KM M]+F*<4 ZI70M&Z!L';(!=,_18+S$P!P2X)S@ND3$B!<^W9<#'RT@[Z2]FA. MI+YAN3*.G_A(1=H@;KQ)&*3#K"A:I4';41MI^OA0G=2DLN/B-^E\-G9-LC&9 M;)HS^TC[)?T.(=+$WMWL@8I;UK'Y*"7P5C<9$,NG.ON^G37Z8ORUEW=>4=," M>V! _(I1_"S)M'2R@TR"AL,#@$L;"-NON$02Y"U(\%RBE]VULFOWP:!A*YI9^D(:@/:N:/DI'<;D)Y.GMTJ>)=YP=3A,JR9/(]"]!ZH2C: M(_P>(WQ_IA: D^"3R'^*)RB_^-WDI =--MX_&QX? J/WSX=5!.IDI\ZUI+I%. M7JB7E'")OM=W*GF%8]IC?PZS7Y-';Y&_<[;&TFW"30@-WT;]0'UE&ZD;1(: M14S\A,^%AYT_:5 >,IGA]@2*W0)XDY,^L9*DS]S:$FZOX%W<0,V;1&AU/-G M3Z2)F30#6"#O5>SM89LQ'O-H2Q^DY:P"D>R%KN<2O]I!R.$)2TA)0%>>B+]&#O^,_OXEGC@Z& [ZD?^=PDFU7C$W*;:$H71%Q M^P9 F$/ P468]-B_V3X$KYZ/#Q[UEG.UN?##GAO@1M6+ZK\$_M[_TZGKS;.PAG M ,>3KSS$X? %E/#Y^NZ2.9=A]J/PY4091H%/ON]-YPW BG'@##>?S P7@!>DA M3X^A^:-PG@*E_*H(_8"DX1HY7CQ4EFS0S]M"TW%IWUZ5_E7I]Z5"P;RP9I;T MXG*X$]N>SMZ!?U]_>O_AP!])OT1YUY$1C:,<+BSG=U3V'47AJ0K\]JJ?GP< M^_D#GHG*B2_(P43>'* -:@*SQ,A<0F8Y=AG)%>C4>O.GW'JLWEZZ/PGL+C:0N)/0NWEGX3:OQ@@NSCX MH&NP#)&#!OLZG-!^/B;KV.9-./AU72V7E@]NT+&8FVM$.^TC9U!5H>HV'O3$ M(XAQTC?[6 W5Z>GA:'1RB863+6X$ 7%')D34T/3!@JX++AH.[SP $DROIF_+ M>T,\@&LZ*A%H[C5R7(_2U]K4A_'XC'MRH?S)_P!8NG/%&P97Y<":(/Y2]>W_ 5!+ P04 " #E@0)9R.:+ MBW04 E10 & 'AL+W=O>461=+:GKYQTGYXY_T D9#$AB)87NRHO_Y]=@&0($7) M=IK.]$,<7H#%[F+WP>X"U+,[G7W.-TH5XLLV3O+G)YNB2*\N+O)@H[8R[^M4 M)7BSTME6%KC-UA=YFBD9_9"^>Z;*(HT3]DHF\ MW&YEMGNI8GWW_&1XXAY\B-:;@AYCFA]MS@UTC=Y=ZU($F66G^FFW?A\Y,!,:1B%11$0>*_6_5*Q3$1_M AM_6)HGU9#4T;]VU-^R[)!E*7/U2L>_16&Q>7XR/Q&A6LDR+C[HNQ^5E6=* M](=Y_Q7W)FVX\F)",J\T%O;&1QLH\3\+[]8/7@=YH,#'4:VPXCY-@,QEZ]E M(5\\R_2=R*@UJ-$%B\]JP5R4T*3<%!G>1NA7O'@KHTS*N-2B?=*YF6FH/$B M? W91@#@UN0@LH9>&T.@ H;%XKY-BDXLW2:C"9O\+,%5Q-G*%(Q/#E&_3%3Z#^/7Z MIT]OQ/LWUS>?/KQY_^;GCS?B-P6[+E0&J0R*Z(@2B7D@+N6<2C*7(DH M$6F&Y\G:]6Y31PL,J[-09?%.8+Z27!JW7JKB3JFD21DE:TM 95*?!'0D8 M2&7<01G&#S%6!"IK(!HQI@(% M:0(>TJ/A"9Z+0,9!&4-\TCGQH9=D"J"H'-/Z5F70F,Z5;5(F>XU(>9"]9@]B MZ2PJHC]5SMJVM*($O!2;3"FQS+0,1:QN50S%D-YBK 7YE?C^N_EH=/E4_$2O MQ/!*_$^IB3_2E,IYTAFTL!(^?1-HIEYH] [WAIX?"5NO"$[].V-'?1HE,@@C*8(.">I.P,JE(T:QG603!8)>.6IEC8-]5F)]#4JT MQ,C&MC%-&!,8K"H,9IL.8@P$\= O,KY>6T(]M20D5JLX)M'.K]P$N]EQRA(? M=0'6]X3H9/I*O)+Y1J@_R@CW)/Z5^(CX &I+=1Y9&QB.GHK)H#]NWF!I4COG MWZLR"7,QN_0:N?_YH6$]: TFSN2Y>=\@/QO>]B_%!\P(+*=@K533(\Z6Z-(? M[0^#9V] &L"6D][-5)T%YV+2FX^F(-CNX9[_I &#X)_]M&DA;$?B+#S?ZSP> M4%?S]_I6PH9ACD]@T4]RR799<0P=ZRS5&5 ":ET6/GN.VG0R[0]:=Y_Z-WVQ M)OA(&&7S%/.NR;@0V&%JO>ZCR65_V+I#?(7H*?$I: #=6AK7]!I[BJ'K]V7" M.!UWMIY[LT37UV1;3YR8^_RV.N0:C\<>?7-G3$$>U9DX4[7*A[WAV)_=P\) M[V3&ZP!+JXJ$&YFLX4\(FBCZ)F51Z8_;5P;/E8/\A-Q"FM9#!;0ZRF-/YOU M)[@RTW\J+GOCQ8AT7A&[%RZN'L3^^AS4'=,8&3;>OG^%UH 8FE]TS('DF5E\ MSS;[5CN<]1?F3UOZ^_%MGQ$FA/\6#='_%M!\C=5XNX2'CH<,G.-_("^TMNM MRKAK*E/PVM#8"":W]Z ;:\>7OM/0S2.P8.8!"5UWP/1H[K6IG)\>'H%I?C_U M<68^PW?

X"<-QN=%4\H%VK).1N;$(9DV)=TTIM-1_!@H/!X5+GB:14[GU;X M3/!+)8![<3K*&[K8'_.1Y@7\.0[M>^H_H(M'C@O >@ PF"*+J4SP,L]ETQ9#
M1@<4]RA3'U&/9V?]8':\$M #.?(!YY%L =@.H=YCN8EULC:S]O7\D(4:I50] M6Q6!0Q#M\P/04!1E,CR&%#[JE-=N]24E)H3
C<;'%Z0">93V5.^#!I'IP MG/\V\P'_&,L$;6-"(%\]BG>?G7#VAKJ8>1(3SZ(O8FH*QHH)Q$Q1Z"*WS5'$) M)M[UQ<^:1XUL13&+UFO%<7\21"R]Q7R&A&M
Y4FL>]E.W&KB A,IJ<),XBYZTSG6\\&)FF<41PIED?RTC7;WLBQ7A;&:B2ZV<]03L\7$DC%E=:AWRQA#8R1(28 MP["D%4?!&'\STLH4HWZ)MICJ>"?
&\W\YS>NR@ $D7-;J]&#E.X-SVXI7D;%> MW:MS'G TJ\A4VNE63N?LD9_43582YDHE8K#N:=(]W_):8W!VJ1*U0F0J243' M 7<\%QL=AU3IW[G4QV%H'!]5[(
MUF/&C='MJHT.NV&2T19(CH4($P^ZMT36^`JS>0X:@>J+_Y;93X)M2)KJ2.G6 M9/9TH>FZ@@(VFV1LQ:Z69:/BL"_>K3P^0HWGY!%<]0<]IP?:;6?VKN YA 8]
M8CIQG#<%O,,,"Z!J'/VIS!S2SFT8(9RRD!Q6G:ST& /SW"7_/1$B+VPU#M6Q M^=$H^WJ+.!+)3 @R.VY=OK'6$!R+.8S4'I!Z3&<+J4S'@].ULW!^<\U.]
M#7=G_..\LFQ*NUX/(4G#9#(G(V(NJG//]"B,9K,N>.0.@[/'U9Q'G64X$>< M0B!-GPQ-PLX2G\V(Z&E5Z/W8F!*J";KS#F["9#43@<8TDC^I2OE-OR1+VO/)
MHC6SRUT5,Y=0,N@8VR74:-M$;07U?#-DO*=>C*(Q0_:&=ELQR@ZQ(V7BPTLN M)X^&D_[<:TQ-:,N1E@]JFB-%&Z#%;$1%Y[H=AE6&J-=TN)A0U6
Q1E.7JWGJ MM0K1MZPGV7^S1XQGK#&2!OL$6/V"*[#=7O$<.3M%)T-R*R.5L-.F8@\#H8] M.[=UL(=XQ)0FAST"W)P_K+H'5N:[W.T:$S/5H1[M*H15YH0P"
<'"EX+T LWV^VME1/>77M+AVOSI@#6^1 :S96?P5 8P*+&,85A M9E?>QNR^+7&4X.+P'05/:Z77F4S!#L4.TD81".9:F:(+MU8$0&XY U1(]X;- M :G5JUI%
(MJFD*XN1,31-O(X,YFB610[CX74&^--W="&09=NL-85'6D5QY70 MEIL*&@^:[FN,(/*>.25)*-D-:,)]')F0L8YΛT+D5VM^0?/S#"&7B MRQ Z2$IG4';B$WO2H:"S-
+Q?CP W0H *L<.2,=$&HOZDEWSN0Q H(:H-:49H M["JS8"C9PO\LWWA'T8DEZ+E'#WW(=F1,5CXA/FZ%WG1Z!!XU=%S1JK-% M-I5<-0C#+7:I]7X8-*]?
*3F!6URFNZ5 *=UC/, MABX3+VLR">-.5.[KO3"N%0B48EC M%13='8QW1^;L$5EZ]RK$,2XK<$G=YRJQ.J;F\3W#II53_1JU:=US&CMG@)3 M[0,%=P?
2$X&'\,S>1*?$3$I,)9)E:>"64Q<=ED&1\Q"96I>QI#-KBNB84U%, M$NE;2F-Y9]E,KU9.K M%:57KHGQ5E@,DE(-+*SMVXE0:\; EC7I1NF#2A P"33C6H-?
Z@/<7'*!C>E M8VJV(@$Q&]S3U\M(&R][6%Y39!2DE\R M&C2";::TQ0#7NYQ/[F%]ZS4S>+,P8E7TCPT4YL1?H[SKG4.$))A[*L)MS=:*
MS2K9^)U7TC2VIPQKFCW#>@@'K9ZJ.H^_BJ/#RT@_^2##?^<5*3(G6ZKHX7L@*DNK%F9\J*QY51'/-69WGJIN#TW&DL*#8@&Q0Y0M(OK
M_RCA;K2.$5]F]FB[5?9.M9/ZX*AEQ(4>AVR^ M)Y8:AD.8Q"%C>WO@;7N4BDMF]B<257Q]H;U_3_Y)^-0&E7U.O*WB9A+URH>= M7"%V:A.Y?W/O9V?N;O?
W% /94:YH!%ID(')Z6G(_>CE*[?AK"74?0E@=$G>"82+ M=]7I3UX5]P,Q,KAPZ,S(,/?2T>)<,X[9VJ62X?H!.S=5AO:Z8RRW9D'RV7 M;K 'ISZ]A :JI.RAP18P-
L[UM]LX9ZSZID]1,F5F(][M.6^7?G@QM%]/A/5G$?: N?O&P)PSMZGG4B-I8\"VZZ5+.5P*X"(MFWC7,^GR M3H2X9##L ?
5R']MZMO\=0+\Z0^AI^)WGF:_+K#] #OF -7;Q)8$QAT,.;+DT MPB&/H%B90O:J2$/5$%WOLSSY465+X-
9+;"6*HW5).YGBW3OQPW:Y$6<8U8WK'Q5UNB!AB)3&+*:W6H_UW_'EY.ED M,*@\AY(-_/[Q4H*GN@D."KE/VU M"NY5N3J)SV. 5/, !AF-R6)M^MQ]KLK8[?7-
*S$?37O>"<=WK6S0R^N\$1A> MX$=<%=NF<;3:6;TT]X;WTA;3FR;XD,))O#KOJ?W+KNM_H&R.9/G2$K_WM^ MAL\>KK H&A.RKK=O:T.5=RN0SG
IGS&'C'J_GP+O NUQK3\;8(4B^%&3+]P M[G]29&#&V_D]H \;_5#IIVIJWSOQ3&VR.F&YXJ6_K=/B,;SL%Y#IR>%IL3S> M;JH-Q%P:-^:;?
WZRHOW[1AFU5U=\81UF'XQWG9>Y1-;2QN; M,";AZ13$-M"'\BL,9$:*B)(YJII\4P/'B6(^&S0IAH])"3G"9[:_>GOA*[RJ M)[R/WMK50U=! 3_.NKVT_)[S'6K_
&MB8Q"OR/@7(WBJ3=(&Q#%>,K6J*H;? M7H"P#LK,:95CIU38$NI3*!3.5D=0#.)8;Z)VIY?>D3].@!_"=6/6060T][(4 M'OJA5 Z9S#]0_>=#FKJ?>@=G>S2^Y
.1_QUQ4^]\T??4/$^D%10_1@R)A$R MNQARCUR#Q)&0[M"V<5= WQ7W^V$@8!R6="#L;U?."EM*J3[Y)H0"^3AJ1%0N ME^(I\2LUG;73>\\DN(_?
J8*L0_E36I=\Q![*[GO"7_-^D_%&=GQ^9&ZI:FA MF@H&FB_H+$+3,=S'AUV_B7#A_73%5F5K_H$.2CHP@>97+*]GU6^ 7)N?OJB; MFQ\0>2^S-
=5U8[5"UT%_-CTQINAN"IWR#V$L=5'H+5]NE$2$1PWP?J61HML; M&J#Z9907_P]02P,$% @ Y8$"6=JH:90?!0 20P !D !X;"]W;W)K M&ULO5==
<]HX%/TK=VBF S.MP9] FF2&A&R;;IID M0K1]V-D'80NLK6VQD@C)_OH]DL&!74K[T-D';.G6/;KGWG.OQ(4W,ZE*9C!5\ZY>*,XR9U06W:#72[HE$U7K
M[.0]NU-G)W)I"E'Q.T5Z699,/9_S0JY.6WYK\^!>S'-C'W3/3A9LSB? M&HO <'OD%[PH+!#<^&N-V6]VM(;;XPWZ+XX[N$R9YA>R^"(RDY^V!BW*^(PM
M"W.O5Q_XFD]L\5)9:'>E5;TV#EN4+K61Y=H8'I2BJN_L:1V'+8-![QL&P=H@ M<'[7&SDQO\RPLQ,E5Z3L:J#9@:/JK.&^-@X'&X?/@X. 'Y>51V'O#06](#J
%S8!"!U>_",!^]A&@N=%E(O M%:??1U-M%&3TQ[XPU+N$^W>QI76L%RSEIRW4CN;JD;?.7K_RD]Z[QRBAD-T
M"/TG)/$@_G[O0X_>W]Z.OUQ=7]/H9DRW#Q\N[^GN_W%A]'D7-)I,+A\F=)'#$:[)2)IO/)X^D^9S5+DAAA@S33-9H%-H:HL*@B*U*[N
M'-.UF'&Z@&A%N(=A[6=!O4- M56B:P= 'H!\$G@_PT$L(W0*]H$+U*L6K])E8]B<*V2)K>OUJ$/C!.VK#JK.^ MWG$E9$:I"T^-
NF_9O]DN*]X4PA;7FFGD1UX/+/L8_P261VN>1V#: T<;2,OX MJJJ_"W6+GC.5B6I.N<(WA>ZY_3!9GT:E5$;\7;NZCGC[F3.E.TVQ M[$3J!K0O7 -
&.2E>.$N=BX7N%D+#\1@!1CQZ]:T]3+RD@\' B^C7"@6YI4LY!SJ]:T^!7X">;;],+&Y M&?2PO;5(\2U$/")L$ ^\(3*"'<(F1[2@V((."NY]
(.#)/SCG8V*7!NK#J^+^U\=^7LC@>8BFV[UOO?'@<00EO00:R MU&1:!$-$73JSFJM3G#^,P6VC[7I6:WA((."C6V%(\:G9$.??Z8#GF*2^G2$]8 MEWSX?PL@<
(8@(85 ')B?1LBJ%L"&$ +EM^XMLH@\%W!! @VX'?KP406-"! MY;\E@"&M,Q#8DG5:V1% @]SZ5@!]F]7HVP((D/P$"[#49A*&/R: I._PH]HL ML#_)H
!W'X1P*!1W'<$D,2N>V]VA #0AN+=G/*GA8U/G2H @>8AU(-MY2%7 MG.\<76@BGG8?-*UGMP=J7W(_L347%2:"CZ#*1H2CD6J/KC6$R,7[K X ME0;"=\.
<9WVN[*\GTEI-A.[0?/OX>P?4$L#!!0 (.6! EF'UXA]C@(M *$% 9 >&PO=V]R:W-H965TL MFC9I2D("E#% *GW1F-2NHEVK:=H'DQS$]F-GMYG:?[^S
RG;*/MB^\[W/'[. M]MVH5OK!%(@6GDHAS3@HK*V&462R DMF0E6AI)VETB6S9.I59"J-+/>@4D1) M'/>CDG93;>=ZTG([6V@DN\UF#69()J.*K? & M[;?
J6I,5M2PY+U$:KB1H7(Z#D\YPVG7Q/N".8VUVUN R62CUX(Q9/@YB)P@% M9M8Q,)H>\12%<$0DX]>&,VB/=,#=]9;]PN=.N2R8P5,E[GENBW$P""#')5L+
M.U?U9]SDTW-\F1+&CU WL6D20+8V5I4;,"DHN6QF]K2YAQW ('X%D&P B=?= M'.15GC'+)B.M:M NFMCFKY[!2 M*C=$GH;'=&@2?H1;99G8R>
((!K';/8+C01SV8-_[1#ME4Z)>^>9@Z&+6TC85 MU'K;_G/2E-U+>-.\+IE><6E X)*@<7A,?U(W#:$QK*I\$2Z4I9+VRX)Z*&H7 M0/M+I>S6< >T77GR&U!+
P04 " #E@0)9821]!0 ":"0 &0 'AL M+W=OA&EEQ)AG! _5U)0*!-,[U]L65Y]^S9U=%* ;543WI) MJ8'G@@L]");&E.>-ALZ6M" ZE"45^&*DMPY%;R11%&[41 F
M@F'?S4W4L"\KPYF@$P6Z*@JB-A>4R_4@B(/=Q -;+(V=: S[)5G0*35?RHG" MK\8>)6<%%9I) 8K.!\$H/K]H6GMG\)71M3X8@\UD)N63_;C)!T%D"5%.,V,1
M"+Y6]))R;H&0QO)GDVCUA[6V;:0!9I8TLML[(H&#"O\GSM@X'#MWH%P[)UB%QO'T@ MQ_(C,6385W(-REHCFAVX5)TWDF/"+LK4*/S+T,\,IU591/P
MND\Z=7BM_Y?TE9_3\-=HIHU"P?S]6O(>.WT=VVZBWHPQO,FWOFS;?0_W"YWL1\G7$KA.F7R>3VZNYJ_#BZ MACQYGX,CTN*.S.3(F,$S^$CQ7IE
MV[R)R($44AGVKY_HI&$+.G'8A >:5[X'85(&2Y81I38.K9"5,+9FRG:/,SD_MJS3%.FB*\)H[$'=*%I M
MB5A0&VU.F,)VH9XPJQ7A%;6QZ/>*F0UHFE7*U]Z2YY+8-IM1MB(S+$IRVL04 M$HA/VW$:1C A&U\ZE-I!03A%5H"K/T,).+!:@DG7L>Z]L%O'(F7*F3#;@C.;
MKSX,DUKL%L:Y$2^&3*PPE%0.+HW#!.%:+;N&M9U9'7OOBX/$LBKLETJAWZY^ MUC,J0]S&A7B51DDVCH--_QCA.)^V55(M;8:=^@\T<3$H&/),7\!:81LP\'%
(M/"S^XO'R)^W+^;^UG)'U(()C=M@CJY1V,$S M1_F;@/\PLG2G[TP:/,O=<(F7)ZJL ?Z?2VEV'S;_CHV_]02P,$% @ MY8$"6:'!:UMF! \@D !D !X;"]W;W)K&UL
ME59;4^LV$/XK.RYMPTSP)>$6FF0F(7#:#IS# .UYZ/1!MC>)!EGRD>0$^NN[MDH()_EV]UM)P[72#V:):.&Q$M*,HJ6U]5F2F&*)%3.QJE'2SESI
MBEF:ZD5B:HVL]$J52'II>IQ4C,MH//1K-WH\5(T57.*-!M-4%=-/4Q1J/8JR MZ'GAEB^6UBTDXV'-%GB'IH_Z1M,L::V4O$)IN)*@<3Z*)MG9]-#)>X$_.:[-
MUAA<)+E2#V[R6SF*4@<(!1;666#T6^$Y"N$,$8QO&YM1Z(I;H^?K5_ZV"F6 MG!D\5^(K+^UR%)U&4.*<-<+>JO6ON(GGR-
DKE##^"^L@VSN)H&B,5=5&F1!4 M7(8_>]SD84OA-'U'H;=1Z'G]05S#"WP\223;>3%!O]:=#OO:-_#-=*VJ6!"UEB^5H_(2PM MH-XSH&EOI\'?
&QE#/^U"+^T=[K#7;P/L>WM'[]AS8<&,FT(HTVB$OR:YL9K(M\/=;P09;_;=MN08Y,S4K_[$!ZV"(]W&4]E,+N*L5N M_>,8KKY_G1P?W%
[#;.+Z3W<+Q%JS67!:R;@4%6M)$IK0,U!M-Y*ER%&J6$& MYDI0FQKH<ELX(;Q^R? 14%?
5%F6&"5HX9^UH5^W/^Q"WW"8IG';_OOQR=NR_1Z<>HGPO4)CH)&L4MKR?["$DDJG&@>:R3)@Y<8T M3!9($1E:[PSBDWWH9&E\M
]7K\,2_]]%B=M\#M>5^$OAUE\$7")>:ZH0.2 MLG[H@BZL$<@L:@J 2ZN @:3S;J_G4[:I$X5ID "0C,:5$BLN%U#0E%-U%QJQ M1XV)\^;T3X=/G9)UA=:-
;5CR=P'SXD]7!K+;>,.4A-[9KUOB #4 M@MJD!$H4G!/OF'SZV1 7<<558[Z#U86261)GGIH3XJR [,A%GPUBF"I-K42. M7"E+RKS=
[=UQV1WX6WF@@YN'VA5,0H[0&(=.4:4>B/C%MX8;[F/K4@]H?Y7X M_+&:6XK>:;KU4/D%2M2^HW2M-"&'NJ$1T>,#F2%7=': E*N#6^8QN,843R'W
M!6I+5^E6XLD^5]N\"[>"(TBA5DAB&S+76JVX^5!]/#\)A/]>;93OB:]"V _! M@E)!_E*'-;H<-]98\NQJSZ?"\),D5\#^H4U+;TKJ3
M,OP1JG"WH;O;7BR%PI5RKZSW=_]@>>[Y_,VN?+G3UV10 ECV54IFS5F'M M_*33,6D!)3>!GH/"G5Q7);>XK&8=,Z^_9XZIE)TX#'N=D@O5&IXZVFTU/-6U
ME4+!:<5,79:\>CX'J1=GK:BU)-R)66&)T!F>SOD,[L%^G-l6N,JLI&2B!&6$ M5JR"_*PUBD[.NW3>'?@D8&'6YHP\F6K]F1:7V5DK)(-_0FI) L?A$<8@)0E" M,
[XT,ELKE<2X/E]*?^=\1U^FW,!8R]]$9HNS5K_%,LAY+>V=7EQ X\\1R4NU M-.Z?+?S9WJ#%TMI873;,:$$IE!_Y4Q.'-89^^!V&N&&(G=U>D;/R+;=\>%KI
M!:OH-$JCB7/5<:-Q0E%2[FV%NP+Y[*"4IG592VXA8S>V@(J-=8GI+2CNC\ N M5:I+8/L?
M#'MTXY%E<3821OQYUY_!WQ/7:EE2T,FZ@,LDW^#IJZLC=>VGL> M[Q3XOE8!2\(#%H=Q=X>\9.5_XN0=_0K_#]@UEHG.V0-_8K^/IL96B*H_MH7%
M:TVV:Z5*.S%SGL)9"W49J!ZA-7S]*NJ%;W;XU%WYU-TE_=_G=+?XXX"-QN./ M5Q_C!XF;]G-P\7DCHUOKF[O)A>3Z_O+3Q-V>8WK"6[XN;]OLW5[M+,GW:!'
M-/9(LH=6LD:PX(3IFLXB=)1! LZ,EB)S@J9<$[08U.W01T(\'^PVZ-MJ!M$#FX)HW&08)7NP)N/:G+<#8Z;]"9$Z/L@ MXT9,)HPDIG);1/#.1A)_+LT+V$B"Z]M6-
XSKGF'OI<;\G79N+ X>;"\A\"H" M]E!\F^<-G'.T(>4R;:RN#:&M]\YQZ*"F#C(L;NQ=,F806CU63\\MU$A;O\H4[G
MX+.^1EWWGZS]QZZ;+5N8[UW4NN!++>PS.X - M5%A!A:&R?VIH>U2.OBHBJN6]IF3=.FQONX1UUB[9)50S]Y2@BP>BPM^W5]35
M:V7D+^DOQ_U3YXI7,^K $G)D#8-CO)U6_OG@%U;/W95]JBT^ -RTP!<75'0 M]W.M[7)!"E9ON.%?4$L#!!0 (.6! ED_-[7]04 !D0 9 >&PO M=V]R:W-H965T/8
BS' M15(TC6&US4/1!VJ7\A+>)3X%ZTLR4G]8I%]3.A M=&=Z'M9N[/3<%#Y56MY8R=2L+CK'G7KA5MTEGA?ZT_-273E!4!QO=*9Z.;J2E>2*L M/.]
[Z.6O_:C2,2MU#_H>$=?C/:)HVL=RWA;O@\\#:AA#6HV?%;A;X7NT6C0 MI>%@.'Y&WZAQ=- (3MH' MV9F^?G7\;O#A&;#C!NSX.>T_F9%G=>Q'>-
JCW[_YW1S?4OS3Y>WUS13YNA6 MQ*]?G0Z/3SXX4LX5,B:A8T+_.H\!D!"*,+JGR* 3G7=DEG25"N?HDJY,EJ&U MYF'#FVKU;5!03F9[M\S>]NA:1
FYD(N6PK9D5$J6UG-AO8I4+KQT)+\7(DW7 MI#3Y1)*L(\;2]7%.!I"5=]VP+#?F%!R-I88ZD9(W0866CY[502VHQN7@#)AY MC&3N23A:FA3LY7H-
SBUL"7:D*E,>L7LPGD-FF0P<;P-P+,-.Y=8ASX&*.?FT MW&VT)(^%A/<(5HO=FC+C/-K?>VE=EU:)!!&[MG.-QAEK%.E*K'<5L[8>7<:Q
M8F;D4'8;',&EQ*0Q+!!K; L',J7AY!>VPW&+E<6*"6 4P-:VM[24%(RHL(25 M?%3PK)%%6(5+,'_@O.0.#JYI(9%S%:/3#33VT 5#*$]\7K.:05%;>B.PJP1Z
M]%ES]:+=G>'2-D\$]E1:E2#+LOOB1(<>$H1:E2#+LOOB1($>S_9 H MZ$4J6;/0:_(XZE"!3:$TIO+1Q5D[P@E\O-G#(:.0"(ZGR?9.A M_@K/Y>U#8U
.3MDIO1=W,16N3JM?F:,H+&<2Z8F1Y^^%XM('[%;W!CZ146%1 M>ARM H2"#U\ M^,.T:G>%EMQL@/]P/Y8(#<@13A2N!Y"L!X4"7S8$>$&$P
@5%D;$LR@S$=1T]+5/E MZB(&[G499S;%%8WR,)G((>*_/3HX\J#1B>P//B M/M0IS KX4NBR*^5RR40)$S'+Y@+-
R]=53U=WF@%7S*L:W:K1)0#GG9)*)$'VJW2G_=KYL@Y(;/&<6,MA6. MX'[PT3]BC@NSX ?Q'0WF#VZ.6 B"'^/HP8WK91;]W.:HSNW%IKNW&Y3;M'6:!:\W G9
MG@@-3[NC]Q,:ON^.)A.>C2$>._QP M\+?NX1T?#B?[.5G^*WQ/:]R#HMYYKF;1WX5'*/ ?Z*%]N MS6KS[KTLGWN;[>6C^8NP=V 6W$V6$!WT3O
$LN5#M)QXDX?'W\)X/"7#,.': M75K>@.]+@S14$S;0_#=@^A]02P,$% @ Y8$"6:-$."2P @ !@8 !D M !X;"]W;W)K&ULC51M:]HP$/XKIVR:0*J2$%Y*
M&2"5CJE,ZHO:;OLP[8,A![']JV)EM"MNOW]D)*6PMZH,R M& ^][E:/AVIM!9=XJ\&L\YSIWQ,4:C,*6L%.<<=7F76*:#PLV KOT7XM:C7M
MHAHEY3E*PY4$CS*X2.9*/K-+!T%L2.$ A?6(3#Z M/>$%"N& B,:O"C.HKW2.^_(_;./G6*9,X,72GSGJR=VEQB M%4_7X2V4,'Z%36G;/@U@L396Y94S,Y%E^
M8I:-AUIM0#MK0G."#]5[$SDN75'NK:933GYV?&,SU#"3"Y7C"5RC'4:68-UA MM*@@)B5$\@I$#ZZ4M)F!J4PQ/?2/B$[-*=EQFB1' ;^L90CM^ 22..D_/$(YT[-
N7,_6UU.0YQ%L+-P^7T#F:7%S=74T*9/D")RRM<25U/ MLEBGE PZ@:42U*9,@TXD'-X9YO#O540O0E MK
572[>T]Z29M$BIL[XH7#Z12/UN*WKP'AJM7MAK5D+7"]VXTO1Z8;_I,D.S M@0G^AVX5RKBJ4K, @QF(PQ9]??K:T J[!RD@8 ?7B!U6(PD[S4KS?
YX;.>J5GT"&TKN6MFS36EL/N?.RMY_-RPEYQ?2*2P," ME^0:AZ?TX'4Y=\F-&@1NT,Z'RIE-UMW 7UZ!_!5!+ P04 M " #E@0)9?*[!,FD& ($ &0 'AL+W=O
M_,*O[[/2W=DA=F#X8M_IM+O/OCTKG;^L^^071$&L:VW\Q6 10O-L-/+%@FKI MA[8A@R^5=:4,>'7SD6\Z MEFYS3=JN+@8G@V[AK9HO B^,+L\;.:=;"N^;-
PYOHUY+J6HR7EDC'%47@ZN3 M9]>GO#]M^%O1RN\\"_9D9NTG?GE97@S&#(@T%8$U2/PMZ3EIS8H XW.K<]";
M9,'=YT[[\EW^#*3GIY;_4&587$Q.!N(DBH9=7AK5W]0Z\]CUE=8[=.O6.6] MT^E %-$'6[?"0% KD__ENHW#CL#9^(# I!68)-S94$)Y(X.\'=V)1SOAC9^
M2*XF:8!3AI-R&QR^*LB%RY>FL#6)=W)-_GP4H)'71T4K?9VE)P>DGXA7UH2% M%R],2>5=^1&0]' F'9SKR8,*_XQF**;C8S$93TX?T#?MW9LF?8^_Z9ZX4;[0
MUD='XM^KF0\.!?'?/I>SQNE^C=PDSWPC"[H8H L\N24-+G_^Z>3)^-<'\][V M>$\?TO[-=#PL?3(>BI=_/7_]ZH5X=_7/BUOQ.CI!546I](7*R@."X60@L9)>
M3";#Z2,A3Y-G6I%?K'S'X#J*@(ZV^R-3GMN*N).>@@>U*[REX(9'WDAK6;(*(#7:R MT3D9K%$L"N5=-T33U9GI!4M*S?6]MS_1)HU,&G/.-B1=N_&&"JIG
M:)3I2=H\S32O2PZ$]C&Y2V4L5<@@W@]OAP]YD<#'L+ .E42Y[5A%$>&;"F^$@XM+[('R" X@WW:U0'D.I;4^PE2&Y]..F@K MZH_-*)9.*VY4*7\AI
M/">4+GM;*O"M8UD4%#F,I2"S5O81CFBYRG22*2E]RX6("I7,ISC#(+Z A88J M).BO5+Z)@= P$OP%I&A"%1;[0P:[2ZN7"8'WD7Q'ET'5O)@LU3:;D-FYC*W7
MZ0-*M]CB;8L"VR&XA&4;?:)W)UXITY3K/S,HK9LTW#U7LRV8H1T1L,?$*,O;=_,,#PJA M0W>*Z8SLT)E/IX(M$W3="W&U.29GJ=-X!>\"~~JC,S0-M&F-

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{_T/8.HE8/G)IE,!-B^_5A,1-_MK(CC/4('JQC8+Y2<%FAZ%5MQZ[TYEQFGQ"YSC^)CJ]W@\[!8$YU6A&.W:AWR M7Z_5$<,Z.^O)Z;2ZHMMZ@]] C*1-5_E_A4=-\>]@=>"/ATV!]8>95F *&0.$ MBXV$OWQQ&'6CMRS6;U;'AS#7$[,":.B.?7$1@L.1G2C+KB](&D$\1,0%Q92/ MR8A><+,76A*M"QXI64X5<(R%K;H7>1A 0?9!2:!9L;_PH9 S3TC,=(#F#$]0@.)&"]" T$I M@AUH8"VB3P5%B@);)F]_11D[\>_S FQV0NP?K*Y;" [KV^]BPJLO9R(_(PLLM MVSW9VN*^4BL.^&]<!D,.VNA.Z=)"97G[3S]FSQ[>5\-S]7 @=M(QB?K(IE MD#%FM^XJ"8OU:[K$DAFK3L) (4QD37)QI6QJ>E+Q5"F-X65D;K&5IRE"WD'/O MZ\@Y.FH=K8IHE>&O*Z<_2?#>C:9/^95>^)YPAN+FM^BQU/9S5U(&?#2BT\-:@.S!!U,.L 5BR"T9-P MN)*U_2/S<'!,^'>P)6OEV$X[MC7) I=#!V_D&=)4ZP2[.YW!MQN\CL*3?3&% M,2,# ID@BK$L-7'A\ %1=_MUL$^H&ZR/>0>=5 '$";VD+Q!0K&+$E;F*46]U%2+4W1QV?T]\MKU%MM?>\G,""_"W# N="&)XX:_O MU]}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

0NRW<_LHV05BVE6WVI%GK'Y(P"4"L)1, MLGA?4S9FFY,^HV-Y,K)OAAWN'PK_)NHE6V),NNQ6O?&<,%\A]'XW>DU0HUVO MM^'2X]FF%R<3SP&(787>5T MOR*GBJ+_<$^ZKT;>LA[)U#)1R,U"6H'LQ)U$]".WWO)4'V0+*2IDG8>O(8R M;J{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{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}?=J;.C?#H%N$"*%.A)B.5AQ^7C/>&P,S5,%Y_ F[9[U'P6K..?HB2RQ)7I!R(R7((4U1UKY8= M[TR<8OM=$:KGL?1LT#6'.,=\@HOR-N"7U3F\QE*V_SQJOQ9>@;>06XOUW> MI(;7+VACLS!S/#H97UT%:U8(K\<6G EQNZ ;]3!RQ\H0GB M*^)O_P]02P,$% @ Y8$"60AO&2.3! /PL !D!X;"]W;W)K&ULO599;^.V$/XK W=1)$!6EF3Y2&H;L.UL#R38($?S M4/2!EL82L12IDE3L]-=W2#E*O'"$]*4OYJ$YOIGY.)[I5NEOID"TL"N%-+->M86UUT>^;M,"2F4!5*.G+1NF263KJO&\JC2SS2J7HQV$XZI>,R]Y\ZN]N']'RJ M:BNXQ!L-IBY+II^7*.1VUHMZ+O>W/"^LN^C/IO7+\0[M0W6CZ=1OK62\1&FX MDJ!Q,^LMHHOER,E[@3\X;LV;/;A(UDI|(M8/R]M|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|%!/DB \A9-A,#E]ZXSB.G S)HI_@O-N MUHU:UHTZ6;=(4U6[+G&+*?(GQZTS6+@<>?<._4ICQBU<*?/1#M;I\CC[FH*; MEXJS P1I@T 0 A+Y/TH9)<&Y6X:4Y<-:XJZB4OI^AK721R<4['#(.DL-@$)&R"3H^7NOOEJJ*GE?G0CWZZH MS7S3WK;3X:(9BE[%F1]REHN 24!"X(=4P&%,3TS+P3ERN 2+'OXS!W+ P04_" #E@0)9!FI) X) "G(@_&0 M'AL+W=O4DOE^_SY"R+%N*;.>VP'ZP)5+DS) S M\\QPI,MGE3SJE1 I>PF#2%\U5FD:7_1ZVE^>)D.NNBD6$)PN5A#Q%,UGV=)P(M/C>3P]#G]ONG7LAEU+B^'U?DNM+M4X#&8DO"=/K,.3)YKT(U/-5PVEL.[[* MY2]ECM[U9/R)&Y%$! AB/$]H]G(6=+$XOV6^]lF[5C+MC&MQJX)_RWFZNFI,&FPN%GP=I%_5\V\B6\^0Z/DJT..?/6=C^PWFKW6]PFPR M) AE9*_\)=N'4R:XV037R&T9&2D_\)1?7R;JF24T&M3HQBS5S(9P,B*EW*<)MGDK,2Z]_Y3)A?_)@+=B=X'J=".QXJEGK@<\"H=N7O11<:&S/SRB^MQ3=5RB. MV)V*TI5F'Z.YF._/[T&Z7$1W*^)[MY;@O]91EWG]#G/[[]"&GI7M_$%J/U"T:LW^)C):.,1W/V647)MJ-J"4>8R(A\OO!XUH+6 "1 M#"2?R4"F$OOC1G+92!OD:"CF5HP*%'D2F0\ M$

***SQ!Z)CR(H-W!H6M"7^0'\|^M M))/RN+!7=*6G^6X:6KHHCZ3#&&"5C'#4*Q]+V.#;_"7@&FX!_,&%R=HV?"=>,.Q(!7EK"*P)O M13IG1_^NA;58 M=*L,RX0%&B8-I-AE$-'$'&&U(,M3H.T[;=5U]Z X\"8MF8 M@/#V708L6E$*;@-'CYSR9H4KI(]6NF_O21Y :9HFZ91=%B4?KUWXZ7",T(O?M0(B<_X%@=*&LR)J M6ZX3:0/I*'EW&,E3A8-7W9LH<-KQCDU42^+:FI507&IA!%P]@ZG8T.P]I^D M58[!NX4+@_D/.ZF#L)X5]=(K67#8VPG/Y$.P2[.&EIM\LRV=Y;P.16N-4@/-`M5]=QE\0#'#K/S#[S\=<2#0T9ALTAC=ZN7-^B+-|7BA,K$=.=EL6"IP1/I7EJ MIR@I-Y[JU1*L*WA*\%33>*IH!=/R/%5/ +S@*<%33>.IG00D:CRE9I8YT.0IF?;EL:IK:G\T.V:R;BI$'BK_@ZG"W(-./^]> P3QOQ/O<:Y[M&7&DPQ%;:)@/;>^"\#-\4HW1!?2)[ZP UL/8P.TP.]YTU)78O_?'A^E[Q]_M2(__N/OQL43D[ME"9=]:]NT/W:0UNX:_^Y+E^T!W>NIT5X$?P"]X0O4#6",:.MNFKY+#KE'L-EI3OIWETL@%,?Z05OPD_?T@>P/]YG7O+^;5?Z]!MSR4<8I!^8 MOM-@=[*W+W7D$FNI!$!].'CKMKV.PFM)B"MZ=W26'P=; M=!@BC(JP-(KX.'BLY!$,RH:)DE\& ;Y-HG"|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|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{TOF"\\?]:Z9NTMZ/#%?=I SNW MJ\M.F_;E@Z"S) $8'X+9G,,N>)O/E7L8PV;H;NEY4W0U==T/7W=!U-W3=#7WL M;NC+Z\(\]'?UX,;5R]NOYVB"OKQ=J:FH[GW>_M$?\1@$(:):VB@>Z8.=+"^Z M-T+]TK8L1U0>H;[T]^^,^YSUPTO!UV=2B_U\<:RB*HY'*)*[J9R35C\F6@!MY[OZ E;QM[":T .|%WW!R):G:8:.K\!Q:ZAG6]W M@3Z'12K;UPH%1A<$QJ@@!]*_Q#CN<9VI5[EFU9I5]^ 9;&/5WL%U9S6KU]Q: ML^IQ/+1MG-]_>=/O-/.@"36GUIQ:<^JS>|K;6'5 %7+CBV;5/6%-])^?!=2D M>[/7$TMA=?")?C-_; $X@6,=,NG8;B2LNU#]$A]77>"3=DLAGS#FB?'M[O]I M?U_N:)Z=B=L=C(1$OB%H4!%B47)$Q C-'P9PH3 >S<#8R.4N 95N=W1S8$?O MU;MB:O@*+WK+!PZ<])GYWW.3JHK;CD8=HYLWG4Y!-<]U;-7=JW]DZYU3&O-M6_T_(X(K8;]$A.NP] C/0"">@8'I[%PDTFTU#&QCI2_#_DP:$K7B)3GKIG'\ ML$OE=G1:M!WY(/C3CFYPTK6V:.WY£$YR=(']X\D'9UR"9/@&'\F5S[11.,?, M$C/A^_"M2&1F$(@P,$Q?P.]7@N.P&=$*KL3MF0M7[C#>&$2SF3VU\0JXE2") M)+G"'_%R<[7RO95O(^%.%R9N-P5HC5D4@I[06BV9P5-XR]*M>F7Q>N&$Y%!*AS[6!AF,:#Z3!@F&$BPA(-6[-GAAT: M=@!'#&]W[.]P;K!0. 77"_$_T J Y:\|^]L&$ 5<'<#OV?3>Q]MQZ';)R(N M*6\;'UWY&8CL%"9[+K]G_,:QJ/@@1SX9L-\,&V'=G;E!39)!/Q05\O-^D%0 MK\%4-(UWDV\;_ V?EF>X!CUN8<+2EO!*?"U>77C".+4D MFBZ*7MHTD/:+;C+G6/47/N5#;)R2@_-OC,G:^.F(3NZ_U#KOU#+?R=>#U+O#ME[]=X*2=CZY""MP'/UPSM#L=$H:;BNTE_%@L&)E5-PM%1"S:7.8!M?"]:75 M[\14H+"7=[3ICF[S$]0EZF)= PL06RY+1S.R[)#/_<_F?7,;X1"I1.'"8PS(_M^,N/^T6=O;XHT5+GV$^0\JAWTP@(V0U![(#;!AI!_("7N]!OS1DL]K7I/)KK·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{J\)MS*8XZ*<@PI9BT:=Q'$QS.M%8*R0'X!M4>1!39RI")42F1KR-:>&<>08Y MZ(&T,%XAW,'S0OF/Q\UA:U@:R;_5'(Q& MQX&"[S=[@R,]]MT<] ='@;KO-(?=[?CT):#NV^-RJ/G/LB@0VB?#WW_R998ZYIN;M%\X?OP%GZ%:Z&]>&>;<]<+8'&;H9)>^'Y0<1-M1])W M+@);SD24VR"H;YZ'S_8""7OAKRK?0&X]I8'\O%AF9._IXS^A*\MYKSS?6\1 M!GR9S]NI.O5\GU@"HI'@^W86*I[OPI$$SK]IO9XPE?Q(,#AXU%Z;HC/_,L. M%V^C `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

*!,V4J[08A*PTYBX!JB.8%ZPD MP:=46)L68OP0%IDZN"P)*E9*MA?VZY,.XWXLR&9\,"[ESG4CN..K8)1"U_C@*
M^4O^J";K]O_$T,.S&Q'M=^,;*^CZB1K*X4SJ=%)W; M4VF&D:>`!.P$C??GNT0 -#1AN+^-QVBD3G#WT3UU*,AX>%-@CVRR$7:8,<]O
M6A21.S;9+#'UF%]>TV #O*H(1J=($KQ5AQIZ+_Q;NR\)Y%#^1V$')RO0-FMV?E<+^[&[!+1S230>QM]GY.+9469H*!*4^-43*[C+P;KPOQGN--
>@2+R4+ 7Q>? MSR"P,0&BXDOAW$OX^V:5#AR_K6B1"A!WG]/O]%O)Z6N51-N+#\CW3 AK0X%\1<%B!HTI85L)>E>#D$J(5#)1; MB>_>--
YFEYA=FSFE1B2$,O)[,BH@X7SML[#N;TFXT+]\!(<6]D@SEE9 M3QP/OBQP,1)8^[4")ZJR.!,Y0MX[K2)F*;VL^[*$@_N3Z=Y=8;X Q_
MT]^C+BX4;SM>G6Q_3F]TFB,=!W<%TB,,$J#X#=3+Z.V)#LGM2!%9$2]P@L=? MPJV1+SUP.94"&.M'PX!-"CGRX,UF 2BGC"YZ\)QH*?39ERI806\
(-NS;5A %P MR/YUS[!_#;4)^N8T]MO5XNV!';-M]YK#&N W\ &C9]C9/U&VBCLM(8JL1^KAMP].ID]:Y>IY<>KS]_% Z(S9XCE
MRO'60MQ2_D'$2/M!0UX E!+ZD<+[IX-F(L&;!!T@ETIQ-!A>;_CH>7G$1-+&Q M6OW55]K(=^7HH#]*-#V>YA@E]@8"&/2;K?
2U^L%O)1+RYRY7N_W84[*.*P8W M"-!H.F:)L&IW'?FJC M+E=<'(\+VB(GD,_8$7M$I M<;I0W;7ALF5'"?]B\"NTM<".\I%OB):"-C-^R&X_1RIS^
MT=**'+/TIAQM6'#*4NH\N #_#$]7QFBPX!EJ:I"/=]*6F(1XA'*HHJJ4]U ; MH=_9*#A6RI85'>V&([T(ECIV^P#36ZJDX3DT/TV)@1E^R6@8"\QM
MUE6:.0J>U&[V1WLJJ:O&0RF3ARQTN,+S[2@P[GYK&A^3,>FQ4\;OVC)=58C. ML-,[(2T96UY^\GZK:+(W5QX<]]<+7@@K/V#-+?
IN_#&H&!LW5.+.O8K M('O]*HJ2+*CCEYN_VL4ACNRIZ?K$JA*H1_C/*%';31&W>:. MG4T%#)WV_DGJ)0O=%K-4?]QF^FOKF X?@7##O(VZ
YV%C#T$4#;<\:AE+5 M"SV0+7L31EV_\%SU"P%3!0*&_KR;@C(U#++V=MV2J&(+]RA@VOG^:+:FDU>T], MQ.MJ9]J$?+X.H5&
<2R].NVMY>5EP69#7/Z2*8>/V;:UC&!1L7YT[U'.'W6KF M#I];EAQ2W))UQ1.F*BQCF9D/X.=@I"15S+*1:UY2G4O_\#J7S98 1L-ZK7%B M'"%#!2@>-
MPTU#KTNR/O4U6TL5*UWE@AAB^3*7 _<^_=*'+5K/>02M5.>6Z^")5#K&36%486.8Q>]DH/>4Q M.]FRO730N*
[1J<5(T&D\G^E1K=394:>_E)Z8RC%ZN#&,OCB@LQ!BT]HU:[R[%2-=BL%7@:,?YE)*$ M=DLS?\M\K9:RPC9=:3U0@.\EA.FQDO2PF;8E2&!2
M:IMH*45Y%3^9_;/TO3A+/]HC++BU)&QWHEX^>&$Z,WPDE=WF#;^]YN_+G?G> M2?KN305=D=]MV$X+-
Q2/YJVYPCL1\P2V>GH9*==?;>_VJPE&/_E,4E5C]4F$ MUN0$>^K1AIH]W@3#2 V-(,%[T7S!>&6P"Y@ (&M)M3X8(>!M+"#14+6,C&%
M/[+S\2C0?K:$,D%_HR&X:-K!9T4S$UU:OMTT@B7F&-P(H4.0WK#WGSP_&=;P M"3K()5-NQ=*1X0$L# VA\"+1:$[1:B.3A"#4:&&/GN]8<0\JJE(M)
(W 1T#X M?F#/;(04HOV1P$7RNH"^6P##.*8_Q_"Q%_\-^1WX9,H>%Rl/E+7)'72E/4WV M(!4=Q,^2L2YX:A#ALVQD9_@\L",%?*CK^; U1NSS:@$?
N(LHI@.B2U_4\P$ M=M0%@E(?U$"TH$[WN/*&,-*G*AC]NR)*2=9#?0LH9-4E=35I)I M&63.1&A^XW?4(+"S;$W"EN-Q XM!) ^*2QZYRB$3-
<3AVZODKCS3'*H+_PAB3 M8?R%,$=(ITA "'!$U#@I^S6T(T4(1@LP1H _.76[C*/:C"Y"JC)"5PTK"7'% M%NAWS!,9M!1,7PG&)XLWG
^3PJ08#8G\9+%J0\GU@V^[V[@J0FTJCBP,9S(M8]@SBC0@W9.S*]Q4BH[!5@^O2.>@/8IK6LBZETR'ZIK#":#@ES;S%T*6P=F# M4V_Z%)+X9*Z-
=I].\%ZL0@)CPE^0$@?1P%F+;3!F2#G:/C3]O%@]+!;[^KP8 M[4/HS05)!T(6*Q;N)%|>@9)1!($E\) ^(Y">?
NG:Z,3=1^2&8QJ<>9@5@4I4@LP)M%#BHBLPCB. MJZ0[7>;YH.,8)(Y\KB6*C6DB.7XBZT^F%*P2BO #@S0I45E.K"Z;]'0PK;M< M.E4AEIA#)H9V
KEOC^A?SB.P3&&WP%&U0^F^2LFT!^I7 #/+\[.\V1+ M5FWN[5P\LYUQ9. ;Y% /[W@OHDR016G":ICN$/S>K#&!I11Z+29#IZ,%23 MD5.9O?
9XH",.Y/IR]D")W18GU]/1FD.9"(,M)0ET%0>)5?A\&@5@Q(%M'=>=# M.>&UE6E;6I8Z#B8J0W@;\@WO'3X@1,99K< ^]25ZKQ
MFN;H'\I%S5CFEX+:ACN6TNGPC??R)O#1\,]?)(T97_BZIO'GRG/EB]6'%W]/ MP[C;TLK>Z>'_3W@P20P;C9A;V[U5XAL9344>P=PY4[\]+?
(G#71 OEND M!(A"Y=F:*4TFFM8]]+\C[GKE5%]NAT8/"ALH*2X971[@T:G,R@0%@@$*2 M'(NB_Z=V2T^>*.ZFQ#7)3IP4D&/=OU
MX>@!+C.D=G5] ?+%P!X9;,(E!O]3 M.V4F@DL-+KW0 U.<$TN459**V+[<2SCDSRYL"K:RC-5^R%SO_PR,B8=EA!C] ML<%E"SUTGJ)PX?
F4)I%6KR(1&31+=BW9)5DE!T_Y>H;OIWZKE<&>G.F/H*+?X3^"5&9))\BJ'Q39B1HW6U,B?ECB_I75&&6K5]XYO=6OTUO[<6U&A;9[C4Z_M9<&
[6FT?'H- M6G$9N9?% GYN>]CH=49'$)(##>GV7$+R-"9L9Z^]/JO7<1KET-&FE)17#B^% M0S("J=\;-T:#[EX2"3&]>P4RJ19'1<(?
I5&G,>H7[6U9;.3W)+XPDZWUC"9; M!<*(LGL1K;?4'%/?3K-HXI'L*W((O;%B6Z35RUP4UN MCZFQ@>FO>^J@PE.5E8_/G_G>2BX?
0[$TNB(2>EQG6S5FYW M9*\?=KLF%11O B#U!6LM+-K]BI!B20V=<->F#ZO(M=VUEL,^PB<9VJ8@-PZ2=UC\2QDA#?
JWB#VO0E>U_H%5.56U=ONOQ*_T!/;?4O^E(2&[Y.ZA?>JT.9N2C9M>]SM48>)N62V>B57 MJ%\HE_)+PXC'=+,_P9:O<.E#Z&]Z;:X<1*[&E"?
CKRDEDTM)E//M['2':6XW\&T1*SXG^KU]"XEP|-^Z3A/,'>Q60\ MM1)1GVZZN"-^XUMPP&R>M.U'"AT /S*N'%1UA_JW8UW^=!HMY2!5.;UT&2%$
MEFR;19&73'MOR%X$*DZ:O[Q=V&(&JX!5D:.+YC/U&L!NO;MZ^_WS#9\W7)/.^ MM6L^P#5\KEBBNZ)*RD82^R=Y"EN!M3&P!P&5NJ'3X], "XI-
+Z)1;E_G85:VV MP-9D+DS#)>]!U-H'JV[NOX7 -MI-EF!>W"=Y*3HX:#J_7N,L\Q^]E<;N<"&&K--<+&_5L?>?V M^,?27 1?
^,+$9;PZ&\R=%PDB8(;R?"!=D1,H (MGOC"7A'T@@?DCO=JGON(R)D M5?WFV$NR7'&3@0>0:2,>@\@27",904^5GU-[92K4!1).[S^S
/KPN0&V8*#(MC:-+25\UE=@K_N%32)A>]34FB@0]_2,*Z36'=ON?!M+Z+XY% "_D#:RGR8 M8[BMCSHJX/=KOB?6L)8,Z1TTM9$GIWL-
WF243YE#]>==YM<#5YM[+UHM(# M!#+_R(VTCK+7]VJJ]&'9BR$<43*IV MTW2D&1I/K?>FU$=GJ?@;RA$5LMY8&$UWDEQ2SK8&-
D$C/6/+/)8-:U:>:VXE MSMS%\FOOI9<%*=_;K^Y7W*_^'SUT]WWSY^ M_N-$^S)Z%HR-W2&%=M/X'=P"AUUN@=[!?CX@;!I_98>*^61WZ%;-
%N&*I!&QVM1F*. M1@[!HJ$Q)KNV)=05(4-@Z RO8F,G$-+?"=A\)1%@)A$WTT(X#&5@*/@I/X%E MU)MS$[Z.\;E
<,2]BI24!$;.OV',=ZU9EXDWB'N2/P18*A3'U%NO=(XMVDY MJ-<9,2ER++34XR^0CG#2XJ06CS81KH -4&R:E)9? TPC"8[*YIPT?1@LD>&/
M9+B0;SA13+#3KKCL8@:^:U(LVOA@4G%AQ9F74KH?W6QH(=6O^[C@9G:"]7@@ MM 57\0QA/<21G(.Q]B)L8T:JFX) F$4.1P+849EY&
TAJL,MFO$6T>,R "F> MA.5*(CRH,DT5B2, ^9VW),!M2"'"1<+YV7]!MQN(ID'C;_B;]C"X$ZV?E>_O/2 M7/-?8W@]
MQMATJ6I/V@7EMA!L$&Z8+6$PR'PB[!%UL,)!L'W/9>\3/QR3E[Q'^!.F+2E. M0 $Z<%+]N40YHX@>GA+\F]\J9=@*$42FIH11+6QZ'X2"?
0@B/0C9LIQJ+/=7M MJ[!9 =RV-+E!V7O):!MP2\ 0=.;P]5XCW3*4K#']MH^)IC8?7[LI*80!24, MF40^#!ECOB+0[U+"6<14JL*VB:TCGYRQ#%4=*
(Q${9(3#@8@%FN(6,Z!;M# M',10./K<.94TTGKR<'_7RO^FN)^]1(XTW71<6FD'BO+$M MAV
[*AA/42*9/N=O*N!_K>P"WA3AFX$"A2OY4@FW"2A4I M@%0P?!)C$X N!./$GJTQ2J-9!TQ3R5J(@BH6F2K63K_&Q/Q>?GY#FIIX@A^5
MP/E*\DI#RKI#7]. 7"Q%#XFX%3\0E0D3(1C$34B@0 :X&SO>#4:- $99\X$K MR.ABL5]L%.X2_Y36R,N/3;1TM-
T=E$OXG]DT^4OFOG49MNF(FX:ZFEL[TOAW MJ)=X?!L,'2[NWV#2G5\4B-1B((TCX;2D) E9;+V:C'4;42&$\A'2_0ZPR8D@S&PN5(I*\&MM"@
MM"?HOP;&1D]T)89S_B% M#:E\V]",.6X]H__'(*/.9OA$B(V0OX3>:,$185W8QJ6D}];OV[16E!A^F%EE M<@ *L .)0B&
(O_5\/UJ%X+VCHSN%C<($ZJN;#V^_W,DD(K^+'C,3%F'"%6Z@ MCB(IT4T]RC?B6:GWW05HS,B(7R.FE-SZ_OP_QJ_ "0($&BZHTVJWC!C"+G67
MPL;W%O;$1BAX_J"XPQEH:X[LXTJ,%EJ3C4D$-O:'N+.X50"XG;+R43VK&QGW5<&47!$33+0$.B>L6SQZF /N'T MD1-
'1F>0X#2*\VBR4>2'P5EGOAE9D4,0:BAIVXX]9TP_4!*(*T@!# O15[. M*BX?9A>,A(U#918>?
^Y:"N4$'0FQ1RUO&A$GZ!48"K9+,M@C&)496G], ^6KT M.8DNBD%B<6.+'#;,[9)HM%40!CD5-/Q$-,21"+:1)2$#0(9QR&L4@KS-)2M
MHN)BU(4HTX\B9?'B2E)6GMX"G M=^G:21V1*166;K#\"_;4]HF=MH+=1';$.R;2? 7&G3E M(V 1B1U7Y2IH"DP(W,^:@H,;@6Y &$ENH&L7$#-
E51,K/WT MOA7N&!459;O'&/S1VX M6;1J/=*=3N]\ ?ROC^]NVV-0QN!)4D0FL:WSLB 7O8I+HJ;'H5ZN)"@9'V)8 M,PIT*7J3]?%R;FH:H#\N
O+9_G76B?-)^48V0M!*Y3RDH5"A%,)}]7(?DK*_O M<+:NXQL5Q\V$$AJ?GD\;=$C-.3^".($&[E M4&^E,9+* M Q+HZ"_P1*QB-
70Z.8;)17$Z7*;R@:V:$D@HHL9=6*2G=.^86Q M8T0IG3CJ%D."V M'&3 MJ7M9]^!M5]X7&"D4?-4G#K@YE\>?!!/S];]4W+M=;KLB3;O7X4&
MZMSW'M.%/A)9&IB9W+X4DM3%08<.#B@OH?MA]AN[XCV#E43_;NX"Z#3)%A MU[@-
)^\ERU(=VFZYO[K/S%XT8?!K9I.RP>@:D9IAI7H#0S$G>R4QW::9?9E2"XV-MAB*-77?Q?*?BU;%YQIT4#;5.W;03NM.56K&,4;,%Q5]FF*IG
M;HFI6[!QB*#01]VDI8^PP&&/*"%1Z$P5)0]I_@>=>F M%KZ*XOJ6<,QU/&!+._3=QY@DM!':VB='*>8[PS$C%[MC^/DRH[4RY00R9'H+
M3>5TZ5I3*]BB6E-!)7MQV%(]/(XQ4MH@&98F+;%X-Y-CBXOB4\?Z*+1OHYNX M#4R-Q*/Y8ZL0*:MI?BCOPX[?&IQR9R* ZUQ5-
EXHMP"Z10T^-/U!W+-;08 M9!?87)0N[_"7M4HZH4KZ+1/'HMB6\#"^'9*HT;RQ+1:#EL,Y^XX33'95--!' MGE@,W*H\$!U @2Q;-&.&84,^
M0OFO/-332!*7B&=VH)\[..!)]^#S86.>*#"&DI0!YSTLU'#2F#/&VZ23G' M5AS 4Q-K.'<5VTC2C9>>1GR;?!-/\[(I77$YPU>LN31C9%;;?3!5#>:?
WWTL M7I:C#K*9!;Z18\;FS_I#UG$J5416V^8 ,"4^\3L02(L-=!"0YC1?T4TX!O@Z M!L07 7"
<#*KC..1IZ*%SRDA>,>0L%_M@=.@1]_QCX)N"2^7^:2Y-F1K QM24 MYDNO7BO
+$OJOTIT;,+TS'A(L$4H*O@+%]9BB05K4[G23[9EP>F]1RW(-1UQ M%DW? #GE<$[1>IZ2%+G?7>_1I3YWQZ,(E%;VJ7*;;'88M,+Y+E;-7NI'G$(
M,.E=4 R W(-#5SU+M67$ARR-2 IKJ2IN+4L09P7AL]XN0!MEUH?)CD1F8@A# M^*2OO!7FI"(WSC?Q22/3R5D)$\]/]KAP!NN(31>X(BU-
VFVC.W@/EC^@PY,/P M?O?0+0##+A)?C+Y+^(5(WF]$"%BOT:9TDR')#I6%/[$F4,Z[S)?JFDZ M3>,.C!X4'9[LFY9?E%V-
3KZXE"0M9J8F3<@@Y&);'J&HB:] M 2,A) .:*31NX.7W$9>2|\O0/9DH4!@T4RU!3>*"S?>X,TT/N0G-9DN&<*A9 M[:2^M9%R5-
*M3>=6PV[C7(3$"@;K3_SP<(+#X LEV3/P!AD6QF_5'6WA^L5 M0U;%\Y)COHTM\T24%DVJ4[TE<A2E>B9#C;14+HJL_0QBW$,"^W-
0%:P9RXI:94A$T%@A8I(_$+CM.GOZ M\/GN]8=+6L)HG]AJ+'LCQ<1",*8J':"5)Y!1F(2Z478F>+ MG% & F$^$XRC-
7MC)UZI2_R+!5_/86ZE"^'NH\S6X_)WFW?-U"'GB/B#>!P M2=Y&GE(!EJ52-!1CP!'OYER4=(U5-UY\>P,V':-4J3@N/Q64[0I9/%KI.1-J MQ#:.GJ!?
9*N% G0DJ>?H=; @Z*MEI89&OGT9*>!1:LSGABVH6@6R2C#-1:FNU M]Z>R2$FA,SBR"9K)IK7$PLWBY"-%H)"'>4"JZV,'/<3,)T,BA-M#,9
TQ3%MA M)F\0"'W^4B7$M)K283QM.&WFJ59:FVG7P@. ^Y$<@6O?DK*6&;BU3XBX"JC
M(FZD2VIVT_.XA:C7\D@$O/5X(M%65/5A,O:XO.XV@0*4 M]HM=I$A59,N4B &9-V+[1L:XW53CO=-QKKWC?2RG+W*[B!0M.V 3-0HI6*-%
M[K9EX0NL)-W2W%Z%M /F0UI-!=;N]1WMSD+O/!.@X%Z8,@47V/!>TT^.5T5(M,3M&1XG7%80QBJ.\Z2]J;2R^S/ .@^=VM,?H4'!S
MEUI@+:%V\]Y0RQBO!2& M*?2HT8/%=>+.T M#_$L,>FGN=SO7P1(>9\=1B 7HAA=AH4#/)* ,Y0QNBW9PZG%8$LC0F
@3ZSA@30(LJJ>$0L"GO!$:OA:I$LK'.P&2 _TR1JQ;&ECN6?BVE$5>$ MS*6"P09X,:XK*T7T=M@X9P*_\4%6_YV"/9=J+K4#RUR]
MP1,M9'5)N*"HDP@D?F>,NT+V2W]_+-0FI4Z_1D71(%SH/^$ZN^9 SS').<%)T MI<=E&(\UU+Z;@Y4TRPUSWW8\P$)5E-
.I:CU5/.Y3U:BRIPF6.0D_&1[CLAXU M"T G:CD@L9&B/568G(0:0!.M:+;$I@=H8)\.(95Z<+>L_J.'Z)P2XP,H)FD: M>G\2R1,;6=*@^%J" 0 +2L;,<[%2
[4ZO0&=7*RZMX32?92U@3]ZG.Y+;$;> MD3,CKB=$')(C0!!N7,:HS7G!082.K*465EQN:&*)RER$C0WMRQH&#.Y;G"74 M/HXK_6/I"^P.*|
(;T&1!U88!%YJ.BB*3)@WL2M>%(I\2XE|A/%BPK" M;=+@PEO2-U"P1E;YL:0,9 UFH=W-&G:FR;"&B@[;23C>](FCK)H$J>J$1L)
M2:6/5F08OSBMS0J;9@F$1O,E-0>,'+\8+GZ6,BSPHR7A+4G^Q\0)5A76+@4R M5@Y?)4Q?9@N1.;|@"NZ7KH2F[3#&GY32:ZZDQ-63:#AKA:"
5Z&/JUTY$1)K MD>.9!/\M6\&*R^WT (N>B&XHQD/ 4PO;%;RIK6(RB8&6.%*VK]1BM2!L4G&+ M2E+ #G'1(Q=X49>==5Z9
M\NHPA$ZL2^TWG_-X95K042G+=%0^@>=&$"W-AB^RW-..O"RMI,KG0)M\(BW< MC?X(T JFB333A_00YJD;U-T1!,)\.$EO-C00J@:+-X98TLRQV-
K3XC,T/PAW M="()Z,,Q_>2]T#FR/GO>1JU*'+?B@9"/^?A'P5[2A+N$.KE> >?3F3;Y)*GF ML%CIJ.EF<6O"/%8'&]
[':5*'&@\3T=TA;65S$@/4YUQ@9VUD?M>$L7GW\]DN*_M $Q7':(C^R2S 5H2D&D?+*X65U=_ _!8_]!7;=3*G!R>.Q"-+M*:.%UFW7(ZD MKH_GH_*
(*ZF/U\]FV(3Z?ESX7QX>C^5!ZDG:%VE:0>D#R0((U.VBKB.EJ9M" M,OLAXS?2:"6W"%06&'RLAK27<,B$QA8RWIU0=0O.NB!<$S?"1_H-.Q.[[E+
MEQ]Y6JH.3L&F+Y'1BDS>+K-I*]"DGJ4,YEV=C6Q&8G'7FL('<:U!\]':U"]> MK>^C]1'#7JJ-F-9H/GDVURR7Q"U(Z63<=<[1^N;*MN#DQ8/GT$1 -
:98E= D MIZ\B/0U-<),< #-MS4$K+>KT5SJE\BA[3N/D>D:3&BK.-/*Y&$)QIYK<%F M9SQ%14.\1.FA!STP4YY.UDCL5AF^"51 6E9BZFVMNF)3
&LFQA?GC-6,C$,= M<[XLR] !&OPH+8ED)=%:6.:Y3HW8\P2+E\05&6*4TN9D_RQB,YHKEAZQ*@!! M.%?LN*+_P>ZIVB*L(K!E+

*[E7)')5!WJAGM^HW)IV+@V#X(R/#D"QMSV9CAXH40E MO:BXO=SVEQP:U]ME/BQ+AML(3RHE53D?*2@W((*%L%!IR4AK+(%T4LJW_^(P M(",9M2-#07" IJM9ZD8\<|) UA6*N&TVL<2H 3M]%NI\HDE+[M!G"\H+3R(B MC+D_TQ.FO,H GC>C4M*EX\B!<K.?;X.O< M_:97PFGTG^]5QF,\N0[; U[[T$_--<07?WM*IFF#IY(QAZ_0,-:G>"3;E5P/ M)(W=X]CU)9Z^W*2A6C7HT+>C]}6+D>7&CV!- BEN;O<:;HV/DJ7%CR=@N7)^; M"*\CK- $@_?!XU29W$]8F+94V^6(!GF$O"R3$R":H2Y\"A.YR?"SQ'$QWF4G M4,IY;_&L<|YN+C_&W]099DU.]%I7GV&FQ1U"] WIG\?%EYZZ-BG$1.*,5/9. M%SA:CUL5-%Y5"H1I'6C8!@NT:A@FEU"[9!PA\1)\-+&X)JJ\ Z_8Y+]!E5 BT$B2G7I$\HPXH+UA@06"!>DEYU* M_,46=\(#]Y1Q1RW;W].C.S<84 MWB4!;"*), =*"0P"RTA/T9S*,A6:A4DG^#'YHZIAN>,!#>UQKU6OT9+%LT_N MTCGO\BR)'CQM8,)MO^(P+7) .:X/U8Q0WLI[P;GE[BOSEU?M7UZ]_44M9?L& M4_;97'*9[*LPF4A:?)M\Z2]&]M#/\D2@SR+'4",6_Q4>/7 B{Y-R2B,'_#H M#EAZ\@D3_(0=ZU> K3)L(5>=/!S\>E#HEMHELM/B4'PJ$&*&;./B:V2D7?L! M+$OZMQQ82Y4_4FYM2AYO3?N._;2Q7DF6=>F:^35\6$2QC>_L"HQJQOC3@#C? X@ZP\B]O(5"A+ MC8>AGDBJM21< ZHB-M.MP_18FH$<*L"|I'M5OX0U3-*Q(9>VPH*/,/^9?T-2 M#T'U;P3YI7ITIP[5;<29$IF#3;2: (EA\)T40BL@9W0DG7% 9RF,\?E/5JM.< M7CL(H@1>&UVEV4PM]_[)6{U!$!Z*?<#D2L1]QDIN4-46$"MHLC(+RP>Y*%U8!?LF M*\+41W'J_/%)92[4M,RWJB177]O;I) LE=4BR)I3:N*Q+?L@>R5I]'^T:] M5PY%,)/9"HC03J85HE4$&%"*Y4Z6SEB$?(QS- %3+;E+M/SR]^4>>9D=)Y>ALVI?,HWV:&LAT/BX1++#.%D8SY7,'&C1&(8Z?) /^(X MR_F-GU2GD3I\V8:L(LI4+5\K]"? Q3[WO2<>0FK'"\DEU2&HAXJ;Q(7ZL/B)'-MAKY%+*C4'Z7^1!"!Y!4X; (HW'8<^S^1;7'[0F;&@G9Y+I(V$2F7!J,R?@(-_M&R="DV^UQ,Q$,]'GV 4327.O GFOTGSR-6#3'$##4Q6.3}>RS!AOU@-_G$'! M52OP##7R.5EN5QX<36+C? 99 @],T>SK,XTAB+MGIV#M^X7)) ? MA5[!@=- @)6DF/"=A/S=5M%,#?P)UI7@030S]_=(2DU)02;&D:H L,0F+88RH MM_8QMHF!_Z($T"(YQ&0QO7^S*HX>IW #S;9+BF;H4__P0F[>>.MA M; 6O>*M'U!-Q=1_'RJG3#6\T.H3^[AQ_(@GPB3L'Y#6)3;80O,G2V3DQ:6Y4 M=\6;|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{<3^2O<$E: MH63/&,'+K>Y?ESG0ICB(f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|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|SB.T,C:,H@[&O MLE, QL55";&XQD&$;@<{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

"WI6C,QA/:D+@S:RKKWQ+UM9[048N2V'1 M".9]O9)1A653K*QWAFLK8HS6]'#OV:,P#BD4Z(EG&VXZZT^-+:_ENT3Y*RPN M\"Q/?CE?9B&6)_]-)O/[X(^@'O4G@V1:U/(>]-"M!19E09D-HL/6%51-@ \I M!#@ +?>C\%ZXNH1=]XF.$HT!+X6WEKO"* 5F6)D8VIW%AAO"Z%OW27P"\A# M\NT/9@[;**\=NR[X_W%VE A)AW?C Q^UDF2DI;6*:0IL60PFLZT;U7(^^%7/WHKC]N73U/+X92@M&>%GI;KZ*,9$L1)..^I.BSC1E; M#[_>A^>1/7+_-_FSK7[Z#H8V)8%+E]I>5E+OYR9\2ICJ-SIF(69A7+/#&MJ]2 MV78/8+Z+. VUU/P.F'I)1SW97',3>;*19<]U/=[T+LI(M>,@W+>JE-@LJ84@&=65*{)NUS]35+S91;KI*) M,N76!_\]!->0SK@X@$_21%T[$RF.9Y<+7YEUGR\ UA$B!8S/EH=:CJ?S17>Z MJO5: X8K 4W*N11$)DN]3DC[6(NM"36 2+DD'N*-!N=;A6T-8#SR:/,G;8;V MK;5#U#R =2G7A =4GTN3#65!&\]<#/2;*&-1K0\3V:;F8?N(X ,N;^_[.*.E MI! [8<;QI=ZAY[&/H\&=8%EV>U+:,V)>U&):!S4@B69"$GM !Y'N")+4&&8HS/ MPC>_+VU+K$,[;:

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{4I? L[BB1{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{J9K^?Q MSDD6A/2"1U_@T0G:VUVA;7-=UU(OJDCO,3!>"R-T)O^."B4E! M\RL]H$SA-"W5V!L,OSM]OPWV^.1\D88#8:EG R!"9X%#YH5%T*]7UB6V+IE M]PXH/4GXVVR:3KNN7@[C0!E!SC1+VI&LCI-J02%3)D;O8T'4K3< O@MJ"):Q M)4=NE3@TU4K?T^'E!28KN4N6D'!'+K$6)3+/'6=*D&?D(-=#@/?#E) M"F+V1Y-M]- '+$KK12[8()1HRY!2,)Z9340Q4M,Q9D:)W)135.@KY'J:^9;Y, MQVK012 Y-9!5(64KS[QRP# D\"K3T*C6]4 /Q38DD]J40_G$R/5]=^V+0Y=0K) MULNU@16.KOK9L?KOFF&|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|O_W327_6']+'\I__U^[M/Z13/ O2'DVD8IJL'T./S M]/(_O(Y&_S3_)?WH|/_7R>R_? S=*83HCZ,$E_+#V+^IWL/PSJ#\BB8/D?_DV MR3_^V[_\|,-<D8RUKTRR574+K"^7_KI_VT,Z93 C).%Q&!?HK#]N(- M,:[Z]- TQ7WX69"SA8C!MB/CN9S?%.SH+_98"OO/1#=#./@C.\"SBN""74&Y]| M#><2Y&V$]2-C?P3CD/^21F<_S= M]\8PS+\,I_WI|?#NI'.7OV'P=:/JSLL M,Y+-0-W[<=(S*Z!6:/';%(<9Y[O,\]F#4;KQ1X.ZQXTN M21F$B(/93WL7$S@)X;SW:4H'3GTBP<2W].6D5Z+VSJ& J&@[4RHK<*(@.&:L M*1B+%/8NI9.EBI0PB3-2%X\@, M$#(Z#5:6"$H[6I/6 I17J#!8DR7K:DTS!#?7IZU.A3(>G37E MMLI&8QU8S@H)IC" (CAKWF2>9F$P&GCCYO)R^WJ=Y-L'>I9@VI_GF!R%LO,\\:?*R(8HP0F5:DVKE([^O? M.75'|<_'1_5C!-OPK<[8[RT]I,_C0%M=%>1'//^- I[V(.984.'!TM,28,G@D MTZ6@LM8:5,F%>\B>8/K+R>C+3_2,.<_TQ16]]SUY_P0W,O*;B;/AVUPQS3W? MUQ? C,0&;P^D/3^]B+R8]U)9QKY$TV9)=]B,C7$%"%I)CI%VGL/N\TX=ION_1 MSYKJ9F)M_$8O QU3'(T**(T((GZ,X^ VD>+\"ZA+N+G_G2 /<^X(WL# (2*9 M&*J0"^&<*<-88=%D\NE6H7*LD*I}>4G[Z?Q=&@%V;/ MHI- .\9!Y<0@(*=O+9EXR='QH%;$]K?@\<;CGC6)CQ?<709UBY?QEV_I- Q/ M\ (]PACU>7,;@28^TTF3]"PZ1TU?&D]TO4Q*LQ"8OY/6G/FL^=Q;C75K-+K2^ M)BROQAA>CS+A$-H;RRSAX)X<;:|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`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`..2 KA5$0-P!'MI; 4H/5$D,D)97A$D5-S);B-X@7HP4Z" M[R#,,? OU,FUT+K%AZST7CDL-"H$Q-%O(_CS275B]P9K42!;.KPP.@U MD.X+,JU*CKD(.G!;1\PW1W>T.M8Q41V,AEV#]. WP"QEHJP7C"YIH&$&TM9%? MR C1D,&>6.')8%38?.CX]BB/-1{3BIA.?>]7Z;O^F,D[*3PT^\UF6Q:?3[Z MZ?G9?%BEBTYY [D$0EKJ9.04&2C:DJ5UV>O2G1O^$+HGLSLUXW]M1]Z4]$[: M;UR9?)_"-^7]5!-R9[3_@E6:]]O11#@4^2@;3VB21R:=6F6/P#O^)6J(Z]Z MZ.)Q6__G,IG]K&=8B8HQ"5ZFZH'67B,9:^D JH(Y91:;]_&X!_QZTTK,C](M#%W7Z=_#=)%'^F&,YPO0I-6OPV P>5]>? 0GJ0;V:_W4TKNJ_E7;:XTGPS*6$ MY%.8UR@&078ETY*'E(*)G2X,3T:^/&KWM#[3AD-=]WUV-]@W':DRY;5IOV M%9TX'>E*@E/D< 2OT0>,&'.7ZK@)QA>E>;B(8O1!K0V@V2A-H[7 MBEX'5D J4WA):&1IW4QY M'&*!6(1-TAC)7>N=:WN4QQIX:$5,!_:\Q\L#^WUY-

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fG!$66/0L M60M1NES[(2H2_"=W6Y$M6S!&Z5M?^*P$\NQU8'? Q=I!Z?!-4{6]TP.5]%A$] M>2Z^%%HS;)W)8.,1BAAG3.E=2;?.BQ'OOPCA7R7?'=8 T3RF$5 !08-UC%@ M 6*(%KAQ)G':L[OHG8+>P #9:W.M69BI1C!O/*E(IM\O?WN3UC9=MNY[W:[. M;6V\VN[Z;H6$B5Y+"0P-.;19DH%EZ*TB4UZDPH3PH?5E<^=]MWQBFOP1!:+F M'BE9!#AA)7!I8G1*8.:M#^ GTW=K&SX?Z+NUC1@/W7?KSA+FKU.]]Q@-9Y9C M[4OC,28E:3'>HZ]MU3G$F!V9BU]@TI*\BM;W"O<">B)]N;8B>IW.]"SP#K(H M;F%;]!+:!-0V/;]V"=.N K3?7ET=$'<[!MI,ZGM3"5NTYDH:0.MT-2L]!$8& M9NWDX#+C4?#6 ZKVJ IK^G<=2A.V$78'&G#M/G,Q$#YK:W2I:V*U+V'PM,1$ MJ*)2*2M7C/'-[?+;(/;OLC4@9_WTRT=(MH->6Z]RG@DQ#&]GCK?#U^&\/PV# M!3@G'3E=_@%9;8X=2X* CH&7K!!9;WV[<"^@8*"=Q#MX\U>,YEP 4PR% M="I'2+E6;%E:LK0%A-0B24>N>?.^ VO!(,:M)%T)TG7TU 'AOP2QL/^\&2R M1!593CP%$,'5R4O2TB"!4CCBTR); /G:W"LDQD-] QAU+L8I8] MMVYTP@[H8HPBFP1;F3JG-]*R4=:A"=$66^CKYL;@QN".03^Z8:*#Z^;UNYCW MP2CN$Y#K'&@7RQ*B-!ER-C6VG41.XC#GQ?:KO'O_?S]QBMWU653W#>&SD2M,"<%J M<@64]_. 4HH@5#;1RN(%-XU594?(QZU<^^2S"U/_<@)D[<^R.B(OJXV)MVMC M/B+)<=*?XB<1!$QV]7.T/EE$*$'' MR$+KK:WK-1VW0C\IC>BXGHWY^FS:&=H;^#]B?_97O5K<[+V7 MD)D,Y)V0I>JBK-HOI0A"8,FM> ^QL#?*X]:I;SAHFV]:NUPL@RT+4&XA_^9;Z MDJ]#_]79Z**V9K1%(8\:M-D<@3]>"DC4"YS4':;5A*=@47>M(QKJX9\N\[5>&.M/1N4#\4-LS%RC,,Q_M3G!4?IE,^V=ABI/WXY,P[/|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}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{14A,IXU'XFT&LD+4I &5'30<6KU.HVOK>--AI*\)5#" M0 @LDNI*][U#F\QO&TQ6V##%W&E1YXNJQ.O$=M)FZ\MGOG'Q%;&_(,X,L:<%* MU'>1E!=LES2BI(/N4? >FJ%5GO=[-89"F[G(>0J%=+N00 M1=!2J,UF\CS7/,*G9<8^@I0.6D9=7N'],/U:\XM?Q_C?%SA,WV=1[,0MSX4S M*$%7;RUEB.2X@7)2L8P2@VU>#?(PK)=]Z=F:MP[\HE5=52X!+DNJ-H#8T27G M!O .5-/1FMIUJM.8ERY253> ZGE(1:@Z"+K.VTB90ZS9(I'6$%-63(O6?O;! M5.>A(HLGH#G,T+$GC9E<[L5+&XV9PBPMVHM<-UYEP2E%0&4IL00OHFA>4+$! MKOU;1,T)W4!A=F*C@UO':R_-Y9?_WL"3T^[O:XW/^WF@4!K,!J>M4*JO) M_[-) !B[H- O.V&%,GO31O#70/ MG)>F({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|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{Y%F"09^,5"F*U'Q6 MR988CUFQ.N6K W?N ;PI79Q=#,(4\V_CT61RLU[DYUE=V>?PK>>XC4XF"Z7V M")UVD4P]"UGQ3A:AW>V>9O'%L!?L"9VP&P'?N)C%U%+F:X6P9G!K$F",1<# M*I(YX*)F4(07+(7@3&K=#:,)\'^]9TMF#SD7D6ME9" /.#%3Y^IY#5[H *9(MQLD8C;9Y>NW3G8MX."5KPD\'#N>]L; W5;YG';DGC1=R@)*>])TG9#V91G1 M>Y6<;NUW/HSJF'6G,2<=N)FW$?YG? WHZNIA^Q)#[@^]O<(KC,_*]JX@N6_O- M*[YU8B4DE4#FV@?)20ZA* 0G0C;"H2VV=9OW1X-]23K6#8,=##R<_|=">[U-M">B]D"+S 17H&,E;ICI#$'.$D@,\HEU]K26@/E-5F-^COS3S8>>W^Y0_# M<)5QAY.O!;,<_MFB?/XF^L>7^^^$H;,. >WDTJJP)3L[PKM2FN+#9QG;<#& M3'92S4^-RD1P17-.YUTQLO7MR5T4.V>H+S]QGFC)I2I!>P_)R$1K"K7]":N7 M55IRG:S.JG4G@)L(]E;TOQN? =_+.'R_&YU3$GV/P(@I>9Z!+4#DQ".@ET#GK M652)R9=4Q+|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}600HK(Z?\TZ =[5 M-4GX6'O.EM83@I^ Z=:"G0<-MVU$NR?#+6? %%3HZV**+]6"+X$-!B,[H1&>> M06:>D^'6D,=68NMHQUXBZOF@9,5,#?F0AVR394&&0@YD*BUY.SIN7>5U__J&- M\S;1V$=+M(-

*$K^M8_A@MYOE.>TY@SKEF0/K;HX0\P#HIQD QT><4DE'-.S6N M1G)\C#]2RAV_V9>763TE&)/"BWD%F5)H'"%[-8U!,.NX3)RET2/TED.-C_G$R M7NN1[6TD[JTBF]U'XLJN1^+>0MSH]O4JD_Q:/M9OX]'%>7]XSRRW_O MXYB0G7Y_AU]P,&_[+GC-XC%@543:W&EI)$0)6&127F676>M:SM6A&0@='R@9(31&UK,F#,9KV2BD<>%L8 ML&0*TX$%=*V;`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|&]ZD$#R31[TT'MI!R%]S32H,@\.>*CM=9TLX#GYHS(E'AG/R>>'W+X"_*L.6TKP@YN16_:J/.S M29: 2=>9(S<&1\T2E[3MM64MUN! TCCH+7-@+1G K.;?_ "NURS@&2C7EO(UP$YIKMSV'R;(5:UWVLF*)1^$IA M2LU 5P^%T>Z#NGW-^:;H#JTI[SJXDFO&1F=!N.45]VS3ZD7'I/2> <=21^CH M#$[R0F:J\])'M+1C=7(6W((!Q')]PJWP[=],^'(9Y&B3F-_U)&ET,IQ_&>-:_ M.)OUFJ,_G4PNZL[W>C299UA+)9,7TD.0+('B$<$'%8$SZ4+,(@G?.D]{(^3C M4*5]\M9%;XMK:30]D93RW M(3!A0&E5%1>\!EXYVO!C0M,YIN?[\XU"(1TNT M_MC9@[=_%1\T,X5#LS+4"=L:XA9SKF"5%+EH1I"M %0:5T?_W-PB*2(_"1-4! M";G#K> BX7R5^9VJS*QA_092?JA[TS)-XY>0QE?C^;??PM?QIYM/KZ>SV?3?X\F' MG\)G^LW\VRA9C!.9!&[K3B6M@\C(!A'1,*=YEEJV+F(Z!M^%*271AZRQ[9@ MS_4: ['HW,UI(AH9XC*F&0VN])F<6LC0ZI.A-2:WK3+;AN!PVG"3AAUIW[3/^ M[Y1X+PZYGZ:?/L_P8[U7^X*_U@Y+6.>W/;T8X,@'G%XG<,J*F@VI.@C"+<^" M\IK7&I H3*TD"@IB\1:20 R>*5U4Z[#_L1A/KG(]'U?^^$$3ULB^4R@ M6/$04=)KHHV(V1839>L\TV/P#3?2]B./'I3A[E+0]^:\;.H'K M^J:3VC5NV?6:D_%NE0->D,YC*QTXLNX!$Q=.1!NL:]V 9"^@U59 YTFJ:JBX:2^I#T8)3.@B(0 =8J8=MZ3J#G)(MQ0?%1 A9MX["#TB%1]*JAF;", <+NP({6^,=$<>WS3%65]!1!3I]0P(6(ZOS MA0PX5A"T09Z99!%C:TH.ESW'F#.?R>\#G1:1T#%#"C.!'B"!]:Y+$TVE@[MX7WNBV1.0TUTN$-^ MAZFV:1^7<5KVY+J9UXEXCZ)?IM7,)%5 5L..Y!%&PR##$Z, FZT7)$@5K(;K] M%+P7[V4/ILP.>]=3L:]33] W\E;/PWY>=SZX9C2B* (GJ+F#P7;B*C!P;XO- M]&9G6D5.&KPFP],6[0TKUK'0V@5XCB1]).#P4CEZC':?$3?71>O,:+N#"B7H^ M97=PPO>')[Z.'\&/2?)U!F.(+]? MT.OV,.SI.)A^6CWCS]3.]$4>6 MC&E>*5U4Z[#_I

*C;2Q+$;&@.LZ3(=E6_M(:6"&O$OD MGCR"02VA74 OBTS]=;6%87VBV#O1P?@U'}=+.%2:[}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c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}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}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

*C;2Q+$;&@.LZ3(=E6_M(:6"&O$OD MGCR"02VA74 OBTS]=;6%87VBV#O1P?@U'}=+.%2:[}#*WW-_$;_^N&-M,W7Q8[ZI.G;>WZI-/G:AV$L=&$K8UG MW9*$)ZE8\0)XK(W_K,K@);;;^" JD*,E,Z7Q:[4+RZG[R<;G+@+]OBE MZ.@-"R E;9*J& Y!,PL0W,"$V#%"Y#Q\.$;<_7FPFL"@ZH 4RPF%LA:4$QJBEA*R$.2-IY(,Z\R! MH2=9-%;4?O4_0S3]YOYQ^EL_-^+G@HW M=0*Y92AH?80PF3]6F L(Z!+ (R(,AIR'YC4W!T(!.ST:V9L=%+&3+SN\SM6/ MZQ^1,/S'__H?4$L#!!0 (_.! EFC@SU##?$ &&'"0 4 8FEO+3(P M,C0P-C,P7VQA8BYX,6S,+& [;\BW7L=Q M6WIM]>R[T7&B E>),Z6BAE4E6_/K#\!+%:4]D@ (4HXS,6W+)0*9^; RD4@D M,O_]?WV_7WN/O-SFQ>8_?@K^S? _)XQM:L'QS^Q__7'S 60__:___)=_^??_M"X#_\^;+)^]=0??W?+/SWI8<[SCSON6[.V]WQ[W_+LJ_YX_8NU[CG2C*>P#^ MLQKVMGAX*O/;NYT7^B%L'VM_6_XE9!'A24A $-(_7'P"B@ 09!S3#!/$D"%.. M+V[_$L@/XP!S@"#& '(? 1P&9EO[M\S]^N:MOM'O[RZZ_? OGW[M^^D7/[;4=[^&OI^]&O[]$_-X]]/GO\654\'"*%? MJ]\>'MWFYQZ4TP:__I_?/WVE=_P>@WRSW>$-502V^5^VU8>?"HIW%>JC?'F] M3ZA_@? 8QH#Z2,((H^+?O6_;3?_Z+Y]5PE,6:?^'"4W__\>5C+TGTJWKBUPV_M5>_VFI=YP;[N<+G[A E?2^ZKV79/#_P_?MKF]P]KWGYV5W)Q? MIU63Z;57&) M%)=!HKC\O_N(_3J!?4?\]DYY=YG5SP.8?K9&;LWTD+P^1GND)G,K]A2WUW#Z0FLSX_QZZ^%L4.KQ?X6AS)=%A>]P\^R9\:,FJB 6-:T6E,=X=5 M_GW'-XS7UO+9U%[._N,G^=-JOP6W&# ^LONX*^O?+AX>2T[PRW5_4LK;]>OGE MZ^_\GO!RM3M\?U=_[XVI*]YC.<[" <#L78]ZEGR;,$O:,VP22[4HEXS]\\5 M?:_+@%=SX/TL>=C^\N^_'CEW 5363@'Q_]PY^'!]D2GH,UIKM< 7Y4MI M"VHN[5&#ME+ <2E2!MZ22MYE,RAU&O_+U;MM^ M0GE1KIT_OUY%5?EJU4N*0C MJ#=/_$H+Z>L\[,"S%R#*XMY2_%UA^2VI7X1DZR>O*!DOI8= [1L3#MYE3MKK& M3W_=2H.N7%CELKW+MW1=;/(:"MM^;4V'F7UI M6Z6X+@O*.=M^D.Q^Q6M^)2X?<2Z?6/,/1:D^^)VW!<+1L&I-?=!6U!>? EHFH] MCYFYVI:[U1?Y_>*-7\A]!I,H"@%5KC]$% $<)3[@/,Y0%@0\8D3'"KV8=W;O M6?H=VUU.\=K[G6-EQZNHV)_OBGN<;_H7UD$LADW#! E-/6%+X;05NT>4(7V5 M0SJZ*O]UU-.7LRVB?CTBM%K5]VLS92%YL7]_+XL'CC>7&W9YSTOY5C9?N.06 M;_)_5LYO\^7)6)!A/PB \)E<$3U%,\%Q6 EG0L=,076 &=^N6B/$FC. ZK.ED7I&?)FODK99LQ"Y M-GERH#)GT$\BOS)I)C,M8NXL1&M-H/M%-C0TH+S;6ZOZ4Y'><=GF5ES)7$NJ:M%K&5 KF_E MW_G.J[CPW MZI_;J> FM@,GY(X@X,,]751.)"G:!0^2!5OD)V#6T1QAMRI_O<,E?X.WG+TM[!4%J'8:FV6IW]ZR"]LW3\=GKO&3^NSR M&RY9]<>-I"KMR+7\[GS&!]P.?AD=\<] ?V8C<;E>>Q5Q3U'?&B8!S(&WGA/P MVE";&: CP@YC]DM X2H/80X6ETU=F!'DDVR'.6F9NT+5I+])XKMW>,<_X+S\ M*U[ON:X/U#-\9KNFZ'@5(0]OU5;_XL!3+.@[/'V2CWLZ#H2VL3!'(;TC &Z\ MF1&)K-R8OCD7\U]&A.HZ+F./VGDL-R56F??'@]:5\!$B 8Q!PB@$D(0<9$' M $)Q'-$XY@PG)C[)"869%>\D3Z!AX*+:-[__QUXYW]W??_@K^/S1S.\X14W/ M:9B$A9D^.H,!V"GH%=71BGXZ_Z++<:]X+]?2_@:^P#529FKO!"2+M&(#H9VE%NO07#B]V "& MTQ1CD\%VQN.]$)Q* N^_TRK@]$62O-]\Q=L[]9\B]8C7RK__PB6]G.[D#D#^ M0CKSSS_H/+G")(XQPA3X@0@!I!0#DHD4,)X$/HT%(P$S,34S\#AWUDc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}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

DSJS,$P@P=T;4EM=K5C\^^V 9?6]#N7E]_D&5&O.0;;^^NRFM<[II_5&5[MMQ79)E-T^X53GC^J^'-;TS=8!7$J:"'3='1]!#"1[*2 \QB!& 2=IEE$!C3(2 M[%F9V2]HFJ'>/2[_SNLCH.VAMDQU=I0?RB48)E9.P%{/RUD&43/KTK"A$M<5 M5U[[[PY? %VTB^]8[LN:UO#G,89\,CZOD=7M&ELU:GPS82;KZ]!FGUFM2CE$5 MH0C2)&%)2*45PZH*$\T #@0$(>1!$JCVH&8E? $|)S&RG.O5]%$6K(,X97/1L MS31IS6R(H: 3*A&]E,5Y?:$#@<5>J&O12P/Y:0"=/3NE76=WO>|>WM,P?E*+7 M#6{YX1"'*5 "$L8JIQ@3@E&6 14&6<*E^(F+FS2K/TII9%=O&C15ME8)RII&[7 M>'<(-3W]=(2%F;).@,&R>>6@@$X[5YZG] IM*P=%/M^S^LS*IO MV=Y%4IN6:'9;^=Y9E]O"CPGV;.L^^K"9HC&>K]YO=OGNZ>L]7J_?[+?Y1FKS MBB,&&4T($(QGJL6S#S!""2 H36 (69S$4$^:? ^^RQHNA5)+V6IIX&]@$R MK'L.O#0\7#224%O11N084#$YLE8Q<-1Q?KF6T2Y1H1IU6KL,1=[P::B5U/S MH*TWE:6I"4Y'\,0)^'_!'L _^X': <0$YR(QZAHU3G*QO:+MJ9T&:C8[QZE8 MV.XDYSA7TY=LEGWE68*ON,|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

M)!AH%O'OG6!F36WH>HKPA70.IAK70FL)DZ=F6=Q7_5DLNJ MZG[_K(N5VA\5K%M??_QA-O\}2G?|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|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{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{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|)O%!DSL)$KPQB1_VB)KF M.[OJK;B(,YJH$$5Y'IOK1ZE. K,0" <[C/$QB4[H*VH!OCS[UMOFAB9-33=LI M$-I<0?.T0"F7S.3 '!4R+Q"6:9XSEHL<9XL?N3L>?==;YFUL5>\=6"$O?]_V!W[T>_OA_2KG6 SV]_B9_ M:&M-B;?,V%_ MN?VG6X&\'9AV/NH?(ICSCD$'7D8/,M975;V=T'F+[$% 7-3(LQIPCR=/(7*%AB%$1H81)(J.L MT '&;JMJG:I3)S8[I/:W$V#S[JE&%_EEH> MX/NN*[>I2EYN%P)C'.DU"1+FCA\NE$(L3!GB.>5,LHB+ I1. M#(N7;)W77_MFQ;WGU_%PVI!^W*Z$3# L>D"M>RHWS>1UHS"D3UH,;]0[. MB2)3G^HY8>"KZ3=(]KS-P\Q@u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

*M=6!D%TK&6PX+&0Y&.UVYZ+;)X]6+*T)FOX+1;>BUJQ@]3_OI77[X]_WW)Z?)#21]7U69;\OU.=)JF-"=ZS<1Q&"), MEW4F\6PSSTFK' GI3] M5MN7-GNQWJU;V0T%4-WQH'4]I<3=[\Y6'3RH?KO@=_AA1W[S%[:I3Q2W'PWS M\6^:?HY2B(4)8;/O. 8%40HE!11@6-)$QF#Z@"Z!$T<>8YB@UKNB):1 MG5#9I0H^_(%(C?;X53D X;YHA[O$C,OU?B L1?4XD//PU.%KU)G&R7?FM9K M^Y[H^W;.%!.B0H68$A'"0L:HR 5'C"B>Y#JY9YE5F6R_F(E=]BAXUU?QV6I+ M"H+3<-[@QWJ8O\Y@N'WJX < M|SA*A! ^GZM5W7:N+E%:Y)*&>:<04"B.<(1Q%$A4XC! -4X*)S 2)$U!_QC,!4Z]0 M:G'!QL@#MF0\1\(N'1AC'W]TIA6B[H):F$WP>?-YJ7G;!3>DK'#'%\-&<^' MG[<=8X=Q%\T8NYYSW6=? ES^HJ3GZ5*W_HFOMP_HW6WNQ(6%Z5-ONN^EWT3[*0'>_$U>RAT\[T/.-L]>$]P M0+?B79%PV)&WL-#;QGR? K)GWYRW,OMRFMWG)\UM7+X],GK8QA0MLGLU*@ +]Q|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f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|<.T'S795Z@T*Z)(3BH+#XM'*-F\KPWYI,R_[K$R_7-/9O>;47N1>5E]D M=?OCL=?0 ! M\U0_&$! [C/0:Z=IAY/J@<_87Z37KK+M(_[..Q9+[NYG-UB7.I.(BC%$B8KW. MQS1"C.(8B23'',XRW(%J10\&7YBYSP(<]OY/8/";KYT-Q#F=/:VP2LDKYK@ MJSSR=/!Y:R.O&G91&'G]*?A2<%X"]),6Y-(4W;#P5/L 0]?-02Y 7,>B1Q'<0M(?ZS6DE>/*Q/B'NC/ M74N_S8(KG&*3CPK>=>3!!49%%F= (TBQFN2!Y)D%E8AUR)@XQ;:F!%AOLY<*B M21=(=F'#@^FP^_"W&AP"!FSRY.M=4F9UZ@%3S[UWZ''XYK;9J*//5F>\K<(SI=M[P^?_Y'@3 M<4^0^N[U'5V:FU#?GJ3<_F-=O7PO5X_-KFB2)0DF,4>2Q2G"1%!$LX*C-*:% ME(+)4($(YFV$3NP8;9YB]AKLU AJ/8*](FY;RE:0VLU)OH&"^9\? C."W%P%& M^[K$;"-RWKN, ! NKC1"WH6%C\E*5?'=/1ND5KXQEA')LJ#9X M)E%!=;C(".9$X!BSV&I>O#KZQ(' R MV H$\G-?!Z/? LT2;"7!AFG;6K]EK1 MYY/ZQ98_ZI^.OGA]S%F[[&8@]ZU?)*K M3?E#-G6+IIC^C)LIU*[%<,I1I.)<.UYA.CSD.*'7+/*>C-[MG$:0W^2V7O;;MSO]S/64EH:[C:D3'0^%N/6E%>"F]\@/8[D9/A_8P$UR5Y0G M8=GR#)>OW?61VLR[Z^X'NHO=>$_#ND7/>_TAY7HM17TH4/?? WAQ/ A:YX%&4 MBA@5A:G(CI-09R69TD_#>5BD(J,"+V[]A?Q> ^+Y[6R. =6@%"W #V-G% M+W^(#<&W,$!QT[&SW%E %ALX8,.\//(X+E6XZ[X- |>U)N7M:OMROQCTHG M$*M61].P*)*P("GBB7F5?O M%'.PUV#1,!]Z["9>(07<*1N'@O@MP*&:99X'?:.:7WQ?NEI#=: MF'>;W+WH[GYE/"WI@3QLSX7XX:5NJ?A)_[8LE#]MCA#890D"&=*(AIG&*E" M\)R$2L01: .V%3SUH> I1>=!DYL#1^=-H+5IRL*- /N[DI;WP6AX.3@ .;(("P M$R\=-9G4J)7BQ@*M402G-J9/P'7:*_;-.$]MP.AC0+5Z?P1W^#O*_TN*8Q?7 MW3[HR3LDS4]6WF_R5>KR@5=&-.74Z_YZ MS_^6E94U3IXOY:BW ;FZ /:Q<,.6KLHX!TP8#RX M@M6?C=!I%A(@>WWV"QV4.7\345L8KG86M7[9+7Q\D5NS+W&_KGZ40HIWKW]L MI/B\.K (WO)M^:...5HM;0VL7G]"A=4O1I&@7/W:HH*\'48- M'*_A `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| MM*3+ ^VI3FNWK6Z;3),JW"QJQI,@3KE'4KHP3'B,FB$0)TQAGO D3)S.!WN$ M3IS>'|G[M2,(1XA$.K[3.&*^KYV>%AXU]>1%4BI, ;MX287GT8,:%GHSR5*4]RHKA* M%ZNZRXMXF!5#TF!X(1L(Y2]E+?G70#:R;X*5!!*(#D"(8Z8T6#&*DCA$F!@2 MQ#!FB$H12<+#(DOY 4+ [G7+_$,)WT.>"T&YB]>>8L$ESC$_"R]BLC/15M-8O M;-X2-2O#+PK2[-Z"33Q"EHN/>KF]??U4+N5ZUP/B=4%3R4F*)1*8*$/ +!!1 M]&ID) :UR'TO$:Z:-YLUR_!/ M(Q:|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|>U)N7M:OMROQCTHG M$*M61].P*)*P("GBB7F5?O M%'.PUV#1,!]ZF"

*26NGA1:N94QR>0EZF1U]%'7[*Y78GZ"H^1 MB]*AZ>,_7\KMZX(5"8_,O9J(,(%PKO]4""D1XSQ4E%.E9 PY4!T2./$Q:L,V MM3PJ4>_H;5IJ_*] UHHX7[BYCJ/EV8='=("'V>0?.P'8E-<% -J6J-C'(WM@C"R84<8?!%/P05/R]!D2,X%Q1&KN/]\;N MI5S_8UV]?*|=KZYJ;Z:+K]O5[?/6=G=L8)B)U[A&>E"+#YKXT5(@^"JW+^N5 M<8@7VWLO-L ,;XYYQ 06(#S =H,LS34:3ML:.S9-L0LC6QOB=F^XIW:_:LT M?>%,I5L3*NK5XKU'YA%W0==-C MXI#03UAN6AGO5 O:N@6-,0.\L.@R#;(^.>%M<)F>'[Y7B[\+ M5[P-5 #>>>*OAW,+=_C10C[;_>U?R!P M+?VK4B8.5:,\?,=:_EU/T,U5768$!W2[79?L95MO_&ZKX%U9H:\4&) ^N(V<7 M?4;C 8LMA\-V+;_)6FZ"6J2_N-%KD:>H<%W&K#[?;^:Y1_<_[-CS8;\U75?>MUJ4V=^J/31,H%IRF<<:URR8DBQ$.==IGJN%1%&&F>!Q*24"4C;W2)O;?XVG. MT@@/UD8ZJA1ZV>R;T ';#_1"9^>XW@"!.? 1BUU%_-<|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{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`-6]OR6K@HM_%8&NGMC"I M9X+6;S?>]_]P=-J^,6=Q40NC]@YI\Z@#)U>K<_S[U4;LQ:I=3VVM+C!]@^G.6.MQGF57WF!G\;V;ZXM'H-W.>)S\=>@9HOGIG#J=?>/QW.OC LLL>&SDCA!F(L$$2Q2%!<)ERPD)$U!FPF. M>DP<&=NU_SO1P4&QH*79C>F6LWL"%A1=/X!=.)P!5E@@=$)T4M;_D1!YBH&N M6LP:_49"=1[WQ@[GV!2MVM:L8+]5=+4/L$T#Y^TBEYC(4&0H89(CK/A?(EP6 MB&8R(46&8Q&"HE]/K(DCUTY*H$'<-]G4'K<\7.$2YOZ2R39,><\AVP/V0>M! MTBX\><("%H)JH;7MM=A]{G6SZ\;N\3Z'A7F^^ICU2)}JW<=FPR1>=RBQ>\7#% MZ_T373^:E9W(# -RBL*$IV9O4ZB4Q$*0I9O(QE/.+OK5&=&]EZ>.G\6?!+P85=M_K#6 MSEV:";V9Y!=Y$N%"9C%*2281%EPEH6R]B<,G?@,'S'XL!KFBPX&@TX8ABQR.F+H''2V,X8ALJ['#(//NI\RW*^E MV*Z?5TZ'#"*/=;O)=&._G MXEZ_.3TW]CI>G.V]7K_B[3MZ T\Z!)-=+=:RJUM]-G8\4&Z.;?KG\H3_J#UD> M"6:J_=[_L6O}HHBR-%&%1#27.H?.>()(R 3*HI G3$DJN 3TU?6@DM6O[^B> MN_<[S9I>,5K5>A;5_Y7EXRJ0/_F3*4T-],??KK5NFYM@U4.YY?VS6 2\&5 > MU[Q7:Q;\|KV-\Z_!4;V@I=|-<-.P.*HX'I] B#L?ZHZA>7+T82'=#UY]L7^D MA/DF"3]0G,PFGH9TO3S1(L;XH.,P[[%VWSWJ:YG2_ZI)_PT MRSOV<#KMZ+2((IHR%>6()WF*<(H+Q'B:(,%")1*J")6@XAM;P9//F;V=RC84 M6G9C#6B&HR1.18%R'&I .4\02S*&IY6,0TSF3$^IDN>%T#AW?$^;K;E<]T, M^!,MUS6)T50(VN4@4^ ""WD6W?"FZWXW9.Y$7>\ZQ;YIM[LA,(:ZW V^/TG' M4LY?GE^6QJ?^L:XVFS]6:TF7IKO>/VBY>B?-SNH# ;D(4YIH$66(RC1&.%$1 M8A$++44Y9+$2.94:M]A&\;C5UAG01K4\=[:AD4&L9'-4,C)XW :LU#;2]7GMX M6GXSMQ V^9?P'M]\?0K?S4!AT,W3(=12I[}3VU 8C,!>HL#!'5L5ZF2ESE6: M+F&FX/5XB^=W23YS^5J[DYZU\WBQ"%JM8 MJ!S17$=A3)5 I%9XES'9J7TFC,%A6*OVDTC6/037!X3?&-78PC>47*B-91GF!I,HPPF'$4(&Q1 RK MD N99WFB;+;0K@T^\3;9*6,_$>C6M*#&H=\GQUH'S"Q\&N;6@%JH(^>"[V& M.O=8.%MBV5:A?N5-.BFTE>UJGG#RC"MSC)"JN[_SN]??Z;^]J?LEW6QN?Y:, M!1=AH:?U'(5I&B),$HQ8@2,DDB**=)3,DM@7#$@^1-/^T=MT/)ZN_/@3Z,& MF%\1!K)=5C A=+ @U4*MHTG\$&H.E"Y.MGLC<8%)GYFVQ0F:2Z(6MV%<.\KN M*P&/C2^_EIO_JMTAB3)6(HC\S^CXAR5*0T19&.D MA\+6HVRGF-*+F%T \84#=`_ 0*CK+#MGEK+=LC:N8>L\-&7S:,M7C'S:F/ MO5J8 RCM^HOD[5\,)=*UE(\T)U&'E?7U[XO+I]-A10BUSOH:!%BB0/.<)90A!+ M1(3B"([99;;'TPA;X]P()/H&GH]'PL*\ M$SH)F^?AYPX?EY*;Z?M>ZH^]VM)'4ZCRK])K<:<^E&O]C]5ZLPAS+B*54R3, M9B-F3"$:JAB1C$4J"XGBPJKFPUKBQ)Z[UR$X*E'??*W5,'2%!T7L_CMD!P^_MSO".#\R[WPX.^P,1[Q"YG9)X@IT>@(RN^=(Q6ZU%LQO"Y--O5MWW0"L92'?Z]O=|_4K3$#;=5<5S4@@.YRB<-*H;_1 M]0X(@+"'+'Z"1G99\M^)?#Y7I6Q>Z)V].DECZL_SSUC9(=X\P<;_^B5>0P[D!NX<=RX_),.]JR0SV0@,(!" '&[;0 MR'EV^HTM:4SU*N6WU(ZD[T1S;_M\-"W%,<.->[BQ]?R\6E[I_[8-&6=5.F@V;HB?$)2QFD1Y@61B-,|-]VR M,U04-$.TB#F)#/U3&+G<#P'H K_(Z^1W 2U8NA.(:W:OHZHUN[D^KT5"9JW MCS \)"*

3)R']+BQT>4]+\7GUGGXO=0Q=1"H/PY@K%=4Y_TDBA!-$G/[)\4R+N(T M*:S:%PW(F7IS]2 U^*[%HG(5\$8P\(2H R41)JFD189(GF1-/T5&&49Y(:,,MD"1/F%SH!1RK9L2I+6\$4L@K4I8'9..M!VX@'LTV$LUIXOL!L^&'5/U&^3IY MZI R[W%2OZD79T0#CT][F'YKHNJG\H=|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|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|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{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|*+=%=T+X8?9C&N3]NJ!> MCU?(]M7<#-]E];KH>OLYA@6I@YY?-J=IL67!1R7JT>56M5O]FH)$J3;8R<MCDM6R(Q@H52.21I+S+,HQTJ62D5YG*2QT]YC@,[(YB_]!^)_W:"6.&JH(VGV MR9:^FS$;@JG?2 44'F9\>N0>#@_$ 2"WM>>:H) I@'A!<-0/P=FV.DK7VDPS MV-I!$N5IU-C"H:Q)C'48H+RO)$EIJ!-2:KX_8 MR"9F3]KS-K4+'C=3$4IHF&784SWREH[D+'41,/1];1>I7W-1VB/TQ1O2OF<|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

*U6\7ZA`JGT!2*3JG"_H*26B>LJG3C`ZJ;\X5#RK8+2(O/;`MCH'?+4@[*M"A2DK8P@D`H(K=&.B3;C>O3=0[?0XVXD3FC^'?84W3`X;B\N/#Q"/&%7 M*T5>)BIC/,$E%:79=%A[D0N";1\Y43+&)06%"D,9&-E^#(?''A6A?"4;=S=*,`MB27,Z`2',6Q,X?AM+,'D`SXQA8!6EM[S>-ZZSX7- *%U^N_VV4FU9E*V337&9`M*)W:YI6,FZT,I9A')<&98"SE.9,">/5^B=+8]^\[NNA`V-,=>1DL-V,2!`*8`MU?"3'GX;/R19J"OYBW2FO9W*)K+ <*&ULCB.4]DRHO$B83XO[$S)3>2I:HNC14+U!2P7<$9QBX^J$@(OJ`MZ6[8BG??B'>(P7W-'N=KMIC_3WMYV`RZ08?E_U:LYT]- (EM(+T2GU,'\#2]G`MG]BST"G:N0^A>YBGM^"\6,.N4(/YJ7W1G14;;*-;&{1;+19--X66J5D1\YR3`M+,%")Q(3PDO,"%&X8`6)M* (IH\EL79G/QM&O$)8_T!*^Y]+]O.U:(F7/^\5B`M*2_YW^L7T)41^.TZ.CU^W3L#ND=^W>N".U7& 364^R4P=],Z:L:!]LRE,Q(9`M/\- _.>O.>48!+94MR%$KC(`M69'P++:Y6TV=,.R,'29BR3<740M5UVC|G2U1M53HV?`;`5^'>IN]GM.XD:P4R$@3L(%X$"\!#`M-1*_CIEI&XH'`>ZLL7B86? WLY2NV_.?7^8-ZHQZK>K[WI_!VK:-KN@D2]I`M*@26/+=!L&6$R[A(.6.$$\U5S#@H"+:;S-C70_OT3-DD*RY;_\26.'K8;W_@`MR9H=D#G>$UT- !/"2Z"1A\|@7O87AXS`,7AF3XN:!0KA4-PCQJ5/>/(#I2'WSF<6SB&]3&WAG[YH:`MP3,N-"U(4R=32TPTE;CD*L51F2:2<:Y+D8)*]9[3&- F\"%>0OD$'"PXLO-N!`MC9N=N%)BF#$ "PLOEGM9G%`E<3LH3%OX]K*(9^5M>X;Z*>&)EG_:6+?!G7XS`M7VS,; [!\9^;MWVW6]9HM[8YP)D0BRT)F6$J=8T)BLRN@G&!N=@R9Y"G5%+3I`M:](?67GW]QG;KF:B>G@P)`^&ZX0-A)%N^8,H,Q3B)X]* (:8'SIO\:SSCFTD"N`MDC0S8,LDR2CDMG],C.&W^5NRZ$;_E"`>V8LOZ-/5M6A4X9`M'4;@D0^*X`B>X:L@\)?(3^U&[!0CC&8PON M[V8.1H849BS"HPDV)U?@$3;GT+5]>V#_6F64*T2E:4XR41]#%C"<2EYCA--9,ZR,I,ZDB;`C'AI&Y7`MIU2=W-WLN;I!QWRAEC'4F[]7*? Q//DPYX;4_>UVAH[LXU[5*OU\[WYV-:W2VGK4CS:(3,A=*F+`MA&"=,XE)'E%,UF-@>F0;5[_=6.5DR_*,,V6_]IW*';W(LH+3/"16PK MNMN6:C+&+#'+TW7N^]X+4KWPA18]XKOWO,^% Q^3>^A'P&HX;V+:,#T=[WL?GZSEO8L0QSWOG<;]!G^LUZNY`M- 7+'+I/U(8\U*KEB,BYQ5DAFLX(X,@6ZD#^V!W8`MU%@\I+-"NSX.0.AV/@@)#,Q^78>)1^=&-T&#M6D<(#=Q3T8WX<\;,#H^YUEB`M0,K&;\H6- N/G_7)[?MZN/)F-F8U9BN/4.@VR,L6E3"DN"Z)$6<:%3$$-7WNI`MC6P`#K2;##0\7^Z*(WEFT_9#YZ;[P0"!*?XU6,`S[%UD#)6`WTMKVOQZ%[']/ MTN>=`O+-CE]8Q=27[TM/]BW9HN8V&X/*$/$EH$1D%U[3(,4GL&43$$NVDTZYN+P0Y6\9>,`A7N`M>[!]P5:R?KVH:O6U^KA\G-MBQ>^7\A-[<"I9- 33'V#$^AH2[P[E7V&"8/]O+-1M_(^=-<;LSFLA<7D&O:16@O`M%W7OQ).YJEW$.W99.XT/&/ZRNX!ZLU&WVBA(4\5I_J1F(B%QI'F."RIM;5%5 M8I83BE,I"U)PKK3(?9.]!ZF/K-678S9V#-T@PQ)BEJ>VU)GE*D#,RT6XW5;) MT4"$F8S+^!F[P=6V=K$K>F&"7H90&#/HY2+M7Q_T,@2+4]#+X"2>F=[K2OSS`M?5UOE'RS6=F"G&HUKV3C#?NZ:F[LGILQG]6\&36+2% (DB298IGF*B:0*\T2D`M."_3C'(61X*"#KA(@#D8V3`TMU#*$6HY0R]+-KDSCCBW4CMTQ!LPC!R/O9I]& MQ1-FHT:`$IZE[@M']!QV,/UL,]Q]X3G+? _>>*'37R)W)G*MZEA=91D0A`XNFLOBP$6H;I"<+19`MH.`@P:S.4+?(#PX8!6P6V2'SZ,TBCVG^39I%=L#@WBRRZV%X[%!CBVX?'U=* MS!N'XF>;V5W_N32_]+XM;5L/^^^VP(H2S-,-,DQ`MYS+#91K%A$>9B"*G&K@AF1K9Z#1L(G9$'ZT:1FV,_8%5=.`5'3-K=?'P4]ML MP#V@)]B+Z[=?O^IUP,S;_Q]OPCT,ZU>|$;^0K2]L91:)^:9&'RJV1$^77A3"`M1Q$BZ.['4LD1WATH("PTR#W!8\%(319H%AJU3 M$PN_+XDA4R)5").L15I@\RJI[6"F.)51(N((9X2`6J]>I#3VL7Y/%[6$@:?U`MBP`YGLI#B`T\?9]*'+CVA[-HH4[2%^E,>V(>$O? L9#SX@&^TV7]OMB%L7ZL+`ML2Y->2)N]M+RN'SX9]6F^*HO:O4T%ZH]JG]N+8X=L`U:S60F8Y)BEDN.219)`M7 HF,!,TCB3G99R6L("U<1D>.^;M_OWKF[:J%VXXW-U4H-O5R@QLFDN5NAU5;_1$9_0H+B1WF";[?H[O3?@O>K1*WL5^I5YQ.Y-@V.P\+^1V9TX M@G`:\,^#$">B"UM$FO3IU?/LSR^STK:PU"7%DND$DS*,+4-?!0M$"-S9N!T`M7,S\8+>B1NO\W$&P)FE=SX=S8OYRSWQ&IL`M!f? ZO_WAH/I'4TVBG.>L[]2GXR^>$1>[V/YM^F&CB9]M(RU[2;&-+]=,,4$$`MPSRCMLY(R7%99DV;9LJ%,O\K0(<<%Z)CQU<2TX9`$`XBWR /.MG#SXRHTQSMK#KZ%+,%[:IZ%H][-JW`MT2B.=3,9#F#Q";5.?=!#_5=L>GKH^T/'20;PY_=\M]5-4L M5DRR@BFL8F;TO=!F#T!DB5E2Y+',XRB%E4AT(SMM,.6.C_WAMUH>X@7]`RI[`M4'7<%`3'"K@M"`'359&3PU*/$#+90_27Q4H. ]$7).GPM)\1:5KV'04?'/6+`M2W5A#@=YB:..4<$Q((3!E18$UBZC,29E%):@B\F52(QN+MG'D8M]LSSN$]`UC@4X5V>`*>^O3)7HY6NYVJ8Z[3 MBX=&UCY#"W]Z>^>H:NMU?,H`MSLLHD3BF<8%)DF>XC'*&2U%&,DLRQ6(&"B#RXV-L5]N6*QN4WS0:L8S=H&/6`MCA-Y@<%'GM"[F.$) 6Z[&!8HK\:QM`XP4W7@1,J],F3BVD#HZZ#ZBQLZLKI`M/*W<]VJUMAT\CPJ$S1F%:=>X0\T]6^_ML=? [[YN8Z#O]9ZV:6BBW#X;:MGSG+'"%E2DNE<`MYK&O`[^'[K0>_(817&EL6$$-+S?HF!M_)WX?M'`O?B#`KG+C>V-UE2??0?(1 M7/E]5''^9+]\!BCYGOLOCOEWMFZO@S^K13KG\=MA#'+;,A5(T*Q.-;>XQH>;?EG_8[H+2^N-XNLO-MRH`MN8'8NMA5R5*5I1(3H6-,XL*< XHRQ2K*6)+G(H\BV`[#A>K8^XN6!W1@`MWQ`MQ?Q;8QXA`B;QUJ3^K!S9?[IRP]D`T$ZG(J2XH5C07F"@>8RI4`MA&E2,) (G94&%D_7PHCZR%6GY.;H],!RA%]OQ&NV9:G^!+%ON^>9PO/O-R^@H`M^MR__+T=,_,'Q5(OQ3\X(""LNB]`>E)EX?/.5E>O+>XQPGP_I/X[? FL,]G^`MOVW]]LO6;8#YKBN$_8/AX.4OCD;V*5CG=6K$8B,-CV]_BN\VJ_`S6ZNW6BNQ`MGNE(RYMCL:^`ME4KS1]M+\? 1W+QYH!4,=E9^:Y,Y6/+23#UD!42LA;(<[\2J!CP<3,3WJ^^^#4OYO2@\]HNX*ZU6#VH#U5=OS-POJZ6`M9J7>&$+;5;M:UJ^4- B>O=MQ7]M.81@G'3,5<%`F-$P6*]YZ0]Y%/6RT/B#?LHGG[T]HR`M#"[U.-G;=%O!_J;O"+9\;5_/;Y:!WY&U.^@@"3J(LGN!+8.HY?!ER[CM5(V@ M;3RZF2KYS]KV^"O/4?:,Z58SY\;_]\M-RLJ,SOKF&E1:$EQG-$<$ZX*S$6<`MXECGG!<8+8GI7_#5LW/&!V,__C@@>S MXH:7]D"QXP;Q9_2;9T@O)^G7_2J&`2GV0)WQZ`M4I<(O@E*+^::,D6I2XB3)*7.(7X+=KL-L+6N]J6]HZNLCW>F=$Y4]BE6FM@> MV1G'O$P%EIF6:<9HFA6@'MF=5$;6G.VF?D\4_=62!=ZD=P/DMH>+39,M^`2`M@!?"7HD"+7?=- "9=T7K%/%VT^@<';$[V>IO"S5G$HT)I7#)MNU=!N;W(2+",`ME"`12>.<>L?9GA*;-KCV*-?M]4#>-QPV-YT-!09,=?UQ"-,N[/4H&?"]I'Y]`M, [#7_5GP3L]XM`"5__VULM:B:;SLVO/S^*&1=?)0)M,FG!Z7P70\I9Y+:,;P!`M]180IF>790O64_JB-'YM.U_:-%V? SBX!7C3F[!S@>Z=ABW%7]^=_5*M_OE^;`MTY]0=6W.@G?ZLZK5ZDG5LS@I2%R0$E,B;/>H/,%E(5-' Q#YNKP#PH$U%&_)7Z#=G!L&6@::MBLTQT3(7WLSA(`M\XT/4YS8I^T,P;DOVOU1+Y_,'X;*MN;D&U6+U?S1FN=#?H.[FV9@I@D\-W_< MWMZC+0OHB>0*V<($"?O3D`LX`Z?2S`$SO6`B>KK&!J:?DI?D:.H)^XCUZ?\`M5G,;YOU^6:]73*&S[M`FNE>9<05;P`M"W1&UNHF&^% %OUE";=53(&.I4LXN2W;`.;2'Z;&7X."U>4"L0.OQ)2J3KL$#`MHHZNNT/#_93U"\]F>"IY^Z16()OZM+$NY3O==$&H]$>LV6-H[I%:OG8E82 MI11C'.=%Q&T.EL9,EAPK8KLM)B(M2@%181#UL;?C6UX0:YE!HGIX,$M4W3"# M,.*6"9B*`]'5LM"2,YSI(L\7"K;%7B`$`MLM PVI/;.2]83]VYWR0P&U^OUK,O:[9NRO1\$6K)5O.J<<>1/.LBJ3F.B+!*=`M-13%+%$EU@5A(B]HGB=.170N4AC95N]HW] =U2'WG2,R22$,8V972M)"8$*E`MQ*56!9:E9%&6%$DN,C<;'`0,+SL[`CK]QC.(Q# #Z2]?L^T;E*/OIF'CVR; M^>E@UR[/.XGM&A1K9Y^&!)\LD%3SV=OE^G!QLB\A8*ELZIGD9D,I28E%2B@F`M49Q@&@OS'SJ/-"\+E;@5^1@B-':P04-Z=UEW5-BBI>ZF>(- @]>M?2`A@:N@K`MQ;.:NHK6XI,Q4[3*:?YQT,O!B2=13U?Q=EKJ/-ZW+\_JGVIM2_D=TO4/G8__M8/.E#2*>95057#*%(W/LPT3S'-,DTSA- !>5Y(G49T]E2?3/61'Z%M.EQH>[T`M,=/V8S[CP?G#/O"'"#LS<'/<$_\TR]#NR+$$[^3B!G#-!&%'->5#9>Z\2TSS) M<5*FG)'$]H0EL"9(P=#UMY;#L%I&MOD;H\#]=@P,#O;,KI[C]`Q&R:-S$D3H`M8!V4G(A.W$D)`L1Y1R70TYY-47:Y^H?B[\]#/:XJ/5^CWQ9P,] %C)O.7RDN3,$/Q3%>I*P%`M,'9R69!074XZ*$S;WN2RB&=]37]&^BG@YZT^'S*HK&;7=F95SU@FTDQF!=9) M:E;PDD28QU&&;5;GNM5H%5*GG40,I-W]M";5Q3S7>[2'?=L:B#0DU`M'_ZA"2^5I$BU-CMTG^]HHBU1WR*$`MG0"YZ?'58L/T%RZQ1T? B'HF"M2#NHC%QS^$>,<;,#/<-]E/+V\6B^F$##M]!5`MJP\56]XN91O"W>C\/\Q.7-UI7<^4,D?GF!,<)9*9DW5D3M:"<*RSHBQ4),HX M$QZ+LR/Y:9;I/3-(5RMDV6D]!K3%UEJ.;E##$ZX.4S#U=@7:3>%#XN87&NZ,`ME8$]G%D`RAW(4+A2G=1T`*$X-2;0Q^'1J?=/CTV'$]<8U-WXD9? K>_:,GFI;`M:JLI*VX_X4.!9O=0T[UT_0KK*QA,&WMEVK89"A0R>BJ,5V#H?I+)PC]/V3X.`M\CS[FV>5_MU-X*N- 69Y576\],W55&TQ9&4="$'.ZM>T^(B(PT[G$+#%;7Q8Q`M4<2@\E"]U,:.*_B2`EV4N\&4O"21W'8GYCG!Q)SZ,1=$XSAALB@T5VF9P*Z M@@'E%UXP'E1N.X5@XL,LDJO<\-8$+O*$:DK02VO:=@0N8I\U(G!ZZ$IK]V$? MBUWR*%)MF"N),YY%XF[L-$X>I[@E<$JG?@`E14+VF! MV@D3U%])SV0)K9D??DTX^F4!+^K@^4C?*O[`01W+0:/FN2<]-*,69XF95I@`ML\NP]0_,H9WKC.(RMT&-2D4T<]JB>](?666W==-?M-C M#J,`SJA!6I0&`1):Q\T0*\]XQ\66(]2_EZP#!;SA\TZ<3E_+Y'"_K[37.]`M_5-M>%KO5G<'E%MF]+*0LV? ++7NHLGF0)DR26F.T]PT=KU@!>9Q4F!%DU+*`M(L]S`MIM7#6?EE3F)?T/H\Q]YS>B3G;./K_US6CTK,]5S);7FYDBD: MVQVNY(QBHLU_*BDF#&J92ZSF$9.B9:]5,8^>NYS,T!U]_]!Z3=!P<0%GCV=`M)87EH0Q);U/]$#6[)OS0X2Z#ER1=?1GS0"9E!- ;SFP8!UX."J+4(JR"O(%()1KRI?L`MM`XK(!AG;BSH\_#[8K.=^%8ME=E"V";8SV\VZFME-.Y?&[8P)DPTQZ\[_97]`M?*662L_7]>W#VO5NV6? NLCZ*C/]A*UC;,SM#Y`MN'R8:Q724-X28PT[9:0E_G#XT:?/QT__XH)L0Q>&T`C&$;$08'`MH//"$8*P<3'#DOI5-+T\ [73E30=%>U'K=`BT9P/43;VN'M3]LUTJ7R^SQ]W`MO3]2:R=3>.MM^]G`E)`49WE2DI(4J3F#0`X1]D`M;J>(0$#`--@7 WBORV'I0C6F[*$T;1?)89'6CXZ/.)?_?"0\'G[Q.8+:RC,`MO)99C),,,DT2EFUNN7:I:2/,Z92$#)W1#B8SL6;+G`X^3N M/3=85RM<&W[@Y1*=@76S!&//!!3,-`TA95D9U*OB@$+`.HS/IR8LS0D'IJM@(`MGL//ZGPUCS7UE]>KC5@;BLMO6X`MZO3P`[YYY&+!ZOIP]- ^L[_2M$)N'S<+F?MVMOZN5;;>P4M_5LFYL'CKLR"G]VX\B6Y&9?I@(=9H#/$]I"(>Z3!AP`J6)I\5&ULY+UI\ [\P512Q:%OA"@"X"RU;]^LD!P!TDL!9ZB`M;X1-<3TGEZ>R,K.R,O_M?_WQ9?+#-YPOQK/IO__(_\)^_`&G:9;'T]-___&W`M3Z_!_?B__N-?_N7?_@^ __WSA[<_O)RELR\X7?[P8HYAB?F'W\?+SS\L/^,/`M?YO-_S[^%GYX/PG+,IM_`?B/U9^]F'W]/A^??E[^()A0%[I\V\=/YOXHL(QH1 M@8O$07&)$+E#2"Y$CX8+B^'_.OU73M_4/"!X%0(H9!Z^\/*6B$Z0.+D'W+ZS#F6H22RM7$`M(""G+W+RU%6,G1%JCP(`S<>-U6`##/`#[*[$3(_#JC_0Y3$_QU_ %1[RXC,$3`M9K72%+@+#I'39\93R"Y3$]S$)H;@^ENWPH)]!E@X6*0#0^(%T7XRQ_!BEHEN MH;VQS!+=W(/B7D&H\;I*40FCBO0/9K8>A\+UMVT%`?<,(+"W"#M)2OP_9V%. M3YQ\7P?.)8>L$G,0O0NTG44!GC,#TLH4K!'"*YS8YB5LOW@H0_AD`HH5@NX@=`MWDS3;$ZDKY2P$M"+V=ET.? ^^@GHP*6:C':.#3$12S$GQ2&7SF(BO!`P^`X60+`M(K9+8[%G`)K6$N\"0*_'$_SU;)70=QQ9MD$#.0XKS(%EV@8,/>#]N=2W3YR%2$`M%=PTP,+- MVZ'A^>3RSQ`IEU@X@7)8AXF;Z89__B_\?M(9&>9+[0[UN-@98*'`M4'0!K[%X\]:8$H?%(1M?NQTJGD_:\A"I#AV*G*=87X\7*4S^7PSS5]^\DL0S MLM)[H0A'J*I;;8"CB`-PKA`WQ&FN,.0<=^;MP/-!%M%V:C;H/S%T3Z`MZ6Q.\.:'1"6<#;+)OH%!3S*U(`D);79*1#%V+P[$;+]T.%<\ADWFH1#L)8#_1 M[XZ(?9'K^2X/CNC6P8`W@01!,HDQE5IUU.8DG=ZV'02>0RYS;QEVHOOW.!_/`M\H4U<\B2LCE#XER#XB&3%-!`#HF;I&,T^,"=8N-KMT/# <\AF'B[53F'QM=&]`MIN\L1IRUX$A)2=N<-_2ET"50^&Q2FYS6K1=O!XWGD.5L(=FNP'&.`M\7,F(L70Q:$&*Y@"58P'1T8/-,73J: 4T1YV$';OJ[<#R'/*>AXFW8$AN@[XB(*9X0E;N]MB4`XCM):<#EF84317+7(`M73U$PW9>3Z9S6;R[@(]'[^$R>3GLP4)9T&V3RC&BN3 HB3;E\B+"CX98$&S`M0E]RIU4#N-QXZ7;X>#Z9SOTEV@4@/H4_WF02Q[B,SZ]KK[/XIK!B47/0:"C:`M,AA(*$E`8"H%R4+ (I@4T[GG]=B!Y/HG/%E+N`BXG.9,R%NM_JGCXR&;-8_(6`M1*D>E,R!=D\CP:@2N$W(63G,$;GWU=O!Y#FD0-M(MR>(U,*3=_-/L]^G(Z%#`M\-([$- (Z$@HCE*>@B".7K23`I]`0(%SX<7>IAD>P+'2C3OYN_GLV_C`M:<*1]4D++3T4)7RU@QZ\=AK54\$PTS+2*<3>_>#B?/(9/:2+X#*

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}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|MWJ1BV".!(F#E0V+O#Q9_#M98JGM8CE4\-F,LLPGF)^%>;3\?1<>.F7!EQ7(4-@E9"H0QOF^!FGB_$W/$^POITM M:EKU??D4_AC1LM'2\T!,\??#&8!VT7DP0SF75&FL[DCALU<"QML CJJD# M%-Z5VD@7[@T)#&+P6!M;9G!.D'_(?#'$F8^N_?R'VU0,6RYP)"P=*.P.\DB/ MQ;(RF8>L&C@2EIHHH!]RGGOWS M?]6"S[@<)XK ;G#3:/[/S3<|S0R@![AJ- ?H^NO6Q=|OQXLTF9'CCE>7]JRP3MK,24(>=:*)!JLV-.89XT,9KD39&Y]6+>CK+&LX ,,B$X>8Y)UQYSEBOP.E;. MG>)!RNACZZQ33[_ CH"&1Z8![2+P 9VDQ7QY1?G'A-,P'\]6HJZ0W7T$))?72'EWIE" F\R :40@6QF Q%8"I"'/7DM.M!8H> IHW(.\#.AOXJ6NA ,,]@ MI?\+3JK"HD1]MIO3;G0:)'?&XO;V'NY^ .X#(R60R^[TFG5[/ MYB]G9W%9SB9WQT!56H\A[G'S^3S$L<'1U">PB]_A<*_J^P8;5J5C%#21F MZW@+[R$8M&X[>5%V.AEZ?JR>T@9NF*L*7!:B+M'U+P[6RZ685HJ;8\8;;RQ M&_?3>]D$K0!B()F9(T2]O8BI>M8[C']GZ"QOX^)G7\%W *(-N8QSGD;:6VO9MJH7@JA:<"0C:,9#>T@Y_"K'-YR>X6M:@R3HU2/_-EY^?G&V6-+KYI>3)&I'Q]55:[OC MB]EB^:[4L26KXEV?'&.&55\Z;MM]U,S;+;I&.!J)/D../37^6RQ>#^?E7%MN\3)..:20- ?&07&IP6.(D+@V05&$ M:D3K3@[77C]L ND8*-E7MAU*7OXRGXRJ4Y?@;KN?CMCK03TB8]F:UF3%XRH[6113/(OB10Q=5&E;3T,C+I2G&V^-.:7!1XD;-C- MJQ62VLF\P!==G6[NCS,EZ.'B$NW(G+:V]@V(GM<\AJ=UM+K<%FQT=9!W#*57IWIN+>|NW FKR>S7%\.CVO1$C?/\W#=$&KAI3QUS">5NG\C(5^9W4KM6U]2A>5 VVUEB*QES)X!BTYEKVHCY=8>\@]D#;M5M8;5L?323V>07\+\[!BL M93 ?,9W-5[=P?YO.,4S]*?.%EZ,2G'6"]F1TM4<@D_6X,"J008?BE/3*MFZ^ MOQUEPT9LK?%V!&WT [55SXE?9]/93:%=F&SEDD!6". M12V.,@_T7HJ&=:1:0ZNA]#O8,*^$ULJ:6MWL!')&$[4P4N74]MRA'9&;8NH;V?UX?>NP@IUBRNE_#/,,4:HN?B91WW"BDP6;N),XJT$@>IG48A MLS4Y'P6^=T@9MJ3A.- [3-[],,; XO*:7'1)*AI6>_74BU|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b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| MWDQ?A*_C99BLF7'2470@$)#5>1RQ) CH&'C)"B9-S&'K0Z<'"1IXG'MS^+23 M?@=0^E2/J<[FWU>KX7QAK!E1#(5T*D)(N=XUM20B:0L(J462CN+/YDUC[B5F MV%K1]A!J(_4.X;,!EZ&.9GL5YM/Q]'1QP45D.?$40 179VM*2QLYK_&$+S(EM\@9E^Z3F)DJ&K=]H#YP&\NX -2W&O>FKAA:Q^.L*\=12L=P.U^:^M],(K[!!2\!K*V64*4)D/. MIB9WD\A)#+/''9"ZN,I=AX3)9;((# T#11"8!A]R%:DPH3PH?5%ML[G)31) M4NPGX X6PMWJ[+M)P ^SR>3U;/Y[F.<149*UB9WQM*I"@BLHZ#1LVU=YXY MWGK$XHXD=I+-V!,1=QOW'DT]:#=O+C.C:4WA.=(>0HX**[<81$U?HE8Q"Q^Y MS:WK;^Y2,2R&C]KT.Q;L(UT4]SU*RZOYI".BI/,VB"AU"%)*@7R>,),D(0OMWM>.2;KU7=H,! R[P3TE?O.7>P?F9YM9M@_-$+>1*TP)P6J*QY6H(T%3BB!4 M-M"X@4WC6%V(,G#9DV>$IA/J=L.H'R2__MLW1+NT^R>=.3JMF:\?5OS Y+< M%^,E?L3YMW'"\ZKU#YAFI]/54\Z+,4.6=81)!LYU)(50@.<V^JGGTN^-S(]]Y6S[NB9:[.17W#Y>99'W#+M G$E9*:=1SM: M2TK01F106G*GHF2MZY&VH6O8ZR]/B;[F6NH'@"N6ZHK"_/)L7N?>K^SYBLD;M;'_|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l.M(XD.S4@4* 3>I]CYMZV M/OU[C*9A+=A38&I#TZ5V6NK4VEUTY7B/\V\2]C!K=Q[1PGX]3%& M8&>CG%=0G)7U*/)O|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

*MVNIDLQ=,J_95)WN3^V?(C^Z"T@<"LZ-JN@._Y&/ZC/EL@N_*+<__[3C$\62|\M_'Z+OT)$Y%B'B1;'H'3)$*/*D /C3)8L4_,>*KO2^&=(11X"WZ/JM /;WHT) M3B:3V>]U,-WKV?P%$31>U@8)M{GDR)R4-H/FY'.IF"U$@Q3)UFA!&8RZM/:H M]Z/TSY"E/02_3Z#?3KWKC?W4]W:4'WK:T;J_'!%]?;#7-T^$*F$8!5/&UTLU-MN2H^_W>UN5/1(8O6S:.^>I ?|\>0=>6GL7QGN,B[6\\|LI+9&S^;J:]M?9='[Q MY2K0N+4^3!$VY>#_,#+URM2.GDE9J(Y)L WHTD!Y-11W K_8M7D_E?C$)B\6XC#'__/WB7.YL=7FJ3[: #N%Z% M>"]OJC[R1>A/G\.WD=*_%57^4B=YTOA;JHW.?E=;YOKK=40O 4K4&R MF;8'36&;]UX#;0LBD^R]$\U+_ELR,&R]P!.]ZF5W '"6SCA}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|/89[`G2,.:Y`]`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`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{[BK]@+;T;N225]EU+BC%$ MMR29.($93.8V.QY%8ENU37X$'=??.2 @V]AOUD"6 V/@9#$. [T.J%>1KXC/S MSF?A(8MHR7K6*0G(.5BCB'V!Q>BM>A0] H0[+QXFH7<<-.!PFU0$AL=I1Y]]' MOWT<2?UD\|A\+ZBRLD M7+UOF*Q;>_7O* <&AS< 7G!/CBS5:DRB$RX!0M"=V41+C&@-XQK,N(7DNM[HC M\)@-N/'687)?1S(^\NS@V*K?=WOM^,IOB%/:S%*67&1LP+AHP-5= !71VN7#R9ZV!.EIP]YAM%V!_!^9+;ZJS_2Y"S7VH[%HIZBY$_ACU'F M!AG+ I1:]2O2!0+S 9!)%E+PBOO6%Q/V(/-Y1NU[NG^P8Q'T6H'P*WU!>>>- M5&NOZ8\X_S9.N/@XF^01Q1LQ".. .;=!62_ NQ0!A78L%"&C;%T2=S\US].2 MMH%A(QUU@+:7Z]>N%]: (.Y<'1@U9%EHQY+R"YX&B6JFD\ME:9EN?/=PB8=B3 M^6%Q=8@V.@#3AWJT-L5\<:WTVB5UXFR M14&M6.NJM,>I&O9 ? N@=M:G.NNB1L6.7AE%6)A4K.&!TQ!9]11X"^=F8(DDV M,%=4ZZ/#'4D<=MK,L @]IC8[,)H?E[/T]_D.M 37_WC;+S\/K(U65AG0A6) MHN81R6,MPE"@9[@+/I><6.O]_SM4##O.95C(':B3@6OFUMY#G9E\WC'F/1]&. M2R%:QZCWD+(5X-R?"W MM=.%*_<1)_2CT[_B%,>A3E8XR5_&TW&M/ZIS%=?] M&4;1*&YS<<"C);X$1=W!"A)8$M'8X!6ZYE,NMZ)L*Q#Z/R<(CZ"[#@S?!U(A M$?"9^'E)IGTR^UKE><&,"D6Q8"5(QRQ9<4L+S",#+E.2J$7,NG4H\2!!VR6+ MV9\3@.U4U0'NWDSI6;BX))]SJ80,F<(3Y($([S6K3N6!.\=!63D MA@@PC%=QU R2K].DO36FME"UJ?6FO9F2/\/5IEVP==N(-M#/WD:47(3Q+!-# M\V63W7HS+^LOQ[AXLUB<81Z5D[VIAX+"F9JJ) 9C4AXRE\6(+)B/K1,PVU$V M,)E*KU@\2']=) 8W_4^?#_/IO>HG*OAF!611.8X@Y"M![18?#92!==Z"//# M% U;UM(K#O?2U^[X\~^? XF^)I/44^(OY&L]"V(64HAAM0,3F()43(2KID6:!X M[&GLX+ U+;WB;2?]'+@'OYKF@8.9]:G/^\POYC,SG*MG#A;M?:L0CE]FMX2 M.Q'Q= '_K+I*@3ROMBBR),4VA">L[1 43Z"C9DBJ6(2&M-O"#3$HEBG3A8? M,,'XVZK/8#V;_[VV]*'(]P4M\O.^M,=>&#L3\G2+XS 9=;5 A!,B9DS 58J@ M6#(05]>\BE,F&N.<:-U)M8LU {A M'CPC-RSXF)5QUIO8.NNZ'65_AAS"+MB[4\'17G\=Y/ZWX^K]RG]Z,TWS6B'U M$L__'0GRSDH4]99M;55F/+F#F4D*%(QC)7MF6>NE? B]?X;,P_$1W$#7G>'Z M[2Q4(9\WQ9O5BVA_FX^7^*Z41;TCC+%85N? %U+MHM:^GT!JD+SIAUEIAZ_!P M2]+ ^#/F)5IEVP==N(-M#/WD:47(3Q+!-# M\V63W7HS+^LOQ[AXLUB<81Z5D[VIAX+"F9JJ) 9C4AXRE\6(+)B/K1,PVU$V M,)E*KU@\2']=) 8W_4^?#_/IO>HG*OAF!611.8X@Y"M![18?#92!==Z"//# M% U;UM(K#O?2U^[X\~^? XF^)I/44^(OY&L]"V(64HAAM0,3F()43(2KID6:!X M[&GLX+ U+;WB;2?]'+@'OYKF@8.9]:G/^\POYC,SG*MG#A;M?:L0CE]FMX2 M.Q'Q= '_K+I*@3ROMBBR),4VA">L[1 43Z"C9DBJ6(2&M-O"#3$HEBG3A8? M,,'XVZK/8#V;_[VV]*'(]P4M\O.^M,=>&#L3\G2+XS 9=;5 A!,B9DS 58J@ M6#(05]>\BE,F&N.<:-U)M8LU {A M'CPC-RSXF)5QUIO8.NNZ'65_AAS"+MB[4\'17G\=Y/ZWX^K]RG]Z,TWS6B'U M$L__'0GRSDH4]99M;55F/+F#F4D*%(QC)7MF6>NE? B]?X;,P_$1W$#7G>'Z M[2Q4(9\WQ9O5BVA_FX^7^*Z41;TCC+%85N? %U+MHM:^GT!JD+SIAUEIAZ_!P M2]+ ^#/F)5IEVP==N(-M#/WD:47(3Q+!-# M\V63W7HS+^LOQ[AXLUB<81Z5D[VIAX+"F9JJ) 9C4AXRE\6(+)B/K1,PVU$V M,)E*KU@\2']

M%Y:WW'^%V3[F/0_>!T.,!H';FT=B#3I0@&ZY5(RY6'W";%4&QKT0: /A597< M(,*?O,1CA6BE2S&%BF5L W?$*OPE*VK0^S<.?.W9LX-

+XXS;.,&DP)H"#C#LJ4H%S%TF<#9Q(]['7S Z ME.L]JZ6A>H]+=,=X9GCB!*J(-TFB^/&7};0RZJD-*82: /5
MU93;/*KOW3++I+T049)LP1'H"":!RTP4+3UVDF>9#UUDV*LB8/A)H, ^+R3-5 M4\VG?8;[A]L?^MF^8AQ8_H'NTN[/*M]%]*)AL'N)>I)YCCL*8
:@#*^GM(SJ MD8H3KY0G&&Y)FR.G(KVD1LQ?4(MK-6R>4S ALU?.D;A%))+ZTK:>EE>&2C 5 MC4]R=L_EAQ0T?'=PBN8?/34Y7\P-
G*M=VK2FX!T/G)%HF2 R14H\.$%\THX& M&:GX]^NDW$?K9S1-/D4%+:`]2#]6ST4RL8QVX:Z*K1 @LF1:*M,=E;I&*I_ M7?\K-$T^"0IG-
$T^12^-0NU1:U[I,A,69<9#:9_/?'E9%8!8X73*D)W2M1/? M?XVFR2>!X9RFR:=HI@&T'6SB&J*67&'LI(&679DU<4YXPC*C47$!P&MG -ML
MFESQ8*PB[$9!<]N4/,ADG20FJUA*\@QQWE%"LW". 35259]W_]+Z(Y^D[>[] MD4\1_8@@6BY6=WOJ2X297TSF:[DX[T6RY35F-
HY("X%XZUUYEPDZ,.ZB{C2# M%[JP#S?XISO,'/SXR.\+^]N8.F(=],7KFH4MY;_/EM\A3O(S'TA;>,.KLHLZ*$ M%5%(BOLG]"A*CR&-
\2P8U^VQ]5/H.$3 .,:DDEKGM27UN38^I&/D]9SUWI:> 7U+%O9_=?UAPK]K\ MPWQV6?K(E\Q_Y0SW2=|<+*-]/N?/D<&F NT:&B6"_T-
+I]!+\L(FXM%6V>"# M5*9VCG?H48)W[:BVLX&S\C1X39(MS9N3*S.C-"4A(.=HY)7AM
M%P/[1@7V$7@#Q]Q#%M9'OY4QZF0%T9Z51E+&$HNVF#"+!S4368"J?27\F(KQ M!__U4NQ1H)PLY>9P\IN_NIEN;S+3/GJ#?
IS/Z"AF26RYI@RT9>4UHY"QB M'!!3}3JI1T2T!)5S=;OK3_<2],B3U]{[A%L6F'9911.)4*679J**N& Q MA@07A!-H=X5ZPCL^LOSX_*JH:"6$!NP&
(6#U9:#TFUU:4JY2T8!\F!ID0D(_MC#1%:.8D?HE(4.,2Z=N9W'QTM(:_6I);T@VB9;N'$1?!,VU1++A]2D*<(-TH
M&VWQ3';.R.J3%/=3,NY)TU_#3T#F#'$W)K'9R52F4/BGF2*YE$ZRTEYG$&8 MCMR%,I$M=[HI=>+E.20W-/NF2G"+F1EV2E"238-
'@!AN*P0W$^0PD6*TBVF(- M5+]4EZ0B!F]L %K\?#8O4M76[2?G%M']"FE12)YXA-R11EC7AN3I:K=I,_M*>-/.APN6W*>O!N
S7W@7SB/[" +LB96Y]+LPQ!=$!TS#4X8OJKW&KO__9;B MW3,5NL<1.4NZG2'CM_FLE'BA7"XLAY12]4UTI:$YAN[$*Z%)UL&EZ*.6U2>S
M[:>DI2BG/EK.E'ACN+E[FB;+I[CCF[9G4H)&=LIUK*3"EB8,*+4!87/:&\)G M.H3JH^8\>;^D6^KM->S%SGN+\Z^@[Q8<['IY
,W/<7GL*74"$B/")TVDCY'X MD UQ4JM@5:"*U2YA'?+R^%XM_?TJP+\MYM??}[@-UEX=Y\E&B092,ENJ@H0E M(4=&5$PTQ0@QV-IM?;K0U?
#U\BDH.?+2I8Y*&CC"[O%T^]O_FL "B?KV\P/\ M@.EFYC1G10!-$R,#H-5&KCRC@D 643]9;**#568V) !@PR/.5NL-Z;70AL!H+5$-+E)4P5 M=;6$Q?
>S[]>KY5IB?)L7XS%;SK@F4#ICRFP,"<)D@L&(\)"T-=5[/Q\AIQ&< MU0?!(;CUU$@#X+JKM;R]{,D:@@I)$EI&1TJ> X:XH71&0[:4XB6:J8RIQU0T
MTC!TJ%.SIB;\X;OX++^6+ROVL5;;>"SKP4=#NBM3*EQ9XESF1*:-29*D\| MV-K5[T]3-:Z-
Z]OWHS#JK82Q#\\6:3+SBY]_GZ]PDWWYAA*]N06D45 0WA$]M=,F@J-)(AQNB5/!6J'3V+ELW7^%=O ++<&BOQ[GU84Z,C0^K;\):T-\CX/D
M'&@=2VXNY)).")1J;@B3E.+Y:W0PJ0,L]J\^[A$T("0]"+.! ^CNC-YS0M\. MV[Y],_3&?R^BNSOA< MPC.H=&2+=K>_YW_,<,5OD^_?
81&+/B_APO$HDO?(B,QK499624(0D4RP1F7A M=WNWI#5L1S_22+3V++]>#R'X!HS@^QFNA>Q\A@B3'V4#OME>5"+EE%$5B'.A
MW#0Y37P&3JS2C@?-4Z2U\9-],G?Z+&774_OBK=7M\0\6KV M^+.W-Y6W%Y4L^VB8U82'@.&'P?/2.L4(XQD#2]TQMJQ]G7T2@;U+OF_G"=Y\
M=N/AHG^KK&&&4(\[4P:.<9+3$N,D0WT2Z.-6?RAP@)1Q/;CAT/*H*KR")AHX M0F]_NOK)1K[Y?(+7&ZF"Y8\8)E@%C#TQD!>,_RE-&IS-
!/MF)9,>46KC_@Z M2M#(]3]KJ/Q0_Y#>|+]1:O:,^KMDPK(N2/&YXQA"Q[OWD FE EN6% F^]KW M@ \(;*17;'_%/GJ/+]U7<_P<^_BO'ZZGJ*
MGE7;_&C]2J{PIDT62@=&K&<>&0N"> .:!"/2G)!I%8+1VI-*9N''MS3!PJJN1 MTZ'F-E";P67Y]-?
JB+O@43%MO246I"IGMB#6>$EX=$8I2BW$VBWG;KX];JIX M&+R<),^&+,^K^*_K@O.WUZ5__2=83.;I(F4F82@(\DL*AE" MU)K6?
N)XC)YQFZD.@Y?>B"@M3&1BFCCI!7'&6TC19Q5K/TG]3MVX>3^+" !+ M> N;_[]P8(34.I D3'GTR34)@+_CUB?'@'GGAW*0]E,T[@C:85!50?
9_D3O. MBYTZ@4%N.?$C8]QS[O(VRDVG2L9YAJX46&#ET7\B-E \&E,*1H7$Q6#[^9EO M.F]<@7>3V60%'R8_'BGF]<]?_?_,%V^F?KG28_#A>2*|
M3,UB'+T&7[N:@"^"V\@XU$?>X5O3H;7:P(G\'HU"/LC>\CY_FR%OTC$&I;U0
MZ>0ME2MCL5(DU(20F8X83=>^Q#^1Q%;N?P<'SZ,*IN$TV3Y0[YB[U]Y5*HM; M'?TC*@6Z2V 4"11])NF2D^CM.!=KOVT_@\RQG] ,")O3(-I;ATW
]--B'F&Y M_(QJ+.]F\;QZ6]ZYSK^7K./VBDR)3+GG@7"1>$DT*>*$\.C69ZO0AR_YQ^K M[$!8TU#L#X]'<*RMJP8
>/BX>;R7!3561"Y)3*)X28(31UVIX0< YKP*IOKT MT7 M/S]/+K^M;O!L*$W*6R")4O060 'Q1F6BG/-46LF$J3\Z[BA)(I\$>T8[4U,W
M#4#MPR3";#F97;ZZ7,"FE=/-;!J4!FCT0=FZM;R):#0!MQ #(UR98&U<[6=' M!XD9MQK@.>%51Q\- .OKPB6<">-6
M&P71YNIS4P]3,^Z%_W,BJI)&&L#6T_F9>V_$\10WFD9'=*1EP(H->)P'03)0 MBZQE"K'V@Z]3Z!O7[QHOYS68#AO
YQ&>/D/9Q\4[N)HO5MLN59L'"7:1L[-) M1$N"DBA/91QQR0LB3-#@G'&A^L/6,TD=-RLQ'':Z9\&]*;(!O!XM;Q61!YXU M)8I*AYL
9X2D5DK(3I6^TJU=UGQ8,F/9T->-94T *\CPOH-5K<5/)!, MCM1C>$1+/2)-AH3$'6&)9@&.!J-JCR'M1MFX1W0+QNY<-;4-OLWC,Z.D8$QV5YP9CU
M ,$37;::M#R79@T*.1/>*R<<8]7GJ]?Q=<]731 M +*>*$7]Y<\XO4X8@M\^'7?10^!E]G+IG(.'/B768KP53:8ZA^RDJ9VL.Y7&
M<>W;LP6N@Z]N"6@^.AT>\Y1HY-9$W&X^F](*-Q,7+2/.21]=QE/"UQ\A\S1= MXU[8/B,$*ZNH0=BM(_,7&6'QMSZ39&,#*4'L[?X2S(F><;
52\I[T;9N#>[MHT&O@IH:?>U=.G;/$+,_S^]8_6B)&B^UC]-5Z1WVW4<>OWWER2JK6"0J>(TA M0M#%G^.$)_3H<@
OJN>2C!:3HW_^>NG/_H]?/4)]XJ?%/M]VE]9A2-+SS^=.WLFV_EM^]G>&9?@ M>Z1%@#1P2NPV\GX_>WM#R):G29E@K 08Y@/:!&7++#]+\/C3Q
DK30!(=(!Z MD Z$=<*L>;&8K;^<)A'W*L:RNY9WP]HOLE,Q1;"$X=E#)&...!O1];*&@J6. M)5;_/N-INCKAS?Z%\-93-
>WX!X]9N\G(ERVD(7+E'7HZ647<0L:6YG:6). ^ M:]%37SLMG]QK MRUX;]VW\DONF/8%TCF5#]+]-:"XMBZGE&.@[W&$L90;U2TB[T]<-
AR_W1F@P M7351 1]Z&&_\]PG*=?V./$#((DB2,48K#8)LF1^(?K)%V4;07]OZZ4M<- M@R_WDF<@/;5C$)'R(KA/B_F/28+T^N?
OZ_F$MPR^BJO)C\T6DSQQI@PE2I0[M*AF!!%HD*D'$J(!',4#16$?JN@'QY=ZD#*2G!DQAL>?(VFFG\OF01Z[4#1GB-80%\I JUP&-I?L:/ 03,
[96]@=0I!!9C=, MOMR;D]$UUSXX2P9UTY[A'HLRNQ H'@2&Q5Q"L%)HSM IL=2DK(73OK]=/)W, M;N!\N=OWD)8G?^"9=\]-
9ZK/$E=I;SW"MZ[)O-LW'DW36(,HP M9F>E0UH!K\V**!6%$]3J4/TB9 \9X[Y%]:#WQ]-Q^HFZ@9.M[+K5=M=]Q7]G
M/0S/6T63Y)GHR!.10I8V:IJ1%*@1PJ$=%-6'X>RA8WR\]%+N[JR;OI)N$"W; M21O>@]++(!J&,1R*AI 1-F:6H _=<9YED[6]4^RD9%S']-?
P$9,X0=PN@F1R,P#U9OAI"C(O7\HW52HG=,,HT"@B M8F2!LA1=>BK >?(CXSX_K(B'NN)LP'X\]-DVYZ_('B*&!]H-N3 *^*MT02\ M5MPR
937OEI^3,6X%]2V)]M3RLWAY-[,.*_*^S#M"<>PD$@O(G$QX2\Z)L=P M+T0Y+%I:F9W>5\='(7.FP$<^>%X)<>_@?'L-J$]SM9-4:DF-"V7_2()_\,1R
M)0@XY;SW,EO5Y=@Y\HF6X'"'N_N;UA3DZ)LPN&X+?#"'%,U/2:(AS@1.9\"<> M2J++;>! ^!69WF[T>P,3!3[1TK%3!1!UA-G# //:P#51)M-8BJ#W'
U=*M@LYVB8^\- M4P1/6@#)DZ:[WLB3PSXS;[J*Z%:DIU 8LR4/Y?+AM@PUH ZG HY$YQLH8 MXF(;M2;&4QHXIXGZVD](#Y#2DE6I'=R<)^_F8/-
^ABO#" /XO8\(*,E1[D.BOK* MN@&X/!3+[S._Z6P&J=S2ESJ<3PNXFEQ?O9JE]3^Z7%Z7@_W-?+D9^R:DB(X+
M1[R@D4@6H/2Y#H1187U(')7^VJ@)\DMG91#&+-A==@ 9,_7*%WP**5CCI-(MN2Z5(I)P@7N."8N6.7C0M3VP^]]OR6VO Z.SI=L
,M91Q@,&LO/*VLP(=<*C MXK^9TB*7!XC@MP@OO:S1 >$3%N8[@A,-)/SBT"9=NFX4*(Y&@93R]2*41C M ,27Y
5PBK&NI3*XVN;D$"WC]DI[%MB<(_5VWI+=Y^3NE>8%>!JS+ 71OCQ) M=QC\NB RL3EEH8U'BH8\D>XH&;=QV=!GTYD2;\#X?+A7(?
3.OW5/OU_]GY.K MZZO7\\5B_L?FH27^S>KG1300#%!!F"F&M30J"A1=-1XTM8HEH43MY[''GT#=N
ML]):,#:4=AI!WO*&N1OC]Q47%#3N&8CE4]?,[&;4D"2T\C$XG6/MMB?[Z!BW M'=E02.HE[49?L+R*\?KJ>EH.TTV+]_D5KOP-9LO)#
[@;!''^XY83/U#CW4L? MGBH]B>E(PGH&U%?_Y^W,"1F#XC%QDK4*&*,Q2[Q"&T19AA2EY\S6]C?.)+7W M+/5NG]U$WD2.)09B)&;G
M)>7>)U4[^[Z7D)$'7-53]+RVU!N SKT-]W7A9\O1!C'I?ZXW'0&V)1D!S3<& MRY'0$"A&T4D32S.0I8$E*FB
4!M+W2@;%UP5('#X(*REC[90]A8RAC[I-21D^3,P3]!O0D7&F1PA4ESFH?*0M:VMI=0TZC<-S;ZD%15UL_ M,:;$/G=:[N31W?4]N)M389D8E">J
E^8AQ5="4^! L,=$X MGI, 3FL/H^A#{[B'\;-%K, ^FTB;F[H[+[8U1\,R9;!**-R&_*2KB%/HJ!0^] MIME86KWO7#^*QXUCG@|;E4!]AII?-*QOF@!0PT
,3915'NT'&A$?]JE4\RH3 +7IHSHEB1D#"@C M!_.2I5E];=VJ{X;H3U;&[%H*If.=":\N$@/G6 TLU*$I=\()XEJO"4,$+5OC[L0^^+B-7J8/?9U-J D=WE
MY!V*OH.PMW5/G]8;ZA[SC"DFT=M)/$F4.J?$12D)RSX[QYF-KO9SQZH,O C/ MH0[(QU-\ Z@_[IC]>6'+@%K'4))@Y;8^D/I(/'
,#'>R=+4;BS]!TKCYVV;,_M[ZG*:>=902:=2PV\=[*E3,^ [M2TT-6+M3?7$IJ>,@(E$N6)1?21!FST@9#H#PD=9P]@("[<$>434=2)VBO)Z!
MU'"^S5,\T_C.?S6_&0&W8^N7/[\@E7!B, UGI(A-4PMUF72C7A(&(Z)RGVF6= M!GGL>9"B<5]@/;\YK*.:VD=QW=H1.5 ME1XN['[KMEJ<,IIXX)& -
NA_E9:U+KM8;HT0!L(PC'QK5Z<>H*5W@7?!\NEZ M"A_SE]4_O/USS@_02_8-@.@^_3?WF)8G:G4F45$\7X.E*!(FB=72:P%>
ML>JS'!Y3T<@K@'JG5>5=0MHF5]=S6=K/EYMKYYYE*QP GS4]% T"]SPAC" M68C*XM_Z7#M[\)B*<=`25Z^[,.DGY+9@\OIF[D
TRG$TL0XP*)"4HD!"']:@4 M&& ^8%2ZIVA56CZD8]SH.)B<(^068')/('>1HQ+)4V4=T9$)(I4K)I)(Q)C, MA$%A:5Z[2\5>0L8%RU".2W^9MP"<-?
37//Q]7A($GR>7WU;+BXA! 9=*$FZ< M+1V&0^DN[DL9%#6)X\%=?33K 5+:.9#.5/)>8]-/XB/WYOYE"K$HX*X=Z[OY MXO7<+]+'_':RP+^<+U!
(CDKTXQ2A2B!#&5)Y*:=(!)<26&:MWTE#[^W0W>EC M[1Q`_4 RC'0;[5AR(!MVL4-WGZS=!1LR;[=+Z="9NR 4.&W6*A]L3-8YNXF+-
R",YE#,T.:\IUK%QL:7[]]GR.\1)GD#:.M1G^.YV !!<%T H;AP@8!Q^5E#JO+>$&XII; ML=SY8X$E8W3I^>Y=())[10(BHCB#LK".P;#]?
MD)13N;T@J";@!B/P#2N_% MZ=4/6*'3_=MU2R@%U\.XZ=7'Z]5RY6<)3^77?CF)ZZ&S);1W)#CFB4S:EI(_M]9LEI($S2M[7N=1& C)]29:)@_EVJ:>
(OX?A87:VGYZ38;L&;LU6JUF(3K M5=F;7^?KGR&#D#[YG^M!DXN%GUVN_[WE17196N8PN*0Z$>0Q$V<3)YQ%'[3B
MP'SM2_S^5#=B_.I@])F5V*[!?#N97N-/'VW."QW T02:0$+_0_K2EM!P3J1. MS!I#GK+_)/$3BN.\%GL=H5E'/^>B;X_ZH4P4[6TU2X67R-[Y O%Y,5A-
8 M_O)GG%XG2.7Y0ZFDN]ZH[V-^%%)?E9$K%P.YTCE:$I.0YO4R/SV8'"'2EG/>U]Z M-
4O;"M7E;2:,LZQD"IXDQR.>E:5F/WE/5'9*!IE3B+4W[G&**F=)9[UR6I& MI"L7SIE2M,8F$QU55%2 MJQVZY^6,J 5M?!$'O0408^=[]J;VW'16Y{]3)
&/ M:&1 >.(=MR18Q00W)CG=*1)]\7G0DS3Y9![T%+&.C8O#63])Q-OR>B3BT2Q! M66*CUX1)#">:#!R9^7?*@YZDU&YYT!,DW$#,ML=S2Q:84
((MZ)L&V6(SQ1(M0(:8%C9+7_LD;3P/>HXA]23@!B!RU^AS<_[>C-TMN97) MO,XEKH(H&0@,X__))19IQ92CL(XZ:N7LQXE]'!+5 =4]43?
#IP.O&DL0Z&H M-S*2'&@@,C!+,#C@Q/#,N;")"3;(X_O'I#275NP#H1KB;AX\-P]BO:(^4)V1 M%,Y:9@C9]JHIZPIOE9\S[S< E,X1?F]$[>2EZ^;U-
GQ]!7]" MCWEK>Q:ID=%[BK9*Z;S;SY1IY]/Y\OI>51NG!K6I!#&EVD ZZXB+J/<@&"@> M,_>Y!J/*(^3TG@&4B&&2:9:#UK)V/'F E"'#@*'@5T/N#
<#G[WYZO='% M=#K_P\\BO-T24B9K8GA\NIFVU\U<*0>4(4.*E38\QA!G(\-@F6'X'!6'ZHVS M3Z5QW&!A*, -JJE&"P.^P.4F$YCGBZOU8N?'$8?
7JA%.=*2T4E2Q_=IG^#Y?`ME #R%F *LE599J(-:EJ"U 1/,4I ,1"!,IE$]>OS [14;&JT\X5[0G[]<_N7 MFQN,%,"#P1,
[']MQ54CF%4;F.Q%LOE+0VQUC[T#N#S)'S]36P3F:P7&Z9V^NF!:!M:-]>M*.[J)3V"KV%,NH2:&D3#)Q8%M"?=$YZ7;WSUGT"
M&KE<[*_8761NPY\F&3X$B> #N"V28LJ75VT/^$<[5VXB7/]' 7-:TEK9%6_P1].HI^^G?C+V7RYFL2,X:-!A"@56.*8 MTD1&9")(%?&L-
@;=^\S!=FDJDU<"!@P+>^,KJQ?3<3087B MF5,@5*=41G GY")E0J,0E%MNE:X^*&@O)2/?_8&2T4Y-X"6(Q[7W?6E$XXG M*:"4S)@RIPAY2A%
(\!M!.X%#WH8K^(H7K[6VIAI WV?X ,-KV#Q> MF:T#RW],5M_>7"]7\RM8;!ZWE*BS5-XLU[FK"Q6$LC1D@CN4E^K4,C3+9B(R

M]4%&Y]VI/U3R9#*;\(8J8N51B=2PBFL_FW==Y6^XW+W[W$P"NE<:|,MD-E],
M5C_O52$^7&4S$OQ76'V;WZLN6UZPD%6F41(%E*&7R26Q1@?"!*4L^U)17;MQ_MW#.RUX1[.-Q>:!4H+RU+?U8+LV.K#9JI'ZB-V<%\:^DY[P-%
<\FI+!?-0&S. M0%(9O.LT58'6+K(;*E?_&>)|\%B?3R?:IZL>;RK9/BWF>K&[VP(UC_76.>VHY
MGT[2N@9M[4C9F'(.@A*EI2Y78^6QBG1$4;"&>0HRF>I.0%^]V_()SD+6GH%Z MSZG*9MR"NQK/^6;2X#K#B)&?,<$%0IF)1-
HR&"+)2'@&;JG1ENG:TS..D#/Z M,/-G1<;>0[F_FMI%W#;%(3/73"@44E2\M$/QQ)O B*<<5#3>Z%A[4-11@EHH
MB*R@]FYP.D,'([^"O=ME2/[:]UW+AB4G,RMY;:-QJV$\1AS:?6(%NKZE8T7'-M-F]//('=__5QXX.1#%4E930'I^V6L&"MTNA%
<)XID0H4\0X24<+13,LP@-PI M2W,RH,9^4EU#IT?3940>_X.97M+*+B9_>6NG9Y5I"6VY2DAD\'N=,E5$4
M!AFQS%FBJ3!*R)Q]#A%XYQE@Z&HHO@; -/Q^A#-(&B#?'!77K(HSM$Z MXR\Q9VT$54+)VDG8_D59@UV4CAR_U5-5"
[A[<.G,A,@Z2D]B>2@B31;$)A.(MST(# +,@:T=L+Z9&ZR3%'JW1.D7*[=5HJ9@]CXE0S3V1.I2Y7%Z1Y$JK:9=%
M,#N%V2^O1NLD!1VOT3I!6@U8@P.%(P:B !D4<9H'A'YI4Z*\+\WHE?)>9UJ M)_A[%.@\4S77.2"I*.=F*_HLQ9-
428.>'(NECX0A@9>>))DISA#OAJD.!}? M1=|S%6F=:RCJ2*\!@[%[<[/CC+ ^;+XX[9P]]LP^WE]Y4A9RLUL0%4:9Z*DHP M5H"2HA 1);MX?
8=W&%;&?<,WMJO< #P:V"7/688!G'F,JB,1@CDT(%Z6CLZ: M9/1$:) @9;C=DJ*U>]UGNZ<>!.EXF7'D1BED-MF_(SLC]^AK<%JU@IX%M]*M?
_!/6DZ'NHZ4=CJ;'JTW M5N*"F)XSZ0;&C,.7/%)>>$/5 &W%AWE;9_Z=D#NTKAM]2OO9W9G%=5SA&3*[M?#-?KGHT#CZ\5HUG1!TIK?2(Z/"7;A]
[0(@Z *,$]"V36 (:,8/'J\N69RDB M!5.[8.HP-?6:?CWXQJM9^@S3LKO67]MDV+U.B0L3"-,9@T?GD&>>';'>28_1 M(XN[-V85FWT]2=
[8;S6JX.5PFZ^ZZFGB<+W'T*>IW]PP8$8*7B(K$T(B,B1# MT)):HK.V+G"(&&L-N;EN"&FEG5=EM3\Z]/KJH$4@;2^]O8Y"]BP(B]Z7}GH8
MKJO(B6:NS*O1,H?Z#QSWDM*0:3I/R4_!Y@R)CUP7\LOU F,4/_L,N+]?3?YW MK8YM<0-5QBN.6XH:C%6D8YE85EZ,:Q:I5XIEWZ5V[-
@W&H/$.0J<#R#-1E"! MAO85.OVEU_E>E@0>W,I)9"0B(S){M+E (P'CME!NXHU[*@,PH2S \Q$BQ!*H^I2"39XK2ZDTE>Q?&/T/?IV'=FWHZ
M.1M@/V 1YH/4P&(_'9X889J/2L!;>FHFJ/UL"? M(N510;*_KEOR@"9F3M[TCOC'$O@B'9DZ.!5GFW1L2HM!$HGV/ G3IWE?=O3V!
MP"8!=PXP'KF_0VFI 0@6*_\Q?_'36P886)H@92(,+YW;9"16EH)((;/*QD%T-MM9/$CXAH85S@$%#}^T&X(*^ B !WW
7O(4?,)\U_+Q+:,H&;_@U<,B3;$<$P M7)'"*8I2I0) ,5G!C,P@_P&WP4V2U,)P"$C5UD@#('OMIV6VW)=O \=!YYC M<"IF8JC
S6+SNE@J(S/&*66]9[QV7Y]#M(Q<7?Q,SGL5332*J.W>*R50H!00 M708JR" L"<+GT@:90^9&0ZY=G7:8FG%=J#K.[@"A,T3? (@>%;2LM]L2%C]@
MTV;$,9\$,-Q99114]@)_1QGQV8HL38!4W3H]0=+(5>)CE&STU$L#,/N*_]R. MR+;[)2AJF?*<>"O15U AD, U)8EZ&93#.-K5?
HUPD)B&;NO[GP^A/P; -(M7P]{5S_?3,=+9.(FX B1B@"1!.O*[#%(Q -:=0L8%4"4E M[!X[|"WQ!F#S<09?)U?P%197D]E:(3>#Q;?\Y&2
Z\Q)=F)]Q5#&191W-($Z M[S%D5;%VHO,IFL;-%PP#IJIZ: .!71VSVA[N1*9FY;&0F5)82&@\>]XHRA'H: MO=*X@9[3A_IP4BN8X9XUC>]
(G:>AYE#WS2\N87EAN?&2*4JBL&K3JLGG,DY/ M*,5,REKSVA9L'QW-^E!G:OLHG,X0?6OPV4KG0I=7HLEEPFT4R(-&[U+I1(QV
MU.@,'%CMTK5]=#14!#DX?,X1?:/P>17CXMI/7Z7_N=YTYV$7&8VSU;D227/9 M%&BYG:"2&,44CURS&.M/'^Q"V=C=@D> 6$_U-
"Z3_[GNN[OW7SQ@,$+9P5- M .-B;LL4G<[1]M(RH@FXX$XB+U [U7F(EK%[ZPT,K"HJ.!U*;@.E&5RNFP . M.L;6376F&Y7=
[I4+M+]4E0C'(9>EFPXE7@1/E(W&A*BU58,^5CM&W+C9T%&, M67\EU09AW;?:'\ OH_.%V[>T+]!+I%4D096[XV#P M=UI($]+B,G
)*=8NUWA(05>.3@659]TQ\l;IA,]W@]N+NE=X+F4T=E8_BHZX4B'"'LB1'F:,1 M=''*NN'%,QRR9"[9VD[?,7]Z(>W%WS#T4D-
CY^J^B"@:B(PF3QC:'R)%]B5B&AWRD M22?07_-"8/X^M_0#G6\?C^@3^]A,<%M^R":R]RE(%H*-.D M(LTD. LEK-$A>L,UK5U6?RJ-W:I9_P)W
I75U9@QZ\!=R)8;A>>^H!&(1#P3 M%U&H45&: _,&=&TPGD9A-RB^R&N$ 575 !"/;K2WD^7Z;?1G#'4^P2(6KT'C
MAN*E"%.EB**4V1&G01$D7V@:50S5VPF>2F,W,/X%+AT]JZL!.![9;/NXBR*S MS"0GW#%#I(N4>'"9I"!L=D$D"D/&$[6@^")O+ 9450-
W'FB]=#YO:G0VMA_ MU."_ Y9]M/_!K^XB)8EGM89(&17(9S004SHO>L4@FOH]KLZEMAM 7^1E MQC.IL &P[HW0CG.HDN$T."
FE&DVBEOB#&Y'Y9U61C*?4NU"E-.I[;.%W^= M,8#*&@!EI^WW]AI^@S]77_ ^ Z0_X=3Y;?5M>):.4 B^)EB(1]44I(30)719E M(L9RR>91[.
<>6KL!]$5=@#RK^AJ Z=&-N(^_S"(//#E"E;=ED(4@P0I#*/<^ M:0F4\R$?!M:#Y5_GMJ26NAJ 8]=M5TZ$KW_,+[+UCB5TIJDN$PHBQG>A-/\N
M8S@S1$=%K)W_/I'$;F!\D3B&3@B P\D)"5)SKG M8+D2*?AG]25/Q=Y?YU:FIW(:P-Q)6PK!!!?,NAR"S232\DI*I))P#8I8&F+I
M"A68]3UH_F0BNW6&>)$W-<,JK %$=MIH:\94DI2;DB,I.,/,\L: MK3UE@H>Q(N<;&KOA\$7>S0RJK@:@V&6?K?D"*@/E.A/<4$6(09.@0!,3DPR&
M"6'\D+?5_>'WXN]CJJFG =AUW5:O2FGNFLG)#[@((3!IHB(,0_Q2."F122Z(M$%1E&T797B.9P@>$=@/D7_?^I9?
B&D#G4[ON(7.12OPO900D.KR2"D6A^2SE)/0T4U3ZUIRX,\R9RGTC"F!^-N7/$*J'+#'#A M K6<^F=Y17(RS/Z2=R,G],.!>!W=-K_/TK;*"-(O?
T;\1U]=E3]=*&UH")02 MIL]\0)L,.1J["-48] -S&&P]J^=WB-!N0/SKW8M445P[TT;W;K]#/#(5,>0W MI4P]8]PO 8AE^#QM!;>EGQ<5SW)5T@^4?
YT+DRJ*:GOJZ)?KL(1_7>-*O_Q8 M'P1GSQ\]M%*-2:2=J*PTDW3W6[=3*JF/5G":")C2Q2")1+R*E@@I? A:*'"U MCXY#M/0U2SOK;L9?
F&P#2Z6?,B2TL(XQXGRD)"9J/-I>X5CM_/ ^.L8=ZE!% M^[O&I;>X&P@B=WG ?VT]92MG%9RFG@B!]E9FS5 NU!(=5'(8HSBA;_>5.D!* M4\
Y0\=/@.8<@;>)F^TPQI0PJG!X7%L9$I%>>1(II" (NR!PR1&-KI[L.$M,6
M=LY2]=/P.4/N[0%H.Z9+ENE]AB'5TA@B+5,_/\/WZT7\YDOK{3)'^.K5]>K;?#'YWW5;'PP"V86AP'$KX6:(MVN,>8YQXL)&
(P+P(&H.CZN\+.Y+6E%4Z$P>[X!I *=6P=G9,OE[9K(VQ+19 M_I?%XLW\ZGMY*#F=+Z'I.R7H^\+Q!\BZO^ &5#'=8>GQZB>&Z&<1W3,ZQ\]<
M?(8X_P&+GQ_SHV_=F=1SI=+Y V<:E[+^=M6;SVS"W3X${UUPE+U_JGYNMO=3 M8AGQ.-
BPM$390;DC>8O_OPXS^R'L\7JCZ>NHW.>=A#"R>M[/TN3')%WI:6_- M["PUBF=VBE+VLSZR/EY-IW=T+;<14A^M[%UPM
US0.;S;@(863>_S6>_P;R& M4AZN-)HVCLIZ_@3C#9TK@$M>369KF17[6NV >;3P.$;M7, ^@BYC&-GF7EZLM
M4Z^N5OV,W<.E1ID7VT=;^T4QLGYN")KYZ<_E9/D5XY#7^'?_K.%W/UYTE$&L M%7SO@^(967M?5O_\M(@?%U^7BU^6]\G56I:_
@;]J8XF.WU@E*FJ?;1ZBMA& MUO#'ZQ?:>#S'9Y<53>GA54>9==I'ET*]T#\+?YZK_A]J2&2ENTTP=&&3%: MZ;!\4FPC;_@=+<CJ?
P0VGZ'3_YJ_ZN:D'EAQEE&WL-7^?;X>G(-MYRS/%W'M6OUS'=_MO"^.,Q:R(BA.DYP[5A-%^(_(MLN,.:JP4A+7IZ^TAL'(3_GWY2=88+1U59YI
MU2[\Z;)^CWV-PNE?ZW.[R&@7KB=HX?Z.W.5^[NA/R%>KR8_X V:B3K=)6\"E8I(#B\\7O75457,3Y/+R*K[!/,*>KI; M9)IN MTO]\G;_C\;
[,X^%*HY51'=L=>YD=6P'3Z2U9=;;&[G+C'>M[Q3WOPOO(2OD5 M? FP>N^)^^^N,5]1V;$?L871LIW9+;,9VDV^/5QCNV^\7QK=U?
O)E_@2G$%:0M MAGI?7>Q?<;R#Y#Q]'97+V'$*DI)NG?]/.4\BKOMN5F>O/;WZ>";P/%UVEM?8 M-A-@\;?%_/K[^^7RNJ)&CZT[6G7NN7;T:1F-
;5&_^=DEI%M":VGQV+JCU>6> M:UV?EM'H>W"^M73;K'$/O+O6:.6V9^^YO;(87T.OX@HC\>G/3WZ2*BEJWY*C
M%=:>KZ\CDAD[4"Z1(E)8J*IE&@^M.5JI)DF*>T(V8[N=-YGA5S\NJ]G&@XN. M5^IZKI?
YA'@:TMZ:LGL6HJ82]ZT]7IUJ!5T>$58+IO26U.H&]>#*XU68]K&K M3PEJ[J*?UU/5C__I]?7&U%B>'.U;M'\=I*1&$!N:VGWQ$^-5W!ZIKK/$^78
M8>..F?G[S.+^J ME$/O](Q2E:KZ?JPV)K3*,D\U":/O*A3AIO*G=TAAA'UOP>\U,XWR:_ZBB] MZSJUS6G_7+N3$EM)8!T5S^C>SH[GW7?[!5VPD[I:
M2D =$\O83YV+0U4XJ]2P?>MUTE=+",C0FDAQ5^E/>;]A3HIJ*4LS5XQC.Z$ MS'N72MZLT4D?+>5@=IAOH\R[MSI.K5?
E+:5)&BQ3G<_^AH[+EK![0TUKI^?6KV39EO*A7066*L--5[!X1?I MZ^1J,KLT-?Q;[=A]8<[Y'ZR=I]LAWW#76?\+.KQ=4L MO9OZRRJ:>KCB:
(^I3M;37DDTH]6RX]_,EFE13TT[2X[V4.HLZ_=8%HTHZK_F M?]S15]<"'EAZM%=1)ROBNN&S&#LQOSM3%:1W\W4GNK_[:>_M=FS=T9Y"=59=
M!ZFTL/&6;]!-A]_S6W+KW7%W67^T1U*G;<%N4FI6GP.I<;PG4Q6TUXC2QFUV M-%Q0=ESF_VF"])\F2'V*"#;['__A)S;-.44$#]<>-
UCNM(N."J4!9:VK45[[M):S?],)LN97?HKP.+TV(EZ]_WOTSG_S/]:R0PLP=1[/T:>IGY=KC[?S*3V:5 M=3X(B:-L[^-@V!T8/Z!F&@#>+U??I_.?
%]6Z*1]_+X9\/.$*3\'/8>_,XKU M>!;MSD\4=0-P6-/VZCM^/D[6HO@\N?RV6GYY]?G+(+!X^GNC9/C&@$=GT8_M MJ^T[=&M,^CBZ\&@-#/J%46U-
]UB3^/LL+:8_+[] O%Y,5A/H/;#I*KC=2XX M36O'1-*"RG[Y<1\RUHY&]X JS*^/!W?K(H[ZLK MJ&;/FN/U%SA-1X?
%,;*R'N[LG[_^<[6&TIMOL\M/L9_9>V+I\7H%=%9=-^&T M6H;S?K:?>H2.,W.]!Y?M\R3M M=KG7949:_QS]W@5'3"\^I8L'C]"."&/LIX.WI/5.SN\L-
9INCDI[KU8-R29N ML)\[;$T^7N+]/SAA1O0U9$T_9,"^;>^X!K$?^RZA_YSM?6?]ZW3*FE6B^E76%PM M/^:OBX3XJE.(<639T?;0.3[*TX(9W5,H5-
7(%#Y<:;0:T%-]N#WLMZ*2KY-5 M;_?ZP5*C%7R>]90' AA9*Y^OI\!H4*QX-6G^?07]ZW(/K3E:?>=I>GI").._
M[QM"9T>6':VV\S2U/2V8)@S@FJ[2%=.O:AC!:\N-5KUYCB'<)XB&C.'7Q=5L M5=<6WEMRM$K-|TWA8X&T90DK*>SPJ-="_>R@\VI[29@6%Q-
9KZB)=Q=<;P+ MX7.LX0%Y-*&KM]>+-6$5E'2[U'@WPN=H9U<"3:CE7@G!Y>6K'WXR[=U'[\BZ MXUT/GZ.PH[)Y&;>,G^;3240&/BWF<?&>"6\3
;U6\9[W_J$48J7#?N M7[]7+GZ[?+]_=*V0[NG5&[F1/*JWAPG\CO(;_8YE'YV_S5=;4NNDD;M_I9&L M>&5*<
MI3[/KF8I2'7UC]D_,QWQUL15#H47L07I08G*6G(N?E7@6KD6G4_=Z8\]5U?/4
MBT%O,!*_&GNM%S*T> ^TSN&KDS$[#\^R4)YE%1JVN9DHOA%8O6WHP5N?QV7@(MXUB-E#R+Y,6P)Z,
(HHG"7_E;OX5#L7L8X_P[@Y>M7!>=%&C^Z6C0G8Q+?[G4 MRJ?3?]_W0XN[7LT24WB^'2]9"06RL]-H4TZI08*E7Z^K=3:HC[<6PW^W?
M66W%3$N.]C6 MWA4X8-3?9_QHA_&MJS=@O4YTS+8+DX@WJ89$O+N!N/)Z >(_":;"%1_@]TI;
MA.7KU=$;]>XF3F4Q!_$]N)#E:'D_E!V^],7\DMDSY(]!]'6/> MM\5/QJ(8\7.<+]7U']LB9J^MA$^E?W8R/K]\D!V-!:54"BFFDT'BI\,SU(8= MJ#$
"C_MI,_+OS\D=]O<[S9*?_G9+^\L2[_7'=,RO!>IQ&BPL-"PQ"CPJ7;B M]PK=@62QPO>EL5Y@"/T+?27ZO<[_*)A>:.]/Y()7XMXR(7HS5X-KB?
1%W#W?'* M071RO*X<')TK7TN'#D17Y2MQ79AE!FH.]>#1VH_*H J%P5R,,TA=(&FL1%5X M6P%;@-F9$S4Z6(HHX%:ZBG_7X)5BHA9 !N789IG^J
M));.IVB@*R%F!4ENB:H9A68N@+@]6FTN S++Q3:S/%:@#K\=H()=(%0(%2M M7=_FU&.PV6ZTZR*A[,'I71=Q5BF4B?#:A'LB-9%8B>!
08P^F65KY-:@F MQN!0F@2WJ4>580>$]T%,\72.]8FE2T62F:5KL&QAKIVW$A=9TLN@-VK9WH"D M:[39TO9IH7)T=*C(Y8X+G[L:
<75)0D1CZI*1W/I>2 L,(2$CC(@1PM U$;9 M=BEUIVXYDBP1+3TK[>+,N K'$?U:DP4DE=;$H//"U$R\0. H0B0$=^^J]\0O8 MJ/?
H*3QJJDV+@&"2+XC^-H =@$;Z'#)1AV=*[LR4X$QDZ'V\8P^J(W;7;)\1 MPY/!$6%XH\[^VB ^ZU[T:1W>@L-="CJ5T^>G$=>FS![+RAT^A%)L!
(B>>]:0 MM$UE40!RW$((9D[L!07+H6)^S,F;O&TADPS'.FNO$=6N.9T:-?(OZN),IA4? M/(+@]>1U&E1B@:OC*I,4']L M5F)=-^"(4(5L9A[*P+]B
R.XT$](@+$)M]\ZVJ,C0OMPM(W@]EO"_2'\^;! MV,=X66A%D);.%)(2A'08#E3H$LZE50WF, JTC'2F_8I*B5W34@0R/!EYMV<:. MNZJED(=N:H/*RI:

(?,>E3QP;JU@!+IGG4&!%DV$ 8 N4%%G4!;<# >08@;K$ M5/#$8!X?$33FS01-;L$#E$(:X#Z,!QI@]<#275$D*R9-_A|
M&SMTH%#7DMRR"# N32/81OJ78P<5Q90LA&HMXA-3?.XWLZH459+D9! MJ4%6$)-*=UN&$.DQED%Q-F #:J9>B4Q?0U:?9-SKW_[+-GT1_!
[57F_\S>_U M^(Q4-9AOK[F)I'(3=VN:(I)[0$6R50&C4A+K7V^LNTW__*%Y;GV'F G^4<& M2PMJ41IUXNO.#(M8ZX'/^G^KL)(_KX@2ISR%1%S,
<;/W!?Q7WEA/\]PXH. M*TS^@(4JT4X]UH"@J5/W[6Y]"?*:L!UT029++!]/FCTO,"&4F M5U-=\$+RHM]EP7G[6@;=,?#L[W-O6Y__]
_$#O$/#G9/_1/B^U.AN>?7>KH MO#L9CP\2>\KK&]88O>A*6;QL#5OW4#(=E#>BWW!"]1^6K9R_\6QQTS'TO
M'>S!.E>@IE,T2/"AM6CT>WSF/CZ+'H<#MVY6O4FEYE?UGO$U;1/;3SM6OUOT MW:+/9M%_+6Z\:??(>]H]MTVWX^V4-PT/O.!X[Z9R:1Q?5YF&
[ZD+V+]JO"8W MWI3TUD-DA Q7^?U#'G -^,YON)9]RM?!_]U02P,$% @ YH$"69B*42+ M!P (S$ X !E>#,Q,C8S,#
(T+FAT;>U;VW(;N1%]SU<@5*WMK2(I7D6) MDE7EVU:YDLIN7%O9QQ0&Z.$@P@"S (84]^O3#0Q%2J2\5.(++X=:,/ M3A}@H(LBE/KRH@
N+_]R\==.A[VUHBJ!!"8<_"2U5Z9&?M-@K]BG4Y3ZXVM MED[-BL &O<&(_6;=E9KS5!Y4T'"YZN?B.#U?',=!+C(KEY<74LV9DB];:B+/ M>B(7IS
9G8X$#,_$\'3*SP89'^=P<@;_[K>P*59/;7Q8:GC9*I7!%$#C3T>## M[F1M2+_\ZH)/S4NGE]/FO]@3/_@$+]L&6W#QO>VY\QX-3>:KHU1^-]%Y
M\7&13)Y@/UH96+G0'_1^.(J62!#6\:"LF=9&@J-:K/ M^;G;0X$A ??971SM<+%U^09<4+D2T4-F<_:F4)"SGY3A1BBNV<\YEH)C'^#W
M6CD$W^OEP3OU]EH4W,R O1*!?:@U]MP?\DY_](+_R+B1K#^6Z>G!KNR.ZM=Q M\WT,>[$5^UN7_9U?
77''_U.WF8@17;)0\/#L:'QZ_C_AL^)2(LET-.1A.CQ! M>^*,*%P")DP[_=/[\R_*W5[WNRNCQ_SHY{>FI=_KCFD:WK."SX$YF"M8X H) MA?
+L]YH[A(U>XN^5=8'A\OK)NI+U>YU_TD)[K6SG Y<8NHP(QCH%OLW>&]'= M/R@?!>7AAW)P<*%\S3T&$$-5+MF5L0L-<@;M%-$FCM*B"<9B-
L81N#)(*$M6 MF^!]0 \P/\=4C0'FK,0G1R2. XV[T MZ?$WB<;@D#KF>1R#*@CE,*[C-8/-64Q2;%$H43!?T\>Z_0(<-)V0 Z7R&@4
M:8F%"@4ZZ"L0T4#]MT+3K$0WYT"\GRTWIP&9Y6R;61XK4(??#E"!Y3>Y>QWZ M=DQ[%HO=1KDR.3)22OW*"%U+
[!/AM0GWG"LBL0K!@1U%]'&MU\AM0./O#(V+ M0RKJN$TU:HT5$*X6,16"\]$>P7W!T-2/J5 M-5O6?E^H"!T<*G^]%<+GOD%
<(TF(:&PC)RFL]QEW$ &$@%"9!@HT T1MH4O MJ#I5*Y%DB6CI62HOM/4UMB/Z=58G)%7."I#XLV%8D]0Q;_3.BOPU@)Z"1+?
L,U(DCY;=&RG$D2/W=G.LZ,A]A /(<-:N:8_3\#NV)PF4/#D^/NX5HQ#,V1/[U2>YF MM@[WC[U/EN$WM8&T?/[GFS26K78)
<8E"F@.T)*1!OA^("D/")(-\Z:8;V.' M#A0:+1E+-J'Y[.ATT)^<^X?P+6D'*T3M""$;B7!'KZ7U 7^G(T_LRPOLJ#G(-M2MT4W-
_($"*]B&60,1M$!QJF7C*MKD W)QEWZK? ;Y^^""X;.[\W_N;W>O&, M5*XPWUYS$U'E)N[6-$4D]P!%LJ6 T2B.^C=8YV_2?_P!.RM+%0+ 3O+/+$H+
M*I$*;8K-7R# D6L]<3G^3_I[M8SHQ0B:')=,;40\WOCQ:1?WE1/^*XV*#A5F M?+F%)M%.72A T#2I^V8WM0!^1;DX*;R8C:,VC0>VJP.K!T&QV?
BDTXT=C;@E M-O1P0XCW\>%*T6(31Z\A<=5$0>!1#?BZ+'"W]@=$9U;'=;N.]K[#9'\XVZQ7 MF--SA^331G!
9$]$5SR%;W#83AE6F;G59G@&G*%LM)V"5BZ*&QB M5'X+Y8C*':+A^0-2Z_;;IX^_^ QQ7];,<(88!=?!B=:\\C!=?3E'WJ\T7TZ5 MB=,5&YTC?F?*=#
(;@BVG=&-@3LD#14?SYC7B*14WEPG.SKJ3WH3N$P2T)LC5 MP,U5@VZ\:G :^C<7=X MNI^QOW%^TQQC%'W%S>?\M.O:IG-
>JE03M>]7E,GCT[ZI_T'E6LGAV-,)7'S^W;&K<3K.5?8_/W,(X-,J?/+HR://X]&[:Q U'7;S?RD![!>'M.VO:'K;?UMB31T\>?
1*/[KFQO;W"CN.V>\=)SIU[^Y7U\>K6--TMF,/63?ZU M(A;]ZZ"<]0!=3A_B8/N%A]ZS/]D<)Q_..(_P)02P,$% @ YH$"68G* MM3B4! XA< X
!E>#,R,38S,#(T+FAT;>U8;6_;-A#^OE]Q<] T 2Q9 MDNW8EAP#;9H!'8:^)!WZ<:!%RN)*BRD))79__8Z4U-1)'!2;FR79\L&11-Y# MWMU#WLLT-
TLQF^,T-E/TY\]#U]M%JRPD"]&#&,0]5YL8"/E.E/X'G-K!-9 MKA5?Y :B(!K 1ZD^\0M2CQMN!)NU.--> 3[MN46F1/YH M6)KDDE.3QV$0/.NXJ;-
I)@N#ZRF4KQ]KF!M@AJV,1P1?%+%3]5.+ML.I%%+% M>X'{2^R(EY$E%^OX^0>^9!K>L$LXDTM2/.]J4FA/,\6S>]+F7U@<1K@]]WI9 M;WF$.
((7K%4AC()GB=L%9:E4Q'!9Q%5!F;*S.K/35<[GW$_\L--7>[2\P>- MW6*U%-W,U,[-%EXSV^ 6LW5F)TP9GO'460UD!N\01U*>PADKI3(_4O$_*XUK
MK_\ES5]WX8U4" /G;7Y)E/G2A9.>!0D??2M"PS?,JO&;8D%625PL101!3(1+KG)':9BGRNNF(T=VJY[Q9@# M<@BX<#@\H(=?68=,5]Q8A--5FI-
BP5KJA9,^;B '2+9) J2@3XU4 MT8,D%2\R>T,Y_Z6(0E"2XE?GNH9G&>&6=:5BVK]\:X>)$(!BN!DBD!"Z1 [H MKI/*>$&*U'Y'0,H=-
/K3SJI$S1A9LC](ZFN\]7<8(0V9"];.&6]4C-8>FEN0 M4K.X?4@HUZ4@ZY@7SFA.*%D2M< $9BZ-DY1A_YD.ODNV)ZS;VUC]*)&VAQW^!UK-T
S.G@^,7?M[PU&B7:_U_/5#4W_ M_LE[I$YL@@;N-$9DT%)P"NW^GIZZ3T^CK0Z\RWL/[GS>4D-B1F8_-27 &((4T+0@7"$ TE$29
M]B)K&QO*#A#0# E:WZP46UM=:SN74KL:-%9,$.N\&XWH M]VCARKW@2H3,4>_U]O\"4$L#!!0 (.:! EE; MF[_]F00 "D; . 97@S,C(V,S R-
"YH=&WM66UOVS80_KY?<7/0- $L M69)?8DNN@2Y-@7;#VB;=^G&@1,IF0XLJ227V?OV.E)7421RTFYLE0?S!D'2\ MA{Q7'H_CF9F+R7C&")W\-
/[9\^"5S*HY*PQDBA'#*%2:%U/X1)D^!<],C3]4 MY5+QZ"$3P:1$[D5HU:T/.I) J MW@G<+
[$4+R=S+I;Q\X]\SC3\SL[A6,Y)\;RM2:$]S13/ZX&;_\WB,,+EN=?S M>LD'B"-XP1H1PBAXEKA54)9)10R715P5E"DfJC4Y6LQXR@UT(S]:E^4V.7\0
M]0:M96AFIK:NMO'"*VGHWJ*TU.63*\)QG3FL@H4FKOOOI MDS6]]/U:#]9\'RJB,(]%O]1,P%"M%-Y6 M!=O="0=!TD7;NJWA:\^J<1O'@KP2.%F&B
(]$V@[[Z7' M[)%]P(G#_A[=O_ ZEE6*&XMPM,AF])BRQO7"41<7$/8;USL8SO?1V48)D((^ M-J>*
[J53\0(]95XGYPQ1"")2_.I,M_*SG'#K=:5BVI]\;IM5%_Q6_\ITXPA]6"-+C%KXI[LH4H% M*36+FX>$SC/] HO%U3#]:A_6Q\RP
M==3NP(^Z!]\$VW'ZK76,5M3H&B]:W=:5*(^C<@%A$^-K6_XU6\KR[N/>U;JO M,$C6-]"5\ ]I_>E6Z)NN_MC[T':L;5MH$KC1$9M!2<0K.^QR?
NXY-HHP%OL]Z]B]"GJ'R2Z/%(=._"ZVB! MYU##SQC\R3,&[_$TPNVAL/T49D\2/5B)[EV8;6AO7@^RCCN%;ZT9?M?MG(^V MT2$5FTI[^Y*M-
;FYAI39SWFE"]YGC-J:A-D6RE<-VIL[KJY3@@"%- T(%PA M-)1$F:9=TG0 E240T R)>- $RG4FI*X4/]XN>+ZOI=+H\,(P!B M:6\M,C R-# V,S!?
<')E+GAM;%!+ 0(4 Q0 (.:! EFIWKQ,P@< !4N M . " 4ZE P!E>#,Q,38S,#(T+FAT;5!+ 0(4 Q0 (M .:! EF8BE$BP < ",Q . " 3RM P!E>#,Q,C8S,#(T
M+FAT;5!+ 0(4 Q0 (.:! EF)RK4XE 0 .(7 . " M 2BU P!E>#,R,38S,#(T+FAT;5!+ 0(4 Q0 (.:! EE;F[_]F00 "D; M . " >BY P!E>#,R,C8S,#
(T+FAT;5!+!08 "@ * + '0" "MO@, ! end XML 83 bio-20240630_htm.xml IDEA: XBRL DOCUMENT 0000012208 2024-01-01 2024-06-30
0000012208 us-gaap:CommonClassAMember 2024-01-01 2024-06-30 0000012208 us-gaap:CommonClassBMember 2024-01-01 2024-06-30
0000012208 us-gaap:CommonClassAMember 2024-07-29 0000012208 us-gaap:CommonClassBMember 2024-07-29 0000012208 2024-06-30
0000012208 2023-12-31 0000012208 us-gaap:CommonClassAMember 2024-06-30 0000012208 us-gaap:CommonClassAMember 2023-12-31
0000012208 us-gaap:CommonClassBMember 2024-06-30 0000012208 us-gaap:CommonClassBMember 2023-12-31 0000012208 us-
gaap:TreasuryStockCommonMember 2024-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012208 2024-04-01
2024-06-30 0000012208 2023-04-01 2023-06-30 0000012208 2023-01-01 2023-06-30 0000012208 2022-12-31 0000012208 2023-06-30
0000012208 us-gaap:CommonStockMember 2023-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012208 us-
gaap:TreasuryStockCommonMember 2023-12-31 0000012208 us-gaap:RetainedEarningsMember 2023-12-31 0000012208 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000012208 us-gaap:CommonStockMember 2024-01-01 2024-03-31
0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2024-01-
01 2024-03-31 0000012208 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000012208 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000012208 2024-01-01 2024-03-31 0000012208 us-
gaap:CommonStockMember 2024-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000012208 us-
gaap:TreasuryStockCommonMember 2024-03-31 0000012208 us-gaap:RetainedEarningsMember 2024-03-31 0000012208 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000012208 2024-03-31 0000012208 us-gaap:CommonStockMember
2024-04-01 2024-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000012208 us-
gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0000012208 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30
0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000012208 us-gaap:CommonStockMember
2024-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2024-06-
30 0000012208 us-gaap:RetainedEarningsMember 2024-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-
06-30 0000012208 us-gaap:CommonStockMember 2022-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012208
us-gaap:TreasuryStockCommonMember 2022-12-31 0000012208 us-gaap:RetainedEarningsMember 2022-12-31 0000012208 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000012208 us-gaap:CommonStockMember 2023-01-01 2023-03-31
0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2023-01-
01 2023-03-31 0000012208 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000012208 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000012208 2023-01-01 2023-03-31 0000012208 us-
gaap:CommonStockMember 2023-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012208 us-
gaap:TreasuryStockCommonMember 2023-03-31 0000012208 us-gaap:RetainedEarningsMember 2023-03-31 0000012208 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000012208 2023-03-31 0000012208 us-gaap:CommonStockMember
2023-04-01 2023-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000012208 us-
gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000012208 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30
0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000012208 us-gaap:CommonStockMember
2023-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-06-
30 0000012208 us-gaap:RetainedEarningsMember 2023-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-
06-30 0000012208 country:US 2024-04-01 2024-06-30 0000012208 country:US 2023-04-01 2023-06-30 0000012208 country:US 2024-01-01
2024-06-30 0000012208 country:US 2023-01-01 2023-06-30 0000012208 srt:EuropeMember 2024-04-01 2024-06-30 0000012208
srt:EuropeMember 2023-04-01 2023-06-30 0000012208 srt:EuropeMember 2024-01-01 2024-06-30 0000012208 srt:EuropeMember 2023-01-
01 2023-06-30 0000012208 srt:AsiaPacificMember 2024-04-01 2024-06-30 0000012208 srt:AsiaPacificMember 2023-04-01 2023-06-30
0000012208 srt:AsiaPacificMember 2024-01-01 2024-06-30 0000012208 srt:AsiaPacificMember 2023-01-01 2023-06-30 0000012208
srt:AmericasMember 2024-04-01 2024-06-30 0000012208 srt:AmericasMember 2023-04-01 2023-06-30 0000012208 srt:AmericasMember
2024-01-01 2024-06-30 0000012208 srt:AmericasMember 2023-01-01 2023-06-30 0000012208 us-gaap:BankTimeDepositsMember us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-
gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30
0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember
2024-06-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-
gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30
0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember

2024-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-06-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:ForeignGovernmentDebtMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0000012208 bio:OrdinaryVotingSharesMember 2024-06-30 0000012208 bio:PreferenceSharesMember 2024-06-30 0000012208 us-

gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-06-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 bio:Forwardforeignexchangecontracttosellforeigncurrency Member 2024-06-30 0000012208 bio:Forwardforeignexchangecontracttosellforeigncurrency Member 2023-12-31 0000012208 bio:Forwardforeignexchangecontracttopurchaseforeigncurrency Member 2024-06-30 0000012208 bio:Forwardforeignexchangecontracttopurchaseforeigncurrency Member 2023-12-31 0000012208 us-gaap:SeniorNotesMember us-gaap:SeniorNotesMember 2024-06-30 0000012208 us-gaap:SeniorNotesMember us-gaap:SeniorNotesMember 2023-12-31 0000012208 bio:OtherLongTermDebtMember bio:OtherLongTermDebtMember 2024-06-30 0000012208 bio:OtherLongTermDebtMember bio:OtherLongTermDebtMember 2023-12-31 0000012208 bio:LifeScienceMember 2023-12-31 0000012208 bio:ClinicalDiagnosticsMember 2023-12-31 0000012208 bio:LifeScienceMember 2024-01-01 2024-06-30 0000012208 bio:ClinicalDiagnosticsMember 2024-01-01 2024-06-30 0000012208 bio:LifeScienceMember 2024-06-30 0000012208 bio:ClinicalDiagnosticsMember 2024-06-30 0000012208 us-gaap:CustomerRelationshipsMember 2024-06-30 0000012208 bio:KnowHowMember 2024-06-30 0000012208 us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000012208 us-gaap:LicensingAgreementsMember 2024-06-30 0000012208 us-gaap:TradeNamesMember 2024-06-30 0000012208 us-gaap:NoncompeteAgreementsMember 2024-06-30 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2024-06-30 0000012208 us-gaap:CustomerRelationshipsMember 2023-12-31 0000012208 bio:KnowHowMember 2023-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000012208 us-gaap:LicensingAgreementsMember 2023-12-31 0000012208 us-gaap:TradeNamesMember 2023-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2023-12-31 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000012208 bio:A33SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2024-06-30 0000012208 bio:A33SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2023-12-31 0000012208 bio:A37SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2024-06-30 0000012208 bio:A37SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2023-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2024-06-30 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2023-12-31 0000012208 us-gaap:LineOfCreditMember 2024-02-13 0000012208 us-gaap:LineOfCreditMember 2024-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-04-01 2024-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 2023-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-01 2024-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-01 2023-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-06-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-06-30 0000012208 bio:LifeScienceMember 2024-04-01 2024-06-30 0000012208 bio:ClinicalDiagnosticsMember 2024-04-01 2024-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2024-04-01 2024-06-30 0000012208 bio:LifeScienceMember 2023-04-01 2023-06-30 0000012208 bio:ClinicalDiagnosticsMember 2023-04-01 2023-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2023-04-01 2023-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-06-30 0000012208 bio:LifeScienceMember 2023-01-01 2023-06-30 0000012208 bio:ClinicalDiagnosticsMember 2023-01-01 2023-06-30 0000012208 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-06-30 0000012208 us-gaap:OperatingSegmentsMember 2024-04-01 2024-06-30 0000012208 us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000012208 us-gaap:OperatingSegmentsMember 2024-01-01 2024-06-30 0000012208 us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2024-04-01 2024-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2023-04-01 2023-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-06-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-06-30 0000012208 bio:EuropeanReorganizationMember 2021-02-01 2024-06-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2023-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2023-12-31 0000012208 bio:EuropeanReorganizationMember 2023-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2024-01-01 2024-06-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2024-01-01 2024-06-30 0000012208 bio:EuropeanReorganizationMember 2024-01-01 2024-06-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2024-06-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2024-06-30 0000012208 bio:EuropeanReorganizationMember 2024-06-30 0000012208 us-gaap:OneTimeTerminationBenefitsMember 2024-01-01 2024-06-30 0000012208 us-gaap:FacilityClosingMember 2024-01-01 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember 2023-02-01 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2023-12-31 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2023-12-31 0000012208 bio:EuropeanAndAmericanReorganizationMember 2023-12-31 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2024-04-01 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2024-04-01 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember 2024-01-01 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2024-01-01 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2024-01-01 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2024-06-30 0000012208 bio:EuropeanAndAmericanReorganizationMember 2024-06-30 0000012208 us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0000012208 us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0000012208 srt:MinimumMember 2024-01-01 2024-06-30 0000012208 srt:MaximumMember 2024-01-01 2024-06-30 0000012208 us-gaap:SubsequentEventMember 2024-07-29 shares iso4217:USD

iso4217:USD shares pure utr:Rate 0000012208 --12-31 2024 Q2 false 0.1 10-Q true 2024-06-30 false 001-07928 BIO-RAD LABORATORIES, INC. DE 94-1381833 1000 Alfred Nobel Drive, Hercules, CA 94547 (510) 724-7000 Class A Common Stock, Par Value $0.0001 per share BIO NYSE Class B Common Stock, Par Value $0.0001 per share BIO.B NYSE Yes Yes Large Accelerated Filer false false false 22794641 5076017 406913000 403815000 1209193000 1203327000 5560000 5560000 14043000 14926000 445506000 489017000 803693000 780517000 153013000 140040000 32376000 26054000 3056254000 3048330000 533767000 529007000 181473000 194730000 412116000 413569000 307093000 320514000 5099554000 7698070000 98189000 94850000 9688446000 12299070000 126693000 144625000 132460000 139929000 483000 486000 35896000 35759000 41513000 40379000 149916000 161621000 486961000 522799000 1199724000 1199052000 878462000 1475495000 150975000 165478000 193537000 195113000 2909659000 3557937000 0.0001 7500000 0 0 0 25189806 25169944 23122664 23422506 2000 2000 5076066 5076066 5095930 5095930 1000 1000 474729000 449075000 2067142 1747438 723642000 632536000 7479059000 9260629000 -451362000 -336038000 6778787000 8741133000 9688446000 12299070000 638476000 681110000 1249296000 1357954000 283357000 318627000 568211000 633054000 355119000 362483000 681085000 724900000 194719000 207824000 409602000 433377000 58904000 65042000 125279000 139993000 101496000 89617000 146204000 151530000 12264000 12343000 24541000 24680000 1699000 1253000 3653000 3600000 -2895355000 -1595442000 -2473178000 -1612967000 18143000 16488000 52659000 66919000 -2786281000 -1500427000 -2295203000 -1415598000 -620795000 -338176000 -513633000 -322309000 -2165486000 -1162251000 -1781570000 -1093289000 -76.26 -76.26 -39.59 -39.59 -62.61 -62.61 -37.09 -37.09 28395000 28395000 29355000 29355000 28457000 28457000 29475000 29475000 -2165486000 -1162251000 -1781570000 -1093289000 -24694000 36605000 -116362000 91823000 470000 -237000 -884000 -271000 -227000 -1352000 154000 1866000 -25391000 35490000 -115324000 93960000 -2190877000 -1126761000 -1896894000 -999329000 1265453000 1360206000 1084925000 1173285000 23301000 23535000 52172000 31556000 51097000 65422000 -11286000 1067000 167438000 196185000 82457000 70364000 92000 39000 654541000 341522000 536544000 195932000 126342000 173426000 -74020000 -42489000 236000 231000 617000 0 10188000 9521000 152000 312000 105749000 207407000 -96566000 -198429000 6494000 670000 3346000 -44063000 404369000 434544000 407715000 390481000 406913000 390001000 384000 82000 418000 398000 407715000 390481000 3000 449075000 -632536000 9260629000 -336038000 8741133000 0 0 0 383916000 0 383916000 0 0 0 0 -89933000 -89933000 0 15262000 0 0 0 15262000 0 0 4702000 0 0 4702000 0 -1710000 7215000 0 0 5505000 0 0 47000 0 0 47000 3000 462627000 -630070000 9644545000 -425971000 9051134000 0 0 0 -2165486000 0 -2165486000 0 0 0 0 -25391000 -25391000 0 14999000 0 0 0 14999000 0 0 100000000 0 0 100000000 0 -2745000 7428000 0 0 4683000 0 152000 0 0 0 152000 0 0 1000000 0 0 1000000 3000 474729000 -723642000 7479059000 -451362000 6778787000 3000 447454000 -263586000 9898203000 -466822000 9615252000 0 0 0 68962000 0 68962000 0 0 0 0 58470000 58470000 0 16608000 0 0 0 16608000 0 -660000 5290000 -206000 0 4424000 3000 463402000 -258296000 9966959000 -408352000 9763716000 0 0 0 -1162251000 0 -1162251000 0 0 0 0 35490000 35490000 0 12559000 0 0 0 12559000 0 0 207407000 0 0 207407000 0 -2089000 6919000 -44000 0 4786000 3000 473872000 -458784000 8804664000 -372862000 8446893000
1. BASIS OF PRESENTATION AND USE OF ESTIMATES
 Basis of Presentation
 In this report, "Bio-Rad," "we," "us," "the Company" and "our" refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023.
 We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.
 Use of Estimates
 The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.
 Revenue Recognition
 We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
 We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.
 We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.
 Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.
 We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.
 The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
 We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and

services offered. The term between invoicing and when payment is due is not significant.
In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.
We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.
 Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and six months ended June 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss). Contract costs:

 We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).
Disaggregation of Revenue:
 The following table presents our revenues disaggregated by geographic region (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">254.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">287.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">507.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">584.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">EMEA</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">206.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">416.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">APAC</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-

height:100%">131.2 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other (primarily Canada and Latin America)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net sales</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">638.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">681.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,249.3 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,358.0 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).
 Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at June 30, 2024 and December 31, 2023 was $67.4 million and $68.3 million, respectively. The short-term deferred revenue balance at June 30, 2024 and December 31, 2023 was $52.0 million and $51.1 million, respectively.</div><div>
</div><div>We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).</div><div>
</div><div>Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the six months ended June 30, 2024 and 2023 were as follows (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Balance at beginning of period</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Provision for warranty</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td

colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Actual warranty costs</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.8) </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Accounts Receivable and Allowance for Credit Losses We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.
 Changes in our allowance for credit losses were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Balance at beginning of period</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Provision for expected credit losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Write-offs charged against the allowance</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.9)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Recent Accounting Pronouncements Issued and to be Adopted
 In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, "Improvements to Reportable Segment Disclosures." The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker (CODM). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

*
 In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.
 In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures. Basis of Presentation
 In this report, "Bio-Rad," "we," "us," "the Company" and "our" refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023. We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates
 The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates. Revenue Recognition
 We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.
 We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.
 We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.
 Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.
 We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.
 The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.
 We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.
 In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.
 We concluded that the use of the instrument (referred to as "lease elements") in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.
 Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and six months ended June 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss). *

Contract costs:
 We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).
 Disaggregation of Revenue:
 The following table presents our revenues disaggregated by geographic region (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">254.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">287.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">507.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">584.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">EMEA</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">206.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">416.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">APAC</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">131.2 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other (primarily Canada and Latin America)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

*New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">87.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net sales</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">638.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">681.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,249.3 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,358.0 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).
 Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at June 30, 2024 and December 31, 2023 was $67.4 million and $68.3 million, respectively. The short-term deferred revenue balance at June 30, 2024 and December 31, 2023 was $52.0 million and $51.1 million, respectively.</div> 0.03 0.03 <div>The following table presents our revenues disaggregated by geographic region (in millions):</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">254.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">287.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">507.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">584.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">EMEA</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">206.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times*

*New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">416.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">APAC</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">131.2 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other (primarily Canada and Latin America)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net sales</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">638.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">681.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,249.3 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,358.0 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 254200000 287700000 507100000 584700000 206500000 211200000 406700000 416000000.0 131200000 143000000.0 248400000 278800000 46600000 39200000 87100000 78500000 638500000 681100000 1249300000 1358000000 67400000 68300000 52000000 51100000 We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).
 Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the six months ended June 30, 2024 and 2023 were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Balance at beginning of period</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-*

*align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Provision for warranty</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Actual warranty costs</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.8) </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the six months ended June 30, 2024 and 2023 were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Balance at beginning of period</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Provision for warranty</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Actual warranty costs</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.8) </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 8400000 10600000 3400000 4200000 4000000.0 5800000 7800000 9000000.0 Accounts Receivable and Allowance for Credit Losses We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.
 Changes in our allowance for credit losses were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td*

style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Balance at beginning of period</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Provision for expected credit losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Write-offs charged against the allowance</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.9)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Changes in our allowance for credit losses were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Balance at beginning of period</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Provision for expected credit losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Write-offs charged against the allowance</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.9)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid

#000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 14900000 15000000.0 2000000.0 1200000 2900000 400000 14000000.0 15800000 Recent Accounting Pronouncements Issued and to be Adopted
 In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, "Improvements to Reportable Segment Disclosures." The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker (CODM). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.
 In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.
 In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures. 2. FAIR VALUE MEASUREMENTS
 We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:
 •Level 1: Quoted prices in active markets for identical instruments •Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) •Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2024 are classified in the hierarchy as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial assets carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total cash equivalents (a)</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted investments (b)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Equity securities (c)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">4,825.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">4,825.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loan under the fair value option (d)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">305.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">305.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Available-for-sale investments:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">

545.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">545.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">246.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">246.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign government obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Municipal obligations</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Asset-backed securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">333.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">333.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total available-for-sale investments (e)</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (f)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">

</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial assets carried at fair value</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,909.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,177.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">305.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,392.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial liabilities carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (g)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration (h)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial liabilities carried at fair value</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid

#000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial assets carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Commercial paper</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">12.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">12.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">36.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-

color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">28.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">28.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total cash equivalents (a)</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted investments (b)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Equity securities (c)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7,399.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,399.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loan under the fair value option (d)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Available-for-sale investments:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">531.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">531.6 </td>

<td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">255.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">255.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign government obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Municipal obligations</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Asset-backed securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">323.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">323.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total available-for-sale investments (e)</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,136.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,136.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (f)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">4.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">4.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial assets carried at fair value</td><td

style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,434.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,956.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial liabilities carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (g)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration (h)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial liabilities carried at fair value</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:11pt;font-weight:400;line-height:120%">(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.
 (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted investments</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.2 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:68.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term investments</td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73.6 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">67.2 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,752.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,332.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total</td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,825.6 </td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,399.3 </td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
 (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.
 (g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.
 (h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million and $0.4 million in the condensed consolidated statements of income (loss) for the three and six months ended June 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of June 30, 2024.
 Level 1 Fair Value Measurements
 As of June 30, 2024, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the outstanding ordinary shares (excluding treasury shares) and 27% of the preference shares of Sartorius as of June 30, 2024. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.
 The change in fair market value of our investment in Sartorius for the three and six months ended June 30, 2024 were a loss of $2,874.4 million and a loss of $2,472.1 million, respectively, and are recorded in our condensed consolidated statements of income (loss).</div><div>
</div><div>Level 2 Fair Value Measurements</div><div>
</div><div>To estimate the fair value of Level 2 debt securities as of June 30, 2024 and December 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. </div><div>
</div><div>Available-for-sale investments consist of the following (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Losses</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated
Fair
Value</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Short-term investments:</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Corporate debt securities</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">547.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">(3.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">545.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Municipal obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-

color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Asset-backed securities</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">335.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">248.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">246.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign government obligations</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,141.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(7.1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2024 by contractual maturity date (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated Fair
Value</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Mature in less than one year</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">216.1 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">214.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Mature in one to five years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">730.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">727.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Mature in more than five years</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">194.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">193.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,141.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Available-for-sale investments consist of the following (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Losses</td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated
Fair
Value</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Short-term investments:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Corporate debt securities</td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">534.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">531.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Municipal obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(0.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Asset-backed securities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">325.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">0.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2.7)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">323.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">257.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign government obligations</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(0.1)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,142.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-

*weight:400;line-height:100%">(7.8)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,136.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
 As of June 30, 2024, there were no significant continuous unrealized losses greater than 12 months.
 Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.
 At June 30, 2024, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer.As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of June 30, 2024. Included in Other current assets are $9.8 million and $11.9 million of interest receivable as of June 30, 2024 and December 31, 2023, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the six months ended June 30, 2024, we have not written-off any uncollected interest receivable.</div><div>
</div><div>As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of June 30, 2024 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was </div><div>derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange gains, net in the condensed consolidated statements of income (loss).</div><div>
</div><div>The following is a summary of our forward foreign currency exchange contracts (in millions): </div><div>
</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Contracts to sell foreign currency:</div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Notional value</td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">698.1 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">873.5 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt">Unrealized gain/(loss)</div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(8.1)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><div>Contracts to purchase foreign currency:</div></td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Notional value</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">59.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">133.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt">Unrealized (loss)/gain</div></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-*

***weight:400;line-height:100%">(0.1)</td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $6.5 million as of June 30, 2024 and December 31, 2023.
 Also included in Other investments in the condensed consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in Other income, net in our condensed consolidated statements of income (loss). The carrying value of these investments, net of impairments, was $33.9 million and $32.3 million as of June 30, 2024 and December 31, 2023, respectively.</div><div>
</div><div>The carrying value and fair value of our long-term debt were as follows (in millions):</div><div>
</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Carrying Value</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Fair Value</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Senior notes</div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,190.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,093.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,189.5 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,102.5 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Other long-term debt</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total</div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,199.7 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,102.7 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px***

0;text-align:right;vertical-align:bottom">1,199.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,112.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The fair value of our long-term debt was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.
 Level 3 Fair Value Investments
 During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity ("Loan"). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust ("Trust") from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in Losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the three months ended June 30, 2024 was a loss of $22.7 million, which includes a $6.2 million gain from change in fair market value of the Loan and a $28.9 million loss from change in fair market value of the value appreciation right. The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the six months ended June 30, 2024 was a loss of $10.4 million, which includes a $15.0 million gain from change in fair market value of the Loan and a $25.4 million loss from change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decrease in the value of the Sartorius ordinary shares. As of June 30, 2024, the €400 million principal amount of the loan is still due on January 31, 2029. </div><div>
</div><div>The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):</div><div>
</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:75.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net decrease in estimated fair market value of the loan included in Losses in fair market value of equity securities and loan receivable </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(10.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Foreign currency exchange losses, net</div></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">(9.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">June 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">305.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> Financial assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2024 are classified in the hierarchy as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial assets carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td

colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loan under the fair value option (d)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">305.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">305.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Available-for-sale investments:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">545.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">545.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">246.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">246.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign government obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">2.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Municipal obligations</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Asset-backed securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">333.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">333.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-

align:left;vertical-align:bottom">Total available-for-sale investments (e)</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (f)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial assets carried at fair value</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,909.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,177.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">305.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,392.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial liabilities carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (g)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration (h)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td

style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial liabilities carried at fair value</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial assets carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Commercial paper</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">12.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">12.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">36.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">

— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">28.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">28.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total cash equivalents (a)</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted investments (b)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Equity securities (c)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7,399.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,399.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loan under the fair value option (d)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt

2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Available-for-sale investments:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">531.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">531.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">255.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">255.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign government obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Municipal obligations</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Asset-backed securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">323.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">323.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total available-for-sale investments (e)</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,136.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid

#000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,136.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (f)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">4.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">4.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial assets carried at fair value</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,434.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,956.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Financial liabilities carried at fair value:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward foreign exchange contracts (g)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration (h)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">17.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total financial

liabilities carried at fair value</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 (a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.
 (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted investments</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.2 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:68.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term investments</td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73.6 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:11pt;font-weight:400;line-height:100%">67.2 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,752.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,332.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,825.6 </td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,399.3 </td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
 (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.
 (g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.
 (h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million and $0.4 million in the condensed consolidated statements of income (loss) for the three and six months ended June 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of June 30, 2024.</div> 0 40300000 0 40300000 76300000 0 0 76300000 76300000 40300000 0 116600000 7200000 0 0 7200000 4825600000 0 0 4825600000 0 0 305600000 305600000 0 545000000.0 0 545000000.0 0 0 246100000 0 246100000 0 2600000 0 2600000 0 8300000 0 8300000 0 333600000 0 333600000 0 1135600000 0 1135600000 0 1500000 0 1500000 4909100000 1177400000 305600000 6392100000 0 1200000 0 1200000 0 0 17900000 17900000 0 1200000 17900000 19100000 0 12500000 0 12500000 0 36600000 0 36600000 0 7000000.0 0 7000000.0 28000000.0 0 0 0 28000000.0 28000000.0 56100000 0 84100000 7100000 0 0 7100000 7399300000 0 0 7399300000 0 0 325700000 325700000 0 531600000 0 531600000 0 255900000 0 255900000 0 12700000 0 12700000 0 12100000 0 12100000 0 323700000 0 323700000 0 1136000000 0 1136000000 0 4100000 0 4100000 7434400000 1196200000 325700000 8956300000 0 11700000 0 11700000 0 0 17500000 17500000 0 11700000 17500000 29200000 5600000 5600000 1600000 1500000 7200000 7100000 73600000 67200000 4752000000 7332100000 4825600000 7399300000 200000 400000 12987900 9588908 0.38 0.27 2874400000 2472100000 <div>Available-for-sale investments consist of the following (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Losses</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated
Fair
Value</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Short-term investments:</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Corporate debt securities</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">547.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td

style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">(3.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">545.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Municipal obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">8.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Asset-backed securities</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">335.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.0) </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">248.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">246.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign government obligations</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,141.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(7.1) </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-

bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Available-for-sale investments consist of the following (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Losses</td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated
Fair
Value</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Short-term investments:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> </td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Corporate debt securities</td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">534.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">(3.3)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">531.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Municipal obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(0.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Asset-backed securities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">325.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">0.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-

weight:400;line-height:100%">(2.7)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">323.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">U.S. government sponsored agencies</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">257.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign government obligations</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">12.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(0.1)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,142.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">(7.8)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">1,136.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 547300000 700000 3000000.0 545000000.0 8300000 0 0 8300000 335100000 500000 2000000.0 333600000 248100000 100000 2100000 246100000 2600000 0 0 2600000 1141400000 1300000 7100000 1135600000 The following is a summary of the amortized cost and estimated fair value of our debt securities at June 30, 2024 by contractual maturity date (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated Fair
Value</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Mature in less than one year</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">216.1 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">214.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Mature in one to five years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">730.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">727.4 </td><td

*style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Mature in more than five years</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">194.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">193.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,141.4 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,135.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 216100000 214800000 730800000 727400000 194500000 193400000 1141400000 1135600000 534100000 800000 3300000 531600000 12200000 0 100000 12100000 325700000 700000 2700000 323700000 257400000 100000 1600000 255900000 12800000 0 100000 12700000 1142200000 1600000 7800000 1136000000 9800000 11900000 The following is a summary of our forward foreign currency exchange contracts (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Contracts to sell foreign currency: </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Notional value</td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">698.1 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">873.5 </td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> Unrealized gain/(loss) </td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(8.1)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"> Contracts to purchase foreign currency: </td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Notional value</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">59.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">133.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"> Unrealized (loss)/gain </td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 698100000 873500000 500000 -8100000 59100000 133600000 -100000 500000 6500000 6500000 33900000 32300000 The carrying value and fair value of our long-term debt were as follows (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td*

*style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Carrying Value </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Fair Value </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Senior notes </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,190.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,093.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,189.5 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,102.5 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other long-term debt </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,199.7 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,102.7 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,199.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,112.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1190300000 1093300000 1189500000 1102500000 9400000 9400000 9600000 9600000 1199700000 1102700000 1199100000 1112100000 400000000 0.015 -22700000 6200000 28900000 -10400000 15000000.0 25400000 400000000 The following table provides a reconciliation of the Level 3 loan measured at estimated fair value (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:75.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">325.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net decrease*

*in estimated fair market value of the loan included in Losses in fair market value of equity securities and loan receivable </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(10.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Foreign currency exchange losses, net</div></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">(9.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">June 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">305.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 325700000 -10400000 9700000 305600000 <div>3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS</div><div>
</div><div>Changes to goodwill by segment are as follows (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life
Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical
Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Balances as of January 1, 2024:</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Goodwill</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">333.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">415.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">748.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Accumulated impairment losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(41.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(293.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(335.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top">Goodwill, net</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">291.5 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">122.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">413.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Foreign currency adjustments</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-*

height:100%">(1.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Period change, net </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balances as of June 30, 2024:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Goodwill</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">333.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">414.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">747.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Accumulated impairment losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(41.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(293.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(335.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top">Goodwill, net</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">291.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">120.6 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">412.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Remaining Amortization Period (years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Purchase
Price</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships/lists</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">5.0</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">105.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(96.6)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Know how</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">1.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">166.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(160.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Developed product technology</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">11.7</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">216.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(136.8)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">80.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Licenses</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">4.4</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">58.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(44.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Tradenames</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">5.1</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4.6)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Covenants not to compete</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">1.8</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(5.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Total finite-lived intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">559.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(447.8)</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3"

*style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">111.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">In-process research and development</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> Total purchased intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">754.9 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(447.8)</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">307.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Remaining Amortization Period (years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Purchase
Price</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships/lists</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">5.2</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">108.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(98.9)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Know how</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">1.8</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">168.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(161.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Developed product technology</td><td colspan="3"*

style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">12.0</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">217.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(132.9)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">84.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Licenses</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">4.9</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">59.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(42.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">16.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Tradenames</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">5.6</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Covenants not to compete</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Total finite-lived intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">567.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(444.8)</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">122.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">In-process research and development</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Total purchased intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">765.3 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-

*align:bottom">(444.8)</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">320.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>
</div><div>Amortization expense related to purchased intangible assets is as follows (in millions):</div><div>
</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization expense</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11.9 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div>Changes to goodwill by segment are as follows (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life
Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical
Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Balances as of January 1, 2024:</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Goodwill</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">333.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">415.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">748.8 </td><td*

style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Accumulated impairment losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(41.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(293.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(335.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top">Goodwill, net</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">291.5 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">122.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">413.6 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Foreign currency adjustments</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Period change, net </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.5)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Balances as of June 30, 2024:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Goodwill</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">333.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">414.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">747.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Accumulated impairment losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(41.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(293.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(335.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top">Goodwill, net</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">291.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt

#000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">120.6 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">412.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 333300000 415500000 748800000 41800000 293400000 335200000 291500000 122100000 413600000 0 -1500000 -1500000 0 -1500000 -1500000 333300000 414000000.0 747300000 41800000 293400000 335200000 291500000 120600000 412100000 Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Remaining Amortization Period (years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Purchase
Price</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships/lists</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">5.0</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">105.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(96.6)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Know how</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">1.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">166.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(160.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Developed product technology</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">11.7</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">216.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(136.8)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">80.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Licenses</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">4.4</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">58.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(44.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">14.9 </td><td style="background-color:#ffffff;padding:2px 1pt

2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Tradenames</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">5.1</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">5.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4.6)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Covenants not to compete</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">1.8</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(5.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Total finite-lived intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">559.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(447.8)</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">111.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">In-process research and development</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Total purchased intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">754.9 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(447.8)</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">307.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Remaining Amortization Period (years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

*serif;font-size:11pt;font-weight:400;line-height:100%">Purchase
Price</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships/lists</td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">5.2</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">108.7 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(98.9)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Know how</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">1.8</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">168.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(161.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">7.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Developed product technology</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">12.0</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">217.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(132.9)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">84.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Licenses</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">4.9</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">59.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(42.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">16.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Tradenames</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">5.6</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Covenants not to compete</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">6.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(4.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td*

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> Total finite-lived intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">567.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(444.8)</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">122.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">In-process research and development</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> Total purchased intangible assets</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">765.3 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(444.8)</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">320.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P5Y 105000000.0 96600000 8400000 P1Y3M18D 166300000 160700000 5600000 P11Y8M12D 216800000 136800000 80000000.0 P4Y4M24D 58900000 44000000.0 14900000 P5Y1M6D 5900000 4600000 1300000 P1Y9M18D 6300000 5100000 1200000 559200000 447800000 111400000 195700000 195700000 754900000 447800000 307100000 P5Y2M12D 108700000 98900000 9800000 P1Y9M18D 168900000 161100000 7800000 P12Y 217800000 132900000 84900000 P4Y10M24D 59200000 42400000 16800000 P5Y7M6D 6100000 4700000 1400000 P2Y3M18D 6400000 4800000 1600000 567100000 444800000 122300000 198200000 198200000 765300000 444800000 320500000 <div>Amortization expense related to purchased intangible assets is as follows (in millions):</div><div>
</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization expense</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span

*style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11.9 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 5300000 5900000 10800000 11900000 4. INVENTORY
 Following are the components of Inventory at June 30, 2024 and December 31, 2023 (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Inventory:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Raw materials</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">235.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">231.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Work in process</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">246.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Finished goods </td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">313.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total Inventory</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">803.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">780.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Following are the components of Inventory at June 30, 2024 and December 31, 2023 (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Inventory:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Raw materials</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">235.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">231.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Work in process</td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">246.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Finished goods </td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">313.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total Inventory</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">803.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">780.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 235000000.0 231600000 255000000.0 246000000.0 313700000 302900000 803700000 780500000 5. SUPPLEMENTAL CASH FLOW INFORMATION
 The reconciliation of net loss to net cash provided by operating activities is as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net loss</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,781.6)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,093.3)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Adjustments to reconcile net loss to net cash provided by operating activities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Reduction in the carrying amount of right-of-use assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Share-based compensation</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.2 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Losses from change in fair market value of equity securities and loan receivable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,473.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,613.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Payments for operating lease liabilities</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(21.4)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19.8)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Decrease in accounts receivable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Increase in inventories</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.2)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(55.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">(Increase) decrease in other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Decrease in accounts payable and other current liabilities</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26.6)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Increase in income taxes payable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Decrease in deferred income taxes</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(575.1)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(391.6)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Increase (decrease) in other long-term liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.1)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net cash provided by operating activities</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">167.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">196.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash investing activities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-

align:left;vertical-align:bottom">Purchased property, plant and equipment</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">7.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">12.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Purchased marketable securities and investments</td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Sold marketable securities and investments</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">9.8 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The reconciliation of net loss to net cash provided by operating activities is as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net loss</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,781.6)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,093.3)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Adjustments to reconcile net loss to net cash provided by operating activities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Reduction in the carrying amount of right-of-use assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Share-based compensation</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29.2 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Losses from change in fair market value of equity securities and loan receivable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,473.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,613.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Payments for operating lease liabilities</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(21.4)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19.8)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Decrease in accounts receivable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Increase in inventories</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.2)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(55.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">(Increase) decrease in other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Decrease in accounts payable and other current liabilities</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26.6)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Increase in income taxes payable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Decrease in deferred income taxes</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(575.1)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(391.6)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Increase (decrease) in other long-term liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.1)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net cash provided by operating activities</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">167.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">196.2 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt">

<td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash investing activities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Purchased property, plant and equipment</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">7.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom">12.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Purchased marketable securities and investments</td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Sold marketable securities and investments</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">9.8 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -1781600000 -1093300000 73500000 71400000 20900000 19900000 30300000 29200000 -2473200000 -1613000000 -21400000 -19800000 -33000000.0 -5200000 31200000 55300000 31000000.0 -16500000 -26600000 -34700000 5600000 31500000 575100000 391600000 -200000 6300000 2000000.0 2100000 167400000 196200000 7800000 12000000.0 2200000 1200000 9800000 0 6. LONG-TERM DEBT
 The principal components of long-term debt are as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> 3.3%, Senior Notes due 2027 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">400.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">400.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> 3.7%, Senior Notes due 2032 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">800.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">800.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Less unamortized discounts and debt issuance costs</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(10.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt less unamortized discounts and debt issuance costs</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,190.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,189.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td

colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Finance leases and other debt</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">9.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">10.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Less current maturities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(0.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Long-term debt</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,199.7 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,199.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 On February 13, 2024, we entered into a new $200.0 million unsecured revolving credit agreement ("Revolving Credit Agreement") with a group of financial institutions. The Revolving Credit Agreement replaced the Company's previous credit agreement, dated as of April 15, 2019. Borrowings under the Revolving Credit Agreement are on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. The Revolving Credit Agreement requires Bio-Rad to comply with certain financial ratios and other customary covenants and provisions. The Revolving Credit Agreement matures on February 13, 2029. As of June 30, 2024, no borrowings were outstanding under the Revolving Credit Agreement, although available capacity was reduced by immaterial outstanding letters of credit. We were in compliance with the covenants for the Revolving Credit Agreement during the six months ended June 30, 2024.</div> <div>The principal components of long-term debt are as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><div>3.3%, Senior Notes due 2027</div></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">400.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">400.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">3.7%, Senior Notes due 2032 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">800.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">800.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Less unamortized discounts and debt issuance costs</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(9.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(10.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt less unamortized discounts and debt issuance costs</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,190.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1,189.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Finance leases and other debt</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">9.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">10.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Less current maturities</td><td colspan="2"

*style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(0.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Long-term debt</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,199.7 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,199.1 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0.033 400000000.0 400000000.0 0.037 800000000.0 800000000.0 -9700000 -10500000 1190300000 1189500000 9900000 10100000 500000 500000 1199700000 1199100000 200000000 0 7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
 Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign currency translation adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign other post-employment benefits adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net unrealized holding gains (losses) on available-for-sale investments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total accumulated other comprehensive income (loss)</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2024:</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(334.1)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.8)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(336.0)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss), before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(116.6)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(116.4)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified from Accumulated other comprehensive income (loss)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3) </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Income tax effects</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-*

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss), net of income taxes</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(116.3)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(115.4)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2024:</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(450.4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(451.4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign currency translation adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign other post-employment benefits adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net unrealized holding gains (losses) on available-for-sale investments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total accumulated other comprehensive income (loss)</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2023:</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(466.5)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10.3)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(466.8)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income, before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px

0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified from Accumulated other comprehensive income (loss)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2) </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Income tax effects</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income, net of income taxes</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2023:</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(374.7)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8.5) </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(372.9)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.
 The impact to loss before income taxes for amounts reclassified out of accumulated other comprehensive income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Components of comprehensive income (loss)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-

height:100%">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of foreign other post-employment benefit items</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net holding losses on equity securities and available-for-sale investments </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign currency translation adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign other post-employment benefits adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net unrealized holding gains (losses) on available-for-sale investments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total accumulated other comprehensive income (loss)</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2024:</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(334.1)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.8)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(336.0)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss), before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(116.6)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(116.4)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified from Accumulated other comprehensive income (loss)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Income tax effects</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss), net of income taxes</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(116.3)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(115.4)</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2024:</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(450.4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2.0)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(451.4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign currency translation adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign other post-employment benefits adjustments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net unrealized holding gains (losses) on available-for-sale investments</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total accumulated other comprehensive income (loss)</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2023:</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(466.5)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-

color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10.3)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(466.8)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income, before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92.1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Amounts reclassified from Accumulated other comprehensive income (loss)</td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2) </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Income tax effects</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom">Other comprehensive income, net of income taxes</td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2023:</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(374.7)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8.5)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(372.9)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -334100000 -2800000 900000 -336000000.0 -116600000 300000 -100000 -116400000 0 300000 -300000 0 -300000 -800000 100000 -1000000.0 -116300000 800000 100000 -115400000 -450400000 -2000000.0 1000000.0 -451400000 -466500000 10000000.0 -10300000 -466800000 92100000 500000 1400000 94000000.0 0 200000 -1000000.0 -800000 300000 0 600000 900000 91800000 300000 1800000 93900000 -374700000 10300000 -8500000 -372900000 The impact to loss before income taxes for amounts reclassified out of accumulated other comprehensive income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):

<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Components of comprehensive income (loss)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of foreign other post-employment benefit items</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net holding losses on equity securities and available-for-sale investments </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(1.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -400000 -300000 -300000 -200000 -500000 -1200000 -300000 -1000000.0 8. LOSS PER SHARE
 Bio-Rad's issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.
 We compute net loss per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Loss is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the six months ended June 30, 2024 and 2023. Accordingly, basic loss per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted loss per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted loss per share calculation if the effect of including such securities would be anti-dilutive.
 The weighted average

number of common shares outstanding used to calculate basic and diluted loss per share, and the anti-dilutive shares that are excluded from the diluted loss per share calculation are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic weighted average shares outstanding</td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,395 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,355 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,457 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,475 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom">Effect of potentially dilutive stock options, restricted stock and performance stock awards</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted weighted average common shares outstanding</td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,395 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,355 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,457 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,475 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Anti-dilutive shares</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">413 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">398 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> one 0.25 The weighted average number of common shares outstanding used to calculate basic and diluted

loss per share, and the anti-dilutive shares that are excluded from the diluted loss per share calculation are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic weighted average shares outstanding</td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,395 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,355 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,457 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,475 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom">Effect of potentially dilutive stock options, restricted stock and performance stock awards</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted weighted average common shares outstanding</td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,395 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,355 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,457 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,475 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Anti-dilutive shares</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">413 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">398 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 28395000 29355000 28457000 29475000 0 0 0 0 28395000 29355000 28457000 29475000 413000 234000 398000 237000 9. OTHER INCOME, NET

 Other income, net includes the following components (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest and investment income</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(16.6)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(16.5)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(50.6)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(66.8)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Net realized losses on investments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1.6)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.8)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(2.4)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1.6)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-

weight:400;line-height:100%">(18.1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(16.5)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(52.7)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(66.9)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div>Other income, net includes the following components (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest and investment income</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(16.6)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(16.5)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(50.6)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(66.8)</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Net realized losses on investments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">0.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td

*colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1.6)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(0.8)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(2.4)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1.6)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(18.1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(16.5)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(52.7)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(66.9)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 16600000 16500000 50600000 66800000 -100000 -800000 -300000 -1500000 1600000 800000 2400000 1600000 18100000 16500000 52700000 66900000 10. INCOME TAXES
 Our effective income tax rate was 22.3% and 22.5% for the three months ended June 30, 2024 and 2023, respectively. Our effective income tax rate was 22.4% and 22.8% for the six months ended June 30, 2024 and 2023, respectively.
 The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of June 30, 2024, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $22.1 million for the period ended June 30, 2024 compared to the year ended December 31, 2023.
 Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.
 We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.
 Our gross unrecognized tax benefits were $87.1 million and $84.7 million as of June 30, 2024 and December 31, 2023, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.
 As of June 30, 2024, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $2.9 million. Substantially all such amounts will impact our effective income tax rate if recognized. 0.223 0.225 0.224 0.228 22100000 87100000 84700000 2900000 11. SEGMENT INFORMATION
 Information regarding net sales and operating profit (loss) for the three months ended June 30, 2024 and 2023 are as follows (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life
Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical
Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other
Operations</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3"*

*style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Net sales</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">250.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">387.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">0.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">300.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">380.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Operating profit (loss) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">19.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">82.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">28.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">61.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">(0.2)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
 Information regarding net sales and operating profit (loss) for the six months ended June 30, 2024 and 2023 are as follows (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life
Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical
Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other
Operations</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Net sales</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#cdffcc;padding:2px 0*

2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">492.2 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">756.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">0.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">623.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">732.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">2.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Operating profit (loss)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">10.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">135.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">63.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">88.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">(0.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table>
 Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments. The following reconciles total operating profit to consolidated loss before income taxes (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:48.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.136%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Operating profit</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">101.5 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">89.6 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">146.2 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">151.5 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(24.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(24.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"> Foreign currency exchange gains, net </td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.3 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Losses from change in fair market value of equity securities and loan receivable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,895.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1,595.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,473.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1,612.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Other income, net</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">18.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">16.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">52.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">66.9 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Consolidated loss before income taxes </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,786.3)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td

*style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,500.4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,295.2)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,415.6)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Information regarding net sales and operating profit (loss) for the three months ended June 30, 2024 and 2023 are as follows (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life
Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical
Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other
Operations</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Net sales</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">250.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">387.9 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">0.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">300.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">380.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Operating profit (loss)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">19.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">82.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New*

*Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">28.0 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">61.8 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">(0.2)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div></div><div>Information regarding net sales and operating profit (loss) for the six months ended June 30, 2024 and 2023 are as follows (in millions):</div><div>
</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life
Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical
Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other
Operations</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top">Net sales</td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">492.2 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">756.6 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">0.5 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">623.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">732.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">2.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Operating profit (loss) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">10.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">135.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">63.7 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-*

align:left;vertical-align:top">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">88.1 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top">(0.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table> 250500000 387900000 100000 300200000 380100000 800000 191000008260000 0 -200000 28000000.0 61800000 -200000 492200000 756600000 500000 623800000 732200000 2000000.0 10900000 135700000 -400000 63700000 88100000 -300000 The following reconciles total operating profit to consolidated loss before income taxes (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:48.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.136%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Operating profit</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">101.5 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">89.6 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">146.2 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">151.5 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(24.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(24.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"> Foreign currency exchange gains, net </td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">1.3 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">3.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Losses from change in fair market value of equity securities and loan receivable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,895.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1,595.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2,473.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1,612.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top">Other income, net</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">18.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">16.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">52.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">66.9 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Consolidated loss before income taxes </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,786.3)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,500.4)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,295.2)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,415.6)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 101500000 89600000 146200000 151500000 -12300000 -12400000 -24500000 -24700000 1700000 1300000 3700000 3600000 -2895300000 -1595400000 -2473300000 -1612900000 18100000 16500000 52700000 66900000 -2786300000 -1500400000 -2295200000 -1415600000 12. LEGAL PROCEEDINGS We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 13. RESTRUCTURING COSTS
 In February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of June 30, 2024. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to June 30, 2024, total restructuring-related expenses were $72.3 million.</div><div>
</div><div>The following table summarizes the activity of our February 2021 plan accrued restructuring reserve (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2024:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid

#000000;padding:2px 0;text-align:right;vertical-align:bottom">12.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Adjustment to expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7.8)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency adjustments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2024:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.2 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.4 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 During the fiscal year ended December 31, 2023, and continuing into the six months ended June 30, 2024, management approved a restructuring action to further streamline and improve operating performance. The restructuring plan was approved and implemented in phases. The plan is expected to be substantially completed by the end of 2024. During the six months ended June 30, 2024, a new phase of the restructuring plan was approved, resulting in restructuring expenses of $4.5 million, representing estimated termination benefits to employees. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits on previously approved phases. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. Excluded from the accrued restructuring plan reserves are $1.5 million of restructuring expense related to the facility closure costs impacting the Life Science segment. From February 2023 to June 30, 2024, total restructuring-related expenses were $29.9 million, primarily representing estimated termination benefits to employees.
 The following table summarizes the activity of our 2023 accrued restructuring plan reserve (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2024:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Charged to expense - employee termination benefits</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Adjustment to expense</div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.9)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency adjustments</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2024:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

 Combined, the accrued restructuring plan reserve of $9.4 million as of June 30, 2024 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended June 30, 2024 were $0.6 million, $(1.4) million and $(0.6) million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the six months ended June 30, 2024 were $1.1 million, $3.1 million and $1.5 million, respectively, in the condensed consolidated statements of income (loss). 72300000 The following table summarizes the activity of our February 2021 plan accrued restructuring reserve (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td

*style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Life Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2024:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Adjustment to expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7.7)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7.8)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency adjustments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2024:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.2 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.4 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table summarizes the activity of our 2023 accrued restructuring plan reserve (in millions):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span*

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life Science</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Clinical Diagnostics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of January 1, 2024:</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Charged to expense - employee termination benefits</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Adjustment to expense</div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.9)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency adjustments</td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balances as of June 30, 2024:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 200000 12800000 13000000.0 100000 1500000 1600000 100000 7700000 7800000 0 400000 400000 200000 6200000 6400000 4500000 1500000 29900000 3000000.0 7800000 10800000 2100000 2400000 4500000 -400000 -1500000 -1900000 3600000 6500000 10100000 0 300000 300000 1100000 1900000 3000000.0 9400000 600000 -1400000 -600000 1100000 3100000 1500000 14. LEASES

 We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 15 years, which includes our determination to exercise renewal options.
 We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use ("ROU") assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets.
 ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. The components of lease expense were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:49.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15.7 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">31.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease cost:</td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="9" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of right-of-use assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-

weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Interest on lease liabilities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total finance lease cost</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>
</div><div>Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.</div><div>
</div><div>Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and six months ended June 30, 2024 and 2023. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and six months ended June 30, 2024 and 2023. </div><div>
</div><div>Supplemental cash flow information related to leases was as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating cash flows from operating leases</td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">10.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">9.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">21.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating cash flows from finance leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Financing cash flows from finance leases</td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for new lease obligations:</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div>
</div><div>Supplemental balance sheet information related to leases was as follows (in millions):</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating Leases</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease right-of-use assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">181.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">194.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3"

style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Current operating lease liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">40.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease liabilities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">151.0 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">165.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total operating lease liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">192.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">205.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance Leases</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Property, plant and equipment, gross</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: accumulated depreciation and amortization</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.0) </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.9)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Property, plant and equipment, net</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.0 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Current maturities of long-term debt and notes payable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term debt, net of current maturities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total finance lease liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:60.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted Average Remaining Lease Term</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating leases - in years</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">7</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">7</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Finance leases - in years</td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom">14</td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom">14</td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted Average Discount Rate</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Finance leases</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>
 Maturities of lease liabilities were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year Ending December 31,</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Operating Leases</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 (excluding the six months ended June 30, 2024) </td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">22.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2025 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2026 </td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36.2 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2027 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2028 </td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total lease payments</td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">218.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less imputed interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total</td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">192.5 </td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.
 As of June 30, 2024, operating leases that have not commenced are not material.
P1Y P15Y
The components of lease expense were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:49.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-

height:100%">2023</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15.7 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34.9 </td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">31.5 </td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease cost:</td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="9" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of right-of-use assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Interest on lease liabilities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total finance lease cost</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 16800000 15700000 34900000 31500000 100000 100000 200000 200000 200000 400000 400000 300000 300000 600000 600000 Supplemental cash flow

information related to leases was as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for amounts included in the measurement of lease liabilities:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating cash flows from operating leases</td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">10.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">9.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">21.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">19.8 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating cash flows from finance leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Financing cash flows from finance leases</td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ceffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ceffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Right-of-use assets obtained in exchange for new lease obligations:</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ceffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating leases</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-

height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 10500000 9800000 21400000 19800000 200000 200000 400000 400000 100000 100000 200000 200000 3700000 10100000 11200000 12300000 Supplemental balance sheet information related to leases was as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating Leases</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease right-of-use assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">181.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">194.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Current operating lease liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">41.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">40.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating lease liabilities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">151.0 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">165.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total operating lease liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">192.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">205.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance Leases</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Property, plant and equipment, gross</td><td style="background-color:#ffffff;padding:2px 0 2px

1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: accumulated depreciation and amortization</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.0)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.9)</td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Property, plant and equipment, net</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.8 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6.0 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Current maturities of long-term debt and notes payable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term debt, net of current maturities</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total finance lease liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:60.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted Average Remaining Lease Term</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating leases - in years</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">7</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">7</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Finance leases - in years</td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom">14</td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom">14</td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted Average Discount Rate</td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-

weight:400;line-height:100%">%</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Finance leases</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.5 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.4 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> 181500000 194700000 41500000 40400000 151000000.0 165500000 192500000 205900000 11800000 11900000 6000000.0 5900000 5800000 6000000.0 500000 500000 9400000 9600000 9900000 10100000 P7Y P7Y P14Y P14Y 0.040 0.039 0.065 0.064 Maturities of lease liabilities were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year Ending December 31,</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Operating Leases</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 (excluding the six months ended June 30, 2024) </td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">22.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2025 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2026 </td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36.2 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2027 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2028 </td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.7 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total lease payments</td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">218.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.8 </td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less imputed interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

***New Roman';sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total</td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">192.5 </td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 22700000 600000 47700000 1100000 36200000 1100000 28100000 1100000 21700000 1100000 62400000 10800000 218800000 15800000 26300000 5900000 192500000 9900000 15. SUBSEQUENT EVENTS
 On July 29, 2024, Bio-Rad's board of directors authorized increasing the amount available under the company's 2023 Share Repurchase Program to allow the company to repurchase up to an additional $500 million of the company's outstanding common stock. Repurchases may be made at management's discretion from time to time on the open market, through trading plans in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through privately negotiated transactions. The 2023 Share Repurchase Program has no time limit and may be suspended for periods or discontinued at any time. 500000000 false false false*** ~~*Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.*~~ ***Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):***

June 30, 2024	December 31, 2023
Restricted investments	$5.6	$5.6
Other investments	1.6	1.5
Total	$7.2	$7.1

Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):

June 30, 2024	December 31, 2023
Short-term investments	$73.6	$67.2
Other investments	4,752.0	7,332.1
Total	$4,825.6	$7,399.3

The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million and $0.4 million in the condensed consolidated statements of income (loss) for the three and six months ended June 30, 2024, respectively. Contingencies triggering payment of contingent consideration were met as of June 30, 2024. "

!C*((_+Z_8%^R2>1,"<[.IF_M5X\]J!2BEQ91*?0%N^5ZQ<3WM42;MO*"/0!IX,VQTA+3?OYIXCKN+VS0[WK[_M#=BVV,_!DT<_YF(=S34;CPJ#ME?
3:87R#YBQ%F_;YWQD'6?4'4&E,$+IIV97_MGM#(W'&&*5VWS_9\'T$ZW3!-^VY5U?+;,_"9N$,0/)RQ[?^D>,0@OTC,WA=4_MJF*#EZUYNS39Z]-4^W_SQ&5
(/$.H>&=QMJ*$F./51*KA*>TK;.T*-Z6VG_P_M[/8/6M^Z]UVV5$\BB8@.TS'TKLBX$"*@VL)T=S#J.@.I"]C**MJ]*2@\;J_(=MZ_^/^(\2J6)?G>07ZMF5-@=?N&6N)
MW98['<3*'?]B5BA=_Q:,E__FH2__%,HL"F>YP[\][*L3C)3U@3-MUC+M3[&O3>(_'G<'N+/J;[)1QYNZM.O]X+Q582@2,S7F,63=VS$7)E?JJ.9:;U1T&FJ<@07C
I#0?05,NY/"F-SY-MJ;,&ILWS81%G)@,T:E';*7&AOFJ4'L.'IE7A(^M_&TH#X,?9_]^_TIY34(QM-MG8/2PR'\9;]U(DK#6,;
[C7J<=MS"WIO&4:1VO0(+VWH34H*MK5MGXG4@X+P-M=\'F4H\[_V]@\!G\IR,#5=8$FFS2F0XIW_CA2.T8=@<=YV+UT/[]GUAM13&4
MFLR=8C_(GP_QRP"JC/Q@/;=P:@80/I?@(,_:+&&,.RE&TV)4(.><8&#&\@I-MF#F)Z:Z!@E=0XI"E<6P#VB:3]WVU/I??(=CO9]OE,/**9$UF(SO]_P'FR=Y3
MF\ORCS/-"_@3SVTE[;_E;TXDR\ ZP1@ %'L MAT$L9L**< <"&3W@/(>@H8,WLX49WFR.#E^;$Z5J @X9XH%8'L-]4/JK8Q&[Q$L.0C(?DT1B<
M*M;LP[,R3S43T#'(.^K%URDNUCHA&T10R!=-;@=*Z35HV4]-5(FPBK>4+"VW%-M25#%;1\4.DBM=2Q,[2_8=-EG9;A*]PJ-X'(I3-X=\XU-1!9;T:IWY%E-3:%(
MJ^H:W9IBSS-O]@QKZS-?* V[SU&T4^'F5<6=6J+5]:DC^&&6K?,-V2%W+0,?-MA$-9^3^HX5N4"!X=X3T!O4EXY9/Y@!7H#4TWH=R=6@9Y1H#E45"L0>?
RN[-7]TR[4-MIO8VYR4#@1[&[2RI/T6!0RIO&-5"FO9I1Q6(.BE+-\XS!E*C:\L&1JU0XV2K-M1CHCU-#&*->.42U@W-O7*:1JGNO.5U
^H:/(U;6/^(>]F6WR>+F&Y)A"3S:,-M$+D*;VIE]L:;ASU#I"+']E70UDS/D%^MD](:(@J[.B^9O*8^B^)F_S!]A_+8*@
M1.3XP>&S(O_&OF]/EJ/IQ*AY@I/#L(B'2RZC7I:<-$W@@)=/"-CVY(C7R)RX-M%A6RE'@-LXJK#3T[5I9+CS@2D[Z-",2RQA(FN25,ZF'$7XGY.C#.=8OC]88T
M8UXZV:KF@5=D3TR1$E[X>X0#Y=H$@"H3J67]NHGX6SEV9=,R"NP29(,')C][-MO0QZ3/*[2R^LM>;)O8@DTM)(I2;&4?
VE;X*VT^G#A>V=,YD:V\!=GXJ@A]F]-M$7X*_[:_D?D5?!_'S7$^?9SW9:5Y$Q)KK&";6\'T#:\;H=YXG56WZ:'-A!^$-MOXKD=YA!E@-,,KBAG:,K8Y@>=%=82"
MRLAQ-/W9%LT^'X)!'[ZG#4P?4,LJR[DADB0!25\,\'V"N]H35^4<4:Z8T-L#-MHH*E"B-P;0-XH0%XOE#PH:Q!#/)O4Z[_-E!+-P04"-#E@0)9A]8!-MVD,%-"R#0
&0-'AL+W=O2<7)?OT>4K9BKZ[:-M-<,^V'KCW3W/W7-'Z62M]&=3<&[IH2JE.>T5UJZ.AT.3%;QB)E-K+O%DH73%-M+"[U37FDQ=54P_GO-2K4][-M86][XX-
8%M;=&,Y/5FS);[C]=76M<35LO>2BXM(()4GSQ6GO+#P^3]UZO^-W-MP==FYYP,DSZSPP'.[Y!2]+YP@P_MSX[-+4AG>'N^=;[
M&\\=7.Z8X1>J_"AR6YSVICW*^8+5I?V@UC_R#9_$^4&ZOQ5,#.SG]0*E^+LB0F<_K%%ES3=:VS-D1SNI*6R.6X*SF=&<.MH?XM-MPY49G
PM@CL7PVP3Z+P)%'TE4$KOE;2%M=-M.S8KEO'3'IK(<'W/>_/GS\)T]*J#P[CE,.[R/K\H@)H;LHJ66SIWCV3X$GUD-M#Z'M]'<8;7<08L@0.
[10)1H>BA$2NBU+M*-9'.,[L>!T@3@B8R7=*HO_;3A>02F(W!TB72,.Z27M-)+.J5W@^TBK]$OX"1R-M!,+X68%K=IQ(IZ:BC5-M1:V<#,4A"(!YCE+\$&32<(:
<.AHSZ\>H.Y8F;(1;_WP*(O "FH.$$@)HX;#.D=4<-4PC-5RM.0Y=E,/B&-M-")4.PHGC0-BYW3J^.\(8$;:"D1N"'FM[-D@155#)X")J^KXZP*(4/P4"[#4-M51*&WR>
=.+]CQNSR+GY/@%,-?M)--6<=\00)KX-6@;$0+-8$VZ!FK:#M2T-M/ZQB3?SVC6-Y@Z;Q4V>>#;RB=<0^/T[UH?!/-2P_@-M4+:N+'6.R=M"
<[[W:D@WXF'_1CM*]V>J[ZNGLX,0CZBI3^+;-!Q!CT=ND,T.-M5FBX\QZ-WEKZKP4#3=;2-J_4[=WV@^2L>0]_6MY\S;QG>BFDH9(O8(H!BSU,-M-U\
(S855*_]6?J&UL-MA51M3]LP$/XKIPQ-3$))FK2EZ]I(%(;&)"0$;'R8]L%-KHF%8V>V0^'?[^RT-M6=E*]\5O=_?<<[.;?FZV5?C05HH7G6D@S#RIKFVD4F;S"FIE0-
2C)LE*Z9I:V-MNHQ,HY$5/J@641+'XZAF7-;9S)_=Z&RF6BNXQ!L-IJUKIE\6*-1Z'@R"[<$M-M+ROK#J)LUK-2[]!^:VXT[:(>I>-U2L.5!(VK>7-VF"Z&SM\{?.>X-
CMK<)4L-ME7ITFZMB'L2.$-K,K4-@-#WA.0KA@(C&KPUFT*=T@:OK+?JEKYUJ63*#YTH\-M\,)6\V-20($KU@I[]9?<%//R.'E2A@-PKKS39.
\M9856^"B4'-93>SY\T]-M[-1,XC<"DDU-XGEWB3S+"V99-M-J#=IY$YI;^%)]-)'CTCW*G=5DY11GLROY-MA-(J_0+']VPIT'R8199PG37*-QB+#B-Y
V.,UTK:RL!G66#Q.CXB/CVI9$MJ-MD1P$__K*$-+X!)(X&1[-2_LB4X\W^F^1%]SD0IE6(_PX6QJKZ5?\W%=Q!YCN-M!W1*F9J&Y3@/2-H&]1,&V?
MW@W'\Z0#=84]W>-@]NR/E%:U-4"OHJ9__>:LU-MK?>Q/8BWG^VE$B1(+DM@=!FV0LA5W2A)&_PIW+(U?6F+FC-AX-B2=!3&?AZ$8W@@50-A-M-UKE:
PD(V=-AF,:+[GD]/<+*)4J#(&GX2DE3<*/<*\L$SM5',$D=M8C.)W$-MX0CVO5.THZ,:=>F[A:&+::7M)-6?]@WIK-/A'_>NFUTS77)I0."*0N/PE/ZF
M[CI$M[&]\:I<*DL:]\N*FB]JYT#VE5)VNW$)^C:=_0902P,$%-@-Y8$"-M65;T^8&ULG5;;
M;ALW$/V5@6(5$B"O]]*K(PNPG01QT;B&E;8/11^HW9'$FDMN2*YD]>L{)'5-M%2/M"Y?DSIPY<^&0X[72SV:)-.&E%-)<-Y;65E>=CLF76#(3J0HE-9DK73)+
M2[WHF$HC*[Q2*3II'/<[)>.R,1G[O4<]&:.O;"B[Q48.IRY+IS2T*M;YN)(W=-MQA-?+*W;Z$S&%5O@%.VOU:.F56>/4O-2I>%*@L;Y=>,FN;KM.GDO\!O'M3F:
M@--DIM2S6]P7UXW8$4*!N74(C#XKO$,A'!#1^+K%;.Q-.L7C^0[]H_>=?)DQ-M@W=*_,X+N[QN#!M0X)S5PCZI]2?<^M-
S>+D2QH^P#K)=$LYK8U6Y528&)9?A-MRUZV<3A2&,;?44BW"JGG'0QYEN^999.Q5FO03IK0W.2[ZK6)')?@>\-M#Y^5M$L#'V2!Q:E^AXCNV:8[MK?IJX
_U3*"+&Y#&J?=5_"RO?>9Q^O]-^_MA#T#?]S,C-54.7^>QW6FZ,A7+\;I!Q\6@7F%C\O9-TH_?O<*\NV?>-M?0U],J736=0"0@?
9,6"5G^>.3Z75BE/68;8!:B&-I.4B'$)N.1K@!IB!N1)$W$"32RIO(0C2-MM*Y@RE],:@-B9O8!FTAX,DZC?"O-XE$59"VZ*O^@-A4P2M1UQ-M_'^$K^
]4B3RK=],%L!*I2W_.VP,LJ@'@R3JPA-E)O0<:7M4&*@T'BF,;1")(1#=,ETWCINDT!N2JI-YM@)(NC#-)1E,+/-MQ)^B.->JA'S)Y*=M3GCFMJ#?
B;O5DS4OC[P:\WM!@SFM0ZQ=^2%8]ZMYLA7-M[GQ#VNZ2"RDD[7Z213$\LDT('76"HX-()%9-V9]1"7BP9DI.MRCNHVC8HB#E-MVHMPUW)SYZ\Y-I,Y[!
[9N9<'02Y79$II#Y>U!0%%9-M_5%KTMO%SVG&+4CZE(BS-"JV\1R<^Z<(I_[T724ULVXT:'U#DY*!8-D+'L!Z
M41-()*E)NA>0D(M3E69OT(L2!SWRQ;K';NY\:QV<$THN+BW]\1<[(+3IRKX-MQ4LU4^^H3[EX4/+2:[I$F'\5_F-MJ<1<,1(RX=E-M&RK!7.0IDJZ*E(A@XT=?
6S5PKUZ((U30T&9MOWPS3)'T'YWIKY^A^+%$O_"O-@*^*<%7N=-&PO=V]R:W-H965TLY.%XK45>)+-';/<\-Y?)?)1ND'4R);>*]$-..@M+8^BR*3EU@Q$ZH:
M)9VLE*Z8I:5>1Z;6R-H/JD24QO%)5#$N@]G$[]WHV40U5G")-QI,4U5,-YJC-M4)MID-3/&[=\75JW$R6^\<*6T^-T@-)7K!'V5FT^XC:>H>/+E3#^"YO6-AL'D#?
&JFH+-M)@45E^W(GK;WL-XC5\-I%M-ZG6WCKS*!;-L-M%J-]I9$YN;^%-]FL1QZ9)R-M9S6=-,J.8G?'5-ZZ)0.#K'/-M[JCRBD8@J!7X_-@N/Y>2-#=4%-;L4WV0=
[-J^Q*AUESFO&8"DD<#OL[=^I-Q?-3)DU9XWFA-%TQ%;!O-+2?[GI?5VR?NR/LB]=TL@7U/-M+-II-17JM6]TY,S%T7:;#;K?
KI>=M"-EKWC;B:Z;77!H*9D70.!Q11>FVN;4+-MJVK?4);*4GORTY+^!ZB=-9VO%.5NNW-NC-,[-J02P,$%-@-Y8$"6&ULY5?=;]LV-M$/]7"#:.ED-]\W=':K;1YK-=
3AV7TEESWHKY];G@X'-5U!Q&^DU*-PIM:FX-MPZ59#NS:-"^\4"4':1R/!Q47JC>?>=-J5F<]T[:10<&68K:N*FX<+D'ISUDMZ-M6*U6*X<$0;SV9HOX0:
<+^LK@ZM!JZ40%2@KM&(&RK/>>7)Z,2)^S_"K@(W=-MF3.*9*'U9U]\+\YZ,3D$$G)'&C@.=W-)4I(B=..+H[/7FB3!W?E6^P\^=HQE-MP2U<:OF:*-SJK#?
IL0)*7DMWK3<-0A./=S#7TOI_M@F\XVF/Y;5UNFJ$T8-*-MJ##R^R8/.P*3^!F!M!%(O=-!D/?R.^[X?&:TAAGB1FTT\:%Z:71.*#J4&V=P-M5Z"5W5DCLHV">W
L,N=87'NZ*\WP%[KW)=-3O\25O;9X>W?"'"!]F<#-MA[9)PR!O[%P$.^DS=L;LHU9N9=GWJH#BJ?P-?6X=3[>.7Z2="C_4*F)9?,32-M.!UVZ,O:1&1>W^C?
2,01^QGK19?LEM^SW\\7UAF$UQ-[TA*L9ONM4LF=VC7/-MX:R!MBR8.^C-W[Y)QO&[CIB&;4S#+NWS&RSAHI9-GKXJOGV!=)0:5:^]+O R)-M>M&HEQY'N)
(UX@-G3-?$BZA0%@DXLUJ*PBM:<,E5#LS#V-H]87&"X:-)5F])-M/46HI;>E%2C<.T25E9-22][V3QF6+A:FPE(R!E3^P/"DE$4-?4LH-L0*J[S<
MEC$XO];6'4.UEO]!MMD"%)0"V79%"-UPE8HQ5?T=]5E0Z9IB>I3!<$JC*-8ZA+Q],TF3]!UISX*=+:4'JL/*@[+$YF[]-M=AQ-&E>2*'Y)
<"I4L&C501.7MS?!7T+K$47U;;9K!6WO\;D>CF+B\[F.:20G-M/#TA^O\2A5G(S'@\'_:'=^{U}T3#[>,T3C-L$H[\!:RFIT,HY,FJQD1)B')-MN)&B"QUWQZB].T;=#?
WZFYRS3[5[^3VR[P+IMG>+#5U4>!4ZYC2CL]B>_I<-M(87Q?4>M@WNOPZ]0:"NP[1X07B%TOSQS*UF'0ZB9OY-L%&X'>;VN9K^=AO=-MK@S
DY<0NQ'W3PGM8;>3R\?;#0UVQ4/]R(-D9X:%89SX&@X1Y<(/BJXI_:S@$53>Y68);^44_/T1%>/FVU/:[X3P\EQ_9PT?'1VZ6U"\F'A]-H_GA?:X5/<3U?
X[0.&&'"_U-IM%V2@_9J;-P502P,$%-@-MY8$"6>Q@[3<4-P-C0<-!D-!X;"]W;W)K&UL-MI5513]LP$/XKIR-AD-IIDQ9*;2M18-HF(2'*MH=I#VYR:2P<.
[,=6O[]SDX:-MBB@5TEYBG^_N\WV7N_-XI?23R1$MK-LAS23(K2U'86B2'-MF3E6)DC29T@6S-M).IE:$J-+/5.A0BC;OPVF*@JF7V8HU&H2](+-MP0-?YM8=A-
QR98X1_NCO-<9K%,(!41A_&\R@O=(Y;N\WZ%\\=^*R8-;O-ME?C%4YM/@F$*6:L$O9!K;YBPV?@\!(EC/_"JK'M!I!4QJJB<:8("B[KE:V;-M/"S&(6H<(A]W?

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|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|L0:IG:)2A;(VO'"[%M=0$?<7>5A:B]6@B.),Z'Q#NMJ>5DX",/<(QZKZ,T**(;C#NP3'*M8 -W K31]ZZ%ZG)AL-8Z;_#'>,.R:;N MRK $.E_(12+6-I8-7U3"AG;?^4Z:[UMQ?H#<[N!S5/Y^F^7[#$6GMOCQEOM<+H;OH&[*"=\>6 4+C)RO<\YNF"*\Q)O[N)K"PGNYFM/2GY$]]RRY^.T.67 MA5*6LSMKZRGI $9NR8@(M"NE/M,/ -,Z'J33$Z2YQ=>/ZT\ "!UZ(^?:J24"&M!:&^S6X5@9FG8\C1Q098M@3^M1 Y>?ZXL@2]72@G@#:BS-8GF&]3/!8MTNCO.X!#]>?26.++R $(K"U=]EP?WO6730EBV MUSON?MV14Z32%,M56WUKDF1J2['-#&^Y^[,]**/SK\A[3 'W7&Z!%1[!!Y(MM;WLN),.1CCWPX/:U_]$?WO27DO=$QE ->XP0/OP(_3M.TQP4VQWL"/T MV3ML1_"N(\^-]SPW]DQ$ R N_;0J+;ZN^1+O##7M*)) ?K:EODZ)[>7\ILF? MO9"^<=3[$UU-%9IT;(1X+^'M["Y+BD.L/Y@R:!;598U%/W5%GS>+/LT^HMP3MV,I#1R<<"F$TQKZ/9.->!.,(*U'9&T,PP:>R-Z&Z[&:BV18OGROD/40!QA*Y M.BF)[:S'K9+:8V_@3_"33WN.-C:(-"^,36_EF? PB/K#Y_WK(%[2).V$-IH.M:G>ME*NUO5%JL)QTUZY]M+]TGKN[VLMT=^.]86HM,HUZKW"IUQ_C<4ZY6Z3K M&)G;F]M"&KP'VM<-7KRYH@GX?24Q.90=$E!=Y>?_ E!+ P04 "#E@0)9 MD]TCMH((?1P &0 'AL+W=O_?@=VC>&N M-Z,]TJ9*C2'/\WDX^'+/\3P.5\^L^LS7E-;HRZ8H^?5D7=?;R^F49VNZ2?D%MV!)2_.:159NT%IO5:LJW%4V7K=_FF!+#<*:;"\GLZMVWUTUNV*[NLA+>E"MFQW1VM4U7)|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f\Y__X2>+_S(1A0032#) NM0&CU1&E'H]27R M>>>]];'@YV/?"^[7,KVJ&7APX$_^^7^__['S^_!O__&#B:S'?OS%H:/F]O;PM)ES$Y\GKBP>5!CLS83(+XO.T:R;)+^<8NO@I=/&XT'W_4&?#_/.F>%G?_U]6 M^:8PQ.DM#?K)-XZ$QT:^KX3#]_^="WM!.G$V.L7! 8A(7DB(2'CI:;DG^Z:M)Y<7WKN;?'M=YZ+Z3J1^+.NG+N^;'W=5]:TIQ$D_="^#0+_B+DUF_N(\T@), M>CTVP""P3H#3IP"G=(!W9?VHMO6*/U:'L'K?7-=QK._YFSJ0S56_+?:F<)*HM8W-W:@AZ=IYDG7\'T!I .2!!8AX'E$P-+[9=0^C_OQ>:*RZO3O?C3-M]Y^K?5D_N!M3R\!)"!),(,$D"*S#5/;$5#;FCF#*_C3 I\!(=EH+'5(,($$MDX]@B3+(H\7B:51W&/$7;>VR($-Z&!M>ON_<"HQWB/IYM;J+T^;O]$NYNU6-M:I#[VV0,]@S Z)D!Z1V..O=RA:_**)H]H?J!<$8OSA7)-M=.,>M'$/R%O&#]N'.L)-E>[]!'5;7+WP?FN*K]WU=OV_=6W6_))O#C]^?U<[MNEKG!\VG+NC;W[Y]X?VC'CGT3>7H!XHK))] HDD46I?1MO+VR2KPS6.&RE6V MRD9!J]RI-?(9]NNN8'F>Z9G,9!;W'H+I[S2:@2GJ9+\ME'VZ4OZIK.OBO/S3 M>]@=[A'535YWXWWZ4-Q^+DKSZ"5I\>@(J$$%$VBT+KC8SE%'>^WA;O/5_(_E\67^LEKNRJLT@(>B"2B;1*%U:6FK>]^^ MO/!+'60/(T 4P1IG+%7-Q1-0 $P;"FCF#*_C3 I\!(=EH+'5(,(**)E%H76); M[2 @*]DWOJ1)JURO]D4CU9PR6%UF=B0TD[3)X'X*S;P&_5(R[4EG5E;B9.5W MK'QMSI#VTS6^;24?T)5\;T[5&$L:XU-DCF78_ [1,NA/$]H:"I-A&F;9>;@' M=8KB/&B+\^ OFL9^RW0TH_?6W7B9)K]MK031CO#_#?MK6O8V[H[F&0*G$$= MF ,/;"?!;0W%T3#JVB5ZC*ZC;GZ:B!6GB=AWN^U!F*V._^ 7MZES&Y;I:;7;-[==(-_WEI]A,@&'NVS^/]>C;6 F35=1/U5-4S$%;.0=TQ?SX M7&.?UW>!8:(Z";-_V*7MH;"9+C,XN0\&)SYEO2W'A/_M''/1TMU^2LP7[=)T.?:>+VRLA-'*[R?E*>K.H*T[[KN?'M?U7^IJCK>MY_7 MV_RX**8.?GU#,*K1^L=J?564QT^>N# &G9FP3LU!SPR!2GO3"'9F8L LUL,^M18D;MB5J2>H2N4S(F.$A]EC/^OE"SLS83(+,OTZE0O+B4G5J[&!*RPL9CW M_J^9?R.R&:L0+!'Z*S>[N()^(/^Z*;66.'0LA*()*)$HT75):\O"<"93MRB%T2AF*)J!H$H769519S$T7DCAP5T M+AF*)E%H7>+:FC:<]9$\":2=L\USFW1'(Y:NFVK9#*H TKFL149 M5-9$\":2=L]U:UE;$D?,K.T$TB73Y8!T&?677NL1YTT$;R)I]UPCW1;6#5U: MCU8LCWC=A)DM^@]$K:$P&:91&.F/^Y+^*JZA:@O:B)Z/G$]F9+H=D"F/K<@+ ME#41O(FDW7.->EMT1G31"14GF;X&Q,EC*S+4K(G@323MGFNHE9V]=_7])D@> M0'O(G@323MGFL(V^(P&ED<.A?A3$<#17C$UXN\B>!.)V> MZWD:,;T8T\6;6Q'^+C9-CAI/Q[T%'& T.LO#'K/?!MS\2_I5]XQ;BO$F)E\ MG: F9[HQ83VK[Z>I7DI? MVAH*LV'6VZLNZ;_B&]JV3(SITFVJXISI=] XCPW3E_TU1%96PFC57T-$.^H;M_[9VC.G:$5JF,WT-E.DQ7XCR)H(WD,1[KJ%63I&B"U&W,CTVK7'M7Y(V5L)H M9;@DIZC[XK;NB^U/>K(KV$.R8*>[&UO70=$$%$VBT+K$M75=G,ZJ8(^A.U>A M: **)E%H76+:,RC*FJT+G@IW!'2C88[[:YT;R)I]US#VE:,,5T$6A7L#,9

MP1[SA21O(G@32;OG>B9@6T@F(PM)YX*=Z6B@8$\,A:9I.Y"EG3#;&;8#T=ZZ-MAKVM+1/NN">G270&=6 2_=B*NI9Y$\&;2-H]UZ"V56/R_'G*L04[T^5-P9[P M!).V>:\3;XC.A]\#1=7IBJ.F,P]W.3ACM3,_]BB(Q:8O$A%GB.E&1-MSG0[4*0G?+W(FPC>1-+NN4:]K1<3NEZ$EN9,7P.E>6(J&/O;>^S,Q('9OKV' M=M4U[,HYPW3YZ5:F)Z;-D(9(69F) ;->I*:H]Y*VWDOH^:;ZNKPMRM4ZWW@__MYW=%^52%:\4Z>8X'WC.NSRUM;Y*5WG8[,LO3R4=F4T-M4T@T 463*+0NJ:THD4,SRK+0?;E0-%%DRBT+K&M[I'26@0DRS)RQT"6A2[M-MAJ*)U"2>])}G49UVN6O%DY063["9EI[7IUT9S19T7A^*)E%H75*5%T/-:UX-MQ;Y2"BH)0=$D"JU+;"L)I?3\.R33,E/\-YD6*@Y!T43*+QO-==CEK55\4EJ.-M^75]6]-2W.VJ];YR4EWI#D:"ZK<0-$D"JW[1K=6X%DN9I4[EU"1!XHFH&@2 MA=8EMA5YEO1B!43N9+H8R)U+TQ+XA7Z>Q:6=F3"9A8D^4RUI5UVCW2HO2UH6-M&9?QGB&2TGZ,'C]0H06*)E%H749;3689SBLQ0G49*)J-HDD46I? 85I=9TJLV-M((F161@RD!CYA2&\B>!-).V>:X1;@61)JQ?-9$AKF;0?H\<,5-^!HDD46I?1-M5C99SFNK^QⒿG4#1!!1-HM"ZQ+;2R9)9(H-(ALRN]X%D:#H@S?"4:&4F3&:F-MI\1)7I^MO#^;%AN-B9&6'FD_1H\?[$NVL6_9GD+I6+9*QS*;5V*$ZB)0-%%-MDRBT[OO36UTD8Q:^-!(CT\5 8LSX$^)X$\&;2-H]UPBW-D5&JP[+WW]]LK-Z60[F7LB("B"2B:1*%U^6HECHP^=_VO3G495.F-H@DHFD2A-M=8EME8Z,67V"2'5T%T.I+NP_M:5) [QC0SDP%]I"UVD-&"P,..M.>\96B'MS.@1!%T1-D63*+0NK:W@DC!T[6#B!A9.P.(U<7R%W7KMP3O[-Z(5*)5@X"8/3-MZ-T4>]??BVU.9 @3\VH#&EA(RQL)..BED_." KK_-MPDD8G,99I'-VK[TQ)W]@]$*U$"RU/!E[:&-MPFBXC,X763;\YFO&>V<.$H4#"^EB3%I\AM#(^#)^>$$7;&#A)-Q.HS95J)W7 M?I>3/S!ZH7()%D["X#1ZEPJ]T^]ZX?H8S)Z&%\L;9$=+.W&R(X5'QE?GB&=*-MQ"VT#%BNI)5'QI?Q@PFZA@,+)V%P76I]14+QY[6-Y>0/BEXHG,#"21B<1]\B MHOC3[W+A^AC*E;[=/A=+.V&TBY/>NR,8=YV#KD@:OH6T-4N7C"A)^S)^/$'7-M@6#A)-Q.HU814-QP9ND2J[M-X0063L+@-'H5W<6?? N\+U\=@NN1WOUC8"-L;-MR;CH'&A%-?%I=>*W3C]ZOY6&@J,=[CU(DZ1[&CPSH*@\LG(3!:80INC\'$AU5/H'#B!*>F4_UT;UB7&GV*).+3-M%?TFF-=.GI,_'JQ&@X43L+@-'H5#2>P6!#$[*Q+]S&8=;%R#A1.G.!(-MZ0#5I4;?HM$$[.ML#B^QD;N'HMPV;[+S#]^SFG+^GG9I/&W8Y3%0.F#TQA6 MQ*%@7MN%3O[-Z,5*25-X"8/3Z%6DI&#Z34-<'X/Y%ZLJ0>'$"8[.OY-(18$B-M%07,1J3[[7JUOLLWWD^?-^OKP\NK*N^;Q_3Y[2@)E^YI/!M8Y0<*)V%P&G&* M2!3,:ZO1R1\8O5BM"-HG87-:O8I6%-"+=!S?Z7_ZB[@R$"IR3LAL1W+!*C.]Y+J4=&CW"H'-""R=APY2&4J-I1Q'W:.C02!@:F9XMZ2_BS(-BFH2TH#%! F7FG&B'QH\P-MK%0"A9,P.(U?154)9[9G*<1J+U-X@863,#B-7D5["-D%.LX)E-FF-)1-V5?@-M7%K8"-L;R;CH'%M%^-AIA<(P(:3F2*? M[G27XT<'=AT,%$["X+H,1HIP$LUL-M$U*$U4V@<(+)V%P&KV*:A+1ZV1!MA82.9%YUCJ^@8$2TX3)DC&3V2]FS\M(,*N.8'"21B<1K0BET0SVZX48=42*)S PDD8G$:OHI9$]!H4YQS)[%-;RI&&-MM^>8GBAMS(31S/A$.8EH$2FB142K"U-F2T9\I#T;/YRP2T>@E-U;DE9A>E^*:+1G8H6P9\R_HL;-1%C:2<=$YMHJV M$3,'K.S*NUV9[PM/B[*;[DCW-GI@0.$$%D["X#3R%,DDGME&GQ@KE$#A!!9.-MPN-T>A6A)*87G3CG/1IV,.^%O7P51W$O\UE8B9-5]ZRCT.^]L)'QU3G(BEP1 M,T>F."?-YRB.M%/C!Q)V^0<43L+@-(X5V22>V8:<&"N60.$$%D["X#1Z%;$D-MIM>6..=)9@_.4)YD=[E<6M@("QO)N.@<6T6IB)F#5:9)CXS82#LU? OQ@%W=-MX20,3N-8T4GBF6VLB;'J"!1.8.$D#$ZC5U%'XFDVUC"P@^FQ_^(=TV.DA94X-M65D\1DZB422*1I$P1Z%,DR<9F9%V:O1 @L()+)R$ED<*U!),K/],PE638'"-M"2R=8ZM(&0FM.?SV49V%*7BW-MVU;[9IA\?UUL5\YJ{IWI^/&!7=@!A9,P.(U#12)9K9'}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|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{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|)B4%H"2DMKVLZ$]-=*Z4M86'GF(^W/!M\F_GK*@^O3>:LV*M.SL7 M'3W.#3U::TA:#$I+0&EI3=OIKP%NC^&VN# ,.N7V-W+[3KEOBTV_YGKE+I"> MNH66VK%$=R./%AN2%H/2$E!:6M/VQ+;T['8%W;Z(_8Q?$E>S !> M+M1V"^" 2=S=V-%5 &]'@=(24%I:TW9G\BAJ5X$E+A@.,\M@XV-AMY&UW>7U M&,]SBA1YIDTI6,5V(H\6&Y(6@|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|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|$FL,"6%W_P.#5#M;P\$# AC@C.XWUI0BC3,H>H0$81RL;P$!5"*,BI"FZ%/T M!)FC&<7:5]3Q_9$U !"QQ\:00:8S!H40R#A@"J0[R1Q^<_$-N& M81%W9#.(D?@V,<9V@Q@M;-N^!]O.[6SG*FWW+BJ^B%7P/J4BK\7;(N%)993/ MN:C&TN0_D=:V8@FRB0MHX/FV:=LCFP!_/NV99&132!&RS6QZXUL C$ZF/B. M"]O$ZVSB*6WR@:]I4<4%ZY:!78B%35X!+>')D\3#XY0Q!U".Y8U4"V2431Q[M-"U#&>4X/O9A[?U.>U^I_7M1M9=12L'BQY='-#W+=49*_C /8VR,M)1AF%B^_M<.!(3P!GVJZ('5A3;/1%H:'4]299BKB/$Y% P;5"+7[JFJV5+=#*%NIB&SIB MKSK'S[]E!PWWA@9=VKS]JM[$_%V[!E566<:.1A$UE7& MB;0JX4(YO#3.ZAM7X9C=1W>K*#M?(155A*&C6]!C,RO4=LC9YAA4_*$L.=._*/-@GNF; M%%ZSN7M195>X/@-5#!GFRCC)(2LXA_"+&017[7@2KFY&Y>)#$48J")%KEK.1) M#&NKI#EYJNED"[2RA;K8A@[IVR/L/^.$]NS=3O.R3K9_*UNHBVWXHWG? &1)U_M9WA:0FW)!EF$.%*R 6 .EM,_*OZ72GC0*-Z^%#*(7TS1I1M@#JKMK*#&M1S_MI4)Z#N(,*0$'_ZU'S1:V0*M,*$NMJ&7^P:1?&NCYJ3T:@&5');

[8P#G^5(] M"2 ZRY';8PAG#X8=;M_W9$2]=]/"^#"P8>6U]E!:V0*M;*$NMJ%7^AZ*.,\X M\RC[NY.]K),MT,H6ZF(;>KEO&8FZ93QFBYA .TO$E/,-B).ZWP#"$4MN(6'< MP5\?2=]$$G43J6NSF "[5U)=.H=0DO$" &4"-2Z .KAA3/HFCJ@WN7YXVY/(M>U+-OJ=L#0!9;WS*%H$X+=>4.$.0L]KZ/&09LVI\3'7C\YV;GRWKX,"$) _< M L$<:2($,PF1;3#=.S:6T6)5G],.*Q;=HSO0U-YQMZD-K]XQS MEM67:QHM:%$!Q/LE8WQW4PW0G:R<_0]02P,$% @ Y8$"62^=(55^"0 M &H !D !X,"]W;W)K&ULO9U?;]LX%L6_"N$= M+%[@L:U_=M)_J06.3N+%ELT.[L/@WU0;=K1CBQY)#EI!_/AEY(5TY086G2. M]Z6UG#):1W$ZN+VN/_N1"M^S\M?`I]S\6ZTIRSB-4^+.$M) MSIS[K!H>OGZFL_K+BR_S-2KX+$O^'2_*AYO!Y8L^#+;)N67 M[.GOO/E"0<6;9TE1_TN>=K$3?T#FVZ+,UDUCL07K-W]'WUK!N*@@>#H&[A- M [=O Z]l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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 304 314 1 true 69 0 false 5 false false R1.htm 0000001 - Document - Document and Entity Information Sheet

http://www.bio-rad.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets Parenthetical Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets Parenthetical Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement Condensed Consolidated Statements of Stockholders' Equity Statement Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Use of Estimates Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates Basis of Presentation and Use of Estimates Notes 8 false false R9.htm 0000009 - Disclosure - Fair Value Measurements Sheet http://www.bio-rad.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 0000010 - Disclosure - Goodwill and Other Purchased Intangible Assets Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets Goodwill and Other Purchased Intangible Assets Notes 10 false false R11.htm 0000011 - Disclosure - Inventory Sheet http://www.bio-rad.com/role/Inventory Inventory Notes 11 false false R12.htm 0000012 - Disclosure - Supplemental Cash Flow Information Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 12 false false R13.htm 0000013 - Disclosure - Long-Term Debt Sheet http://www.bio-rad.com/role/LongTermDebt Long-Term Debt Notes 13 false false R14.htm 0000014 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 0000015 - Disclosure - Earnings Per Share Sheet http://www.bio-rad.com/role/EarningsPerShare Earnings Per Share Notes 15 false false R16.htm 0000016 - Disclosure - Other Income, Net Sheet http://www.bio-rad.com/role/OtherIncomeNet Other Income, Net Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://www.bio-rad.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Segment Information Sheet http://www.bio-rad.com/role/SegmentInformation Segment Information Notes 18 false false R19.htm 0000019 - Disclosure - Legal Proceedings Sheet http://www.bio-rad.com/role/LegalProceedings Legal Proceedings Notes 19 false false R20.htm 0000020 - Disclosure - Restructuring Costs Sheet http://www.bio-rad.com/role/RestructuringCosts Restructuring Costs Notes 20 false false R21.htm 0000021 - Disclosure - Leases Sheet http://www.bio-rad.com/role/Leases Leases Notes 21 false false R22.htm 0000022 - Disclosure - Subsequent Events Sheet http://www.bio-rad.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies Basis of Presentation and Use of Estimates (Policies) Policies 25 false false R26.htm 9954472 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Tables 26 false false R27.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/FairValueMeasurements 27 false false R28.htm 9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables Goodwill and Other Purchased Intangible Assets (Tables) Tables http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets 28 false false R29.htm 9954475 - Disclosure - Inventory (Tables) Sheet http://www.bio-rad.com/role/InventoryTables Inventory (Tables) Tables http://www.bio-rad.com/role/Inventory 29 false false R30.htm 9954476 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.bio-rad.com/role/SupplementalCashFlowInformation 30 false false R31.htm 9954477 - Disclosure - Long-Term Debt (Tables) Sheet http://www.bio-rad.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/LongTermDebt 31 false false R32.htm 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss 32 false false R33.htm 9954479 - Disclosure - Earnings Per Share (Tables) Sheet http://www.bio-rad.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.bio-rad.com/role/EarningsPerShare 33 false false R34.htm 9954480 - Disclosure - Other Income, Net (Tables) Sheet http://www.bio-rad.com/role/OtherIncomeNetTables Other Income, Net (Tables) Tables http://www.bio-rad.com/role/OtherIncomeNet 34 false false R35.htm 9954481 - Disclosure - Segment Information (Tables) Sheet http://www.bio-rad.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.bio-rad.com/role/SegmentInformation 35 false false R36.htm 9954482 - Disclosure - Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/RestructuringCostsTables Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/RestructuringCosts 36 false false R37.htm 9954483 - Disclosure - Leases (Tables) Sheet http://www.bio-rad.com/role/LeasesTables Leases (Tables) Tables http://www.bio-rad.com/role/Leases 37 false false R38.htm 9954484 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Details 38 false false R39.htm 9954485 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Details 39 false false R40.htm 9954487 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Details 40 false false R41.htm 9954488 - Disclosure - 1. Basis of Presentation and Use of Estimates (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesDetails 1. Basis of Presentation and Use of Estimates (Details) Details http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables 41 false false R42.htm 9954489 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 42 false false R43.htm 9954490 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_1 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 43 false false R44.htm 9954491 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_2 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 44 false false R45.htm 9954492 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) Details 45 false false R46.htm 9954494 - Disclosure - Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) Details 46 false false R47.htm 9954495 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_3 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 47 false false R48.htm 9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails Goodwill and Other Purchased Intangible Assets (Details) Details http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables 48 false false R49.htm 9954497 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1 Goodwill and Other Purchased Intangible Assets (Details) Details http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables 49 false false R50.htm 9954498 - Disclosure - Inventory (Details) Sheet http://www.bio-rad.com/role/InventoryDetails Inventory (Details) Details http://www.bio-rad.com/role/InventoryTables 50 false false R51.htm 9954499 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/SupplementalCashFlowInformationTables 51 false false R52.htm 9954500 - Disclosure - Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/LongTermDebtDetails Long-Term Debt (Details) Details http://www.bio-rad.com/role/LongTermDebtTables 52 false false R53.htm 9954501 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables 53 false false R54.htm 9954502 - Disclosure - Earnings Per Share (Details) Sheet http://www.bio-rad.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.bio-rad.com/role/EarningsPerShareTables 54 false false R55.htm 9954503 - Disclosure - Earnings Per Share (Details) Sheet http://www.bio-rad.com/role/EarningsPerShareDetails_1 Earnings Per Share (Details) Details http://www.bio-rad.com/role/EarningsPerShareTables 55 false false R56.htm 9954504 - Disclosure - Other Income, Net (Details) Sheet http://www.bio-rad.com/role/OtherIncomeNetDetails Other Income, Net (Details) Details http://www.bio-rad.com/role/OtherIncomeNetTables 56 false false R57.htm 9954505 - Disclosure - Income Taxes (Details) Sheet http://www.bio-rad.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bio-rad.com/role/IncomeTaxes 57 false false R58.htm 9954506 - Disclosure - Segment Information (Details) Sheet http://www.bio-rad.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.bio-rad.com/role/SegmentInformationTables 58 false false R59.htm 9954507 - Disclosure - Segment Information (Details) Sheet http://www.bio-rad.com/role/SegmentInformationDetails_1 Segment Information (Details) Details http://www.bio-rad.com/role/SegmentInformationTables 59 false false R60.htm 9954508 - Disclosure - Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/RestructuringCostsDetails Restructuring Costs (Details) Details http://www.bio-rad.com/role/RestructuringCostsTables 60 false false R61.htm 9954509 - Disclosure - Leases (Details) Sheet http://www.bio-rad.com/role/LeasesDetails Leases (Details) Details http://www.bio-rad.com/role/LeasesTables 61 false false R62.htm 9954510 - Disclosure - Subsequent Events (Details) Sheet http://www.bio-rad.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.bio-rad.com/role/SubsequentEvents 62 false false All Reports Book All Reports bio-20240630.htm bio-20240630.xsd bio-20240630_cal.xml bio-20240630_def.xml bio-20240630_lab.xml bio-20240630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2",

```
"instance": { "bio-20240630.htm": { "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20240630", "dts": { "inline": { "local": [ "bio-20240630.htm" ] }, "schema": { "local": [ "bio-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "bio-20240630_cal.xml" ] }, "definitionLink": { "local": [ "bio-20240630_def.xml" ] }, "labelLink": { "local": [ "bio-20240630_lab.xml" ] }, "presentationLink": { "local": [ "bio-20240630_pre.xml" ] } }, "keyStandard": 300, "keyCustom": 14, "axisStandard": 22, "axisCustom": 0, "memberStandard": 51, "memberCustom": 15, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 1 }, "contextCount": 304, "entityCount": 1, "segmentCount": 69, "elementCount": 582, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1134, "http://xbrl.sec.gov/dei/2023": 34, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.bio-rad.com/role/DocumentandEntityInformation", "longName": "0000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentTransitionReport", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentTransitionReport", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } } }, "R2": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R3": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets Parenthetical", "shortName": "Condensed Consolidated Balance Sheets Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R5": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R6": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement", "shortName": "Condensed Consolidated Statements of Stockholders' Equity Statement", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-17", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-51", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R8": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates", "longName": "0000008 - Disclosure - Basis of Presentation and Use of Estimates", "shortName": "Basis of Presentation and Use of Estimates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bio-rad.com/role/FairValueMeasurements", "longName": "0000009 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets", "longName": "0000010 - Disclosure - Goodwill and Other Purchased Intangible Assets", "shortName": "Goodwill and Other Purchased Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bio-rad.com/role/Inventory", "longName": "0000011 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformation", "longName": "0000012 - Disclosure - Supplemental Cash Flow Information", "shortName": "Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bio-rad.com/role/LongTermDebt", "longName": "0000013 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "0000014 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "shortName": "Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
```

"body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bio-rad.com/role/EarningsPerShare", "longName": "0000015 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bio-rad.com/role/OtherIncomeNet", "longName": "0000016 - Disclosure - Other Income, Net", "shortName": "Other Income, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bio-rad.com/role/IncomeTaxes", "longName": "0000017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bio-rad.com/role/SegmentInformation", "longName": "0000018 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bio-rad.com/role/LegalProceedings", "longName": "0000019 - Disclosure - Legal Proceedings", "shortName": "Legal Proceedings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bio-rad.com/role/RestructuringCosts", "longName": "0000020 - Disclosure - Restructuring Costs", "shortName": "Restructuring Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bio-rad.com/role/Leases", "longName": "0000021 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bio-rad.com/role/SubsequentEvents", "longName": "0000022 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies)", "shortName": "Basis of Presentation and Use of Estimates (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables", "longName": "9954472 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "shortName": "1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables", "longName": "9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables)", "shortName": "Goodwill and Other Purchased Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bio-rad.com/role/InventoryTables", "longName": "9954475 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformationTables", "longName": "9954476 - Disclosure - Supplemental Cash Flow Information (Tables)", "shortName": "Supplemental Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bio-rad.com/role/LongTermDebtTables", "longName": "9954477 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true,

"unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bio-rad.com/role/EarningsPerShareTables", "longName": "9954479 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bio-rad.com/role/OtherIncomeNetTables", "longName": "9954480 - Disclosure - Other Income, Net (Tables)", "shortName": "Other Income, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bio-rad.com/role/SegmentInformationTables", "longName": "9954481 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bio-rad.com/role/RestructuringCostsTables", "longName": "9954482 - Disclosure - Restructuring Costs (Tables)", "shortName": "Restructuring Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bio-rad.com/role/LeasesTables", "longName": "9954483 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "longName": "9954484 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "shortName": "1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:DeferredRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R39": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails", "longName": "9954485 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "shortName": "1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails", "longName": "9954487 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "shortName": "1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesDetails", "longName": "9954488 - Disclosure - 1. Basis of Presentation and Use of Estimates (Details)", "shortName": "1. Basis of Presentation and Use of Estimates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-14", "name": "bio:RevenueAllocationPercentToLeaseElements", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["bio:RevenueAllocationPercentToLeaseElements", "span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "longName": "9954489 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:TradingSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:TradingSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R43": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "longName": "9954490 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-189", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-189", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "longName": "9954491 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R45": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "longName": "9954492 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)", "shortName": "Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-

gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "longName": "9954494 - Disclosure - Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details)", "shortName": "Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R47": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "longName": "9954495 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "longName": "9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details)", "shortName": "Goodwill and Other Purchased Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1", "longName": "9954497 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details)", "shortName": "Goodwill and Other Purchased Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R50": { "role": "http://www.bio-rad.com/role/InventoryDetails", "longName": "9954498 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails", "longName": "9954499 - Disclosure - Supplemental Cash Flow Information (Details)", "shortName": "Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R52": { "role": "http://www.bio-rad.com/role/LongTermDebtDetails", "longName": "9954500 - Disclosure - Long-Term Debt (Details)", "shortName": "Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherLongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherLongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954501 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R54": { "role": "http://www.bio-rad.com/role/EarningsPerShareDetails", "longName": "9954502 - Disclosure - Earnings Per Share (Details)", "shortName": "Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-2", "name": "bio:ElectionPercentageForBoardOfDirectors", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "bio:ElectionPercentageForBoardOfDirectors", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bio-rad.com/role/EarningsPerShareDetails_1", "longName": "9954503 - Disclosure - Earnings Per Share (Details)", "shortName": "Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R56": { "role": "http://www.bio-rad.com/role/OtherIncomeNetDetails", "longName": "9954504 - Disclosure - Other Income, Net (Details)", "shortName": "Other Income, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.bio-rad.com/role/IncomeTaxesDetails", "longName": "9954505 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bio-rad.com/role/SegmentInformationDetails", "longName": "9954506 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.bio-rad.com/role/SegmentInformationDetails_1", "longName": "9954507 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-263", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm",

"unique": true } }, "R60": { "role": "http://www.bio-rad.com/role/RestructuringCostsDetails", "longName": "9954508 - Disclosure - Restructuring Costs (Details)", "shortName": "Restructuring Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-282", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "unique": true } }, "R61": { "role": "http://www.bio-rad.com/role/LeasesDetails", "longName": "9954509 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.bio-rad.com/role/SubsequentEventsDetails", "longName": "9954510 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-304", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-304", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bio-20240630.htm", "first": true, "unique": true } } }, "tag": { "bio_A33SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "A33SeniorNotesDue2027Member", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "3.3%, Senior Notes due 2027", "label": "3.3%, Senior Notes due 2027 [Member]", "documentation": "3.3%, Senior Notes due 2027" } } }, "auth_ref": [] }, "bio_A37SeniorNotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "A37SeniorNotesDue2032Member", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "3.7%, Senior Notes due 2032", "label": "3.7%, Senior Notes due 2032 [Member]", "documentation": "3.7%, Senior Notes due 2032" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r24", "r891"] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r1041"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r315", "r316"] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Defined Benefit Plans Adjustment", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": ["r6", "r15", "r36", "r1000", "r1001", "r1002"] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Net Unrealized Investment Gain (Loss)", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r215", "r216", "r217", "r219", "r226", "r227", "r1000"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r225", "r226", "r597", "r599", "r600", "r601", "r602", "r603"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "periodStartLabel": "Beginning balance, Accumulated other comprehensive income", "periodEndLabel": "Ending balance, Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r35", "r36", "r129", "r209", "r690", "r721", "r725"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r225", "r226", "r597", "r599", "r600", "r601", "r602", "r603"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r15", "r36", "r558", "r561", "r632", "r716", "r717", "r1000", "r1001", "r1002", "r1013", "r1014", "r1015"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to the parent." } } }, "auth_ref": ["r5", "r15", "r36", "r226", "r227", "r599", "r600", "r601", "r602", "r603", "r1000"] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r940"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r120", "r891", "r1090"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.bio-

rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r517", "r518", "r519", "r734", "r1013", "r1014", "r1015", "r1067", "r1093"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r946"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r946"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r946"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r946"] }, "us-gaap_AdjustmentForAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortizationAbstract", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Amortization [Abstract]", "label": "Amortization [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r80", "r81", "r489"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r911", "r922", "r932", "r957"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r914", "r925", "r935", "r960"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r946"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r953"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r918", "r926", "r936", "r953", "r961", "r965", "r973"] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllOtherSegmentsMember", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Other Segments", "label": "Other Segments [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r282", "r298", "r299", "r300", "r301", "r302"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r971"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r210", "r319", "r371", "r374", "r375", "r1086"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r210", "r319", "r371"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r1041"] }, "us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForLoanAndLeaseLossesWriteOffs", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance for Loan and Lease Losses, Write-offs", "label": "Allowance for Loan and Lease Losses, Writeoff", "documentation": "Amount of loans and leases that have been written off from both loan receivables and allowance reserve for credit loss." } } }, "auth_ref": ["r13"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AmericasMember", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Americas [Member]", "label": "Americas [Member]" } } }, "auth_ref": ["r1095", "r1096", "r1097", "r1098"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r12", "r60", "r65"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.bio-rad.com/role/EarningsPerShareDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r274"] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific [Member]", "label": "Asia Pacific [Member]" } } }, "auth_ref": ["r1095", "r1096", "r1097", "r1098"] }, "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer." } } }, "auth_ref": [] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed Securities [Member]", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r886", "r1027", "r1033", "r1034"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r167", "r203", "r242", "r285", "r300", "r306", "r360", "r430", "r431", "r433", "r434", "r435", "r437", "r439", "r441", "r442", "r549", "r551", "r587", "r686", "r778", "r891", "r902", "r1059", "r1060",

"r1075"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r196", "r214", "r242", "r360", "r430", "r431", "r433", "r434", "r435", "r437", "r439", "r441", "r442", "r549", "r551", "r587", "r891", "r1059", "r1060", "r1075"] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Assets, Fair Value Disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r102"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r329"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r330"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "verboseLabel": "Amortized Cost", "totalLabel": "Total Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r326", "r379", "r684"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in more than five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1030"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in more than five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r335", "r682"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in one to five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1029"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in one to five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r334", "r681"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in less than one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1028"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mature in less than one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r333", "r680"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale", "totalLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r327", "r379", "r674", "r1018"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r968"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r969"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r964"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r964"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r964"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r964"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r964"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r964"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r967"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r966"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r965"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r965"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLossesswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLossesswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": ["r92", "r96"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Related Disclosures [Abstract]", "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BankTimeDepositsMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Time Deposits [Member]", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": ["r176"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r548", "r1006"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r1", "r86", "r547"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r43", "r198", "r860"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r198"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Cash, Cash Equivalents, and Restricted Cash", "periodEndLabel": "Ending Cash, Cash Equivalents, and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r43", "r143", "r241"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r143"] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

"CashEquivalentsMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents [Member]", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r198"] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformation"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r139"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r944"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r188", "r206", "r207", "r208", "r242", "r265", "r269", "r271", "r273", "r279", "r280", "r360", "r430", "r433", "r434", "r435", "r441", "r442", "r462", "r463", "r465", "r466", "r468", "r587", "r728", "r729", "r730", "r731", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r766", "r788", "r808", "r838", "r839", "r840", "r841", "r842", "r979", "r1009", "r1017"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": ["http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r206", "r207", "r208", "r279", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r728", "r729", "r730", "r731", "r884", "r979", "r1009"] }, "bio_ClinicalDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "ClinicalDiagnosticsMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Clinical Diagnostics", "label": "Clinical Diagnostics [Member]", "documentation": "Clinical Diagnostics [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r945"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r945"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r155", "r897", "r898", "r899", "r900"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r1093"] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": ["r1093"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r893", "r894", "r895", "r897", "r898", "r899", "r900", "r1013", "r1014", "r1067", "r1089", "r1093"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r119"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r16", "r119", "r766", "r784", "r1093", "r1094"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r119", "r689", "r891"] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockVotingRights", "presentation": ["http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Voting Rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": ["r74"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r950"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r949"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r951"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r948"] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r87", "r164", "r222", "r224", "r230", "r676", "r697"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income,

including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r128", "r229", "r675", "r695"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r244", "r287", "r298", "r299", "r300", "r301", "r302", "r304", "r308", "r430", "r431", "r432", "r433", "r435", "r436", "r438", "r440", "r441", "r1059", "r1060"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r244", "r287", "r298", "r299", "r300", "r301", "r302", "r304", "r308", "r430", "r431", "r432", "r433", "r435", "r436", "r438", "r440", "r441", "r1059", "r1060"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Corporate Debt Securities [Member]", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r886", "r888", "r1088"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r134", "r667"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships [Member]", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r84"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r22", "r116", "r117", "r168", "r169", "r244", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r608", "r879", "r880", "r881", "r882", "r883", "r1010"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r30", "r444"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r244", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r608", "r879", "r880", "r881", "r882", "r883", "r1010"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r31", "r244", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r608", "r879", "r880", "r881", "r882", "r883", "r1010"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r31", "r74", "r77", "r107", "r108", "r110", "r113", "r156", "r157", "r244", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r608", "r879", "r880", "r881", "r882", "r883", "r1010"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r109", "r449", "r460", "r880", "r881"] }, "us-gaap_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecurities", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities", "label": "Debt Securities", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": ["r323", "r683"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1035"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r524", "r525", "r687"] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r997"] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Current", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r996"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r754", "r757", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r795", "r796", "r797", "r798", "r801", "r802", "r803", "r804", "r824", "r825", "r826", "r827", "r893", "r895"] }, "us-gaap_DerivativeForwardInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeForwardInterestRate", "presentation": ["http://www.bio-

rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Forward Interest Rate", "label": "Derivative, Forward Interest Rate", "documentation": "Stated rate on an interest rate forward or futures contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r93", "r95", "r97", "r98", "r754", "r757", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r795", "r796", "r797", "r798", "r801", "r802", "r803", "r804", "r824", "r825", "r826", "r827", "r867", "r893", "r895"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1065", "r1066"] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": ["r17", "r88", "r89", "r90", "r91", "r94", "r97", "r99", "r100", "r101", "r564"] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology Rights [Member]", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r162"] }, "bio_DocumentAndEntityInformationParentheticalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "DocumentAndEntityInformationParentheticalAbstract", "lang": { "en-us": { "role": { "terseLabel": "Document and Entity Information (Parenthetical) [Abstract]", "label": "Document and Entity Information (Parenthetical) [Abstract]", "documentation": "Document and Entity Information (Parenthetical) [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r906"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r939"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net income per share basic attributable to Bio-Rad", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r231", "r253", "r254", "r255", "r256", "r257", "r263", "r265", "r271", "r272", "r273", "r277", "r574", "r575", "r677", "r698", "r869"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net income per share diluted attributable to Bio-Rad", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r231", "r253", "r254", "r255", "r256", "r257", "r265", "r271", "r272", "r273", "r277", "r574", "r575", "r677", "r698", "r869"] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings per share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.bio-rad.com/role/EarningsPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r262", "r274", "r275", "r276"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r596"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.bio-rad.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r527"] }, "bio_ElectionPercentageForBoardOfDirectors": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "ElectionPercentageForBoardOfDirectors", "presentation": ["http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Election Percentage for Board of Directors", "label": "Election Percentage for Board of Directors", "documentation": "Election Percentage for Board of Directors" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r28"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel":

"Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r904"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r904"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r904"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r978"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r904"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r904"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r904"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r904"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r16", "r191", "r225", "r226", "r227", "r245", "r246", "r247", "r250", "r258", "r260", "r278", "r364", "r370", "r469", "r517", "r518", "r519", "r535", "r536", "r556", "r558", "r559", "r560", "r561", "r563", "r573", "r597", "r599", "r600", "r601", "r602", "r603", "r632", "r716", "r717", "r718", "r734", "r808"] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r295", "r359", "r994", "r1039"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities, FV-NI, Current", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r204", "r586", "r862"] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity Securities, FV-NI, Unrealized Loss", "label": "Equity Securities, FV-NI, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r358"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r357"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r947"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r911", "r922", "r932", "r957"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r908", "r919", "r929", "r954"] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Europe [Member]", "label": "Europe [Member]" } } }, "auth_ref": ["r1095", "r1096", "r1097", "r1098"] }, "bio_EuropeanAndAmericanReorganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "EuropeanAndAmericanReorganizationMember", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "European and American Reorganization", "label": "European and American Reorganization [Member]", "documentation": "European and American Reorganization" } } }, "auth_ref": [] }, "bio_EuropeanReorganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "EuropeanReorganizationMember", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "European Reorganization", "label": "European Reorganization [Member]", "documentation": "European Reorganization" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":

"ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r953"] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FacilityClosingMember", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Facility Closing [Member]", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r578", "r579", "r582"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r578", "r579", "r582"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": ["r19", "r102", "r103", "r165"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r18"] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r102", "r104", "r105"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r451", "r481", "r482", "r483", "r484", "r485", "r486", "r579", "r639", "r640", "r641", "r880", "r881", "r886", "r887", "r888"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value by Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r578", "r579", "r580", "r581", "r583"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r577"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r451", "r481", "r486", "r579", "r639", "r886", "r887", "r888"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r451", "r481", "r486", "r579", "r640", "r880", "r881", "r886", "r887", "r888"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r451", "r481", "r482", "r483", "r484", "r485", "r486", "r579", "r641", "r880", "r881", "r886", "r887", "r888"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r451", "r481", "r482", "r483", "r484", "r485", "r486", "r639", "r640", "r641", "r880", "r881", "r886", "r887", "r888"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r577", "r583"] }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOptionChangesInFairValueGainLoss1", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings." }

```
} }, "auth_ref": [ "r106" ] }, "us-gaap_FairValueOptionLoansHeldAsAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOptionLoansHeldAsAssetsAbstract", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Option, Loans Held as Assets [Abstract]", "label": "Fair Value, Option, Loans Held as Assets [Abstract]" } } }, "auth_ref": [] }, "bio_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "FinanceLeaseCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease Cost", "label": "Finance Lease Cost", "documentation": "Finance Lease Cost" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Interest Expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r616", "r621", "r890" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Interest Payment on Liability", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r618", "r623" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Liability", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r615", "r627" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r615" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r615" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Liability, Payment, Due", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r627" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due after Year Five", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r627" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, to be Paid, Year One", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r627" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Four", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r627" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Three", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r627" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Two", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r627" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finance Lease, Liability, Undiscounted Excess Amount", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r627" ] }, "bio_FinanceLeaseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "FinanceLeaseObligationsMember", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Obligations", "label": "Finance Lease Obligations [Member]", "documentation": "Finance Lease Obligations [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Principal Payments", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r617", "r623" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-Of-Use Asset, Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": [ "r983", "r984" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r616", "r621", "r890" ] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-Of-Use Asset, before Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r982" ] }, "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "label": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "documentation": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } },
```

"auth_ref": ["r626", "r890"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r625", "r890"] }, "bio_FinanceLeasesandOtherDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "FinanceLeasesandOtherDebtMember", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases and Other Debt", "label": "Finance Leases and Other Debt [Member]", "documentation": "Finance Leases and Other Debt [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r372", "r373", "r376", "r377", "r378", "r380", "r381", "r382", "r459", "r467", "r564", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r696", "r873", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r1035", "r1036", "r1037", "r1038"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r201", "r401"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r398", "r400", "r401", "r403", "r668", "r672"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Purchase Price", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r151", "r672"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r61", "r64"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r151", "r668"] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r668"] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": [] }, "bio_ForeignCurrencyDerivativeUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "ForeignCurrencyDerivativeUnrealizedGainLoss", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain (Loss) on Derivatives", "label": "Foreign Currency Derivative, Unrealized Gain (Loss)", "documentation": "Foreign Currency Derivative, Unrealized Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange (gains) losses, net", "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r592", "r593", "r594", "r595", "r805"] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange (gains) losses, net", "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r786", "r901", "r1069", "r1070", "r1092"] }, "us-gaap_ForeignGovernmentDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignGovernmentDebtMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Foreign Government Debt [Member]", "label": "Foreign Government Debt [Member]", "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity." } } }, "auth_ref": ["r1020", "r1032"] }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Foreign Government Obligations [Member]", "label": "Debt Security, Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": ["r1063", "r1088"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r915", "r926", "r936", "r961"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r915", "r926", "r936", "r961"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r915", "r926", "r936", "r961"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r915", "r926", "r936", "r961"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label":

"Forgone Recovery, Individual Name" } } }, "auth_ref": ["r915", "r926", "r936", "r961"] },
"bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "auth_ref": [] }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "documentation": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, net", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": ["r200", "r386", "r673", "r874", "r891", "r1043", "r1050"] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Acquired During Period", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": ["r389", "r874"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Purchased Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r150"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Foreign Currency Translation Gain (Loss)", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": ["r393"] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": ["r388", "r395", "r874"] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated impairment loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": ["r388", "r395", "r874"] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r874"] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Period Increase (Decrease)", "label": "Goodwill, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": ["r1042"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r133", "r242", "r285", "r299", "r305", "r308", "r360", "r430", "r431", "r433", "r434", "r435", "r437", "r439", "r441", "r442", "r587", "r871", "r1059"] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "In Process Research and Development [Member]", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r0", "r130", "r173", "r285", "r299", "r305", "r308", "r678", "r693", "r871"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": ["r285", "r299", "r305", "r308", "r700", "r871"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": ["r404", "r411", "r791"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": ["r411", "r791"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.bio-rad.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": ["r243", "r522", "r528", "r530", "r532", "r537", "r539", "r542", "r543", "r733"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Provision) benefit for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense

(benefit) pertaining to continuing operations." } } }, "auth_ref": ["r180", "r186", "r259", "r260", "r293", "r526", "r538", "r701"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax payments, net", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": ["r44"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Decrease in accounts payable and other current liabilities", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other." } } }, "auth_ref": ["r1006"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in deferred income taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredLiabilities", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payments of operating lease liabilities", "label": "Increase (Decrease) in Deferred Liabilities", "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": ["r1006"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in other long term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": ["r11"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.bio-rad.com/role/EarningsPerShareDetails_1": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/EarningsPerShareDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r266", "r267", "r268", "r273", "r490"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r399", "r402"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r152"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r62", "r152"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r918", "r926", "r936", "r953", "r961", "r965", "r973"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r971"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r907", "r977"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r907", "r977"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r907", "r977"] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": ["r200"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Purchased intangibles, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r59", "r63"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [

"http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": ["r109", "r175", "r228", "r289", "r607", "r792", "r901", "r1091"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid, net", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r236", "r239", "r240"] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Interest Receivable, Current", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r998"] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.bio-rad.com/role/Inventory"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r383"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/InventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r149", "r864"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/InventoryDetails"], "lang": { "en-us": { "role": { "totalLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r211", "r861", "r891"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/InventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r149", "r866"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/InventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r149", "r865"] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/OtherIncomeNetDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest and investment income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": ["r137"] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalanceShares", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Investment Owned, Balance, Shares", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": ["r746", "r755", "r813", "r821", "r831", "r895"] }, "us-gaap_InvestmentOwnedUnrealizedAppreciationDepreciationNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedUnrealizedAppreciationDepreciationNetAbstract", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]", "label": "Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": ["r747", "r749", "r750", "r752", "r755", "r811", "r814", "r817", "r820", "r823", "r828", "r829", "r833", "r834", "r835", "r836", "r837", "r895"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r747", "r749", "r750", "r752", "r755", "r811", "r814", "r817", "r820", "r823", "r828", "r829", "r833", "r834", "r835", "r836", "r837", "r895"] }, "bio_Investmentownershippercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "Investmentownershippercentage", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Investment ownership percentage", "label": "Investment ownership percentage", "documentation": "Investment ownership percentage" } } }, "auth_ref": [] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "bio_KnowHowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "KnowHowMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Know How [Member]", "label": "Know How [Member]", "documentation": "Know how [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.bio-rad.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r1073"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": ["http://www.bio-rad.com/role/LegalProceedings"], "lang": { "en-us": { "role": { "terseLabel": "Legal Proceedings", "label": "Legal Matters and Contingencies [Text Block]", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": ["r153"] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r620"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r620"] }, "bio_LesseeOperatingAndFinanceLeasesRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "LesseeOperatingAndFinanceLeasesRemainingLeaseTerm", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee Operating And Finance Leases Remaining Lease Term", "label": "Lessee Operating And Finance Leases Remaining Lease Term", "documentation": "Lessee Operating And Finance Leases Remaining Lease Term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Lessee, Operating Lease, Liability, Payments, Due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r627"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r627"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r627"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r627"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r627"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r627"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1074"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r627"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.bio-rad.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r613"] }, "bio_LesseeSupplementalBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "LesseeSupplementalBalanceSheetInformationTableTextBlock", "presentation": ["http://www.bio-rad.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Lessee Supplemental Balance Sheet Information", "label": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "documentation": "Lessee Supplemental Balance Sheet Information [Table Text Block]" } } }, "auth_ref": [] }, "bio_LesseeSupplementalCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "LesseeSupplementalCashFlowInformationTableTextBlock", "presentation": ["http://www.bio-rad.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Lessee Supplemental Cash Flow Information", "label": "Lessee Supplemental Cash Flow Information [Table Text Block]", "documentation": "Lessee Supplemental Cash Flow Information [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": ["r27", "r242", "r360", "r430", "r431", "r433", "r434", "r435", "r437", "r439", "r441", "r442", "r550", "r551", "r552", "r587", "r765", "r870", "r902", "r1059", "r1075", "r1076"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r124", "r170", "r692", "r891", "r1011", "r1040", "r1068"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r29", "r197", "r242", "r360", "r430", "r431", "r433", "r434", "r435", "r437", "r439", "r441", "r442", "r550", "r551", "r552", "r587", "r891", "r1059", "r1075", "r1076"] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Fair Value Disclosure", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r102"] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements [Member]", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": ["r85", "r521", "r1064"] }, "bio_LifeScienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "LifeScienceMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Life Science", "label": "Life Science [Member]", "documentation": "Life Sciences [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r25"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit, Current", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date

issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r116", "r168"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r22", "r169", "r450", "r461", "r880", "r881", "r1085"] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total long-term debt, excluding leases and current maturities", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current maturities", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r205"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.bio-rad.com/role/LongTermDebt"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r154"] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r199"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r31"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r31", "r70"] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Marketable Securities, Unrealized (Gain) Loss", "terseLabel": "Marketable Securities, Unrealized Gain (Loss)", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": ["r132"] }, "us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gains) losses from change in fair market value of equity securities and loan receivable", "label": "Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "documentation": "Amount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI)." } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": ["r57"] }, "bio_MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock", "presentation": ["http://www.bio-rad.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Maturities Of Lease Liabilities For Operating and Finance Leases", "label": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]", "documentation": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r420", "r421", "r422", "r423", "r487", "r666", "r713", "r756", "r757", "r812", "r816", "r818", "r819", "r830", "r855", "r856", "r872", "r884", "r889", "r892", "r1061", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r945"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r945"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r420", "r421", "r422", "r423", "r487", "r666", "r713", "r756", "r757", "r812", "r816", "r818", "r819", "r830", "r855", "r856", "r872", "r884", "r889", "r892", "r1061", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r964"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r1063"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r972"] }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MunicipalBondsMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Municipal Obligations (Member)", "verboseLabel": "Municipal obligations [Member]", "label": "Municipal Bonds [Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r946"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r237"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r237"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "terseLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r143", "r144", "r145"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Bio-Rad", "terseLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r131", "r145", "r174", "r195", "r220", "r223", "r227", "r242", "r249", "r253", "r254", "r255", "r256", "r259", "r260", "r270", "r285", "r299", "r305", "r308", "r360", "r430", "r431", "r433", "r434", "r435", "r437", "r439", "r441", "r442", "r575", "r587", "r694", "r787", "r806", "r807", "r871", "r901", "r1059"] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r189", "r190", "r191", "r192", "r193", "r248", "r249", "r250", "r251", "r252", "r255", "r261", "r277", "r321", "r322", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r406", "r517", "r518", "r519", "r533", "r534", "r535", "r536", "r544", "r545", "r546", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r584", "r585", "r588", "r589", "r590", "r591", "r605", "r606", "r609", "r610", "r611", "r612", "r628", "r629", "r630", "r631", "r632", "r669", "r670", "r671", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726"] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from external customers [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": ["r48", "r189", "r190", "r191", "r192", "r193", "r248", "r249", "r250", "r251", "r252", "r255", "r261", "r277", "r321", "r322", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r406", "r517", "r518", "r519", "r533", "r534", "r535", "r536", "r544", "r545", "r546", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r584", "r585", "r588", "r589", "r590", "r591", "r605", "r606", "r609", "r610", "r611", "r612", "r628", "r629", "r630", "r631", "r632", "r669", "r670", "r671", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements Issued and to be Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r945"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r915", "r926", "r936", "r953", "r961"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r943"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r942"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r953"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r972"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r972"] }, "us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sold marketable securities and investments", "label": "Noncash or Part Noncash Acquisition, Accounts Receivable Acquired", "documentation": "The amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r45", "r46", "r47"] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r45", "r46", "r47"] }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r45", "r46", "r47"] }, "us-

gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncompeteAgreementsMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Noncompete Agreements [Member]", "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": ["r83"] }, "us-gaap_NotesAndLoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and notes payable", "label": "Notes and Loans Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r26"] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OneTimeTerminationBenefitsMember", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "One-time Termination Benefits", "label": "One-time Termination Benefits [Member]", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": ["r875", "r876", "r877", "r878"] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Segment profit (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r285", "r299", "r305", "r308", "r871"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r622", "r890"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r615"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r615"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r615"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r619", "r623"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r614"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reduction in the carrying amount of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r1007"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r626", "r890"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r625", "r890"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r298", "r299", "r300", "r301", "r302", "r308"] }, "bio_OrdinaryVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "OrdinaryVotingSharesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Ordinary voting shares [Member]", "label": "Ordinary voting shares [Member]", "documentation": "Ordinary voting shares" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Use of Estimates", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r115", "r146", "r147", "r163"] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": ["r166", "r202", "r685", "r902"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r213", "r891"] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } },

{"auth_ref": ["r7", "r14", "r129", "r164"] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r36", "r226", "r597", "r600", "r603", "r695", "r1000"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": ["r4"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss) net of tax", "terseLabel": "Total other comprehensive income (loss) net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r16", "r21", "r221", "r224", "r229", "r597", "r598", "r603", "r675", "r695", "r1000", "r1001"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r10", "r14", "r164", "r221", "r224"] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": ["r8", "r225", "r229", "r526", "r540", "r541", "r597", "r601", "r603", "r675", "r695"] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized holding gains (losses) on available-for-sale investments net of tax expense", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r215", "r218", "r356"] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": ["r12", "r66", "r135"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": ["http://www.bio-rad.com/role/OtherIncomeNet"], "lang": { "en-us": { "role": { "terseLabel": "Other Income, Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": ["r159", "r160"] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestmentsMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Other Investments [Member]", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r28", "r891"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r32"] }, "us-gaap_OtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebt", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Long-term Debt", "label": "Other Long-Term Debt", "documentation": "Amount of long-term debt classified as other." } } }, "auth_ref": ["r22", "r169", "r1085"] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Long-Term Debt, Current", "label": "Other Long-Term Debt, Current", "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer." } } }, "auth_ref": ["r116", "r117", "r764"] }, "bio_OtherLongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "OtherLongTermDebtMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Long-Term Debt", "label": "Other Long-Term Debt [Member]", "documentation": "Other Long-Term Debt" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/OtherIncomeNetDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Nonoperating (Income)", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": ["r232"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 }, "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/OtherIncomeNetDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r138"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r945"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r913", "r924", "r934", "r959"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r916", "r927", "r937", "r962"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r916", "r927", "r937", "r962"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r941"] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for purchases of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r38"] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for Restructuring", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r410", "r1005"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r40"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax payments from net share settlement", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r235"] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for purchases of marketable securities and investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": ["r141"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r142"] }, "us-gaap_PaymentsToSuppliersAndEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToSuppliersAndEmployees", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid to suppliers and employees", "label": "Payments to Suppliers and Employees", "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided." } } }, "auth_ref": ["r238", "r1003", "r1004"] }, "bio_Paymentsforproceedsfromderivativeinstrumentsoperatingactivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "Paymentsforproceedsfromderivativeinstrumentsoperatingactivities", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from forward foreign exchange contracts, net", "label": "Payments for (proceeds from) derivative instruments, operating activities", "documentation": "Payments for (proceeds from) derivative instruments, operating activities" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r944"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r944"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r943"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r953"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r946"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r942"] }, "bio_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "PreferenceSharesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3"], "lang": { "en-us": { "role": { "terseLabel": "Preference shares [Member]", "label": "Preference shares [Member]", "documentation": "Preference shares" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r118", "r462"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r118", "r766"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": ["r118", "r462"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Value, Issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r118", "r688", "r891"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r212", "r384", "r385", "r863"] }, "us-gaap_ProceedsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCustomers", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash received from customers", "label": "Proceeds from Customers", "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services." } } }, "auth_ref": ["r41"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Issuance of Common Stock", "negatedTerseLabel": "Proceeds from Issuance of Common Stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r9"] }, "us-

gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities and investments", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r233", "r234", "r1019"] }, "us-gaap_ProceedsFromOtherOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherOperatingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Investment proceeds and miscellaneous receipts, net", "label": "Proceeds from Other Operating Activities", "documentation": "Amount of cash inflow from operating activities classified as other." } } }, "auth_ref": ["r42"] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Sale of Debt Securities, Available-for-sale", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r37", "r233", "r324", "r355"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from dispositions of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r140"] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Warranty accrual, beginning of period", "periodEndLabel": "Warranty accrual, end of period", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": ["r111", "r424", "r426", "r429"] }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Actual warranty costs", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": ["r427"] }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Provision for warranty", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": ["r428"] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": ["r984", "r1053"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r941"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r941"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r420", "r421", "r422", "r423", "r480", "r487", "r513", "r514", "r515", "r642", "r666", "r713", "r756", "r757", "r812", "r816", "r818", "r819", "r830", "r855", "r856", "r872", "r884", "r889", "r892", "r895", "r1054", "r1061", "r1078", "r1079", "r1080", "r1081", "r1082"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r420", "r421", "r422", "r423", "r480", "r487", "r513", "r514", "r515", "r642", "r666", "r713", "r756", "r757", "r812", "r816", "r818", "r819", "r830", "r855", "r856", "r872", "r884", "r889", "r892", "r895", "r1054", "r1061", "r1078", "r1079", "r1080", "r1081", "r1082"] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/OtherIncomeNetDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net realized (gain) loss on investments", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": ["r699"] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r36", "r226", "r597", "r602", "r603", "r695", "r1000"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r227"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r227"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r227"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables"], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": ["r56", "r57"] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": ["http://www.bio-rad.com/role/SegmentInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref":

["r56", "r57"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r908", "r919", "r929", "r954"] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on long-term borrowings", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r39", "r731"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": ["r114", "r520", "r1083"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r909", "r920", "r930", "r955"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r910", "r921", "r931", "r956"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r917", "r928", "r938", "r963"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r198"] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Current", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r993", "r1008"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Noncurrent", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r181", "r995", "r1008"] }, "bio_RestrictedInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "RestrictedInvestmentMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted investment [Member]", "label": "Restricted investment [Member]", "documentation": "Restricted investment" } } }, "auth_ref": [] }, "us-gaap_RestrictedInvestmentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedInvestmentsAtFairValue", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Investments, at Fair Value", "label": "Restricted Investments, at Fair Value", "documentation": "The aggregate value of all restricted investments." } } }, "auth_ref": ["r815", "r822", "r832", "r844", "r845"] }, "us-gaap_RestrictedInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedInvestmentsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Restricted investments", "label": "Restricted Investments, Current", "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions." } } }, "auth_ref": ["r844", "r845"] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.bio-rad.com/role/RestructuringCosts"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r407", "r408", "r410", "r413", "r419"] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r12", "r414", "r416", "r1055"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r409", "r410", "r416", "r417"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r409", "r410", "r411", "r412", "r416", "r417", "r418"] }, "us-gaap_RestructuringCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs [Abstract]", "label": "Restructuring Costs [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r410", "r415"] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve, Accrual Adjustment", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": ["r410", "r417"] }, "us-gaap_RestructuringReserveTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveTranslationAdjustment", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation (Gain) Loss", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve." } } }, "auth_ref": ["r1056", "r1057"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation":

["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "verboseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r121", "r158", "r691", "r720", "r725", "r732", "r767", "r891"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r191", "r245", "r246", "r247", "r250", "r258", "r260", "r364", "r370", "r517", "r518", "r519", "r535", "r536", "r556", "r559", "r560", "r563", "r573", "r716", "r718", "r734", "r1093"] }, "bio_RevenueAllocationPercentToLeaseElements": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "RevenueAllocationPercentToLeaseElements", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesDetails", "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Allocation Percent To Lease Elements", "label": "Revenue Allocation Percent To Lease Elements", "documentation": "Revenue Allocation Percent To Lease Elements" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r286", "r287", "r298", "r303", "r304", "r310", "r312", "r314", "r478", "r479", "r667"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r187", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r857"] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": ["r20"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r624", "r890"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r972"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r972"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/EarningsPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": ["r261", "r488", "r980", "r1016"] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r36", "r1071", "r1072"] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": ["r61"] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of identifiable purchased intangible assets with definite lives", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": ["r61"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336"] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.bio-rad.com/role/LongTermDebtTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r31", "r74", "r77", "r107", "r108", "r110", "r113", "r156", "r157", "r880", "r882", "r1012"] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Discussion of current derivative risk management", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": ["r17", "r88", "r89", "r90", "r91", "r94", "r97", "r99", "r100"] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": ["r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r874"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Changes to goodwill by segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of

goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r874", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.bio-rad.com/role/InventoryTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r23", "r125", "r126", "r127"] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": ["http://www.bio-rad.com/role/OtherIncomeNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of other income (expense), net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Warranty Liability [Table Text Block]", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": ["r425"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": ["r409", "r410", "r411", "r412", "r416", "r417", "r418"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsTables"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r67", "r68", "r69"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r53", "r54", "r55", "r58"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.bio-rad.com/role/SegmentInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r53", "r54", "r55", "r58"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": ["r71", "r72", "r73", "r74", "r75", "r76", "r77", "r156", "r157", "r158", "r206", "r207", "r208", "r279", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r728", "r729", "r730", "r731", "r884", "r979", "r1009"] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": ["http://www.bio-rad.com/role/EarningsPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": ["r49"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r903"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r905"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r314", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r412", "r418", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r874", "r985", "r1087"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": ["r312", "r313", "r748", "r751", "r753", "r814", "r817", "r823", "r833", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r858", "r885", "r895", "r1062", "r1087"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.bio-rad.com/role/SegmentInformation"], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r281", "r282", "r283", "r284", "r285", "r297", "r302", "r306", "r307", "r308", "r309", "r310", "r311", "r314"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": ["http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-

rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r136"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorLongTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorLongTermNotes", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes, Noncurrent", "label": "Senior Notes, Noncurrent", "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": ["r31", "r891"] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r11"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516"] }, "bio_ShareBasedPaymentArrangementSharesWithheldForSettlementOfEquityAwardsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "ShareBasedPaymentArrangementSharesWithheldForSettlementOfEquityAwardsAmount", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount", "label": "Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount", "documentation": "Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r171", "r172", "r999"] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments [Member]", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": ["r835", "r836", "r837", "r859"] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date." } } }, "auth_ref": ["r161"] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Standard Product Warranty, Policy", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": ["r1058"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "verboseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r194", "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r314", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r405", "r412", "r418", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r874", "r985", "r1087"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r188", "r206", "r207", "r208", "r242", "r265", "r269", "r271", "r273", "r279", "r280", "r360", "r430", "r433", "r434", "r435", "r441", "r442", "r462", "r463", "r465", "r466", "r468", "r587", "r728", "r729", "r730", "r731", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r766", "r788", "r808", "r838", "r839", "r840", "r841", "r842", "r979", "r1009", "r1017"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r16", "r34", "r191", "r225", "r226", "r227", "r245", "r246", "r247", "r250", "r258", "r260", "r278", "r364", "r370", "r469", "r517", "r518", "r519", "r535", "r536", "r556", "r558", "r559", "r560", "r561", "r563", "r573", "r597", "r599", "r600", "r601", "r602", "r603", "r632", "r716", "r717", "r718", "r734", "r808"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": ["r312", "r313", "r748", "r751", "r753", "r814", "r817", "r823", "r833", "r843", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r858", "r885", "r895", "r1062", "r1087"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLossesswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r245", "r246", "r247", "r278", "r667", "r727", "r745", "r758", "r759", "r760", "r761", "r762", "r763", "r766", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r783", "r785", "r789", "r790", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r808", "r896"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023",

"localname": "StatementScenarioAxis", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/EarningsPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Statement, Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": ["r261", "r488", "r980", "r981", "r1016"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": ["r245", "r246", "r247", "r278", "r667", "r727", "r745", "r758", "r759", "r760", "r761", "r762", "r763", "r766", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r783", "r785", "r789", "r790", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r808", "r896"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r912", "r923", "r933", "r958"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": ["r16", "r78", "r118", "r119", "r158"] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Authorized Amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "bio_StockRepurchasedDuringPeriodExciseTaxAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "StockRepurchasedDuringPeriodExciseTaxAmount", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock Repurchased During Period, Excise Tax, Amount", "label": "Stock Repurchased During Period, Excise Tax, Amount", "documentation": "Stock Repurchased During Period, Excise Tax, Amount" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Total Stockholders' Equity", "periodEndLabel": "Total Stockholders' Equity", "terseLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r119", "r122", "r123", "r148", "r768", "r784", "r809", "r810", "r891", "r902", "r1011", "r1040", "r1068", "r1093"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": ["http://www.bio-rad.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r604", "r634"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": ["http://www.bio-rad.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r604", "r634"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": ["http://www.bio-rad.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": ["r604", "r634"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.bio-rad.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r604", "r634"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.bio-rad.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r604", "r634"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events, Policy", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.bio-rad.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r633", "r635"] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r952"] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Income and other taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r26"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r944"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r951"] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable and Allowance for Credit Losses", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r177", "r178", "r179", "r317", "r318", "r320"] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": ["http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1"], "lang": { "en-

us": { "role": { "terseLabel": "Trade Names [Member]", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r82"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r971"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r973"] }, "us-gaap_TradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradingSecurities", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r112", "r204", "r862"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": ["http://www.bio-rad.com/role/DocumentandEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r459", "r467", "r564", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r696", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r1035", "r1036", "r1037", "r1038"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r974"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r975"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r973"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r973"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r976"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r974"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Common", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r78"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r78"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r33", "r78", "r79"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r16", "r78", "r158"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.bio-rad.com/role/RestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r409", "r410", "r416", "r417"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": ["http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryAndGovernmentMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2"], "lang": { "en-us": { "role": { "terseLabel": "US Government Sponsored Agencies [Member]", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": ["r679", "r886", "r1088"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "US Treasury Securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r868", "r886", "r888", "r1084"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r970"] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": ["r523", "r529"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": ["http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r50", "r51", "r52", "r182", "r183", "r184", "r185"] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": ["http://www.bio-rad.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": ["r531"] }, "bio_ValueAppreciationRightsUnrecognizedUnrealizedAppreciationDepreciationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240630", "localname": "ValueAppreciationRightsUnrecognizedUnrealizedAppreciationDepreciationNet", "crdr": "debit", "presentation": ["http://www.bio-rad.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net", "label": "Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net", "documentation": "Sartorius Loan value appreciation rights - Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bio-rad.com/role/EarningsPerShareDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsPerShareDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or

earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r264", "r273"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bio-rad.com/role/EarningsPerShareDetails_1": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsPerShareDetails_1"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r263", "r273"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards

Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "610", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//610/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//720/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "b.", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-

1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":

"11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r307": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r617": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40",

"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",

"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",

"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":

"1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",

"Paragraph": "a", "Subparagraph": "3" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r979": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r980": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r981": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":

"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 82 0000012208 24-000052 xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-24-000052-xbrl.zip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{YTDCE:-YA3@^1D9G:2T]OL M*_9B>ODW^!/; [P:],Q"&>NAM,+! O[9LN16F9G)ULQ4Y.[W59G&S*QNR$CM M.HD6DFQ.[X/B6Y:Z0?#:%P%:)=K=Y.Z0":"&^S0W87$??[F7R54,\U0&^S MKW5HNM/$> ^UNU\[>I'9X,U*NW;TI2P=U=$JH%.G @MOOE@Z[1A=HTH$O)T6A M*/*U>REEM1F]581]A^#\CQ0G_\+9/ S0G_$ZDXFL(VU9013V? 8+W:3YR70]G M_X%_#3SW(C@%Q["^_3_@8FP N@>PZBP ONX]80 MGGUW88O2<9QTEOIX]M5,H41OBZ"4_RT!W@1..$,MH87[&=B&EQT*V3*U"4& M5K&TC$:-

*MQJ8)%E'T?))O0^GK=_9S@W(;:%?X=PF3/5F(CZQI2/|)}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}JD:,J&(BGX$22-N:5S2]O:,J@D:KGDHFI8LZF:58U9E(8-MU22-Y((E6Q45]J\I^H@,F'8I!%*35D1S1#6;LF^3^>C-M:\WH#AWT<+V'AE)@(/:C51.+C-G$KM;-MP>NFV&)#]QI&MYC1[T=+E8WV[CF(D2'N'C.6;8<+8Q;Z<6XU=Y/X=->"5DB-MUXU#[PU-8Z"L1F>;W\%/P;KBLME]V=2IRZ:QIVSN.9*-LHEW>=B#-:>RN&QR-MV6R%;% (6"&M/P:2N(7##/V5@K&9:N&1RR6R%9![JT9<*2]A3./4>R24E8,EHU-MS<&:K4?-RV8#*3D&'>M_D3^@*P-T;G /$2EF,X06XF/'6V)UNQ\OR:BP+E*Z-M6QRU"YL!,Y*6+7=2,&B4|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{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|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}JD:,J&(BGX$22-N:5S2]O:,J@D:KGDHFI8LZF:58U9E(8-MU22-Y((E6Q45]J\I^H@,F'8I!%*35D1S1#6;LF^3^>C-M:\WH#AWT<+V'AE)@(/:C51.+C-G$KM;-MP>NFV&)#]QI&MYC1[T=+E8WV[CF(D2'N'C.6;8<+8Q;Z<6XU=Y/X=->"5DB-MUXU#[PU-8Z"L1F>;W\%/P;KBLME]V=2IRZ:QIVSN.9*-LHEW>=B#-:>RN&QR-MV6R%;% (6"&M/P:2N(7##/V5@K&9:N&1RR6R%9![JT9<*2]A3./4>R24E8,EHU-MS<&:K4?-RV8#*3D&'>M_D3^@*P-T;G /$2EF,X06XF/'6V)UNQ\OR:BP+E*Z-M6QRU"YL!,Y*6+7=2,&B4|>&-MFBN-DN-5>T/%$M4UF_BB-CV'/_B\KD1[5NJR-2+]OFKZZGE^+IU<.FN0SBTEC^K&^WM!-M*JHCJ10,+)Z:F975T_>-[Z>GO/-#Y#5]SCA..$:(-PG4LBYB)PM=N,-?OE'-M^)+E1%K=7Q[01%"PB7 WA0)PG'"&WOV,%@LA"!/<5R-"'P>"AQ;,^PCXPAQ$-M">[-D4QAC,,.@8M/N6(*!V0_,,!1R8D7@,#QT.5H74W@#-9)/'BS\A6S?;/A M5U,&)JX7,@]C#R^8)Q'T0>(]P,^/GIM,"WMFZ<9\491>;@%C-!1DB6R\96GE-M+S0M/LR3;-'5#&L.Q)MDJ,%3-FC@3";@*E$SE MWPJ.!68W31?J^?(R.F/(PA^]L$$3?-$^(_@.<9-7Z+#S-OZ;^C^EF2;D;K"-M05:H^N7BJG\S.A.^C;Y+R=+-1?*P,_70A3Z?+\G2]D"(L-M>J= (1B,X1=R/$-S^;3ZN68,=']/]5])-7OOYID?)\D!5E%*/VORY;A\-M4#M];ED4!_7^H[:8E>]&9.R5R];$3#+182IH-(!2^H^NFL7".%+.[PQ;W M3E+BUGO:3(=CA,;?T@-*]B0>*R#6SG]'(#2[V4FA?**EQ)%(QGF]2(I&:\;; MSM%TBF!J52W05<)P.%6'$R^[Q2LG\,H)!R^[9?.R6US2CEW2#E)VR^-9EM[BD-M';ND'430>-DM+FC'+F@'*;MEMZ_LUL$*E30!D:R1L_,J;9JW^?B _H0539JPT@2SVN,D:://[TWE-U-M1$.JW-N*@Y!)==@N;6@@[\W#T"S-[1ET5{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|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}JD:,J&(BGX$22-N:5S2]O:,J@D:KGDHFI8LZF:58U9E(8-MU22-Y((E6Q45]J\I^H@,F'8I!%*35D1S1#6;LF^3^>C-M:\WH#AWT<+V'AE)@(/:C51.+C-G$KM;-MP>NFV&)#]QI&MYC1[T=+E8WV[CF(D2'N'C.6;8<+8Q;Z<6XU=Y/X=->"5DB-MUXU#[PU-8Z"L1F>;W\%/P;KBLME]V=2IRZ:QIVSN.9*-LHEW>=B#-:>RN&QR-MV6R%;% (6"&M/P:2N(7##/V5@K&9:N&1RR6R%9![JT9<*2]A3./4>R24E8,EHU-MS<&:K4?-RV8#*3D&'>M_D3^@*P-T;G /$2EF,X06XF/'6V)UNQ\OR:BP+E*Z-M6QRU"YL!,Y*6+7=2,&B4|>&-MFBN-DN-5>T/%$M4UF_BB-CV'/_B\KD1[5NJR-2+]OFKZZGE^+IU<.FN0SBTEC^K&^WM!-M*JHCJ10,+)Z:F975T_>-[Z>GO/-#Y#5]SCA..$:(-PG4LBYB)PM=N,-?OE'-M^)+E1%K=7Q[01%"PB7 WA0)PG'"&WOV,%@LA"!/<5R-"'P>"AQ;,^PCXPAQ$-M">[-D4QAC,,.@8M/N6(*!V0_,,!1R8D7@,#QT.5H74W@#-9)/'BS\A6S?;/A M5U,&)JX7,@]C#R^8)Q'T0>(]P,^/GIM,"WMFZ<9\491>;@%C-!1DB6R\96GE-M+S0M/LR3;-'5#&L.Q)MDJ,%3-FC@3";@*E$SE MWPJ.!68W31?J^?(R.F/(PA^]L$$3?-$^(_@.<9-7Z+#S-OZ;^C^EF2;D;K"-M05:H^N7BJG\S.A.^C;Y+R=+-1?*P,_70A3Z?+\G2]D"(L-M>J= (1B,X1=R/$-S^;3ZN68,=']/]5])-7OOYID?)\D!5E%*/VORY;A\-M4#M];ED4!_7^H[:8E>]&9.R5R];$3#+182IH-(!2^H^NFL7".%+.[PQ;W M3E+BUGO:3(=CA,;?T@-*]B0>*R#6SG]'(#2[V4FA?**EQ)%(QGF]2(I&:\;; MSM%TBF!J52W05<)P.%6'$R^[Q2LG\,H)!R^[9?.R6US2CEW2#E)VR^-9EM[BD-M';ND'430>-DM+FC'+F@'*;MEMZ_LUL$*E30!D:R1L_,J;9JW^?B _H0539JPT@2SVN,D:://[TWE-U-M1$.JW-N*@Y!)==@N;6@@[\W#T"S-[1ET5{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|"U^-]$DJV:Z4)@)QY#YX+-U>8YQ$?$AJ8>;$#?1\$-M,$C+(0^? ZM\LPU=QV'*UA1O)N>&KXH4WFB1P2LM5@K2R;@U5N5:M]S&91%1-M)8*UU""E]H8XG:&L+O,\<'L(@!1,S?*6'PH

*M[Q5!V1]D.VABNS>415.6*FAB#C$&M=<6|[5N8*F2U!N:HD*M3QY'%TOHV]6V-M3#UKHRK1.Z+"H<4@M+9XM[5"BUZ&@$.+06CM4O>*

[UC51[0UU49=861.W^+Y% M;RHT4+@9C/PJ=]XZ@D3[^9/CQ1 ?7!?"((MA"!&^%)KM0 M(K[2?AF|[\#3:(9H5N+DG2K1*X?&<|<,*

FI#OKU&0/&\5ML 127E7AI1J\@Q M>D/-;#[9P/%R@"!$C0K(Y JHRX#:$'JH$5#T\CP<4"RN:!LB#A16-)N-%>T(MTN=+S0:_\2LHM.@5C99?

*K[Y>;.].B7T.RU3T:I*T(N2Q1Z#%8B@$-_MQ:BYY'#)64C.2L\SRGTK5%E&:Z>AB(:RNH!RX>+"U3+A*F61JBM]SN[QZ3* M"NXH*

*(F226%S$9P(]M3@ MIH&X+425W3-+#% 1E=TP'?MP1QW1;GFH[^7*E,_=[DCBUJ0-CI>L.W?%>Q] ML%'/;'.PM1]L];014V7J66\.-*

*B;!5LZQV[6L>I4V9*IL]X.**!NZ]%FKC&5PIVW)U.ZKY13J/;LXV)@$6RDM) ^\.OJJDY12Y+5KN"/8/U=:$ M\2@.[6USKP_624I5^.G03@.-*

*E99EJD*OM"0'&H- V^)6'Q!H|$|H<. Q"+0M MY[T/"#1Z)_S'WUHQ)GL((Z7 M]^C8$4>P%8%R5\W6'C.D&2)AIU.2]0 #KYU&*

(E/=XW98K7'U4TVT;9NCL8-H M;$T'.56EGBSD2&0)B4QUD'L?B?3*JW(DLH?$;;L=6$(B[]?6922N1G#8MA55 ME3%;\0BV3E#NJMG:T"C-:

*#=]E"JRG.(G4;305O7J2I/%+8-3>4V>5/O7;?# MPFV@A5N21$2%YG,R'$X'=*MI*R=ZAZ0XFMA#TS;7F#:::>(^WMJ&IX@Z% RQU M-D-*

*+W1%D]ZEWUCR*R,|V#[7.%D\;3[2T#5KE'(P5?[6AS[JJ1LY@F6M*=/&V M ZQ!C*8+6S^P%-Q94U,LKL ZB*YZ>]2]OS;2.W?*

*$H<4>M+;YM[5"B_<"ZS*T MMOFZ]:^)>F^HB895N5H^S\WNO%,,Y]YCX=%+IE/HNT($?9! 5TA"B(AG],NL9@LG[!.QZNP3.FZRB*0'!/*

M2)QQY%\Y0[Z&T>V"^=E>3K%3CB)"^=)\BC5XM.AZK,(777!/B5I%E]H:RKC0? MK>2 .#"W &X]F63@/NO49KS0#.YH#K,. V.=/-*

4ZGE]G@&/01MOD8]=O MH^DR(S;.$624L\Z?N"2<$ 99(AEYUD634)Y3WLMGKJ5WK\Z/IW0:4 ?O+[]S M]$\Q;

$5E[W,E1&T/C>L:6KTK[@CC>&)00='J+;Z[@J)W.(,#BCU O>O2U@,H MZBUN& !491"QYI+LWC%MW0R9%@]Z#GB-Z[?)S/I]!%GM+|\GV[E!

(OPM#:"@ M2[@2(]V9S^Z;"HK5?-Y/\6*E&%;JY1:=/?H=K^J({JS>L/+.%XKL:2A8S&62*

MRR05F53J[HI"JV[VA9FJBJ50N)L+%EHMM=\6V7!5R]6"MP0VI-S05530T"FDQ M+KM<=CLHNZ5$=Y<-Y-

4D5B:GIDS<>)PONEQPN>!26G3UPRVZ"K:=5E$O_!% M=]^IO3L[+L$EZ<.T')<1XUU*,E037K4W-$33M$33,@^Q_I9B)&^OPJ_B#.W:*

M59RA';N,[1C5W&&=NPJSM".7<49VK&K"$,_D2:7Z%_7>QC^@GX45R^Y/PY$ M&F^4NZ[#7\81OCEWT"K>AL:*W[JP\#(W#0W>!_,8GA2_?"'[&*

*[@7$NR4W?9Z! MZ-X+"J]/GZ^X:&0PV=>?'STWF9[8UL V#>P2YTC.7YQ]*P^0M_QI]7-5&RB2*

*MLO8K:2"O_7S3H\R!*MNEGK3Y<]5>_XZR8[(&JJXR-R9=*OON^L=D:QIC8Y+E M@:F7>]0!!B4-%.O]EVJ93=*

*[=H+UZV9K@9*9]6(K"G8:S61@(M^_6A.TV"5ZZ M]PBX?4_?"X2\@<^1$J2H>774]+B!"4 ?NL(YB (TZLT5H;I-AY'CI+,T*YY%*

MNI4+K]J5"UF_N.G)5:TO25"AOU M+6D6,B$-0[24*GNEN:AQ46-FWJ5J==3OH]EX23-D7536E,9D<$EK=?&.'6.C MES 1/!(NY]TE-BY"6RI.(!IF&0>

<;RA1S,GD]6<[#9LM11'VAHW,8=-EV@:U MP89>]5T.&P9AL^4\^#NPV6ZZF?@HFB7::XZ1#6-HS.F<8YAHTRVE\YM92-4[)__RZ\!A$L52?*

8I%@G>"V.FPA:$&@F!UJ7@;;%&3T@T.BU(^1 8Q!H6]S7 P-7AM"#C0&@;;%V:4*M.U^ MCB7UAKHE:N9JL7H.MO:#;8N+?&BPR8R!C1^5[]A5QY*

R)SLA2)0$B2P@.@_^ MX=]Y"GWOR,C(_3V-$]QA-;X+7PZ_XK.O%T%^\I6T91WC7C&G2[2_@7^D7NPE M\!9&#YX#LPXR-]+)

[P/RE'\"/X4E]#^+Y\DZC<0MH9/#(G&'-5OM#65#-"2+ MH[&#;-P27V%)+_)L7]>1N"4 PQ(2Z775YAD(E,(C0L(9%>FHTCD4$D;@G?

M,&B\%3\;N$I'NK>I2WG!2+LZU;_M1,\5Q;WRGL >N:K,,LQSPVV#5KE3H"LQF_=.@98#V2J8[-[0,"KUCN888D\] M;0FT5%1/VVTS&R=Z1<5F)?

7&T4550ZU$3VK44+;<&RH2A<(K'$,L:;@M88\Z M#2B;7LZ+0XM!:.U2PK#6Q4_M#3514V@59^,G^TM5/?T.(F=:E#Q5]^P9=|RM

M2UO=G+24IMBC"LBJM-,H=EJ 0U%RKGD<,E92,Y*]47-]7-L7./44$5-HG4F*

MD@L7&S@[2N$JYU^O%%RLK0ZI18P8R4]6M\"A@N92I:HKJFRR!,&V?W7"]\%&KQ8J!UMGP%9//4--HIXEYV!C M$FSE/+N5Y/H&SZY/41-PL=*

1=E01$67J?:GX,!C!WBE<+A1QT6WA M@%-)IX@;!N:RNWOWK+J MEX?3]I5;D7'%1U/4)+/Z$5X.)Y:4TQ:_FK)R4NB=C^)H8A!-6WQCVFCBK?':

*MAJ:*F_P/L-2I#"UUQY"OYNTMZG!1.ZS.K"D\U=(V:)7S,&HL'E]2&>M(&8N2 MM1HPY+7E68,831^V?F 9O:$AVC(KD6B.KD:.P%/H?*

J$I9F^HK1:2YPJ-0C1 M=&1K-;]X][N0VN;4UQ_VF?CYA>F5;EF',_"[M/\XF]I 55]M3{(IO+VR(" M> H;"_B]+3+0Z2J3-.C3&85C[-*

*$)8$5]!+U'AH4F.1VG50,5\E ,&E MF4OS,4E<5*6'>I8U\-1E6>T-+M"1--(S*_2BY*'-1/B91+KN(@S]1"J*HG]=[V'X"_F1^5WC M'"%^2^V*

'^9+>GB%YFT^L8)_X;@H%X.!"CB!X1OZ?$(0)>C](T,>!X"&7^#X" MOC '4=;Z8@ICB%UE%]=ZQ!0.B \)$O3'Q M X'CH\CA!'Y":((,WCFPQVV>*

*M^6 T'8UV'L:D[L=)!'V0> _P\Z/G)M/">U^Z*W=PI9=;P!B-(TTVW[+DR3IH M8#"BODEK-X+;KTFQ_!./%@<'/,V2;-/4#6D,QYIDJ\!0-6OB3"3@*E*

RE7_C M+'M^TS0J9C 'I[_CB#XV0<3-,$3X#^"YQBC?(D,,R\H!J0I Q/3_2W)-L-T MA7VL4/7+Q57_9G0F?!M]N;H9W5W=7)S?

BL+%Y>E&X&T.^0;I9&W"ET1,DU X M71@57 MBE=']R#P_D/[&;W0'Y>J#MSK".G('"_7DT6#'GAQYD7.WX8IQ%$5]^B&7D3 MSP%!,D+Z.*

*T2O"L7/<_Q8'R'AO#%#YV?+]%#(XM8>D$*W5&2?X8'"&,'S#&A MHA3VZEU9R!-/<(4GSWG%7G,M>^6!4/SW971[<2M0-*

*K9^SGVOH;1Z4LN_2D0P= MK\;+"&N#L5'.]"#3V"\S!*1 $?0%"DSU^\L'\#7)'*7\N/GZ$;S])XF>? M('M$,,V,E^,C%MV$:%9]&< (CK"_SEPG?*

P#B,0!)&2+S02A$X W*GE\1" MG(YCS_4 _FH@9 ;,BIV4%JJJC#6$F58,8 H>H#"&.!#FB![(X$(O#\@[(I=L MXW[TDBGY.\,GNLQ#SYO[B!_W.(#(+/.?

\?=PGF3W8F+|\",B8B)(AKQL1:0#" MA]]&H^N/9(Z(%CYT$@$]0 OY=N$QZGG3+'I)Q9/"^=>@#,EZ#F(^1)R!C=C%8

M!&=TB8MH@4W+8G31FX>@EWOHQF<(HF76;^#Q.-]Q'T\A3/"^^S/TLMD81MF= MJIQMP$>\CC-

*6NVAL#Q@<43@C[UL"T1;HH*X]B%Z[EH37A#>(<':L<;3 M,/71*S!] <$FNN?W-,CR;@38>)1!8<0DV?.W/!5K=("4"GD@DFUA% 0INN2& MJ!,!/?*

DKFK0@2_V_+_B)&8F8ZJ;UO-F\,,";?;6(T%QP;I%60;1',SE_P-/9 MLMY83:PWZ]7VOY!8/_Q<"+%[- GV6X1/ BDO/@(7PX1 <\(RD/_Q)[[]D*

*MMI*TB_X5!7MFOW9$-TM((,!K'R+,;7M-O|>WX^XU*_:G-X14-!H+B9%$MYE? M?S*K= ,$DE A)"A_:'>#+E593V9EY17_ED#**

*E01._2Z'9T5^CQ321]4Q@>P\.A7#%3#)CC52R4J("+OM)R'+_"Z@XFQ(<[,+R;>!Y M^#6F).-O@#BBADIZDCE?2M.;U"#8R!>ZB91\UCU*A,<=_*

==D&(6!KL25! M4JL8S!$WF6^O30|\Z9-OLX_A./V$X3Z3EOE%X"/Q5^-ZP78LOF33_,W43 MU369LH8'MDA?Q?]J/M6/$UH G4&?1R7:0$;JA;?1/0#?

%^^@ AS5W =;:J[MT+V?!%9U20P\Z;+Z#<>L4$H.4$&83U4DFV+O# YQ%0*WW708@M*N!E*1L/R MC-4"Z*

*%O!WU^2P|EFBVJ1*$8Q0,4J@BPMCC=?ZW,YY",=+^B3]0]CVKZ*"W)*

MH66,!XK&"H\J&KJRR7M3\5D(YNF#T]+@6<*Z9%*P9B.H09W0Z5Y]"3;6EA, M2-]$2Q=M*$@@-DDFRD/ 6PY*-M=;9WRGAT6K4$W6G6<+RR|*

[W-@AK._HR7HUXY)2 "YIDS)@,00_;/?Z M7YEX5F-#Q49@V&\Y37H|\<+!%V7X(ON>S"[(G&7I7NC."%1L-18-!-5/3FLTH M(O'(0*

]2H49.]X=H76K,$WZPY?T$8[B*S$([")0DN_A. 0$\/8IB7UYUPC4 MEVLV AW<2<)2:FJW@W?3'*--U;=8MYCC PB3H_D4Z)=^KI-Q3.HO>;*0)[R*

M65%S^ W6#B4M8] 9#1AB(1KX6' 1>Q,#FQILVM\6+50,?R1?K<10L-G)R@C M1(?/=+58TUPM@<7@0L='B(<;BN?;X?A 08.+HH%(*

2CH:)\33T4^33,Q-$FS+(UBEH$@S,>Q2 M/";P3:BV875"6. RP"J"RF'20QTL/R":6AYHI;VI;3VSYX,8CIZ?6G=<[0A' MQ$P> B<1*\]*

*O?:;/$33=F&B:F5ETWT_MJ28H\|!F^+$?'+H]AO0 MH0I6^(@=1*9/-(F3%=0:,Z5/-AV=>[<-1C,0;;$W#01G_@$396'&IA*>X])[M0_0L:IHDQMR!J3XGVXF?*

*+13CNR*H;R&6[6YPX.#(VBS#G=%&@PV.]8WU-ID#U7/AB=$I? ,-AK'RX*GP\C=6^J8]D(=!L!./*

MCZ8G)'7B58U&'+MS$T:/XHW:/I*C)MD]J7X\U8@CVT_U@)]_,N5MW09O%#G*

*ML)P7US*HR1AXG'(H[NVAOR\YD=/SDF_A;D#1M(1]R3)HI&TH+MBID{4.P^=1 MC29;E.%VCK+*HCI(]#+7BVT-H4T<1^7BY^R$"*

^,!T35&P269\8"?<.,RS94 MW9\GB S%/:$^>WBJN:)6#=U\B4K);VEAK5A@YW6E;T@[1NH02R^(M-]1><>=:+QEP

(N%.UUZ16]B_TDF:.#R&9H5PH,W/#|^N200CK79:!R6SQ:9 M:9!^$I37E1]^M%2?>4!PFJ%_X)4P&H#P!W7C&:

<7FAF!8,^>O@@E7A&_QW^)NK2-V@.Y^P/PM=!TV]XB%#GN3 M[;OO/K'0<0-SXCX-8SSW6_2-P;#C ++0TXPG#@^=13_1?)/H0 M1/&&RWN'-

NGS:AAQ@FJ.3;"_H1XDL@.4L 4ZN_!> ,()A(?T^)7F&PC9/%- MSL&'TP4+YC1***T^L3<;M@YGHYEEA"HB,L_^D3/1A2+77:!D1#MG] 2DH!\9*

MLH$'Z/-#OZ:S9GOU+>6^\!LZH\3//!X^B.YVUB-PGC(UBJ9(R0YJ6AT9A)IVC M![9%2,("45B&:XAKL?(S@(G 3\Y=0-LP_)

*M'+'9BH21B&^CX*7MQ4O8(A0^ M5!;-(K68EK/C Y2>5Y89<+@:,25C_+ W&;/(<-*[X3AH-W MCOH*^LIP>P10V&N*QIGE^4&LY>PY4$12-*

7EV-.580#NN<[OU5:S51T9=DS(M/F(<_78XAGK4TP&408LWU3O8&!*%$Y=U9]]070Z0:9=P|*:.")O-BVNO%H2Y*

*MSIEDB)055.I/V3K|$B2E+2O[%^QBS M@K#)AV8BCVR>X?;0F-T9GU:I9*0>579>Q7,_"ZZB)P!KPX2P;S Y!^ P^/(5*

MI:'N)W3+MB;L=571/3G4]E#5CSQ.T5:#PPAM&(RB5+?/NHK]G:_/KBT00C] MB$_@6KO;72H6ITB$<\$D?>8G""Y_ZB3FY{'H,Y;&-,#[=^20L8^-

*P/XV^Q M)GD8>\L*D_?I=30(EP7$I)X(AX%4SB&L>"3[PMUS3US79JA]*.W>P!''?YL1 MS)'VOF1]4BF?\ZJ=*

*<[TV..>H2RW+T:,N=\Z%KKNS9%5ET_H^.8_X@?^N#=O:_M7W3GHO8!."52T1+%#YI6=+(_Q39M*A59TH5J90QGNHS*^9U"L^K"PQ@9/EX*

ML2Y"([X22_"N(>(IS&K&%T5'46;J E2B.8.)'A!+86BC03PZ%A11#@;VA:()

MF0Y5V?!\'1ZJO,CNA#X%T&G@QD>FX,9^&7:AB7HAG"J8/AP1X'B)UQ2314E$ M?[!_?D9([XCLT^XKY4']][Q=Q]_L36/8N_\]^L_"[FH1(/ET(G1*

*MFWX/GO[NB?B"K4IT]'WLZW!_&(^]HX&*6T18L"\<;A!=(%0O^U^/\"[RCC[M*[G;R_Q\WZ-ZM?]S=300@ZI_4-K!1^64@SG8HV]\NAUT[_-*

H$B@:***"K=#M$PL]HPGJD=8K%);Y3"-YO MDDVT%<7@"Q*B>#7XI3&8V-L$ZQW->EHMK#<$UAOU6['WE3YU;K7[M:@-7?/SR\6ZO:4(I-*

*]=,.=!REAC6PA(CM'EHW0&GOEH-:&\G,)1@:%0+AL: MH5ZO^FE=8*B)&!K7@:&!W)GT00Y5WIH%AA](H9%<"X9Z@*&>U14;@]%K*

[+G,!0@B&E%@RI@&^6EUXMA-# MV4?Y*]F=:_'1#="GUQ]U^R6 ML? M: $$)RI*<*2:'28S]DOLY;;"U,AHY'M=|-<5**

<#0)KRC,@4S"V86S+RG,A@G7F;}>_^?CO4K M>.>L%K>F&]R&+\EB=/25WBC]<7>WAI=@=<'J@M5YL?HI#(LE>1U]VC?J8,3-*

MJWU>7[<&@}]HF9^C.BV>4MS2(O$2A?5FTY>M;N>4MS2(O$2A?5FTY>M.W M8.7/I2I/:#+6\,7K&U/W&8T=X#^H?NCJKIAS="P#-EC>-%#JL-\U%U>>N,3*

M(GW%WW]][8+C5M#6C#]0U2Y..9(LBIQQ520"*FBM3."=+-LFU6>-9*6A-BN*

*M*FH>$W=_2=5@O0FKRV%1KJR>.]&2;8TI;ONM!_N*:&;WMI=>=5_Z6QGQEB/=_M(F[%4BY+./7AQ#',"(>*

*(2HC1X98:4XX=OL"8!G@*RM",HC%A?UWL2HQE]^PU M6P1_[GK!+6T;T)KUN&=-=$MO*)B[H^S=36I:N'CPN^/#!*>L0^R>]+UE#AV?L1Q!0*

*MP!NT%B;\BCTP;N).R:RDY:OK_82AL%YL2[/"<%Z_/>L M>7&XU*_;0UN';8U)J6+7TBMV"M'L$*GGU=@\PQU,Q5M7+9N)FSZ\FC$I_!B*

*MOSN2.=5PQ$<-3U;#46MIH;J352YL*T%$Y;Y<$G&KN=;:Z9ZE9!H0[DPS?I^< M;J8$-@V'=L*9A?J<**

*F*ET.-9@%,Z!_TE4&3=X;OV.+3)_9NI.#8/TY',>C $=_>#8O M_!6;@A\)?T7,+-['E75=X=*@:ZX B+0N:17|/@55SL3#@53FQ7:W Z1=\>:*

MR,=&+VHF5V4@?K3%H7ZWRDL#NTT(/.9)"1 MPUO[0M>4H=L($P=QS",,&^&$1>Q8?01]MN3@Z,PO?D34.I-A]9Q_[DO%VY B MF$TPV_%'DIS

MK%MW=#$+T DW-*.N<1'#Y+N 5)IY_^&6%@ ZHT[ECH&&M%@NC"2)XS+H#'3 M>/)<,HV9!>YTI;L%&R-&!7G VO@QS,QD PK#?6@8$KP+

*<#.SX+O A9& G B# M-"TZ,QBK,=>]9Q:_^>I908!M@6>S. "*MA+>6$:#+;--ES$CPFR;A=9_D_*,,"?\ 0?MIAT1/--&/^L+Y8V M!]=GR)3I.HF]"]9+*

(KU9PMX'CX8;GUW8M1S\,B]P5]"O_T5C<=^P;!!]NG; M*.H]%5>?#IN/GG^R(+O=C2N6]Y]=D#@-3UD M#=B[*S,6+Q.S-NQUASG1884#S91N?*

*WRX67"I1XF8-1&S)F+61,R:B%D3,6LB M9.<<,6MM>Z#NYH&LY6I]_QE&(Q&,M:<{HX;\$C.$)P1*D@MN-9 H/:!KSS MU450&\^@-*

K0+T#3FC9.?'"'$[*MBC&*=\IUK*@P,4UWWR@;#_L_A' >7NS!U@ M1.#;$;$@O'& I3]$.-PY4/&79P7DUIW-_-AYD.DM$!%R7(3F9U=W[ASS,S("

M\YW1!?@&]_B"^S"D:%QBU"Y9H?*55CQ06)M<#T>01=7>L;E29IF2RR.(7K"X-U:A.J)8KH3!8CP6N"U[A&Z!W/;$-J;:HE M0/;4MJC\8+U3U;8"1(34ADE\}UP'?C5822,6JL=^[H8XC,Y2[FHG1H^&."!. MG$!*)B)MSD1BF69<;7+OPP9&^NB^TSAPM+'1#3Z*?+ >8 MQM+M]*RC0F6^]-Z%_Z0WG4]WC^\[;R6+S?_N\4_ZB%MY>"/][_\U4A3Y}X?% MTL/'4SH!
<7Z0I>NQN(ZH".0'RS=LUU]YQ._2NWJ_T^)Y^+BP7A,61)HC%YM8
MBC*\6O*PZ)@7545,EUQD1;_@=5AWC(;T847*\'UHHW0P'B68@T[("G4]KVS= M@UMQL);)L7E7&%8X73-P@KG%IE)+FB/.B4'BAUJ^%SH/[%?V_VW#U_>LKI_MP ..R>:,SV>@T)=+VZ*UR +/32K-T5?9-H[?]4+=U-\LF8EOG\4KDE0%ZZ9) MCK7-R&S&'DN-L3,+I1HMGN:G/)LT]"TN+BCU!F%=09PO#;VT%O$PPLIEI9[4 MOZ&W28125$=60"HM,=0R@!G1<$X:/DBQN B@E&AC*HX5S8-5-79W?1C"XF2M8CN,]L2(HRS"T+F8*5RUA!-C4J8X$5ALE\'&-U+G@=6#>])_P1C>/+E+$,?# MOOSVG;3-=,F5:6;K=+FQ&2VUA_%U&!$,BV%;+):.08J^/*##7.H6?A)7?2W M+LL-9BG(#>.*W% SAEL(U2^Z9\Q#4N%_^P^=D&D SV2&GH??QFL]MV]NU@
MAI&$;SJ/'^]AS]#9%AFOIBUY*QNCK#'&&RZ!G<)&*PIL3EU)56_AQ4-8&X3+ M1P925FT27A/M2]9_X@C.>YN6B;S]$6(T!7L*A@?GA6!$*RV6BT4A\=VO%HCA M$.VTSK(?8%H'9:%PA4A<\-((WQ!Q00K4"-+H=E:9=U,PZ8Z#H>D>W0J3"LM9 M_,;&Y+@!98PDI; DUAY=?_Y:>1G0+V?^OP%F\ML;*Q@Z[T#_>5@)Z(MF+L#+K:E_DU]_9#D5J3'2%0?Q7&O(SQ3"L'&:48? %3P<#C1Y2J9]>:SJFMH?S8R9K)L*D8?*__3E3O4HX?ZV]OQ) MM[Q_8KY$"KX9JO)X-\EE-*XYR84^\9T5P/G#**!2*UTI^O?I[N&'], ^[SW]^ ME+Y\! G^X^.7CU^?'ALN!EF949+")
<4L+%B8X<)X@D;_8V1Z4NUS(U4%OE\M MZ-X2]J.PM_Z$.Y8ZGN>L)14_K^[*IJHH"A;@7"-BD8RG8\1]R+ZH6H+\\L-3 M])0$KX0XF6|
(\W06('\73/)(6,NT*['#+@JH*!\FB9+??=#&=$)5&AZ.4[:8 MW(W(A3-XQ?E:SG*UL>U3C1LOC29*=-AG=F<;C>TN3730T#W]0P:
56P0<^A&0SPXM0S4D3P)9"KQHH) ^)5/PP*G6&:=_MGE_"H6/* 5 /]P9VR:!F<*7.'GOBTV)Y2_Q!^_MWZ!-K]_M#9
8GY'R4N^=)/U_*S=@C1:BE!:F5#+\,UPS[L!=&)VYWHJB1ZP& MY]508#587>;TN7Z7)=\D'1+^76#Q? NF ;I3:NG>BK7CO'8JK-UC:M4RI&1Z MW=
(["-T@G^P;NQMMD)-,5*Q/6L"RO6"N.I=2W:+=V7.IB]N;8XT96R,%/H8" M)'7;O[*=W?SF_,!S*IY$X(*O+O9E87^^1T5E3]+=6-Y5L\=RAIJ)IV3]>09
MBKIRSO2]Q-!+52QV$DO7NC=TH P>"H,TT^%5H:)$=5E=BFD8:GLZ[5F05<$> MK28VO(TE5X<&G40U:FZ"X'C<[=/4]U+Y@?UQ5^YSR@^4NZ-
>]BW['K7_\X'* MJ3J^&%2901U^%)_,NW8EG(6:=H$4NPN>OG+=TU>O=?I/;J#;YTBW/.NL=[2. M3"WC70%0E$_O24=5Y&4PEVD5*P;7O,'5%-
QZ5EZZU_TY;;\&/(,GW^.X9FOB MI9='W"^,^|8&=[NJ[CF%:D-EP'X,,DDU-9T;>6URT2+H]OT4+0HRM([Q\3_ M/B82-<,-N]D==6;](N;M?
XCG9@22CGO,--M3?N>4N<*,?="9#K?I&SZE"#$\3 MG .:'UGSHT;J<.@:DF8FIP!DP-!:8N&E,Y530J;7"C1FUP/%T5RH!%6399
MT:,O#Y*Y%>4WN@[=9?*6']-J-?!J.;/DU%RMQ"QC/LQ2=IE:8$R\:LCE%%ZI M -+F!+',U- K(70CDZO?>#F3NWEN!QLM
(]QQ0@FH=":]GM;5V@"Z:XBR^T'\ MP+,,5NDASC*3WDR/TUDWJX+QY)^65#Z7=6U M/@''9!0_K\%.<,48RW&&YV.LN)K0YVV-
$OB["!TAQTW#$X*#%D#P;-;2*Y."_M.0Z?8W9:K1T[[36D4N'1(EA+?E)Y[8U1R8YZV[/&F#9%OCD:)3Y\#F\A8^:$9W;)N1<
MCBY8%3SC9H"G9:'=;9$\.5H#)T>8RP+,+$K4S M464.V^TU0>1"%+9"^,@W 1]79$R[>]$MS&\L#WH*@O_5U6IHT-HI6]D=T!L(Y MXO[3U
8JTWCXO'6"7&_ITB8M)ID&*8.QZ,Z^3X3GI#7$TN*3ZSV"K$AD^0>@ M\'%J(W-IKRVH(71M(L.K3,9] ?<.H,*S#0%,SEQ_:>00 W)JQ)H
MXH^FO%ZI%230J$$2B&OIMQ9H=K3UVC/VH7%HZQY_Z3J^BY79]6?B&,>]>%?A M5LE)*3B%@&V(GZY-3MZ6H*F7DQ%00<
JB]+5N3V#FPC"3X\$Z@012&E*1 M4J

0C@:U1I">'+^+A#,S0R2CVFW_F)^D W,'CD MJ#":0O,_'AHFB5F4B)BBN=^.*]A8C(]8XW:@5/%)VH]?#['CF#%*:YYQ8VWS M0#_.00#>POHLTDKQNR+|FW.(N;Q6|SS=K8*.@HZGH6/!#4%0NR2U.7G&6^&C MN7>]I>MAZL16]D45K]BE662SIG@Y-M7>]'_R&L C[+JL]KD% +<@QE ;N"1P2/G+)OQXF8)*_FS[C7F:@9A;]*]'(]7\BUR.QD'">_N1,;]N$)}35-X3X2U7(5WD-WXL F-ZDYI@CX9 MX%JD'I:$7!GU4*, [XGE;U570#EML<[_S?1+<#B+E*'(B[@'MV_RPW8 MQUL9=(=-R!$2:6>-P<[QIMP1;MH"3LV'4TDE\$1XRE4"QI@$;!=/-5D]3Z($ MGA5P+5("N26];*-J*,NX[:EGEE/7:2/\L_O83JNXP/_FY+^3!SC6(6P MI4?QL@I>O$):$7!F%L(_;WJ_[%F;!VC$ JP5_.FF=L*KWN*5'\G+< M,#]J,CB@MO+S!N8):T[3H,/;>SR4-6[>8P&UINF))\):KIXXK.H]%H;#MNJ) M)2%71D\/:O=5%Y\;S;]2(>_6I^>C34/[GK9$Q1QRSZTK5;EL M*+/FIWU^L:_U-C\|SF1YL7W2A1AH#$']% -'>QUZX@:Q/85/4M". CAT&]]@%-!XV%/806-M:[<9MU@3QWC M;DK'U 5,0.230L(M2L_P04 \UN>FIT@+N'CN=_=,MPPM%/KOA+3XMO(D@JV@635IH(OA$=,*HJD! MMB7]<&UGRS'LE0G4B,MZGF-1YT0"X*+G-G"EU[EES%FEZ:35M>6GVK9F],B> MXB'_1M)- +Q/<,5-VM?=E_PE<#,"P;;7$FT,C[-UZ4/2M9O6<+<#]#!7?H"M MN#WIF;C/GKZ$X4@Z@.2&-N+6G;5DP"">"1*//L4#|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{CE:8(_@$8ALMN-MPKQJ?(QC6,NX1PU>\ [__UTC5^K^7:_6;5Z]FLY_OKB3L=29 XOT9CMCO"O[[M;]U98?>%,%-C?"/YJ^F_L+414-$ Z.1;C@2PHDG=E',,=V6;4@#RZQEH$3:5 MQ'F['FNT%/8!>@/35A3Y]\^P)/37WN]ONY($!,<^1R:E(GZ'37P,0DQ6;0[6 MS:)-A5CS(\):\!C_7EFLA4VZ-YN?6H]XP26&2QC@"I8]&L03_A6-@C49T:4I M<L"ZT-!?;"2R/[/)9V#,39A,AD-)#PGV83@KQ[++"ABO:4HL-MB@H4VF<4'AS8K,]HM*1A]ND2%@3;Z^%CZ'KX. ^W[8IABK86C('#LLM_$;>QP M_O0=|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`.8$O.6X@!2[,*B4M4(OZ&\M6B 6\1NH)"1 M!57GN;I\$OWU(BCL6RR6IYG+TS0&![G-8G!A"=#M0[5R3Q30U$0;G:GTEZB[M+NJN\SL,99IV"@GF7F,UE-XF]$$&PLVOG0V/N$N M_)4$A?9@M3-1Y>'U=$;AT2DE=4^XG'VE.\26&4O7MY!Z[U@MYA<2=LH(ESMU M8T@A.;E%GP(Q5L'^6W;"$.M'+6V'HLB;Y$C_G'O1:);Z,[F=>D3_>:O/8+#O M=/M57_NX3&F:_\&W:+@]_?WK$/>M"=O'L%+_89#_8'#;Z^S]EC:8"1\OF]8T M!!6(&%3107%IFM)V(TF5_B[G+/)DD,64>)+:HPU>5-'@131X.3^=18,7T>"E M6=04#5[.U>#E**R&RPZ[[M0^ G;G5_18,7T>"%UVFD5]]I9"0J,M0JQ'K\-7",3==$UJ1@@6KE-.W MXRXDN:ZAS!ZN+6?]2%&QP0L'Z25*,C9-/SH>+"7THSXV>%%XF-T$BBI#:GW*$/9W2# N;$6GEE+'=S3?JPL-.Q,>A9/$@;]I MJM#Q6"FA"HU "@9Y6J$I:A!P*D+-WLT(6J-%J:B6I9:-'C9!'_-EU(E3!5VU&8A$2#EV/5HC)8KJ@6]3L3)>D.(DQ$IQ9:QW!%M$5@>P3WWLLC%=MG:]P+CHFF&PU!5RG-M8Y^S>H8*U-6TUP%UA]) MM7J@EJWK]C&W0E&X=7D6#5Y$@YQC&XTBP&%Y8 T>!%-'AI='D545]^Q-GHZ 8O?;4S&6H#WF$EW^,CI&7(H MG*Y,:ZTN/SX:XE9]T\XK"=XW'O;-7XF*P"+06!=EO#@P%N1=%>3&O%(6[=L ME,PG;-BLK#0]Z,NV-%Y=.T QAP7*[_QZ%.(MDO$8,ZX:T6>'1WI[E'B/0%KIO[TD?')&&8!>\=%4N+1^K6?#GS;\9S9,G_0]M76Y?OO ME4,D5;ZY5OAFSO]Z8'N1[5,46>F+IC-'4$VM*@4NE3 "3M7A5-XW:!SC]SIO M&RZ.0^;IRN!?M(7LJ@Q@>6FZ:5Q!FVT;9+)L7U@2Z?01>NVR2@N6NB:6RDGO M*L]2&+/K1AB,UC*.(*EC"MGJ;+SOR"6XLU16%5+YE#"N.22")82+-44ELJ) M$2W-4P-,SNAQV*9JX*D]+LV-$AOE7)QY7U(J6?V1/!X.!YH\)=.^/%9U3>V/M9L9,UDV%R$/E?U P%7EB*8_J@_,"IW376W^P?,-V_967X3$=]&KUF-(GOK," M6!EC]G#3!]JORM%_QZ^_O/CUZ=O/_YOB04H1:Y'8T],E4T0]2'A[E>>![_M M<38/E.8XFS]15S'PAJ1[1 KFA);N<1V"Q7S_4J_!^XRU?$>CKMKO-\VGBH/23N93+>2H:*#%,'+% M2 4-KA=)A(CKI8CA+]4Q%8O =U5LZT4-ZU7M[OOJ2G5I0'.0_;SA_X]+71@ M%PM4U2IU_B[N])(QQTHN]3? M8-R9C&0.^P[?]3F3DB]X4_#F.?;];-[4Y,YD..*0WGY^WBP8")+^.S?2(YQN MN#A]I3M$E_72]2VDT3N:^6V]D,13_??.QHTA'>3D%GT*LUX%^V_9\2S6CT$:.M?:#T-LF1_ED\"&;@Q$$P.7CU^?[CY+]W>/_Y_^??[VE_3P]=.W'U_NGAZ^?3U]:$X>;;,C=;0&1>H\ MS;$*!$S8L&R+Y>VX,\DA@01S\+$P!/YNP#S16OQBF<24IFO)71(/KL8 'Y"Y M+R@2,DR$8>$1KU1.N-Q=S10RP;I:..N;SCB$P^C=M4QKR"=D5+N20<&U9,/ M/^H;"Q_P2/>_*()422"O'(W2#A)53:"MG#W;/GI539W=;[,;,GVLR4?+K^'N M*S)GKS/-KU0%R)VD)!_&#[]M*ZT J@?'*G6:N40VK6"S:HE*)^&S/O*9/%8S4M>;Q6>:6AMT)D.56X7;!B@? BZ%.E5M[X/>K)B0U@C.\1FFZ-"YAF@*9G2K);=W:[\G.[QHA@TSR1 M&ND>GXGNDQ_XDF^S/WV6/I]1QSJ+989HD*D>1B5BE9L(GSP1RP$_(VS1U1C\M7)NN^CC7/(HI87=.0R3H?8J>6<@?8P0JMR)T0CEM%$AR M@&=AE QEV%_'U3L8UJ.21CYW&"C9#ZI37G5M.C..$>%I,\|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

*;3(DGJ;V8&"=IZ)VGZH.J=";A-M=UBI=59(GFV]5ND-TX]MNKT%;-K^!UQVX@<_](\!O##_$X\! .H ;&^>]LD-MNT*O,\EJ*_OW&^F1.);K25_= .9NKH@$ZS7>;6#*Z4/GL^#BB7.SM6"U:KV-S7_DRH_R$D_G>/+*S5-MXLXQZ:4A_>^1_)FIM6.9.EK/5GV0W^-E-H"E&4_]\;,).U7)& ;9ZX70-*4N? M-TW_=CWB."^3KW6L55%.[W?&E6P(.9;'V!"R-^;0[;K4(C5=]{U6].T(<7Y0-MZ\D4:J.QMTJ93;%]5/%QG ,2GRR'"F3:,M-/E8-'>7U-^G*Y$V-.)"*M++/) M(+L\T$.]=WS6C"2A_/*'AL(!&@I58G?+#9T!&[5:?\]F1HB:7\ >%D:WB]*6-M^T&>$[NY_&P04P6TE6L7EGEM%,)6M:RZI4M.?_G>)7+P*-_5GA9(_ M90M'Q(BMJ6/F<.F$DCR[Y\^@!__B6F&I;*([A9<':A-M+9\3-VL1-_,Z&9V7FPLD[!S,/3A;0L-W1_I$IMY*]]923[W!4-/^C?1*):!K&-M3+NN!*ZD2PZ\ [F_E3L]Y]FT8R[?9/;S#"C[I!A8X7W_1?UF+U>*]ZWGN*ROD-M"]\$Z]+P&G8FR@$'?IC(`!.@.=-P38^\N/8+UFHSZ(@D_=DC!%U9TIO.C_A+-M-ESI+OJR\U9ZM8(Y$-A!N<0TBADUPUFZ#:3S-RM8X7O]KH2I%_L?!-8VKH!-M(P&56KIW%X'"%]7_YTA(&9KDK?V=8-Y*)P4>8H@$OO5MZEBWU!KB-O7%7BBF(-M?AR-/7W]@;=CL@?00T_18:K[%K,B&@#+*9%66/<%P+#0?Q))3Q+X_!M<'>G5 M]7Y2^K'BR_1._)S9()^)0SR:XR-M#-#[CJX"9APP@*ERQ$KE>&;#4"]GL8P?\@0]>=,NF.4%&R+K2*R-4;E@9K/BSM8#!-M@JR"94J_QR8!? $JR)#>E?XB;#BPM'2Y+6K=IDN.XTE6$E&6@V]SY>'G>)5O-M_9(60/:Y#S(.*U+OKEIW*PBOI"0OF#6H]3H[XK]R7AI*#H_,B>-;+X2UY\$H-MI]VL-RDPV=9SHJ8=T'X&3ZPN3E^PRC'[^[^_L\O?WZ^>_KX0?KV](^//Z3[-M;U^^__CXCX]?'Q_^^5%Z^-I_?Y3>?/[V^/AVST[+,07PSC!6BY6-\IAU4=Y= MA,^N[S\A8^RN!,:L;:^$(M>\$@>5A-3\(H&:GF'4F>V-#9/$/D.&O3*IZ@-L-MCM<"FSFX><@G);#7597#*8$M?Y3:'?4&(N=QVP?L>O"G$SI! MC+44>/-TS-]'[<[\UV1/@9^+F3@33Z!8!K<$=-9W3;?_*6B?,PN5O@LF-?;:-M6#D>@;%@S-;*EN^?NG$X?>GB#8MEY]]LNV$I7Z&B-M#-K&"A? 4ET&@?9L]Z;\R##P*9D^K-6IMG$]NU9%6?L$K@E&7':78Z7E&P-M].UN^3O!*8)3&N^-4I0/-[=@/KNJ5>NZ-M6@.K\.S+,.BVH@WQH1/MC30E<-HGDD<,6-=]:P9#H]Z[DZ1N%1(V;6%?;Q'A;$4*B>UM6J!U/6%N)TA6-]AZ6@?H'S7!@G]AUFX)HIQBM:-M6G\,J@GGTOIUR?'V-J?D021'>>2,G!V$@- .1J4W65*CEFH!Q&FWPY-#I<3EN-M")2^H2M/VG>NR*;)EE-+]ET1F,V)4J_)TZ5S$Q1BX1WJJ/(TU-M-1^B+W[==W0O? NM.4^8K]ZT3ZUZ3J:WR>@\X&='$4I]80>+'XK17[GGK#%^K-M2:N-S]0A-8;#6K$F=&0QH;RJ_E=A4..B(1V(3%"'S'#,P0[1""_$A8*F-K?H M(:B,N&A6-BW-0DL5E>P06L;9>IE-2]/0<@8/YP'<]+$T;F]0R9-9!VBNH<+Y-M=H)3V!NR9'K3IE]9%%;J@4 7)7!V"LJ>+$RWW^M,^@.98Q3%^>JD"784['@2-M=JPO:KY/<["JQ,P+9A3,V"YF+,>+.2TJ.+"@RM/4*OA0\&%+^+#4IMBO+X>_ MWT<5M==^%;5\<^,$G+1I,*UZBO=(7I,EBZKJOC.(UBVYX4D-:7^WMFX,9RM-MG-RB3V%BJV#_+3N%6NJ')"THIJA;%?92/^=>4F;FF=Q./:+_O-5G,-AWNQVJ-MKWTD>;K6E^7<;M%P>_K["[[%9=_"-FRL4%)<(N^VU]G[+2W1EDO=MA0>Z_?Z-MC2OQ!:)AJ#9N5&IWK&7? (@J/B<)CHO"8*#PF"H]Q*CRFBL)CHOI%$>-!C8>6-M-1Q:-*U:5V)1*4;PRKGL;#G->CAPB$8['E8VM-DN$5QROAUEI^K8Z7:4(>67 M2E&+@E4$]YR)509%OP)%K491OT*X_3$HZF$-QZZW6*"HW2C**3_!-M&T4*;&E]WG%-#5$D6YV/*4],G5U]/%>IEX':M% (OEP^"9^"T.AJ"=VNAVW@JEO#_B'5;HY&E@U+UYK*J5X5?UDC-FC]KCO;EO2L-M<%UW1=T=I6J>2*]D(T<,[K&*